CA2896577C - Inhibitor of apoptosis protein (iap) antagonists - Google Patents
Inhibitor of apoptosis protein (iap) antagonists Download PDFInfo
- Publication number
- CA2896577C CA2896577C CA2896577A CA2896577A CA2896577C CA 2896577 C CA2896577 C CA 2896577C CA 2896577 A CA2896577 A CA 2896577A CA 2896577 A CA2896577 A CA 2896577A CA 2896577 C CA2896577 C CA 2896577C
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- unsubstituted
- formula
- cancer
- c6alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091007065 BIRCs Proteins 0.000 title abstract description 24
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 title abstract description 24
- 239000005557 antagonist Substances 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 793
- 150000003839 salts Chemical class 0.000 claims abstract description 324
- 125000003118 aryl group Chemical group 0.000 claims description 382
- 125000001072 heteroaryl group Chemical group 0.000 claims description 359
- 229920006395 saturated elastomer Polymers 0.000 claims description 165
- -1 methylene dioxy Chemical group 0.000 claims description 151
- 206010028980 Neoplasm Diseases 0.000 claims description 147
- 201000011510 cancer Diseases 0.000 claims description 144
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 125
- 229910052717 sulfur Inorganic materials 0.000 claims description 122
- 125000004429 atom Chemical group 0.000 claims description 98
- 125000005842 heteroatom Chemical group 0.000 claims description 77
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 63
- 125000000217 alkyl group Chemical group 0.000 claims description 59
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims description 56
- 229910052757 nitrogen Inorganic materials 0.000 claims description 55
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 53
- 229910052736 halogen Inorganic materials 0.000 claims description 45
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 43
- 150000002367 halogens Chemical class 0.000 claims description 43
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 42
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 25
- 230000033115 angiogenesis Effects 0.000 claims description 23
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 22
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 22
- 201000005202 lung cancer Diseases 0.000 claims description 22
- 208000020816 lung neoplasm Diseases 0.000 claims description 22
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 22
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 20
- 125000002837 carbocyclic group Chemical group 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 20
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 206010006187 Breast cancer Diseases 0.000 claims description 17
- 208000026310 Breast neoplasm Diseases 0.000 claims description 17
- 206010060862 Prostate cancer Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 16
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 16
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 16
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 16
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 201000002528 pancreatic cancer Diseases 0.000 claims description 16
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 16
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims description 14
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 14
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 14
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 13
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- 125000001544 thienyl group Chemical group 0.000 claims description 13
- 201000009030 Carcinoma Diseases 0.000 claims description 12
- 201000004681 Psoriasis Diseases 0.000 claims description 11
- 206010039491 Sarcoma Diseases 0.000 claims description 10
- 201000000053 blastoma Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 201000008184 embryoma Diseases 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 9
- 206010039710 Scleroderma Diseases 0.000 claims description 9
- 230000003463 hyperproliferative effect Effects 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 8
- 206010021263 IgA nephropathy Diseases 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims description 8
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 8
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 8
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 208000010749 gastric carcinoma Diseases 0.000 claims description 8
- 208000005017 glioblastoma Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 201000003068 rheumatic fever Diseases 0.000 claims description 8
- 201000000849 skin cancer Diseases 0.000 claims description 8
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 8
- 201000000498 stomach carcinoma Diseases 0.000 claims description 8
- 206010046766 uterine cancer Diseases 0.000 claims description 8
- 206010000050 Abdominal adhesions Diseases 0.000 claims description 7
- 208000003120 Angiofibroma Diseases 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 206010011017 Corneal graft rejection Diseases 0.000 claims description 7
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 7
- 208000010412 Glaucoma Diseases 0.000 claims description 7
- 206010029113 Neovascularisation Diseases 0.000 claims description 7
- 206010043189 Telangiectasia Diseases 0.000 claims description 7
- 206010052428 Wound Diseases 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- 230000001969 hypertrophic effect Effects 0.000 claims description 7
- 208000002780 macular degeneration Diseases 0.000 claims description 7
- 230000002107 myocardial effect Effects 0.000 claims description 7
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 230000037390 scarring Effects 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 208000009056 telangiectasis Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 4
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 208000003807 Graves Disease Diseases 0.000 claims description 4
- 208000015023 Graves' disease Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 206010047642 Vitiligo Diseases 0.000 claims description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 208000007475 hemolytic anemia Diseases 0.000 claims description 4
- 201000011486 lichen planus Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 abstract description 247
- 239000000203 mixture Substances 0.000 abstract description 62
- 238000000034 method Methods 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 216
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 144
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 95
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 94
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 55
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 52
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 51
- 238000002360 preparation method Methods 0.000 description 43
- 101150041968 CDC13 gene Proteins 0.000 description 42
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 42
- 239000000047 product Substances 0.000 description 37
- 229910052799 carbon Inorganic materials 0.000 description 36
- 239000003921 oil Substances 0.000 description 35
- 235000019198 oils Nutrition 0.000 description 35
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 30
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 28
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 26
- 238000003818 flash chromatography Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 description 23
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 description 23
- 238000005481 NMR spectroscopy Methods 0.000 description 23
- 125000004404 heteroalkyl group Chemical group 0.000 description 23
- 229940079593 drug Drugs 0.000 description 22
- 238000005160 1H NMR spectroscopy Methods 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 150000001412 amines Chemical class 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 19
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 19
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 16
- 230000006907 apoptotic process Effects 0.000 description 15
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 15
- 125000006239 protecting group Chemical group 0.000 description 15
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 14
- 150000001299 aldehydes Chemical class 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 13
- 101100264173 Homo sapiens XIAP gene Proteins 0.000 description 13
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 13
- 229910021529 ammonia Inorganic materials 0.000 description 13
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- VLHQXRIIQSTJCQ-LURJTMIESA-N (2s)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)N(C)C(=O)OC(C)(C)C VLHQXRIIQSTJCQ-LURJTMIESA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 125000004434 sulfur atom Chemical group 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 8
- 239000007832 Na2SO4 Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 102000011727 Caspases Human genes 0.000 description 6
- 108010076667 Caspases Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 6
- 125000002843 carboxylic acid group Chemical group 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 125000001041 indolyl group Chemical group 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 150000002825 nitriles Chemical class 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 6
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 5
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 5
- 125000004474 heteroalkylene group Chemical group 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- UQNRTPFLTRZEIM-MRWUDIQNSA-N (2s)-2-amino-3-hydroxy-n-[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide;hydrochloride Chemical compound Cl.C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 UQNRTPFLTRZEIM-MRWUDIQNSA-N 0.000 description 4
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 4
- 101150082208 DIABLO gene Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- 238000006058 Ugi-reaction Methods 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 150000001350 alkyl halides Chemical class 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 150000005840 aryl radicals Chemical class 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 239000012039 electrophile Substances 0.000 description 4
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 4
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012038 nucleophile Substances 0.000 description 4
- VOFNECDJUWZSFW-UHFFFAOYSA-N oxazepine-7-carboxamide Chemical compound NC(=O)C1=CC=CC=NO1 VOFNECDJUWZSFW-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- DZMVCVHATYROOS-ZBFGKEHZSA-N soblidotin Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1 DZMVCVHATYROOS-ZBFGKEHZSA-N 0.000 description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- OOKIODJYZSVHDO-QMYFOHRPSA-N (2s)-n-tert-butyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NC(C)(C)C)CCC1 OOKIODJYZSVHDO-QMYFOHRPSA-N 0.000 description 3
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 3
- JZPGURKWXUBQLP-UHFFFAOYSA-N 2-[[2-(2-methylpropylsulfanyl)-1,3-benzothiazol-6-yl]iminomethyl]phenol Chemical compound CC(C)CSC1=NC2=C(S1)C=C(C=C2)N=CC3=CC=CC=C3O JZPGURKWXUBQLP-UHFFFAOYSA-N 0.000 description 3
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 3
- 102100021676 Baculoviral IAP repeat-containing protein 1 Human genes 0.000 description 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100021239 G protein-activated inward rectifier potassium channel 2 Human genes 0.000 description 3
- 101710158550 G protein-activated inward rectifier potassium channel 2 Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 108010000817 Leuprolide Proteins 0.000 description 3
- 108010006696 Neuronal Apoptosis-Inhibitory Protein Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol ( L-threo-sphinganine) Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010002687 Survivin Proteins 0.000 description 3
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 3
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 3
- 150000008052 alkyl sulfonates Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960004630 chlorambucil Drugs 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 229960000684 cytarabine Drugs 0.000 description 3
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 3
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- KLEPCGBEXOCIGS-XUZZJYLKSA-N ethyl N-[4-[[(2S,4S)-2-(imidazol-1-ylmethyl)-2-(4-methoxyphenyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1SC[C@H]1O[C@](CN2C=NC=C2)(C=2C=CC(OC)=CC=2)OC1 KLEPCGBEXOCIGS-XUZZJYLKSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 150000003948 formamides Chemical class 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 229950003600 ombrabulin Drugs 0.000 description 3
- 229940127084 other anti-cancer agent Drugs 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 102000007863 pattern recognition receptors Human genes 0.000 description 3
- 108010089193 pattern recognition receptors Proteins 0.000 description 3
- 229960002340 pentostatin Drugs 0.000 description 3
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229960003440 semustine Drugs 0.000 description 3
- 108010047846 soblidotin Proteins 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229950006050 spiromustine Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 108010029464 tasidotin Proteins 0.000 description 3
- 229960003087 tioguanine Drugs 0.000 description 3
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 2
- HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 description 2
- PFJFPBDHCFMQPN-RGJAOAFDSA-N (1s,3s,7s,10r,11s,12s,16r)-3-[(e)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 description 2
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2s)-n-benzyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 2
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- CNTMOLDWXSVYKD-PSRNMDMQSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-phenylbutanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound OC(=O)C(/C)=C/[C@H](C(C)C)N(C)C(=O)[C@H](C(C)(C)C)NC(=O)[C@@H](NC)C(C)(C)C1=CC=CC=C1 CNTMOLDWXSVYKD-PSRNMDMQSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 2
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 2
- RTHKPHCVZVYDFN-UHFFFAOYSA-N 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-ol Chemical compound NC1=NC=CC(C=2C3=C(O)C=CN=C3N3C(N)=NC=CC3=2)=N1 RTHKPHCVZVYDFN-UHFFFAOYSA-N 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- 101150032367 BIRC8 gene Proteins 0.000 description 2
- 101710177962 Baculoviral IAP repeat-containing protein 3 Proteins 0.000 description 2
- 102100027515 Baculoviral IAP repeat-containing protein 6 Human genes 0.000 description 2
- 102100027517 Baculoviral IAP repeat-containing protein 8 Human genes 0.000 description 2
- 101150104237 Birc3 gene Proteins 0.000 description 2
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 2
- LDZJNMJIPNOYGA-UHFFFAOYSA-N C1=C(OC(C)=O)C(OC)=CC=C1C1=C2C3=CC(OC)=C(OC(C)=O)C=C3C=CN2C2=C1C(C=C(OC)C(OC(C)=O)=C1)=C1OC2=O Chemical compound C1=C(OC(C)=O)C(OC)=CC=C1C1=C2C3=CC(OC)=C(OC(C)=O)C=C3C=CN2C2=C1C(C=C(OC)C(OC(C)=O)=C1)=C1OC2=O LDZJNMJIPNOYGA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
- 101100452644 Drosophila melanogaster Ilp2 gene Proteins 0.000 description 2
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930126263 Maytansine Natural products 0.000 description 2
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- URCVCIZFVQDVPM-UHFFFAOYSA-N N-[2-(4-hydroxyanilino)-3-pyridinyl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 URCVCIZFVQDVPM-UHFFFAOYSA-N 0.000 description 2
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 2
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- QPWBZVAOCWJTFK-UHFFFAOYSA-L [2-(azanidylmethyl)-3-hydroxy-2-(hydroxymethyl)propyl]azanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC(C[NH-])(CO)CO.[O-]C(=O)C1(C([O-])=O)CCC1 QPWBZVAOCWJTFK-UHFFFAOYSA-L 0.000 description 2
- ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 2
- 229960004176 aclarubicin Drugs 0.000 description 2
- SMPZPKRDRQOOHT-UHFFFAOYSA-N acronycine Chemical compound CN1C2=CC=CC=C2C(=O)C2=C1C(C=CC(C)(C)O1)=C1C=C2OC SMPZPKRDRQOOHT-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 229950004955 adozelesin Drugs 0.000 description 2
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000000747 amidyl group Chemical group [H][N-]* 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 2
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 2
- 229950001858 batimastat Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229950008548 bisantrene Drugs 0.000 description 2
- 229950006844 bizelesin Drugs 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229950009494 bropirimine Drugs 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 2
- 229950007509 carzelesin Drugs 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 108010046713 cemadotin Proteins 0.000 description 2
- BZXULYMZYPRZOG-UHFFFAOYSA-N centaureidin Chemical compound C1=C(O)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 BZXULYMZYPRZOG-UHFFFAOYSA-N 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- NQGMIPUYCWIEAW-OVCLIPMQSA-N chembl1834105 Chemical compound O/N=C/C1=C(SC)C(OC)=CC(C=2N=CC=CC=2)=N1 NQGMIPUYCWIEAW-OVCLIPMQSA-N 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 108010083340 cryptophycin 52 Proteins 0.000 description 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 2
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 2
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 2
- 229950002389 diaziquone Drugs 0.000 description 2
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 108010045524 dolastatin 10 Proteins 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229950004203 droloxifene Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 2
- 229950001426 erbulozole Drugs 0.000 description 2
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 2
- 229950006566 etanidazole Drugs 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 150000002224 folic acids Chemical class 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 229950006905 ilmofosine Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 108010021336 lanreotide Proteins 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960003951 masoprocol Drugs 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 229960004296 megestrol acetate Drugs 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- LWYJUZBXGAFFLP-OCNCTQISSA-N menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 2
- 229950002676 menogaril Drugs 0.000 description 2
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229950008017 ormaplatin Drugs 0.000 description 2
- 229960001744 pegaspargase Drugs 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- VPAWVRUHMJVRHU-VGDKGRGNSA-N perfosfamide Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 2
- 229950009351 perfosfamide Drugs 0.000 description 2
- NDTYTMIUWGWIMO-UHFFFAOYSA-N perillyl alcohol Chemical compound CC(=C)C1CCC(CO)=CC1 NDTYTMIUWGWIMO-UHFFFAOYSA-N 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 229960004293 porfimer sodium Drugs 0.000 description 2
- 229950004406 porfiromycin Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000003881 protein kinase C inhibitor Substances 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 2
- 229950005230 rogletimide Drugs 0.000 description 2
- MOCVYVBNJQIVOV-TVQRCGJNSA-N rohitukine Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C)=CC2=O MOCVYVBNJQIVOV-TVQRCGJNSA-N 0.000 description 2
- 229950008902 safingol Drugs 0.000 description 2
- CGFVUVWMYIHGHS-UHFFFAOYSA-N saintopin Chemical compound C1=C(O)C=C2C=C(C(=O)C=3C(=C(O)C=C(C=3)O)C3=O)C3=C(O)C2=C1O CGFVUVWMYIHGHS-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UWPXRVDIKGZQQW-UHFFFAOYSA-N sodium;(3-fluoro-4-methoxyphenyl)-(2,3,4,5,6-pentafluorophenyl)sulfonylazanide Chemical compound [Na+].C1=C(F)C(OC)=CC=C1[N-]S(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F UWPXRVDIKGZQQW-UHFFFAOYSA-N 0.000 description 2
- XBUIKNRVGYFSHL-IAVQPKKASA-M sodium;[(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2r)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] hydrogen phosphate Chemical compound [Na+].OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)([O-])=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 XBUIKNRVGYFSHL-IAVQPKKASA-M 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 2
- HAOCRCFHEPRQOY-JKTUOYIXSA-N spongistatin-1 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C(Cl)=C)O[C@@H]2[C@@H]1C HAOCRCFHEPRQOY-JKTUOYIXSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 150000003461 sulfonyl halides Chemical class 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 229960002197 temoporfin Drugs 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical group CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229950002376 tirapazamine Drugs 0.000 description 2
- ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 description 2
- TVPNFKRGOFJQOO-UHFFFAOYSA-N topsentin b1 Chemical compound C1=CC=C2C(C3=CN=C(N3)C(=O)C=3C4=CC=C(C=C4NC=3)O)=CNC2=C1 TVPNFKRGOFJQOO-UHFFFAOYSA-N 0.000 description 2
- 150000004654 triazenes Chemical class 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 229960002730 vapreotide Drugs 0.000 description 2
- 108700029852 vapreotide Proteins 0.000 description 2
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 2
- 229960003895 verteporfin Drugs 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- 229960001771 vorozole Drugs 0.000 description 2
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229950003017 zeniplatin Drugs 0.000 description 2
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 1
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- KQODQNJLJQHFQV-UHFFFAOYSA-N (-)-hemiasterlin Natural products C1=CC=C2C(C(C)(C)C(C(=O)NC(C(=O)N(C)C(C=C(C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-UHFFFAOYSA-N 0.000 description 1
- 229930007631 (-)-perillyl alcohol Natural products 0.000 description 1
- OTWVIYXCRFLDJW-QMVMUTFZSA-N (1-hydroxy-1-phosphonooxyethyl) dihydrogen phosphate;rhenium-186 Chemical compound [186Re].OP(=O)(O)OC(O)(C)OP(O)(O)=O OTWVIYXCRFLDJW-QMVMUTFZSA-N 0.000 description 1
- JRZGPXSSNPTNMA-SNVBAGLBSA-N (1r)-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=CC=C2[C@H](N)CCCC2=C1 JRZGPXSSNPTNMA-SNVBAGLBSA-N 0.000 description 1
- FNEOHTTZLPHOSX-KZNAEPCWSA-N (1r)-1-[(2r,5r)-5-(hydroxymethyl)oxolan-2-yl]tridecan-1-ol Chemical compound CCCCCCCCCCCC[C@@H](O)[C@H]1CC[C@H](CO)O1 FNEOHTTZLPHOSX-KZNAEPCWSA-N 0.000 description 1
- XJYQGNNBDGDYCE-DXBBTUNJSA-N (1r)-1-[(2r,5r)-5-[(1s)-1-hydroxypent-4-enyl]oxolan-2-yl]tridecan-1-ol Chemical compound CCCCCCCCCCCC[C@@H](O)[C@H]1CC[C@H]([C@@H](O)CCC=C)O1 XJYQGNNBDGDYCE-DXBBTUNJSA-N 0.000 description 1
- BKSBGCVGYLOQJZ-LLVKDONJSA-N (1r)-1-isocyano-1,2,3,4-tetrahydronaphthalene Chemical compound C1=CC=C2[C@H]([N+]#[C-])CCCC2=C1 BKSBGCVGYLOQJZ-LLVKDONJSA-N 0.000 description 1
- MNHVIVWFCMBFCV-AVGNSLFASA-N (2S)-2-[[(2S)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-6-diazo-5-oxohexanoyl]amino]-6-diazo-5-oxohexanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(O)=O MNHVIVWFCMBFCV-AVGNSLFASA-N 0.000 description 1
- MXABZXILAJGOTL-AUYMZICSSA-N (2S)-N-[(2S)-1-[(2S)-1-[(2S,3S)-1-[(2S)-1-[2-[(2S)-1,3-dihydroxy-1-[(E)-1-hydroxy-1-[(2S,3S)-1-hydroxy-3-methyl-1-[[(2Z,6S,9S,12R)-5,8,11-trihydroxy-9-(2-methylpropyl)-6-propan-2-yl-1-thia-4,7,10-triazacyclotrideca-2,4,7,10-tetraen-12-yl]imino]pentan-2-yl]iminobut-2-en-2-yl]iminopropan-2-yl]imino-2-hydroxyethyl]imino-1,5-dihydroxy-5-iminopentan-2-yl]imino-1-hydroxy-3-methylpentan-2-yl]imino-1-hydroxy-3-methylbutan-2-yl]imino-1-hydroxy-3-phenylpropan-2-yl]-2-[[(2S)-2-[[(2S)-2-[[(Z)-2-[[(2S)-2-[[(Z)-2-[[(2S)-2-[[[(2S)-1-[(Z)-2-[[(2S)-2-(dimethylamino)-1-hydroxypropylidene]amino]but-2-enoyl]pyrrolidin-2-yl]-hydroxymethylidene]amino]-1-hydroxypropylidene]amino]-1-hydroxybut-2-enylidene]amino]-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxybut-2-enylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-1-hydroxypropylidene]amino]pentanediimidic acid Chemical compound CC[C@H](C)[C@H](\N=C(/O)[C@@H](\N=C(/O)[C@H](Cc1ccccc1)\N=C(/O)[C@H](CCC(O)=N)\N=C(/O)[C@H](C)\N=C(/O)[C@@H](\N=C(/O)\C(=C\C)\N=C(/O)[C@H](Cc1ccccc1)\N=C(/O)\C(=C\C)\N=C(/O)[C@H](C)\N=C(/O)[C@@H]1CCCN1C(=O)\C(=C\C)\N=C(/O)[C@H](C)N(C)C)C(C)C)C(C)C)C(\O)=N\[C@@H](CCC(O)=N)C(\O)=N\C\C(O)=N\[C@@H](CO)C(\O)=N\C(=C\C)\C(\O)=N\[C@@H]([C@@H](C)CC)C(\O)=N\[C@H]1CS\C=C/N=C(O)\[C@@H](\N=C(O)/[C@H](CC(C)C)\N=C1\O)C(C)C MXABZXILAJGOTL-AUYMZICSSA-N 0.000 description 1
- MRJQTLJSMQOFTP-JGTKTWDESA-N (2S)-N-benzyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide hydrochloride Chemical compound Cl.CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 MRJQTLJSMQOFTP-JGTKTWDESA-N 0.000 description 1
- KJTPWUVVLPCPJD-VGOFMYFVSA-N (2e)-7-amino-2-[(4-hydroxy-3,5-dimethylphenyl)methylidene]-5,6-dimethoxy-3h-inden-1-one Chemical compound O=C1C=2C(N)=C(OC)C(OC)=CC=2C\C1=C/C1=CC(C)=C(O)C(C)=C1 KJTPWUVVLPCPJD-VGOFMYFVSA-N 0.000 description 1
- BUSGWUFLNHIBPT-XYBORKQMSA-N (2e,4e,6e)-7-[(1r,5r,6s)-3-[[(2e,4e)-5-cyclohexylpenta-2,4-dienoyl]amino]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-5-yl]hepta-2,4,6-trienoic acid Chemical compound C([C@]([C@H]1O[C@H]1C1=O)(O)/C=C/C=C/C=C/C(=O)O)=C1NC(=O)\C=C\C=C\C1CCCCC1 BUSGWUFLNHIBPT-XYBORKQMSA-N 0.000 description 1
- LCADVYTXPLBAGB-AUQKUMLUSA-N (2e,4e,6z,8e,10e,14e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide Chemical compound OCC(C)NC(=O)C(\C)=C\C=C\C=C/C=C/C(/C)=C/C(C)C(O)C(\C)=C\C(C)CCC1=CC=CC=C1 LCADVYTXPLBAGB-AUQKUMLUSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2r)-2-[[(4r)-4-[[(2s)-2-[[(2r)-2-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- SWTGJCNCBUCXSS-ISUZDFFFSA-N (2r)-3,4-dihydroxy-2-[(4s)-2-phenyl-1,3-dioxolan-4-yl]-2h-furan-5-one Chemical compound OC1=C(O)C(=O)O[C@@H]1[C@H]1OC(C=2C=CC=CC=2)OC1 SWTGJCNCBUCXSS-ISUZDFFFSA-N 0.000 description 1
- RCGXNDQKCXNWLO-WLEIXIPESA-N (2r)-n-[(2s)-5-amino-1-[[(2r,3r)-1-[[(3s,6z,9s,12r,15r,18r,19s)-9-benzyl-15-[(2r)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopent Chemical compound N([C@@H](CCCN)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H]1C(N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NC(/C(=O)N[C@H](C(=O)O[C@H]1C)C(C)C)=C\C)C(C)C)[C@H](C)CC)=O)C(=O)[C@H]1CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CCCC(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C RCGXNDQKCXNWLO-WLEIXIPESA-N 0.000 description 1
- PAYBYKKERMGTSS-MNCSTQPFSA-N (2r,3r,3as,9ar)-7-fluoro-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol Chemical compound N=C1C(F)=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 PAYBYKKERMGTSS-MNCSTQPFSA-N 0.000 description 1
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 description 1
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2s)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
- XDZGQQRZJDKPTG-HBNQUELISA-N (2s)-2-[(3s,6s)-6-[2-[(1r,2r,4as,8as)-1-hydroxy-2,4a,5,5,8a-pentamethyl-2,3,4,6,7,8-hexahydronaphthalen-1-yl]ethyl]-6-methyldioxan-3-yl]propanoic acid Chemical compound O1O[C@H]([C@H](C)C(O)=O)CC[C@@]1(C)CC[C@]1(O)[C@@]2(C)CCCC(C)(C)[C@]2(C)CC[C@H]1C XDZGQQRZJDKPTG-HBNQUELISA-N 0.000 description 1
- CUCSSYAUKKIDJV-FAXBSAIASA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1h-indol-3-yl)propanoyl]-methylamino]-3-phenylpropanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-n-[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpent Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CUCSSYAUKKIDJV-FAXBSAIASA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- JRBXPUUAYKCCLQ-QMMMGPOBSA-N (2s)-2-amino-2-[3-hydroxy-4-(hydroxymethyl)phenyl]acetic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(CO)C(O)=C1 JRBXPUUAYKCCLQ-QMMMGPOBSA-N 0.000 description 1
- QQFXIBJLIYDCLO-YUMQZZPRSA-N (2s)-3-hydroxy-2-[[(2s)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoyl]amino]propanoic acid Chemical compound CC(C)(C)OC(=O)N(C)[C@@H](C)C(=O)N[C@@H](CO)C(O)=O QQFXIBJLIYDCLO-YUMQZZPRSA-N 0.000 description 1
- HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- RDIMTXDFGHNINN-UHFFFAOYSA-N (3R,9R,10R)-1-heptadecen-4,6-diyne-3,9,10-triol Natural products CCCCCCCC(O)C(O)CC#CC#CC(O)C=C RDIMTXDFGHNINN-UHFFFAOYSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- LSXOBYNBRKOTIQ-MQHIEMKOSA-N (3s,10r,13e)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NCC(C)(C)C(=O)O[C@@H](CC(C)C)C(=O)OC([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 LSXOBYNBRKOTIQ-MQHIEMKOSA-N 0.000 description 1
- LSXOBYNBRKOTIQ-RQUBOUMQSA-N (3s,10r,13e,16s)-10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NCC(C)(C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 LSXOBYNBRKOTIQ-RQUBOUMQSA-N 0.000 description 1
- TVIRNGFXQVMMGB-OFWIHYRESA-N (3s,6r,10r,13e,16s)-16-[(2r,3r,4s)-4-chloro-3-hydroxy-4-phenylbutan-2-yl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H](O)[C@@H](Cl)C=2C=CC=CC=2)C/C=C/C(=O)N1 TVIRNGFXQVMMGB-OFWIHYRESA-N 0.000 description 1
- GWMHBVLPNWHWGW-CNYBTUBUSA-N (3s,6z)-3-benzyl-6-[[5-(2-methylbut-3-en-2-yl)-1h-imidazol-4-yl]methylidene]piperazine-2,5-dione Chemical compound N1C=NC(\C=C/2C(N[C@@H](CC=3C=CC=CC=3)C(=O)N\2)=O)=C1C(C)(C=C)C GWMHBVLPNWHWGW-CNYBTUBUSA-N 0.000 description 1
- FRCJDPPXHQGEKS-BCHFMIIMSA-N (4S,5R)-N-[4-[(2,3-dihydroxybenzoyl)amino]butyl]-N-[3-[(2,3-dihydroxybenzoyl)amino]propyl]-2-(2-hydroxyphenyl)-5-methyl-4,5-dihydro-1,3-oxazole-4-carboxamide Chemical compound C[C@H]1OC(=N[C@@H]1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCNC(=O)c1cccc(O)c1O)c1ccccc1O FRCJDPPXHQGEKS-BCHFMIIMSA-N 0.000 description 1
- GTEXXGIEZVKSLH-YPMHNXCESA-N (4as,12br)-8,10-dihydroxy-2,5,5,9-tetramethyl-3,4,4a,12b-tetrahydronaphtho[2,3-c]isochromene-7,12-dione Chemical compound O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1[C@@H]1C=C(C)CC[C@@H]1C(C)(C)O2 GTEXXGIEZVKSLH-YPMHNXCESA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- VTTMWBPZTZHGLU-IVSQCGTASA-N (4s,7r,8s,9s,13z,16s)-4,8-dihydroxy-16-[(e)-1-[2-(hydroxymethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-5,5,7,9,13-pentamethyl-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(CO)=N1 VTTMWBPZTZHGLU-IVSQCGTASA-N 0.000 description 1
- GRPYHMFJRWZUEE-AXBXVSCFSA-N (4s,7r,9as)-4-[[(2s)-2-(methylamino)propanoyl]amino]-5-oxo-n-[(1r)-1,2,3,4-tetrahydronaphthalen-1-yl]-3,4,7,8,9,9a-hexahydro-2h-pyrrolo[2,1-b][1,3]thiazepine-7-carboxamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)CCS[C@H]2CC[C@H](C(=O)N[C@H]3C4=CC=CC=C4CCC3)N21 GRPYHMFJRWZUEE-AXBXVSCFSA-N 0.000 description 1
- DGUZQZXTUHDVHK-IQOMPXODSA-N (4s,7s,9as)-4-[[(2s)-2-(methylamino)propanoyl]amino]-5-oxo-n-[(1r)-1,2,3,4-tetrahydronaphthalen-1-yl]-3,4,7,8,9,9a-hexahydro-2h-pyrrolo[2,1-b][1,3]oxazepine-7-carboxamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)CCO[C@H]2CC[C@@H](C(=O)N[C@H]3C4=CC=CC=C4CCC3)N21 DGUZQZXTUHDVHK-IQOMPXODSA-N 0.000 description 1
- BFKTWACJXKSKBZ-JDLVMGNASA-N (4s,9as)-4-amino-7-(indole-1-carbonyl)-3,4,7,8,9,9a-hexahydro-2h-pyrrolo[2,1-b][1,3]oxazepin-5-one Chemical compound O=C1[C@@H](N)CCO[C@H]2CCC(C(=O)N3C4=CC=CC=C4C=C3)N21 BFKTWACJXKSKBZ-JDLVMGNASA-N 0.000 description 1
- HLAKJNQXUARACO-ZDUSSCGKSA-N (5'r)-5'-hydroxy-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one Chemical compound O=C([C@@]1(O)C)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-ZDUSSCGKSA-N 0.000 description 1
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- LKBBOPGQDRPCDS-YAOXHJNESA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O)(O)CC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 LKBBOPGQDRPCDS-YAOXHJNESA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- RCFNNLSZHVHCEK-YGCMNLPTSA-N (7s,9s)-7-[(2s,4r,6s)-4-amino-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 RCFNNLSZHVHCEK-YGCMNLPTSA-N 0.000 description 1
- VHZXNQKVFDBFIK-NBBHSKLNSA-N (8r,9s,10r,13s,14s,16r)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](F)C4)=O)[C@@H]4[C@@H]3CC=C21 VHZXNQKVFDBFIK-NBBHSKLNSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- MHFRGQHAERHWKZ-HHHXNRCGSA-N (R)-edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@@H](OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-HHHXNRCGSA-N 0.000 description 1
- KQODQNJLJQHFQV-MKWZWQCGSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical compound C1=CC=C2C(C(C)(C)[C@@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-MKWZWQCGSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
- OJRZEKJECRTBPJ-NGAMADIESA-N (z,5s)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- XKEHLMZHBXCJGZ-UHFFFAOYSA-N 1,4,7,10,13,16,19-heptaoxacyclohenicosane Chemical compound C1COCCOCCOCCOCCOCCOCCO1 XKEHLMZHBXCJGZ-UHFFFAOYSA-N 0.000 description 1
- JBCHLRJXUSEBMN-UHFFFAOYSA-N 1,4,7,10,13,16-hexaoxa-19-azacyclohenicosane Chemical compound C1COCCOCCOCCOCCOCCOCCN1 JBCHLRJXUSEBMN-UHFFFAOYSA-N 0.000 description 1
- NBXKUSNBCPPKRA-UHFFFAOYSA-N 1,4,7,10,13-pentaoxa-16-azacyclooctadecane Chemical compound C1COCCOCCOCCOCCOCCN1 NBXKUSNBCPPKRA-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2r)-oxiran-2-yl]methyl]-3-[[(2s)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- XSTAOBURMHGXDG-UHFFFAOYSA-N 1-(2,2-dimethoxyethyl)-2-isocyanobenzene Chemical compound COC(OC)CC1=CC=CC=C1[N+]#[C-] XSTAOBURMHGXDG-UHFFFAOYSA-N 0.000 description 1
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 description 1
- YQYBWJPESSJLTK-HXFLIBJXSA-N 1-(2-chloroethyl)-3-[(2r,3s,4r,6s)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea Chemical compound CO[C@@H]1C[C@@H](NC(=O)N(CCCl)N=O)[C@H](O)[C@@H](CO)O1 YQYBWJPESSJLTK-HXFLIBJXSA-N 0.000 description 1
- RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 description 1
- JQJSFAJISYZPER-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,3-dihydro-1h-inden-5-ylsulfonyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JQJSFAJISYZPER-UHFFFAOYSA-N 0.000 description 1
- SNYUHPPZINRDSG-UHFFFAOYSA-N 1-(oxiran-2-ylmethyl)-4-[1-(oxiran-2-ylmethyl)piperidin-4-yl]piperidine Chemical compound C1CC(C2CCN(CC3OC3)CC2)CCN1CC1CO1 SNYUHPPZINRDSG-UHFFFAOYSA-N 0.000 description 1
- MDKFBOKRJCLOEH-UHFFFAOYSA-N 1-[5-(4-amino-3-methylphenyl)-2-(3,4,5-trimethoxyphenyl)-2h-1,3,4-oxadiazol-3-yl]ethanone Chemical compound COC1=C(OC)C(OC)=CC(C2N(N=C(O2)C=2C=C(C)C(N)=CC=2)C(C)=O)=C1 MDKFBOKRJCLOEH-UHFFFAOYSA-N 0.000 description 1
- JLHZYDALLVHMAM-UHFFFAOYSA-N 1-[5-[4-(dimethylamino)phenyl]-2-(3,4,5-trimethoxyphenyl)-2h-1,3,4-oxadiazol-3-yl]ethanone Chemical compound COC1=C(OC)C(OC)=CC(C2N(N=C(O2)C=2C=CC(=CC=2)N(C)C)C(C)=O)=C1 JLHZYDALLVHMAM-UHFFFAOYSA-N 0.000 description 1
- ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
- PTCSLGONLAYNQB-UHFFFAOYSA-N 1-isocyanonaphthalene Chemical compound C1=CC=C2C([N+]#[C-])=CC=CC2=C1 PTCSLGONLAYNQB-UHFFFAOYSA-N 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- XQQZRZQVBFHBHL-UHFFFAOYSA-N 12-crown-4 Chemical compound C1COCCOCCOCCO1 XQQZRZQVBFHBHL-UHFFFAOYSA-N 0.000 description 1
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- NUXKIZBEPYVRKP-RWBWKAGLSA-N 1xa5 Chemical compound O([C@]12[C@@H]3N(C)C4=C([C@]53CCN3CC=C[C@@]([C@@H]53)(CC)C2)C=C(C(=C4)OC)[C@]2(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C2)C[C@@](C3)(O)CC)C(=O)N(CCCl)C1=O NUXKIZBEPYVRKP-RWBWKAGLSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 description 1
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 1
- NJWBUDCAWGTQAS-UHFFFAOYSA-N 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 NJWBUDCAWGTQAS-UHFFFAOYSA-N 0.000 description 1
- HHYOOLILMDESPS-UHFFFAOYSA-N 2-(diethoxymethyl)benzaldehyde Chemical compound CCOC(OCC)C1=CC=CC=C1C=O HHYOOLILMDESPS-UHFFFAOYSA-N 0.000 description 1
- PDWUPXJEEYOOTR-UHFFFAOYSA-N 2-[(3-iodophenyl)methyl]guanidine Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
- SOLIIYNRSAWTSQ-UHFFFAOYSA-N 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-n-pyridin-4-ylacetamide Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2C(C(=O)C(=O)NC=2C=CN=CC=2)=C1 SOLIIYNRSAWTSQ-UHFFFAOYSA-N 0.000 description 1
- KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 description 1
- XXVLKDRPHSFIIB-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 XXVLKDRPHSFIIB-UHFFFAOYSA-N 0.000 description 1
- MHXVDXXARZCVRK-WCWDXBQESA-N 2-[2-[4-[(e)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol Chemical compound C1=CC(OCCNCCO)=CC=C1C(\C=1C=CC=CC=1)=C(C(F)(F)F)/C1=CC=CC=C1 MHXVDXXARZCVRK-WCWDXBQESA-N 0.000 description 1
- FDDKBIMQTFVKFO-WGCWOXMQSA-N 2-[4-[(e)-3-[4-(3-chlorophenyl)piperazin-1-yl]prop-1-enyl]-5-methylpyrazol-1-yl]pyrimidine;hydrochloride Chemical compound Cl.C1=NN(C=2N=CC=CN=2)C(C)=C1\C=C\CN(CC1)CCN1C1=CC=CC(Cl)=C1 FDDKBIMQTFVKFO-WGCWOXMQSA-N 0.000 description 1
- PXJJOGITBQXZEQ-JTHROIFXSA-M 2-[4-[(z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium;iodide Chemical compound [I-].C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCC[N+](C)(C)C)=CC=1)/C1=CC=CC=C1 PXJJOGITBQXZEQ-JTHROIFXSA-M 0.000 description 1
- HYHJFNXFVPGMBI-UHFFFAOYSA-N 2-[[2-chloroethyl(nitroso)carbamoyl]-methylamino]acetamide Chemical compound NC(=O)CN(C)C(=O)N(CCCl)N=O HYHJFNXFVPGMBI-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- NIXVOFULDIFBLB-QVRNUERCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-6-sulfinamide Chemical compound C12=NC(N)=NC(S(N)=O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NIXVOFULDIFBLB-QVRNUERCSA-N 0.000 description 1
- SCJGXQSJGQUCFA-YSMBQZINSA-N 2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]aniline;hydrochloride Chemical compound Cl.C1=C(N)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 SCJGXQSJGQUCFA-YSMBQZINSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- DSWLRNLRVBAVFC-UHFFFAOYSA-N 2-methylsulfinyl-1-pyridin-2-ylethanone Chemical compound CS(=O)CC(=O)C1=CC=CC=N1 DSWLRNLRVBAVFC-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- ULWCBTJBSAGPPB-UHFFFAOYSA-N 2h-isoindole-4-carboxamide Chemical compound NC(=O)C1=CC=CC2=CNC=C12 ULWCBTJBSAGPPB-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- GRLUHXSUZYFZCW-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine;dihydrochloride Chemical compound Cl.Cl.C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 GRLUHXSUZYFZCW-UHFFFAOYSA-N 0.000 description 1
- GTJXPMSTODOYNP-BTKVJIOYSA-N 3-[(e)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 GTJXPMSTODOYNP-BTKVJIOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- FWUKGPHKUHZKGF-UHFFFAOYSA-N 4,4-dimethoxy-2,2-dimethylbutanal Chemical compound COC(OC)CC(C)(C)C=O FWUKGPHKUHZKGF-UHFFFAOYSA-N 0.000 description 1
- JHTAVDBZYBVMTL-UHFFFAOYSA-N 4,4-dimethoxy-2,2-dimethylbutanenitrile Chemical compound COC(OC)CC(C)(C)C#N JHTAVDBZYBVMTL-UHFFFAOYSA-N 0.000 description 1
- LIETVYHJBSLSSW-UHFFFAOYSA-N 4,6,9-trihydroxy-8-methyl-3,4-dihydro-2h-anthracen-1-one Chemical compound OC1CCC(=O)C2=C1C=C1C=C(O)C=C(C)C1=C2O LIETVYHJBSLSSW-UHFFFAOYSA-N 0.000 description 1
- JARCFMKMOFFIGZ-UHFFFAOYSA-N 4,6-dioxo-n-phenyl-2-sulfanylidene-1,3-diazinane-5-carboxamide Chemical compound O=C1NC(=S)NC(=O)C1C(=O)NC1=CC=CC=C1 JARCFMKMOFFIGZ-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- HQFSNUYUXXPVKL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C1CCN(CCC=2C=CC=CC=2)CCC1 HQFSNUYUXXPVKL-UHFFFAOYSA-N 0.000 description 1
- OUQPTBCOEKUHBH-LSDHQDQOSA-N 4-[2-[4-[(e)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenoxy]ethyl]morpholine Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C(C=C1)=CC=C1OCCN1CCOCC1 OUQPTBCOEKUHBH-LSDHQDQOSA-N 0.000 description 1
- CTSNHMQGVWXIEG-UHFFFAOYSA-N 4-amino-n-(5-chloroquinoxalin-2-yl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C(Cl)=CC=C2)C2=N1 CTSNHMQGVWXIEG-UHFFFAOYSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- NSUDGNLOXMLAEB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=CC(O)=C1C=O NSUDGNLOXMLAEB-UHFFFAOYSA-N 0.000 description 1
- APNRZHLOPQFNMR-WEIUTZTHSA-N 5-[(e)-5-[(1s)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enyl]phenazin-1-one Chemical compound C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1C\C=C(/C)CC[C@@H]1C(=C)CCCC1(C)C APNRZHLOPQFNMR-WEIUTZTHSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- VGULLEUAAMBZTQ-UHFFFAOYSA-N 5-desacetylaltohyrtin A Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C VGULLEUAAMBZTQ-UHFFFAOYSA-N 0.000 description 1
- DQOGWKZQQBYYMW-LQGIGNHCSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 DQOGWKZQQBYYMW-LQGIGNHCSA-N 0.000 description 1
- PXBZKHOQHTVCSQ-QZTJIDSGSA-N 5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 PXBZKHOQHTVCSQ-QZTJIDSGSA-N 0.000 description 1
- ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 description 1
- VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
- OTSZCHORPMQCBZ-UHFFFAOYSA-N 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1h-benzimidazole;hydron;chloride Chemical compound Cl.ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 OTSZCHORPMQCBZ-UHFFFAOYSA-N 0.000 description 1
- LRHPCRBOMKRVOA-UHFFFAOYSA-N 6-[2-(2-hydroxyethylamino)ethyl]indeno[1,2-c]isoquinoline-5,11-dione Chemical compound C12=CC=CC=C2C(=O)N(CCNCCO)C2=C1C(=O)C1=CC=CC=C12 LRHPCRBOMKRVOA-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- ZNTIXVYOBQDFFV-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.O=C1NC(N)=CC2=C1N=CN2 ZNTIXVYOBQDFFV-UHFFFAOYSA-N 0.000 description 1
- LJIRBXZDQGQUOO-KVTDHHQDSA-N 6-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LJIRBXZDQGQUOO-KVTDHHQDSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- GOYNNCPGHOBFCK-UHFFFAOYSA-N 7-[4-(dimethylamino)-5-[(2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl)oxy]-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(O)=C1C(OC3OC(C)C(OC4OC(C)C5OC6OC(C)C(=O)CC6OC5C4)C(C3)N(C)C)CC(CC)(O)C(O)C1=C2O GOYNNCPGHOBFCK-UHFFFAOYSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- LPDLEICKXUVJHW-QJILNLRNSA-N 78nz2pmp25 Chemical compound OS(O)(=O)=O.O([C@]12[C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@@]5([C@H]34)[C@H]1N(C)C1=C5C=C(C(=C1)OC)[C@]1(C(=O)OC)C3=C(C4=CC=CC=C4N3)CCN3C[C@H](C1)C[C@@](C3)(O)CC)C(=O)N(CCCl)C2=O LPDLEICKXUVJHW-QJILNLRNSA-N 0.000 description 1
- JPASRFGVACYSJG-UHFFFAOYSA-N 8,10-dihydroimidazo[4,5-a]acridin-9-one Chemical class N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 JPASRFGVACYSJG-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- ZUZXYJOSNSTJMU-UHFFFAOYSA-N 9-cyclohexyl-2-n,6-n-bis[(4-methoxyphenyl)methyl]purine-2,6-diamine Chemical compound C1=CC(OC)=CC=C1CNC1=NC(NCC=2C=CC(OC)=CC=2)=C(N=CN2C3CCCCC3)C2=N1 ZUZXYJOSNSTJMU-UHFFFAOYSA-N 0.000 description 1
- UMBVAPCONCILTL-MRHIQRDNSA-N Ac-Asp-Glu-Val-Asp-H Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O UMBVAPCONCILTL-MRHIQRDNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- NQGMIPUYCWIEAW-UHFFFAOYSA-N Antibiotic SF 2738 Natural products COc1cc(nc(C=NO)c1SC)-c1ccccn1 NQGMIPUYCWIEAW-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- MJINRRBEMOLJAK-DCAQKATOSA-N Arg-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 1
- DRCNRVYVCHHIJP-AQBORDMYSA-N Arg-Lys-Glu-Val-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DRCNRVYVCHHIJP-AQBORDMYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108700032558 Aspergillus restrictus MITF Proteins 0.000 description 1
- 241001263178 Auriparus Species 0.000 description 1
- YOZSEGPJAXTSFZ-ZETCQYMHSA-N Azatyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=N1 YOZSEGPJAXTSFZ-ZETCQYMHSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 102100021677 Baculoviral IAP repeat-containing protein 2 Human genes 0.000 description 1
- 101710177961 Baculoviral IAP repeat-containing protein 2 Proteins 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 101150032866 CDC11 gene Proteins 0.000 description 1
- BQDMLOCSSRUPFF-UGKGYDQZSA-N C[C@H](N(C)C(=O)OC(C)(C)C)C(=O)N[C@@H](COCc1ccccc1)C(=O)OCc1ccccc1 Chemical compound C[C@H](N(C)C(=O)OC(C)(C)C)C(=O)N[C@@H](COCc1ccccc1)C(=O)OCc1ccccc1 BQDMLOCSSRUPFF-UGKGYDQZSA-N 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000004041 Caspase 7 Human genes 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- PPASFTRHCXASPY-UHFFFAOYSA-N Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 Chemical compound Cl.Cl.NCCCNc1ccc2c3c(nn2CCNCCO)c4c(O)ccc(O)c4C(=O)c13 PPASFTRHCXASPY-UHFFFAOYSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- DFDTZECTHJFPHE-UHFFFAOYSA-N Crambescidin 816 Natural products C1CC=CC(CC)OC11NC(N23)=NC4(OC(C)CCC4)C(C(=O)OCCCCCCCCCCCCCCCC(=O)N(CCCN)CC(O)CCN)C3(O)CCC2C1 DFDTZECTHJFPHE-UHFFFAOYSA-N 0.000 description 1
- LUEYTMPPCOCKBX-KWYHTCOPSA-N Curacin A Chemical compound C=CC[C@H](OC)CC\C(C)=C\C=C\CC\C=C/[C@@H]1CSC([C@H]2[C@H](C2)C)=N1 LUEYTMPPCOCKBX-KWYHTCOPSA-N 0.000 description 1
- LUEYTMPPCOCKBX-UHFFFAOYSA-N Curacin A Natural products C=CCC(OC)CCC(C)=CC=CCCC=CC1CSC(C2C(C2)C)=N1 LUEYTMPPCOCKBX-UHFFFAOYSA-N 0.000 description 1
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- PQNNIEWMPIULRS-UHFFFAOYSA-N Cytostatin Natural products CC=CC=CC=CC(O)C(C)C(OP(O)(O)=O)CCC(C)C1OC(=O)C=CC1C PQNNIEWMPIULRS-UHFFFAOYSA-N 0.000 description 1
- SPKNARKFCOPTSY-UHFFFAOYSA-N D-asperlin Natural products CC1OC1C1C(OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- OALVLUFFPXEHFO-UHFFFAOYSA-N Diazonamide A Natural products O1C=2C34C(O)OC5=C3C=CC=C5C(C3=5)=CC=CC=5NC(Cl)=C3C(=C(N=3)Cl)OC=3C=2N=C1C(C(C)C)NC(=O)C(NC(=O)C(N)C(C)C)CC1=CC=C(O)C4=C1 OALVLUFFPXEHFO-UHFFFAOYSA-N 0.000 description 1
- KYHUYMLIVQFXRI-SJPGYWQQSA-N Didemnin B Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)O KYHUYMLIVQFXRI-SJPGYWQQSA-N 0.000 description 1
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- VQNATVDKACXKTF-UHFFFAOYSA-N Duocarmycin SA Natural products COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C(C64CC6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-UHFFFAOYSA-N 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 102000007989 Effector Caspases Human genes 0.000 description 1
- 108010089510 Effector Caspases Proteins 0.000 description 1
- NBEALWAVEGMZQY-UHFFFAOYSA-N Enpromate Chemical compound C=1C=CC=CC=1C(C#C)(C=1C=CC=CC=1)OC(=O)NC1CCCCC1 NBEALWAVEGMZQY-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- UKIMCRYGLFQEOE-UHFFFAOYSA-N Epothilone F Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2(C)OC2CC1C(C)=CC1=CSC(CO)=N1 UKIMCRYGLFQEOE-UHFFFAOYSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- ITIONVBQFUNVJV-UHFFFAOYSA-N Etomidoline Chemical compound C12=CC=CC=C2C(=O)N(CC)C1NC(C=C1)=CC=C1OCCN1CCCCC1 ITIONVBQFUNVJV-UHFFFAOYSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010072471 HTI-286 Proteins 0.000 description 1
- ZBLLGPUWGCOJNG-UHFFFAOYSA-N Halichondrin B Natural products CC1CC2(CC(C)C3OC4(CC5OC6C(CC5O4)OC7CC8OC9CCC%10OC(CC(C(C9)C8=C)C%11%12CC%13OC%14C(OC%15CCC(CC(=O)OC7C6C)OC%15C%14O%11)C%13O%12)CC%10=C)CC3O2)OC%16OC(CC1%16)C(O)CC(O)CO ZBLLGPUWGCOJNG-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- 229940083346 IAP antagonist Drugs 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000001483 Initiator Caspases Human genes 0.000 description 1
- 108010054031 Initiator Caspases Proteins 0.000 description 1
- 108700022013 Insecta cecropin B Proteins 0.000 description 1
- 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- GSDBGCKBBJVPNC-BYPYZUCNSA-N L-lombricine Chemical compound NC(=[NH2+])NCCOP([O-])(=O)OC[C@H]([NH3+])C([O-])=O GSDBGCKBBJVPNC-BYPYZUCNSA-N 0.000 description 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ZHTRILQJTPJGNK-FYBAATNNSA-N Leinamycin Chemical compound N([C@@H](C=1SC=C(N=1)\C=C/C=C/C(=O)[C@H](O)/C=C(C)/CC1)C)C(=O)C[C@@]21S(=O)SC(=O)[C@]2(C)O ZHTRILQJTPJGNK-FYBAATNNSA-N 0.000 description 1
- ZHTRILQJTPJGNK-UHFFFAOYSA-N Leinamycin Natural products C1CC(C)=CC(O)C(=O)C=CC=CC(N=2)=CSC=2C(C)NC(=O)CC21S(=O)SC(=O)C2(C)O ZHTRILQJTPJGNK-UHFFFAOYSA-N 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- LMVRPBWWHMVLPC-KBPJCXPTSA-N Leptolstatin Natural products CC(CC=CC(=CC(C)C(=O)C(C)C(O)C(C)CC(=CCO)C)C)C=C(C)/C=C/C1CC=CC(=O)O1 LMVRPBWWHMVLPC-KBPJCXPTSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- BLOFGONIVNXZME-UHFFFAOYSA-N Mannostatin A Natural products CSC1C(N)C(O)C(O)C1O BLOFGONIVNXZME-UHFFFAOYSA-N 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 108700021154 Metallothionein 3 Proteins 0.000 description 1
- 102100028708 Metallothionein-3 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 101100533558 Mus musculus Sipa1 gene Proteins 0.000 description 1
- HFPXYDFQVINJBV-UHFFFAOYSA-N Mycaperoxide B Natural products O1OC(C(C)C(O)=O)CCC1(C)CCC1(O)C2(C)CCCC(C)(C)C2CCC1C HFPXYDFQVINJBV-UHFFFAOYSA-N 0.000 description 1
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- BNQSTAOJRULKNX-UHFFFAOYSA-N N-(6-acetamidohexyl)acetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N-3,4-tridhydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- GTEXXGIEZVKSLH-UHFFFAOYSA-N Naphterpin Natural products O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1C1C=C(C)CCC1C(C)(C)O2 GTEXXGIEZVKSLH-UHFFFAOYSA-N 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- BUSGWUFLNHIBPT-UHFFFAOYSA-N Nisamycin Natural products O=C1C2OC2C(C=CC=CC=CC(=O)O)(O)C=C1NC(=O)C=CC=CC1CCCCC1 BUSGWUFLNHIBPT-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 1
- WQLDJUQUFZDTSD-XXODBJNXSA-N O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(C)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(C)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 WQLDJUQUFZDTSD-XXODBJNXSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- VTAZRSXSBIHBMH-UHFFFAOYSA-N Ophiocordin Natural products OC1=CC(C(=O)O)=CC(O)=C1C(=O)C1=C(O)C=CC=C1C(=O)NC1C(OC(=O)C=2C=CC(O)=CC=2)CCCNC1 VTAZRSXSBIHBMH-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- LKBBOPGQDRPCDS-UHFFFAOYSA-N Oxaunomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC=C4C(=O)C=3C(O)=C2C(O)C(CC)(O)CC1OC1CC(N)C(O)C(C)O1 LKBBOPGQDRPCDS-UHFFFAOYSA-N 0.000 description 1
- FRCJDPPXHQGEKS-UHFFFAOYSA-N Parabactin Natural products CC1OC(=NC1C(=O)N(CCCCNC(=O)c1cccc(O)c1O)CCCNC(=O)c1cccc(O)c1O)c1ccccc1O FRCJDPPXHQGEKS-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- 229920001774 Perfluoroether Chemical group 0.000 description 1
- APNRZHLOPQFNMR-UHFFFAOYSA-N Phenazinomycin Natural products C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1CC=C(C)CCC1C(=C)CCCC1(C)C APNRZHLOPQFNMR-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 239000004721 Polyphenylene oxide Chemical group 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 102100032420 Protein S100-A9 Human genes 0.000 description 1
- PICZCWCKOLHDOJ-UHFFFAOYSA-N Pseudoaxinellin Natural products N1C(=O)C2CCCN2C(=O)C(CC(N)=O)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)C1CC1=CC=CC=C1 PICZCWCKOLHDOJ-UHFFFAOYSA-N 0.000 description 1
- XESARGFCSKSFID-UHFFFAOYSA-N Pyrazofurin Natural products OC1=C(C(=O)N)NN=C1C1C(O)C(O)C(CO)O1 XESARGFCSKSFID-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- ZQUSFAUAYSEREK-WKILWMFISA-N SB-239063 Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)[C@@H]2CC[C@@H](O)CC2)=N1 ZQUSFAUAYSEREK-WKILWMFISA-N 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- YADVRLOQIWILGX-MIWLTHJTSA-N Sarcophytol A Chemical compound CC(C)C/1=C/C=C(C)/CC\C=C(C)\CC\C=C(C)\C[C@@H]\1O YADVRLOQIWILGX-MIWLTHJTSA-N 0.000 description 1
- 102100030333 Serpin B5 Human genes 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- GCEUCUGYUPYUEC-UHFFFAOYSA-N Spongistatin 3 Natural products COC1CC2CC(=O)C(C)C(OC(=O)C)C(C)C(=C)CC3CC(C)(O)CC4(CCCC(CC(=O)OC5C(C)C(OC(CC(=C)CC(O)C=CC(=C)Cl)C5O)C(O)C6(O)CC(O)C(C)C(CCCC=C/C7CC(O)CC(C1)(O2)O7)O6)O4)O3 GCEUCUGYUPYUEC-UHFFFAOYSA-N 0.000 description 1
- JOEPUFOWFXWEDN-UHFFFAOYSA-N Spongistatin 5 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC(Cl)=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 JOEPUFOWFXWEDN-UHFFFAOYSA-N 0.000 description 1
- BTCJGYMVVGSTDN-UHFFFAOYSA-N Spongistatin 7 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 BTCJGYMVVGSTDN-UHFFFAOYSA-N 0.000 description 1
- GLMCWICCTJHQKE-UHFFFAOYSA-N Spongistatin 9 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC(Cl)=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 GLMCWICCTJHQKE-UHFFFAOYSA-N 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- PTTJLTMUKRRHAT-VJAKQJMOSA-N Taccalonolide A Chemical compound C([C@@H]1C(=O)[C@@H]2O)[C@@H]3O[C@@H]3[C@H](OC(C)=O)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2[C@@H](OC(C)=O)[C@H]3[C@@]4(C)[C@](C)(O)C(=O)OC4=C[C@@H](C)[C@@H]3[C@@]2(C)[C@@H](OC(C)=O)[C@H]1OC(C)=O PTTJLTMUKRRHAT-VJAKQJMOSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- WXZSUBHBYQYTNM-UHFFFAOYSA-N Tetrazomine Natural products C1=CC=2CC(N34)C(N5C)C(CO)CC5C4OCC3C=2C(OC)=C1NC(=O)C1NCCCC1O WXZSUBHBYQYTNM-UHFFFAOYSA-N 0.000 description 1
- UPGGKUQISSWRJJ-XLTUSUNSSA-N Thiocoraline Chemical compound O=C([C@H]1CSSC[C@@H](N(C(=O)CNC2=O)C)C(=O)N(C)[C@@H](C(SC[C@@H](C(=O)NCC(=O)N1C)NC(=O)C=1C(=CC3=CC=CC=C3N=1)O)=O)CSC)N(C)[C@H](CSC)C(=O)SC[C@@H]2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-XLTUSUNSSA-N 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- IBEDDHUHZBDXGB-OEJISELMSA-N Tubulysin A Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(O)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C IBEDDHUHZBDXGB-OEJISELMSA-N 0.000 description 1
- IBEDDHUHZBDXGB-UHFFFAOYSA-N Tubulysin A Natural products N=1C(C(=O)NC(CC(C)C(O)=O)CC=2C=CC(O)=CC=2)=CSC=1C(OC(C)=O)CC(C(C)C)N(COC(=O)CC(C)C)C(=O)C(C(C)CC)NC(=O)C1CCCCN1C IBEDDHUHZBDXGB-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical compound C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 description 1
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 241000218220 Ulmaceae Species 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- MHDDZDPNIDVLNK-ZGIWMXSJSA-N Zanoterone Chemical compound C1C2=NN(S(C)(=O)=O)C=C2C[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CC[C@H]21 MHDDZDPNIDVLNK-ZGIWMXSJSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- ZZWKZQDOSJAGGF-VRSYWUPDSA-N [(1s,2e,7s,10e,12r,13r,15s)-12-hydroxy-7-methyl-9-oxo-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-15-yl] 2-(dimethylamino)acetate Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](OC(=O)CN(C)C)C[C@H]21 ZZWKZQDOSJAGGF-VRSYWUPDSA-N 0.000 description 1
- VUPBDWQPEOWRQP-RTUCOMKBSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1S,2S)-3-[[(2R,3S)-5-[[(2S,3R)-1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-5-oxopentan-2-yl]amino]-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate Chemical compound C[C@@H](O)[C@H](NC(=O)C[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1cnc[nH]1)C(=O)NC(O[C@@H]1O[C@@H](C)[C@@H](N)[C@@H](O)[C@H]1O)C(O)c1nc(cs1)-c1nc(cs1)C(=O)NCCCC(N)CC(=O)NCCCNCCCCN VUPBDWQPEOWRQP-RTUCOMKBSA-N 0.000 description 1
- SPKNARKFCOPTSY-XWPZMVOTSA-N [(2r,3s)-2-[(2s,3r)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 description 1
- IVCRCPJOLWECJU-XQVQQVTHSA-N [(7r,8r,9s,10r,13s,14s,17s)-7,13-dimethyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C[C@]2(C)[C@@H](OC(C)=O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 IVCRCPJOLWECJU-XQVQQVTHSA-N 0.000 description 1
- PQNNIEWMPIULRS-SUTYWZMXSA-N [(8e,10e,12e)-7-hydroxy-6-methyl-2-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)tetradeca-8,10,12-trien-5-yl] dihydrogen phosphate Chemical compound C\C=C\C=C\C=C\C(O)C(C)C(OP(O)(O)=O)CCC(C)C1OC(=O)C=CC1C PQNNIEWMPIULRS-SUTYWZMXSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- KMLCRELJHYKIIL-UHFFFAOYSA-N [1-(azanidylmethyl)cyclohexyl]methylazanide;platinum(2+);sulfuric acid Chemical compound [Pt+2].OS(O)(=O)=O.[NH-]CC1(C[NH-])CCCCC1 KMLCRELJHYKIIL-UHFFFAOYSA-N 0.000 description 1
- JJULHOZRTCDZOH-JGJFOBQESA-N [1-[[[(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3-octadecylsulfanylpropan-2-yl] hexadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(CSCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 JJULHOZRTCDZOH-JGJFOBQESA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- NAFFDQVVNWTDJD-UHFFFAOYSA-L [4-(azanidylmethyl)oxan-4-yl]methylazanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC1(C[NH-])CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 NAFFDQVVNWTDJD-UHFFFAOYSA-L 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] n-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- REKQCRSUOJRCDV-UHFFFAOYSA-N [isocyano(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C([N+]#[C-])C1=CC=CC=C1 REKQCRSUOJRCDV-UHFFFAOYSA-N 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Chemical group CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical group 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- RUGAHXUZHWYHNG-NLGNTGLNSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 RUGAHXUZHWYHNG-NLGNTGLNSA-N 0.000 description 1
- IGCAUIJHGNYDKE-UHFFFAOYSA-N acetic acid;1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound CC([O-])=O.CC([O-])=O.O=C1C2=CC=CC=C2C(=O)C2=C1C(NCC[NH2+]CCO)=CC=C2NCC[NH2+]CCO IGCAUIJHGNYDKE-UHFFFAOYSA-N 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- QAWIHIJWNYOLBE-OKKQSCSOSA-N acivicin Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
- 229950008427 acivicin Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 229950000616 acronine Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- HLAKJNQXUARACO-UHFFFAOYSA-N acylfulvene Natural products CC1(O)C(=O)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-UHFFFAOYSA-N 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- DPGOLRILOKERAV-AAWJQDODSA-N adecypenol Chemical compound OC1C(CO)=CCC1(O)N1C(N=CNC[C@H]2O)C2N=C1 DPGOLRILOKERAV-AAWJQDODSA-N 0.000 description 1
- WJSAFKJWCOMTLH-UHFFFAOYSA-N adecypenol Natural products OC1C(O)C(CO)=CC1N1C(NC=NCC2O)=C2N=C1 WJSAFKJWCOMTLH-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000005107 alkyl diaryl silyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010949 ambamustine Drugs 0.000 description 1
- 229950004821 ambomycin Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 108010070670 antarelix Proteins 0.000 description 1
- ACPOUJIDANTYHO-UHFFFAOYSA-N anthra[1,9-cd]pyrazol-6(2H)-one Chemical compound C1=CC(C(=O)C=2C3=CC=CC=2)=C2C3=NNC2=C1 ACPOUJIDANTYHO-UHFFFAOYSA-N 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- IOASYARYEYRREA-LQAJYKIKSA-N aphidicolin glycinate Chemical compound C1[C@]23[C@]4(C)CC[C@H](O)[C@](C)(CO)[C@H]4CC[C@@H]3C[C@@H]1[C@@](COC(=O)CN)(O)CC2 IOASYARYEYRREA-LQAJYKIKSA-N 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000034720 apoptotic signaling pathway Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010055530 arginyl-tryptophyl-N-methylphenylalanyl-tryptophyl-leucyl-methioninamide Proteins 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- TWHSQQYCDVSBRK-UHFFFAOYSA-N asulacrine Chemical compound C12=CC=CC(C)=C2N=C2C(C(=O)NC)=CC=CC2=C1NC1=CC=C(NS(C)(=O)=O)C=C1OC TWHSQQYCDVSBRK-UHFFFAOYSA-N 0.000 description 1
- 229950011088 asulacrine Drugs 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229950004810 atamestane Drugs 0.000 description 1
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 1
- 229950006933 atrimustine Drugs 0.000 description 1
- 108010093161 axinastatin 1 Proteins 0.000 description 1
- PICZCWCKOLHDOJ-GHTSNYPWSA-N axinastatin 1 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)=O)C(C)C)C(C)C)C(C)C)C1=CC=CC=C1 PICZCWCKOLHDOJ-GHTSNYPWSA-N 0.000 description 1
- 108010093000 axinastatin 2 Proteins 0.000 description 1
- OXNAATCTZCSVKR-AVGVIDKOSA-N axinastatin 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 OXNAATCTZCSVKR-AVGVIDKOSA-N 0.000 description 1
- UZCPCRPHNVHKKP-UHFFFAOYSA-N axinastatin 2 Natural products CC(C)CC1NC(=O)C2CCCN2C(=O)C(NC(=O)C(CC(=O)N)NC(=O)C3CCCN3C(=O)C(Cc4ccccc4)NC(=O)C(NC1=O)C(C)C)C(C)C UZCPCRPHNVHKKP-UHFFFAOYSA-N 0.000 description 1
- 108010092978 axinastatin 3 Proteins 0.000 description 1
- ANLDPEXRVVIABH-WUUSPZRJSA-N axinastatin 3 Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)[C@@H](C)CC)C1=CC=CC=C1 ANLDPEXRVVIABH-WUUSPZRJSA-N 0.000 description 1
- RTGMQVUKARGBNM-UHFFFAOYSA-N axinastatin 3 Natural products CCC(C)C1NC(=O)C(CC(C)C)NC(=O)C2CCCN2C(=O)C(NC(=O)C(CC(=O)N)NC(=O)C3CCCN3C(=O)C(Cc4ccccc4)NC1=O)C(C)C RTGMQVUKARGBNM-UHFFFAOYSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- OPWOOOGFNULJAQ-UHFFFAOYSA-L azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+) Chemical compound N.[Pt+2].NC1CCCC1.[O-]C(=O)C(O)CC([O-])=O OPWOOOGFNULJAQ-UHFFFAOYSA-L 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 229950005951 azasetron Drugs 0.000 description 1
- HRXVDDOKERXBEY-UHFFFAOYSA-N azatepa Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
- MIXLRUYCYZPSOQ-HXPMCKFVSA-N azatoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H]3N2C(OC3)=O)=C1 MIXLRUYCYZPSOQ-HXPMCKFVSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 229950004295 azotomycin Drugs 0.000 description 1
- 150000004200 baccatin III derivatives Chemical class 0.000 description 1
- XYUFCXJZFZPEJD-PGRDOPGGSA-N balanol Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-PGRDOPGGSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000005875 benzo[b][1,4]dioxepinyl group Chemical group 0.000 description 1
- 229950005567 benzodepa Drugs 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229950002370 bisnafide Drugs 0.000 description 1
- NPSOIFAWYAHWOH-UHFFFAOYSA-N bistratene A Natural products O1C(CC(=O)C=CC)CCC(O2)(O)CC(C)C2CCCNC(=O)C(C)C2OC(CCC(C)C=C(C)C(C)O)CCCCC(C)C1CC(=O)NC2 NPSOIFAWYAHWOH-UHFFFAOYSA-N 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- PZOHOALJQOFNTB-UHFFFAOYSA-M brequinar sodium Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229950002361 budotitane Drugs 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229950009338 caracemide Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229950005155 carbetimer Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- WIUSFZNUZWLLDZ-UHFFFAOYSA-N caribaeolin Natural products C1=CC(OC)(C(=CC2C(C(C=CC2C(C)C)(C)O)C2)COC(C)=O)OC1(C)C2OC(=O)C=CC1=CN(C)C=N1 WIUSFZNUZWLLDZ-UHFFFAOYSA-N 0.000 description 1
- KGOMYXIKIJGWKS-UHFFFAOYSA-N caribaeoside Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(C=CC1C(C)C)(C)O)C1C=C2COC1OCC(O)C(O)C1OC(C)=O KGOMYXIKIJGWKS-UHFFFAOYSA-N 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229950010667 cedefingol Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- CCWSQXBMKLEALQ-WMZOPIPTSA-N centaureidin Natural products CO[C@@H]1[C@@H](Oc2cc(O)c(OC)c(O)c2C1=O)c3ccc(OC)c(O)c3 CCWSQXBMKLEALQ-WMZOPIPTSA-N 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- HZCWPKGYTCJSEB-UHFFFAOYSA-N chembl118841 Chemical compound C12=CC(OC)=CC=C2NC2=C([N+]([O-])=O)C=CC3=C2C1=NN3CCCN(C)C HZCWPKGYTCJSEB-UHFFFAOYSA-N 0.000 description 1
- KGOMYXIKIJGWKS-DKNGGRFKSA-N chembl1916173 Chemical compound C(/[C@H]1[C@H]([C@](C=C[C@@H]1C(C)C)(C)O)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O KGOMYXIKIJGWKS-DKNGGRFKSA-N 0.000 description 1
- OWSKEUBOCMEJMI-KPXOXKRLSA-N chembl2105946 Chemical compound [N-]=[N+]=CC(=O)CC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CCC(=O)C=[N+]=[N-])C(O)=O OWSKEUBOCMEJMI-KPXOXKRLSA-N 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- ZWVZORIKUNOTCS-OAQYLSRUSA-N chembl401930 Chemical compound C1([C@H](O)CNC2=C(C(NC=C2)=O)C=2NC=3C=C(C=C(C=3N=2)C)N2CCOCC2)=CC=CC(Cl)=C1 ZWVZORIKUNOTCS-OAQYLSRUSA-N 0.000 description 1
- DCKFXSZUWVWFEU-JECTWPLRSA-N chembl499423 Chemical compound O1[C@@H](CC)CCCC[C@]11NC(N23)=N[C@]4(O[C@H](C)CCC4)[C@@H](C(=O)OCCCCCCCCCCCCCCCC(=O)N(CCCN)C[C@@H](O)CCN)[C@@]3(O)CC[C@H]2C1 DCKFXSZUWVWFEU-JECTWPLRSA-N 0.000 description 1
- 150000004035 chlorins Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- ARUGKOZUKWAXDS-SEWALLKFSA-N cicaprost Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
- 229950000634 cicaprost Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- JKNIRLKHOOMGOJ-UHFFFAOYSA-N cladochrome D Natural products COC1=C(CC(C)OC(=O)Oc2ccc(O)cc2)c3c4C(=C(OC)C(=O)c5c(O)cc(OC)c(c45)c6c(OC)cc(O)c(C1=O)c36)CC(C)OC(=O)c7ccc(O)cc7 JKNIRLKHOOMGOJ-UHFFFAOYSA-N 0.000 description 1
- SRJYZPCBWDVSGO-UHFFFAOYSA-N cladochrome E Natural products COC1=CC(O)=C(C(C(OC)=C(CC(C)OC(=O)OC=2C=CC(O)=CC=2)C2=3)=O)C2=C1C1=C(OC)C=C(O)C(C(C=2OC)=O)=C1C=3C=2CC(C)OC(=O)C1=CC=CC=C1 SRJYZPCBWDVSGO-UHFFFAOYSA-N 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical class C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- GLESHRYLRAOJPS-DHCFDGJBSA-N conagenin Chemical compound C[C@@H](O)[C@H](C)[C@@H](O)C(=O)N[C@@](C)(CO)C(O)=O GLESHRYLRAOJPS-DHCFDGJBSA-N 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- 229950007258 crisnatol Drugs 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical class C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- YFGZFQNBPSCWPN-UHFFFAOYSA-N cryptophycin 52 Natural products C1=CC(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 YFGZFQNBPSCWPN-UHFFFAOYSA-N 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- PESYEWKSBIWTAK-UHFFFAOYSA-N cyclopenta-1,3-diene;titanium(2+) Chemical compound [Ti+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 PESYEWKSBIWTAK-UHFFFAOYSA-N 0.000 description 1
- YXQWGVLNDXNSJJ-UHFFFAOYSA-N cyclopenta-1,3-diene;vanadium(2+) Chemical compound [V+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 YXQWGVLNDXNSJJ-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 108010041566 cypemycin Proteins 0.000 description 1
- YJTVZHOYBAOUTO-URBBEOKESA-N cytarabine ocfosfate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 YJTVZHOYBAOUTO-URBBEOKESA-N 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- YCWXIQRLONXJLF-PFFGJIDWSA-N d06307 Chemical compound OS(O)(=O)=O.C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC.C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC YCWXIQRLONXJLF-PFFGJIDWSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- WRPLJTYNAMMOEE-TXILBGFKSA-N desmethyleleutherobin Chemical compound O([C@H]1C[C@H]2C(C)=CC[C@@H]([C@H]2\C=C(CO[C@H]2[C@H]([C@H](O)[C@H](O)CO2)OC(C)=O)/[C@]2(O)O[C@@]1(C)C=C2)C(C)C)C(=O)\C=C\C1=CN(C)C=N1 WRPLJTYNAMMOEE-TXILBGFKSA-N 0.000 description 1
- WRPLJTYNAMMOEE-UHFFFAOYSA-N desmethyleleutherobin Natural products C1=CC2(C)OC1(O)C(COC1C(C(O)C(O)CO1)OC(C)=O)=CC1C(C(C)C)CC=C(C)C1CC2OC(=O)C=CC1=CN(C)C=N1 WRPLJTYNAMMOEE-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 1
- 229950001640 dexormaplatin Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 description 1
- 229950005878 dexverapamil Drugs 0.000 description 1
- 229950010621 dezaguanine Drugs 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005105 dialkylarylsilyl group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- YKBUODYYSZSEIY-PLSHLZFXSA-N diazonamide a Chemical compound N([C@H]([C@]12C=3O4)O5)C6=C2C=CC=C6C(C2=6)=CC=CC=6NC(Cl)=C2C(=C(N=2)Cl)OC=2C=3N=C4[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](O)C(C)C)CC2=CC=C5C1=C2 YKBUODYYSZSEIY-PLSHLZFXSA-N 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- KYHUYMLIVQFXRI-UHFFFAOYSA-N didemnin B Natural products CC1OC(=O)C(CC=2C=CC(OC)=CC=2)N(C)C(=O)C2CCCN2C(=O)C(CC(C)C)NC(=O)C(C)C(=O)C(C(C)C)OC(=O)CC(O)C(C(C)CC)NC(=O)C1NC(=O)C(CC(C)C)N(C)C(=O)C1CCCN1C(=O)C(C)O KYHUYMLIVQFXRI-UHFFFAOYSA-N 0.000 description 1
- 108010061297 didemnins Proteins 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- CZLKTMHQYXYHOO-QTNFYWBSSA-L disodium;(2s)-2-[(2-phosphonatoacetyl)amino]butanedioic acid Chemical compound [Na+].[Na+].OC(=O)C[C@@H](C(O)=O)NC(=O)CP([O-])([O-])=O CZLKTMHQYXYHOO-QTNFYWBSSA-L 0.000 description 1
- SVJSWELRJWVPQD-KJWOGLQMSA-L disodium;(2s)-2-[[4-[2-[(6r)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 SVJSWELRJWVPQD-KJWOGLQMSA-L 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229950005133 duazomycin Drugs 0.000 description 1
- 229930192837 duazomycin Natural products 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229960005510 duocarmycin SA Drugs 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 229950005678 ecomustine Drugs 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229950011461 edelfosine Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 elsamitrucin Drugs 0.000 description 1
- 229950005450 emitefur Drugs 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010625 enloplatin Drugs 0.000 description 1
- 229950001022 enpromate Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229950004926 epipropidine Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003265 epirubicin hydrochloride Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 description 1
- FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 description 1
- UKIMCRYGLFQEOE-RGJAOAFDSA-N epothilone f Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 229950009537 epristeride Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- 229960001766 estramustine phosphate sodium Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- HYSIJEPDMLSIQJ-UHFFFAOYSA-N ethanolate;1-phenylbutane-1,3-dione;titanium(4+) Chemical compound [Ti+4].CC[O-].CC[O-].CC(=O)[CH-]C(=O)C1=CC=CC=C1.CC(=O)[CH-]C(=O)C1=CC=CC=C1 HYSIJEPDMLSIQJ-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- XPGDODOEEWLHOI-GSDHBNRESA-N ethyl (2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(F)=CC=1)C1=CC=CC(N(CCCl)CCCl)=C1 XPGDODOEEWLHOI-GSDHBNRESA-N 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- JEFPWOBULVSOTM-PPHPATTJSA-N ethyl n-[(2s)-5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamate;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.C=1([C@H](C)NC=2C=C(N=C(N)C=2N=1)NC(=O)OCC)C1=CC=CC=C1 JEFPWOBULVSOTM-PPHPATTJSA-N 0.000 description 1
- ISVXIZFUEUVXPG-UHFFFAOYSA-N etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NMUSYJAQQFHJEW-ARQDHWQXSA-N fazarabine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 1
- 229950005096 fazarabine Drugs 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- IKIBJHWXDSKRKV-UHFFFAOYSA-N fijianolide B Natural products CC1CC(=C)CC(O)C2OC2CC(OC(=O)C=C/CC3OC(C)(CC=C3)C1)C(O)C=CC4CC(=CCO4)C IKIBJHWXDSKRKV-UHFFFAOYSA-N 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229950006000 flezelastine Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229950005682 flurocitabine Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 229950004217 forfenimex Drugs 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- UXTSQCOOUJTIAC-UHFFFAOYSA-N fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
- 229950005611 fosquidone Drugs 0.000 description 1
- 229950010404 fostriecin Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229950004410 galocitabine Drugs 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- 108700032141 ganirelix Proteins 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000002406 gelatinase inhibitor Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- FXNFULJVOQMBCW-VZBLNRDYSA-N halichondrin b Chemical compound O([C@@H]1[C@@H](C)[C@@H]2O[C@@H]3C[C@@]4(O[C@H]5[C@@H](C)C[C@@]6(C[C@@H]([C@@H]7O[C@@H](C[C@@H]7O6)[C@@H](O)C[C@@H](O)CO)C)O[C@H]5C4)O[C@@H]3C[C@@H]2O[C@H]1C[C@@H]1C(=C)[C@H](C)C[C@@H](O1)CC[C@H]1C(=C)C[C@@H](O1)CC1)C(=O)C[C@H](O2)CC[C@H]3[C@H]2[C@H](O2)[C@@H]4O[C@@H]5C[C@@]21O[C@@H]5[C@@H]4O3 FXNFULJVOQMBCW-VZBLNRDYSA-N 0.000 description 1
- 108010057806 hemiasterlin Proteins 0.000 description 1
- 229930187626 hemiasterlin Natural products 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000007857 hydrazones Chemical group 0.000 description 1
- SOCGJDYHNGLZEC-UHFFFAOYSA-N hydron;n-methyl-n-[4-[(7-methyl-3h-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide;chloride Chemical compound Cl.C1=CC(N(C(C)=O)C)=CC=C1NC1=CC(C)=NC2=CC=C(NC=N3)C3=C12 SOCGJDYHNGLZEC-UHFFFAOYSA-N 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
- 229950002248 idoxifene Drugs 0.000 description 1
- TZBDEVBNMSLVKT-UHFFFAOYSA-N idramantone Chemical compound C1C(C2)CC3CC1(O)CC2C3=O TZBDEVBNMSLVKT-UHFFFAOYSA-N 0.000 description 1
- 229950009926 idramantone Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003507 interferon alfa-2b Drugs 0.000 description 1
- 229940109242 interferon alfa-n3 Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229940028862 interferon gamma-1b Drugs 0.000 description 1
- 108010042414 interferon gamma-1b Proteins 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 229960003795 iobenguane (123i) Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950010897 iproplatin Drugs 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 229950000855 iroplact Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229950010984 irsogladine Drugs 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- RIWNFZUWWRVGEU-UHFFFAOYSA-N isocyanomethylbenzene Chemical compound [C-]#[N+]CC1=CC=CC=C1 RIWNFZUWWRVGEU-UHFFFAOYSA-N 0.000 description 1
- DWOIXRLFJBZDSB-MLLHTCFKSA-N isoeleutherobin a Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](OC(C)=O)[C@@H]1O DWOIXRLFJBZDSB-MLLHTCFKSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 description 1
- 229950007654 itasetron Drugs 0.000 description 1
- FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 1
- GQWYWHOHRVVHAP-DHKPLNAMSA-N jaspamide Chemical compound C1([C@@H]2NC(=O)[C@@H](CC=3C4=CC=CC=C4NC=3Br)N(C)C(=O)[C@H](C)NC(=O)[C@@H](C)C/C(C)=C/[C@H](C)C[C@@H](OC(=O)C2)C)=CC=C(O)C=C1 GQWYWHOHRVVHAP-DHKPLNAMSA-N 0.000 description 1
- 108010052440 jasplakinolide Proteins 0.000 description 1
- GQWYWHOHRVVHAP-UHFFFAOYSA-N jasplakinolide Natural products C1C(=O)OC(C)CC(C)C=C(C)CC(C)C(=O)NC(C)C(=O)N(C)C(CC=2C3=CC=CC=C3NC=2Br)C(=O)NC1C1=CC=C(O)C=C1 GQWYWHOHRVVHAP-UHFFFAOYSA-N 0.000 description 1
- 108010091711 kahalalide F Proteins 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960001739 lanreotide acetate Drugs 0.000 description 1
- MSBQEQDLFWWWMV-XZZGLLCESA-N laulimalide Chemical compound C(/[C@H](O)[C@H]1OC(=O)\C=C/C[C@@H]2C=CC[C@H](O2)C[C@H](CC(=C)C[C@H](O)[C@@H]2O[C@H]2C1)C)=C\[C@@H]1CC(C)=CCO1 MSBQEQDLFWWWMV-XZZGLLCESA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- KDQAABAKXDWYSZ-SDCRJXSCSA-N leurosidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-SDCRJXSCSA-N 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 108010020270 lissoclinamide 7 Proteins 0.000 description 1
- RBBBWKUBQVARPL-SWQMWMPHSA-N lissoclinamide 7 Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C2=N[C@@H]([C@H](O2)C)C(=O)N[C@@H](C=2SC[C@H](N=2)C(=O)N[C@H](CC=2C=CC=CC=2)C=2SC[C@H](N=2)C(=O)N1)C(C)C)C1=CC=CC=C1 RBBBWKUBQVARPL-SWQMWMPHSA-N 0.000 description 1
- RBBBWKUBQVARPL-UHFFFAOYSA-N lissoclinamide 7 Natural products N1C(=O)C(N=2)CSC=2C(CC=2C=CC=CC=2)NC(=O)C(N=2)CSC=2C(C(C)C)NC(=O)C(C(O2)C)N=C2C2CCCN2C(=O)C1CC1=CC=CC=C1 RBBBWKUBQVARPL-UHFFFAOYSA-N 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- BYRPTKZOXNFFDB-UHFFFAOYSA-N lithium;bis(trimethylsilyl)azanide;oxolane Chemical compound [Li+].C1CCOC1.C[Si](C)(C)[N-][Si](C)(C)C BYRPTKZOXNFFDB-UHFFFAOYSA-N 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 229950000909 lometrexol Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- XDMHALQMTPSGEA-UHFFFAOYSA-N losoxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO XDMHALQMTPSGEA-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229950005634 loxoribine Drugs 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 lurtotecan Drugs 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229950001474 maitansine Drugs 0.000 description 1
- 125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- BLOFGONIVNXZME-YDMGZANHSA-N mannostatin A Chemical compound CS[C@@H]1[C@@H](N)[C@@H](O)[C@@H](O)[C@H]1O BLOFGONIVNXZME-YDMGZANHSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960003846 melengestrol acetate Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108700025096 meterelin Proteins 0.000 description 1
- KPQJSSLKKBKWEW-RKDOVGOJSA-N methanesulfonic acid;5-nitro-2-[(2r)-1-[2-[[(2r)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.[O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 KPQJSSLKKBKWEW-RKDOVGOJSA-N 0.000 description 1
- BKBBTCORRZMASO-ZOWNYOTGSA-M methotrexate monosodium Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 BKBBTCORRZMASO-ZOWNYOTGSA-M 0.000 description 1
- 229960003058 methotrexate sodium Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical class CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229950008541 mirimostim Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- DRCJGCOYHLTVNR-ZUIZSQJWSA-N mitindomide Chemical compound C1=C[C@@H]2[C@@H]3[C@H]4C(=O)NC(=O)[C@H]4[C@@H]3[C@H]1[C@@H]1C(=O)NC(=O)[C@H]21 DRCJGCOYHLTVNR-ZUIZSQJWSA-N 0.000 description 1
- 229950001314 mitindomide Drugs 0.000 description 1
- 229950002137 mitocarcin Drugs 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229950000911 mitogillin Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 108010026677 mitomalcin Proteins 0.000 description 1
- 229950007612 mitomalcin Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229950001745 mitonafide Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229950005715 mitosper Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229950008012 mofarotene Drugs 0.000 description 1
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- AARXZCZYLAFQQU-UHFFFAOYSA-N motexafin gadolinium Chemical compound [Gd].CC(O)=O.CC(O)=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 AARXZCZYLAFQQU-UHFFFAOYSA-N 0.000 description 1
- WIQKYZYFTAEWBF-UHFFFAOYSA-L motexafin lutetium hydrate Chemical compound O.[Lu+3].CC([O-])=O.CC([O-])=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 WIQKYZYFTAEWBF-UHFFFAOYSA-L 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- PAVKBQLPQCDVNI-UHFFFAOYSA-N n',n'-diethyl-n-(9-methoxy-5,11-dimethyl-6h-pyrido[4,3-b]carbazol-1-yl)propane-1,3-diamine Chemical compound N1C2=CC=C(OC)C=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2C PAVKBQLPQCDVNI-UHFFFAOYSA-N 0.000 description 1
- SXEPYAAYPZBIEE-LLVKDONJSA-N n-[(1r)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide Chemical compound C1=CC=C2[C@H](NC=O)CCCC2=C1 SXEPYAAYPZBIEE-LLVKDONJSA-N 0.000 description 1
- CRJGESKKUOMBCT-PMACEKPBSA-N n-[(2s,3s)-1,3-dihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-PMACEKPBSA-N 0.000 description 1
- NKFHKYQGZDAKMX-PPRKPIOESA-N n-[(e)-1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]benzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 NKFHKYQGZDAKMX-PPRKPIOESA-N 0.000 description 1
- TVYPSLDUBVTDIS-FUOMVGGVSA-N n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- ARKYUICTMUZVEW-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3C=CC(=CC=3)N(CCCl)CCCl)C=2)C)=CN1C ARKYUICTMUZVEW-UHFFFAOYSA-N 0.000 description 1
- KIHAIHODXPSBCW-UHFFFAOYSA-N n-benzhydrylformamide Chemical compound C=1C=CC=CC=1C(NC=O)C1=CC=CC=C1 KIHAIHODXPSBCW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UMJJGDUYVQCBMC-UHFFFAOYSA-N n-ethyl-n'-[3-[3-(ethylamino)propylamino]propyl]propane-1,3-diamine Chemical compound CCNCCCNCCCNCCCNCC UMJJGDUYVQCBMC-UHFFFAOYSA-N 0.000 description 1
- WRINSSLBPNLASA-FOCLMDBBSA-N n-methyl-n-[(e)-(n-methylanilino)diazenyl]aniline Chemical compound C=1C=CC=CC=1N(C)\N=N\N(C)C1=CC=CC=C1 WRINSSLBPNLASA-FOCLMDBBSA-N 0.000 description 1
- CGRYTQQVSFZYCI-UHFFFAOYSA-N n-naphthalen-1-ylformamide Chemical compound C1=CC=C2C(NC=O)=CC=CC2=C1 CGRYTQQVSFZYCI-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- JZGDNMXSOCDEFQ-UHFFFAOYSA-N napavin Chemical compound C1C(CC)(O)CC(C2)CN1CCC(C1=CC=CC=C1N1)=C1C2(C(=O)OC)C(C(=C1)OC)=CC2=C1N(C)C1C2(C23)CCN3CC=CC2(CC)C(O)C1(O)C(=O)NCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O JZGDNMXSOCDEFQ-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 108010032539 nartograstim Proteins 0.000 description 1
- 229950010676 nartograstim Drugs 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 229950010159 nemorubicin Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229940125745 nitric oxide modulator Drugs 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- ZLLOIFNEEWYATC-XMUHMHRVSA-N osaterone Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZLLOIFNEEWYATC-XMUHMHRVSA-N 0.000 description 1
- 229950006466 osaterone Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002923 oximes Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229950000370 oxisuran Drugs 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- ZFYKZAKRJRNXGF-XRZRNGJYSA-N palmitoyl rhizoxin Chemical compound O1C(=O)C2OC2CC(CC(=O)O2)CC2C(C)\C=C\C2OC2(C)C(OC(=O)CCCCCCCCCCCCCCC)CC1C(C)C(OC)C(\C)=C\C=C\C(\C)=C\C1=COC(C)=N1 ZFYKZAKRJRNXGF-XRZRNGJYSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- RDIMTXDFGHNINN-IKGGRYGDSA-N panaxytriol Chemical compound CCCCCCC[C@H](O)[C@@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-IKGGRYGDSA-N 0.000 description 1
- ZCKMUKZQXWHXOF-UHFFFAOYSA-N panaxytriol Natural products CCC(C)C(C)C(C)C(C)C(C)C(O)C(O)CC#CC#CC(O)C=C ZCKMUKZQXWHXOF-UHFFFAOYSA-N 0.000 description 1
- 229950003440 panomifene Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LPHSYQSMAGVYNT-UHFFFAOYSA-N pazelliptine Chemical compound N1C2=CC=NC=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2 LPHSYQSMAGVYNT-UHFFFAOYSA-N 0.000 description 1
- 229950006361 pazelliptine Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- DOHVAKFYAHLCJP-UHFFFAOYSA-N peldesine Chemical compound C1=2NC(N)=NC(=O)C=2NC=C1CC1=CC=CN=C1 DOHVAKFYAHLCJP-UHFFFAOYSA-N 0.000 description 1
- 229950000039 peldesine Drugs 0.000 description 1
- 229950006960 peliomycin Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 235000005693 perillyl alcohol Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- LCADVYTXPLBAGB-GNCBHIOISA-N phenalamide A1 Natural products CC(CO)NC(=O)C(=CC=CC=C/C=C/C(=C/C(C)C(O)C(=CC(C)CCc1ccccc1)C)/C)C LCADVYTXPLBAGB-GNCBHIOISA-N 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- 229950001030 piritrexim Drugs 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- JKPDEYAOCSQBSZ-OEUJLIAZSA-N plomestane Chemical compound O=C1CC[C@]2(CC#C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKPDEYAOCSQBSZ-OEUJLIAZSA-N 0.000 description 1
- 229950004541 plomestane Drugs 0.000 description 1
- 229920000570 polyether Chemical group 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 229960001586 procarbazine hydrochloride Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 239000000784 purine nucleoside phosphorylase inhibitor Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- MKSVFGKWZLUTTO-FZFAUISWSA-N puromycin dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO MKSVFGKWZLUTTO-FZFAUISWSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229950002225 retelliptine Drugs 0.000 description 1
- 229940100552 retinamide Drugs 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229940120975 revlimid Drugs 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 229960004356 riboprine Drugs 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950003733 romurtide Drugs 0.000 description 1
- 108700033545 romurtide Proteins 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- YADVRLOQIWILGX-UHFFFAOYSA-N sarcophytol N Natural products CC(C)C1=CC=C(C)CCC=C(C)CCC=C(C)CC1O YADVRLOQIWILGX-UHFFFAOYSA-N 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- DRNXZGJGRSUXHW-UHFFFAOYSA-N silyl carbamate Chemical class NC(=O)O[SiH3] DRNXZGJGRSUXHW-UHFFFAOYSA-N 0.000 description 1
- 229950009089 simtrazene Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229940075439 smac mimetic Drugs 0.000 description 1
- 229950004296 soblidotin Drugs 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940006198 sodium phenylacetate Drugs 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
- 229950004225 sonermin Drugs 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229950004796 sparfosic acid Drugs 0.000 description 1
- 229950009641 sparsomycin Drugs 0.000 description 1
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
- XKLZIVIOZDNKEQ-UHFFFAOYSA-N sparsomycin Natural products CSCS(=O)CC(CO)NC(=O)C=CC1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-UHFFFAOYSA-N 0.000 description 1
- YBZRLMLGUBIIDN-NZSGCTDASA-N spicamycin Chemical compound O1[C@@H](C(O)CO)[C@H](NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)[C@@H](O)[C@@H](O)[C@H]1NC1=NC=NC2=C1N=CN2 YBZRLMLGUBIIDN-NZSGCTDASA-N 0.000 description 1
- YBZRLMLGUBIIDN-UHFFFAOYSA-N spicamycin Natural products O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 description 1
- 229950004330 spiroplatin Drugs 0.000 description 1
- 108010032486 splenopentin Proteins 0.000 description 1
- DTFYGLNONOLGOT-UHFFFAOYSA-N spongistatin 2 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC=C)OC1C2C DTFYGLNONOLGOT-UHFFFAOYSA-N 0.000 description 1
- VGULLEUAAMBZTQ-YGHPZBLNSA-N spongistatin 3 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](OC(C)=O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C(Cl)=C)OC1[C@@H]2C VGULLEUAAMBZTQ-YGHPZBLNSA-N 0.000 description 1
- KRUKGDRIKMPUNX-JWFNSJLHSA-N spongistatin 4 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](OC(C)=O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C(Cl)=C)OC1[C@@H]2C KRUKGDRIKMPUNX-JWFNSJLHSA-N 0.000 description 1
- KRUKGDRIKMPUNX-UHFFFAOYSA-N spongistatin 4 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C KRUKGDRIKMPUNX-UHFFFAOYSA-N 0.000 description 1
- GQOOASKKXHUNEJ-PYATXCCJSA-N spongistatin 6 Chemical compound C([C@H](C[C@@]1(O2)C[C@H](O)C[C@H](O1)\C=C/CCC[C@H]1[C@@H](C)[C@H](O)C[C@@](O1)(O)[C@@H]1O)OC)C2CC(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=C)C[C@@H](O2)C[C@@](C)(O)C[C@]2(O2)C[C@H](OC(C)=O)CC2CC(=O)O[C@H]2[C@H](O)[C@@H](CC(=C)C[C@@H](O)\C=C\C=C)OC1[C@@H]2C GQOOASKKXHUNEJ-PYATXCCJSA-N 0.000 description 1
- WYJXOZQMHBISBD-UHFFFAOYSA-N spongistatin 8 Natural products C1C(=O)C(C)C(C2C)OCC2=CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC(C(C(CC(=C)CC(O)C=CC=C)O2)O)C(C)C2C(O)C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC22CC(OC)CC1O2 WYJXOZQMHBISBD-UHFFFAOYSA-N 0.000 description 1
- RSHMLTSGIURLKH-SJMMKZBFSA-N spongistatin-2 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C=C)O[C@@H]2[C@@H]1C RSHMLTSGIURLKH-SJMMKZBFSA-N 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 229950007841 sulofenur Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-H suramin(6-) Chemical compound [O-]S(=O)(=O)C1=CC(S([O-])(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O)C)C=CC=3)C)=CC=C(S([O-])(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-H 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960005566 swainsonine Drugs 0.000 description 1
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 1
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- PTTJLTMUKRRHAT-KYDPQNDISA-N taccalonolide A Natural products O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H]2[C@]3(C)[C@H](OC(=O)C)[C@H]4O[C@H]4C[C@@H]3C(=O)[C@H](O)[C@H]2[C@@H]2[C@@H](OC(=O)C)[C@H]3[C@@]4(C)[C@@](O)(C)C(=O)OC4=C[C@@H](C)[C@@H]3[C@@]12C)C PTTJLTMUKRRHAT-KYDPQNDISA-N 0.000 description 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 108700003774 talisomycin Proteins 0.000 description 1
- 229950002687 talisomycin Drugs 0.000 description 1
- 108010021891 tallimustine Proteins 0.000 description 1
- 229950005667 tallimustine Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229950010168 tauromustine Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- RNVNXVVEDMSRJE-UHFFFAOYSA-N teloxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCNC RNVNXVVEDMSRJE-UHFFFAOYSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229950008703 teroxirone Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WXZSUBHBYQYTNM-WMDJANBXSA-N tetrazomine Chemical compound C=1([C@@H]2CO[C@@H]3[C@H]4C[C@@H](CO)[C@H](N4C)[C@@H](N23)CC=1C=C1)C(OC)=C1NC(=O)C1NCCC[C@H]1O WXZSUBHBYQYTNM-WMDJANBXSA-N 0.000 description 1
- ZCTJIMXXSXQXRI-UHFFFAOYSA-N thaliblastine Natural products CN1CCC2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC2=C(CC3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-UHFFFAOYSA-N 0.000 description 1
- ZCTJIMXXSXQXRI-KYJUHHDHSA-N thalicarpine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC2=C(C[C@H]3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-KYJUHHDHSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005985 thienyl[1,3]dithianyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 108010062880 thiocoraline Proteins 0.000 description 1
- UPGGKUQISSWRJJ-UHFFFAOYSA-N thiocoraline Natural products CN1C(=O)CNC(=O)C(NC(=O)C=2C(=CC3=CC=CC=C3N=2)O)CSC(=O)C(CSC)N(C)C(=O)C(N(C(=O)CNC2=O)C)CSSCC1C(=O)N(C)C(CSC)C(=O)SCC2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 150000003587 threonine derivatives Chemical class 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 108010013515 thymopoietin receptor Proteins 0.000 description 1
- 229950010183 thymotrinan Drugs 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- ONYVJPZNVCOAFF-UHFFFAOYSA-N topsentin Natural products Oc1ccc2cc([nH]c2c1)C(=O)c3ncc([nH]3)c4c[nH]c5ccccc45 ONYVJPZNVCOAFF-UHFFFAOYSA-N 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 229960004167 toremifene citrate Drugs 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000005106 triarylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 229950003873 triciribine Drugs 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 229960000538 trimetrexate glucuronate Drugs 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 108010061145 tubulysin A Proteins 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- WMPQMBUXZHMEFZ-YJPJVVPASA-N turosteride Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(C(C)C)C(=O)NC(C)C)[C@@]2(C)CC1 WMPQMBUXZHMEFZ-YJPJVVPASA-N 0.000 description 1
- 229950007816 turosteride Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229950008261 velaresol Drugs 0.000 description 1
- XLQGICHHYYWYIU-UHFFFAOYSA-N veramine Natural products O1C2CC3C4CC=C5CC(O)CCC5(C)C4CC=C3C2(C)C(C)C21CCC(C)CN2 XLQGICHHYYWYIU-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- BCXOZISMDZTYHW-IFQBWSDRSA-N vinepidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@H](C2)CC)N2CCC2=C1NC1=CC=CC=C21 BCXOZISMDZTYHW-IFQBWSDRSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- UFOVYHGILLJGLP-UHFFFAOYSA-N vitilevuamide Chemical compound N1C(=O)C(NC(=O)CCC(O)=O)CSCC(C(NC(C(=O)NC(=C)C(=O)NC(CC(C)CC)C(=O)NC(C(=O)N(C)C(C(O)COC)C(=O)NC(CO)C(=O)OC2C)C(C)C)C(C)CC)=O)NC(=O)C3CCCN3C(=O)C(CC=3C=CC=CC=3)NC(=O)C2NC(=O)C(CC(C)CC)NC(=O)C(C)NC(=O)C1CC1=CC=CC=C1 UFOVYHGILLJGLP-UHFFFAOYSA-N 0.000 description 1
- 108010079700 vitilevuamide Proteins 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- DVPVGSLIUJPOCJ-XXRQFBABSA-N x1j761618a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 DVPVGSLIUJPOCJ-XXRQFBABSA-N 0.000 description 1
- 229950005561 zanoterone Drugs 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- FYQZGCBXYVWXSP-STTFAQHVSA-N zinostatin stimalamer Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1OC1C/2=C/C#C[C@H]3O[C@@]3([C@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(C)C=CC2=C(C)C=C(OC)C=C12 FYQZGCBXYVWXSP-STTFAQHVSA-N 0.000 description 1
- 229950009233 zinostatin stimalamer Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
Abstract
Provided herein are compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. Provided herein are compounds having the structure of Formula B-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
Description
INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS
[0001]
[00021 SUMMARY OF THE INVENTION
[0003] Described herein are compounds that modulate the activity of certain proteins involved in apoptotic pathways, or signaling pathways associated with inflammation and/or autoimmune diseases and/or cell division and/or angiogenesis. In some embodiments, the compounds described herein are antagonists of inhibitor of apoptosis proteins (IAPs). In some embodiments, the compounds described herein are pan-IAP
antagonists. In some embodiments, the compounds described herein are useful for the treatment of cancer, inflammatory diseases, and/or autoimmune diseases as described herein.
[0004] In one aspect, provided herein are compounds having the structure of Formula A-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof: '
[0001]
[00021 SUMMARY OF THE INVENTION
[0003] Described herein are compounds that modulate the activity of certain proteins involved in apoptotic pathways, or signaling pathways associated with inflammation and/or autoimmune diseases and/or cell division and/or angiogenesis. In some embodiments, the compounds described herein are antagonists of inhibitor of apoptosis proteins (IAPs). In some embodiments, the compounds described herein are pan-IAP
antagonists. In some embodiments, the compounds described herein are useful for the treatment of cancer, inflammatory diseases, and/or autoimmune diseases as described herein.
[0004] In one aspect, provided herein are compounds having the structure of Formula A-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof: '
2 X1 X \
wl R3LJA,, Formula A-I
wherein, W1 is 0, S, N-RA, or C(R8a)(R8b);
W2 is 0, S, N-RA, or C(R8c)(R8d); provided that W' and W2 are not both 0, or both S;
RI is H, C1-Coalkyl, C3-C6cycloalkyl, ¨C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -CI-C6alkyksubstituted or unsubstituted aryl), or -Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
when X' is 0, N-RA, S, S(0), or S(0)2, then X2 is c(R2aR2b);
or:
X1 is CR2cR2d and X2 is CR2aR2b, and R2' and R2 together form a bond;
or:
X' and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring;
or:
X' is CH, and X2 is C=0, C=C(re )2, or C=NR` ; where each RD is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C1-C6a1kyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloa1kyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloa1kyl), -Ci-C6alkyl-(substituted or unsubstituted G-05heterocycloalky1), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
RA is H, Ci-C6alkyl, -C(=0)Ct-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a, R2b, R2c, -2d, x are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6heteroa1kyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -CI-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl) and -C(=O)RD;
RD is substituted or unsubstituted CI-C6a1kyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -CI-C6alkyksubstituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -CI-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 is -NHR5, -N(R5)2, -N(R5)3 or -0R5;
each R' is independently selected from H, C1-C3alkyl, C1-C3haloalkyl, C1-C3heteroalkyl and -Ci-C3alky1-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is ¨NHC(=0)R7, -C(=0)NHR7, ¨NHS(=0)7R7, -S(=0)2NHR7; ¨NHC(=0)NHR7, -NHS (=0)2NHR7, ¨(Ci -C3 alkyl)-NHC(=0)R7, ¨(C 1-C3 alkyl)-C(=0)NHR5, ¨(Ct -C
wl R3LJA,, Formula A-I
wherein, W1 is 0, S, N-RA, or C(R8a)(R8b);
W2 is 0, S, N-RA, or C(R8c)(R8d); provided that W' and W2 are not both 0, or both S;
RI is H, C1-Coalkyl, C3-C6cycloalkyl, ¨C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -CI-C6alkyksubstituted or unsubstituted aryl), or -Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
when X' is 0, N-RA, S, S(0), or S(0)2, then X2 is c(R2aR2b);
or:
X1 is CR2cR2d and X2 is CR2aR2b, and R2' and R2 together form a bond;
or:
X' and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring;
or:
X' is CH, and X2 is C=0, C=C(re )2, or C=NR` ; where each RD is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C1-C6a1kyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloa1kyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloa1kyl), -Ci-C6alkyl-(substituted or unsubstituted G-05heterocycloalky1), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
RA is H, Ci-C6alkyl, -C(=0)Ct-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a, R2b, R2c, -2d, x are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6heteroa1kyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -CI-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl) and -C(=O)RD;
RD is substituted or unsubstituted CI-C6a1kyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -CI-C6alkyksubstituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -CI-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 is -NHR5, -N(R5)2, -N(R5)3 or -0R5;
each R' is independently selected from H, C1-C3alkyl, C1-C3haloalkyl, C1-C3heteroalkyl and -Ci-C3alky1-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is ¨NHC(=0)R7, -C(=0)NHR7, ¨NHS(=0)7R7, -S(=0)2NHR7; ¨NHC(=0)NHR7, -NHS (=0)2NHR7, ¨(Ci -C3 alkyl)-NHC(=0)R7, ¨(C 1-C3 alkyl)-C(=0)NHR5, ¨(Ct -C
3 alkyl)-NHS(=0)2R7, ¨(Ci-C3alky1)-S(=0)2NHR7; ¨(Ci-C3alkyl)-NHC(-0)NHR7, ¨(Ci-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-C10heterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from C1-C6alkyl, C1-C6haloa1kyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-Ciocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH)),-CH(substituted or unsubstituted heteroary1)2, -(CH)),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted hetcroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), or -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R", R", and R" are independently selected from H, Ci-C6alkyl, C1-C6fluoroalkyl, C1-C6 alkoxy, C1-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
lea and led are as defined above, and R" and R" together form a bond;
or:
Rga and led are as defined above, and le and R8e together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8' and R8d are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycic comprising 1-3 hcteroatoms selected from S, 0 and N;
or:
R82 and R8b are as defined above, and R8c and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, heterospirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alkyl) -C(=0)0H, -C(=0)NH2, -C(=0)C -C3alkyl, -S(=0)2CH3, -NH(C -C4alkyl)-0H, -NH(C1 -C4alky1) -0 -(Ci -C4alkyl), -0 (C -C4alkyl)-NH2 ; -0(C -C4alkyl)-NH-(C -C4alkyl), and -0(C -C4alky1)-N-(Ci -C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[0005] In one aspect, provided herein are compounds having the structure of Formula A-XXI, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
a 2 X "1-----W2 R
R8b R5 N R8a Formula A-XXI
wherein, W2 is 0, S, or C(R8e)(R8(I);
R1 is H, or Ci-C6alkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, C1-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a, and R2b are independently selected from H, substituted or unsubstituted C1-C6alkyl, and ¨
C(=0)RB;
RB is substituted or unsubstituted C1-C6alkyl, -C1-C6a1kyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-C,heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
each R7 is independently selected from C1-C6alkyl, C1-C6haloa1kyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-Ciocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH)),-CH(substituted or unsubstituted heteroary1)2, -(CH)),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted hetcroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), or -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R", R", and R" are independently selected from H, Ci-C6alkyl, C1-C6fluoroalkyl, C1-C6 alkoxy, C1-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
lea and led are as defined above, and R" and R" together form a bond;
or:
Rga and led are as defined above, and le and R8e together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8' and R8d are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycic comprising 1-3 hcteroatoms selected from S, 0 and N;
or:
R82 and R8b are as defined above, and R8c and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, heterospirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alkyl) -C(=0)0H, -C(=0)NH2, -C(=0)C -C3alkyl, -S(=0)2CH3, -NH(C -C4alkyl)-0H, -NH(C1 -C4alky1) -0 -(Ci -C4alkyl), -0 (C -C4alkyl)-NH2 ; -0(C -C4alkyl)-NH-(C -C4alkyl), and -0(C -C4alky1)-N-(Ci -C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[0005] In one aspect, provided herein are compounds having the structure of Formula A-XXI, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
a 2 X "1-----W2 R
R8b R5 N R8a Formula A-XXI
wherein, W2 is 0, S, or C(R8e)(R8(I);
R1 is H, or Ci-C6alkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, C1-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a, and R2b are independently selected from H, substituted or unsubstituted C1-C6alkyl, and ¨
C(=0)RB;
RB is substituted or unsubstituted C1-C6alkyl, -C1-C6a1kyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-C,heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
-4-RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted CI-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or Ci-C3fluoroalkyl;
each R5 is independently selected from H, Ci-C3a1kyl, Ci-C3haloalky1, Ci-C3heteroalkyl and -C1-C3alkyl-(C3-C,cycloalkyl);
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C)-Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -CI-C6alkyl-(substituted or unsubstituted C3-Ciocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0,1 or 2;
R8a and Rgb are independently selected from H, C1-C6alkyl, and C1-C6fluoroalkyl;
RC and R" are independently selected from H, Ci-C6alkyl, and C1-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -Nfl(C1-C4alkyl), -NH(Ci-C4alkyl02, -C(=0)0H, -C(=0)NF2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-0H, -NH(CI-C4alkyl)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(CI-C4alky1)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alkyl),, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[0006] In one aspect, provided herein are compounds having the structure of Formula B-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
R3 is Ci-C3alkyl, or Ci-C3fluoroalkyl;
each R5 is independently selected from H, Ci-C3a1kyl, Ci-C3haloalky1, Ci-C3heteroalkyl and -C1-C3alkyl-(C3-C,cycloalkyl);
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C)-Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -CI-C6alkyl-(substituted or unsubstituted C3-Ciocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0,1 or 2;
R8a and Rgb are independently selected from H, C1-C6alkyl, and C1-C6fluoroalkyl;
RC and R" are independently selected from H, Ci-C6alkyl, and C1-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -Nfl(C1-C4alkyl), -NH(Ci-C4alkyl02, -C(=0)0H, -C(=0)NF2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-0H, -NH(CI-C4alkyl)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(CI-C4alky1)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alkyl),, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[0006] In one aspect, provided herein are compounds having the structure of Formula B-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
-5-w2 wl U
Formula B-I
wherein, R1 is H, Ci-C6alkyl, C3-C6cycloalky1, ¨C1-C6alkyl-(substituted or unsubstituted C3-C6cycloa1kYD, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, ¨Ci-C6alky1-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 is selected from N-RA, then X2 is C=0, or CR2c'-'K2d, and X3 is cR2aR2b;
Or when X' is selected from S. S(0) and S(0)2, then X2 is cR2c.-.K2d, and X3 is cR2aR2b;
Or when X1 is 0, then X2 is selected from CR213.2d and N-RA, and X3 is cR2aR2b;
or:
when X' is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X' is cR2aR2b;
or:
)(1 is cR2eR2f and )(2 is cR2c-2d, tc and R2' and R2' together form a bond, and X3 is CR2aR2b;
or:
X1 and X3 are both CH, and X2 is C=0, C=C(Rc),, or C=NRc; where each Rc is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is cR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl
Formula B-I
wherein, R1 is H, Ci-C6alkyl, C3-C6cycloalky1, ¨C1-C6alkyl-(substituted or unsubstituted C3-C6cycloa1kYD, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, ¨Ci-C6alky1-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 is selected from N-RA, then X2 is C=0, or CR2c'-'K2d, and X3 is cR2aR2b;
Or when X' is selected from S. S(0) and S(0)2, then X2 is cR2c.-.K2d, and X3 is cR2aR2b;
Or when X1 is 0, then X2 is selected from CR213.2d and N-RA, and X3 is cR2aR2b;
or:
when X' is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X' is cR2aR2b;
or:
)(1 is cR2eR2f and )(2 is cR2c-2d, tc and R2' and R2' together form a bond, and X3 is CR2aR2b;
or:
X1 and X3 are both CH, and X2 is C=0, C=C(Rc),, or C=NRc; where each Rc is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is cR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl
-6-ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR2eR
2/-;
RA is H, CI-C6alky1, -C(=0)Ct-C6a1kyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
W1 is 0, S, N-RA, or C(R8a)(R8b);
W2 is 0, S, N-RA, or C(R8c)(R8(); provided that W1 and W2 are not both 0, or both S;
R2a R2b, R2c, R2d R2e, and R2 x21 a are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted Ci-C6heteroalky1, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloa1kyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl) and -C(=0)1e;
le is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, (substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2' C5heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is C1-C3alkyl, or CI-C3fluoroalkyl;
R4 is -NHR5, -N(R5)2, -N(R5)3 or -OW;
each R5 is independently selected from H, Ct-C3alkyl, CI-C3haloa1kyl, Ci-C3heteroalky1 and -C1-C3alky1-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-
2/-;
RA is H, CI-C6alky1, -C(=0)Ct-C6a1kyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
W1 is 0, S, N-RA, or C(R8a)(R8b);
W2 is 0, S, N-RA, or C(R8c)(R8(); provided that W1 and W2 are not both 0, or both S;
R2a R2b, R2c, R2d R2e, and R2 x21 a are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted Ci-C6heteroalky1, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloa1kyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl) and -C(=0)1e;
le is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, (substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2' C5heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is C1-C3alkyl, or CI-C3fluoroalkyl;
R4 is -NHR5, -N(R5)2, -N(R5)3 or -OW;
each R5 is independently selected from H, Ct-C3alkyl, CI-C3haloa1kyl, Ci-C3heteroalky1 and -C1-C3alky1-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-
7 membered ring;
R6 is ¨NHC(=0)R7, -C(=0)NHR7, ¨NHS(=0)2fe, -S(=0)2NHIe; ¨NHC(=0)NHR7, -NHS(=0)2NHR7, ¨(Ci-C3alkyl)-NHC(=0)127, ¨(Ci-C3alkyl)-C(=0)NHle, ¨(Ci-C3alkyl)-NHS(=0)21e, ¨(Ci-C3alkyl)-S(=0)2NHR7; ¨(Ci-C3alkyl)-NHC(=0)NHIe, ¨(Ci-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-C10heterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from Ci-C6alkyl, C1-C6haloalkyl, C1-C6heteroalky1, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C loheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -CpC6alkyl-(substituted or unsubstituted C3-C, ocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), or -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R82, 8b, R", and R8d are independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, alkoxy, Ci-C6hetcroa1kyl, and substituted or unsubstituted aryl;
or:
R8a and Rsd are as defined above, and Rgb and R8e together form a bond;
or:
R' and led are as defined above, and R" and R" together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S. 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8 and R8d are as defined above, and Rga and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
Rga and le are as defined above, and Rge and led together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
R6 is ¨NHC(=0)R7, -C(=0)NHR7, ¨NHS(=0)2fe, -S(=0)2NHIe; ¨NHC(=0)NHR7, -NHS(=0)2NHR7, ¨(Ci-C3alkyl)-NHC(=0)127, ¨(Ci-C3alkyl)-C(=0)NHle, ¨(Ci-C3alkyl)-NHS(=0)21e, ¨(Ci-C3alkyl)-S(=0)2NHR7; ¨(Ci-C3alkyl)-NHC(=0)NHIe, ¨(Ci-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-C10heterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from Ci-C6alkyl, C1-C6haloalkyl, C1-C6heteroalky1, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C loheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -CpC6alkyl-(substituted or unsubstituted C3-C, ocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), or -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R82, 8b, R", and R8d are independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, alkoxy, Ci-C6hetcroa1kyl, and substituted or unsubstituted aryl;
or:
R8a and Rsd are as defined above, and Rgb and R8e together form a bond;
or:
R' and led are as defined above, and R" and R" together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S. 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8 and R8d are as defined above, and Rga and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
Rga and le are as defined above, and Rge and led together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
-8-
9 PCT/US2013/072064 where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, Ct-C4a1kyl, fluoroalkyl, C1-C4 alkoxy, fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(C1-C4alky1)21 C(-0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(Ci-C4alkyl)-OH, -NH(Ci-C4alkyl)-0-(Ci-C4alkyl), -0(CI-C4alkyl)-Nt12; -0(C -C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or CI-C3alkyl.
[0007] In one aspect, provided herein are compounds having the structure of Formula B-XXII, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
xl R1 R26\c,\Fw2 )LN
R2a 0 R8a Formula B-XXII
wherein, W2 is 0, S, or C(R8')(R8d);
R1 is H, or C1-C6alkyl;
X1 is 0, N-R', S, S(0), or S(0)2;
RA is H, Ci-C6alky1, ¨C(=0)Ct-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R22 and R2b are independently selected from H, substituted or unsubstituted Ci-C6alkyl, and ¨
C(=O)RD;
RD is substituted or unsubstituted C1-C6alkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-C3heterocycloalkyl), ¨C [-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or Ci-C3fluoroalkyl;
each R5 is independently selected from H, C1-C3alkyl, CI-C3ha1oa1ky1, C1-C3heteroalky1 and -C1-C3alkyl-(C3-05cycloalkyl);
each R7 is independently selected from Ci-C6alky1, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloa1kyl), -C1-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R and Rgb are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
R8c and led are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, CI-C4alkyl, Ci-C4 fluoroalkyl, C1-C4 alkoxy, C fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alky1)2, -C(=0)0H, -C(=0)NH2, -C(=0)Ci-C3alkyl, -S(=0)2CH3, -NH(Ci-C4alkyl)-OH, -NH(Ct-C4alkyl)-0-(C1-C4alkyl), -0(CI-C4alky1)-N H2; -0(C -C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or CI -C3alkyl.
[0008] In one aspect, provided herein are compounds having the structure of Formula C-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
X2¨X1 R
kAri U ______________________________ On, 0 R3<
Formula C-I
wherein,
[0007] In one aspect, provided herein are compounds having the structure of Formula B-XXII, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
xl R1 R26\c,\Fw2 )LN
R2a 0 R8a Formula B-XXII
wherein, W2 is 0, S, or C(R8')(R8d);
R1 is H, or C1-C6alkyl;
X1 is 0, N-R', S, S(0), or S(0)2;
RA is H, Ci-C6alky1, ¨C(=0)Ct-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R22 and R2b are independently selected from H, substituted or unsubstituted Ci-C6alkyl, and ¨
C(=O)RD;
RD is substituted or unsubstituted C1-C6alkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-C3heterocycloalkyl), ¨C [-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or Ci-C3fluoroalkyl;
each R5 is independently selected from H, C1-C3alkyl, CI-C3ha1oa1ky1, C1-C3heteroalky1 and -C1-C3alkyl-(C3-05cycloalkyl);
each R7 is independently selected from Ci-C6alky1, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloa1kyl), -C1-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R and Rgb are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
R8c and led are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, CI-C4alkyl, Ci-C4 fluoroalkyl, C1-C4 alkoxy, C fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alky1)2, -C(=0)0H, -C(=0)NH2, -C(=0)Ci-C3alkyl, -S(=0)2CH3, -NH(Ci-C4alkyl)-OH, -NH(Ct-C4alkyl)-0-(C1-C4alkyl), -0(CI-C4alky1)-N H2; -0(C -C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or CI -C3alkyl.
[0008] In one aspect, provided herein are compounds having the structure of Formula C-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
X2¨X1 R
kAri U ______________________________ On, 0 R3<
Formula C-I
wherein,
-10-R1 is H, Ci-C6alkyl, C3-C6cycloalkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substitutcd or unsubstituted heteroaryl);
when X' is selected from N-RA, S, S(0) and S(0)2, then X2 is CR2cR-2(1, and X3 is CR2aR2b;
or when Xt is 0, then X2 is selected from CR2'R2d and N-RA, and X3 is CR2aR2b:
or:
when X1 is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is CR2aR2b;
or:
X' is CR2eR2t and X2 is CR2eR2d, and R2' and R2' together form a bond, and X3 is CR2aR2b;
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR Rze 21-;
RA is H, C1-C6alkyl, -C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
W1 is 0, S, N-RA, or C(R8a)(1e);
W2 is 0, S. N-RA, or C(10(10; provided that W1 and W2 are not both 0, or both S;
R2a R2b, R2c, R2d ¨2e, x and R2f are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl) and -C(=0)RB;
RE is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-
when X' is selected from N-RA, S, S(0) and S(0)2, then X2 is CR2cR-2(1, and X3 is CR2aR2b;
or when Xt is 0, then X2 is selected from CR2'R2d and N-RA, and X3 is CR2aR2b:
or:
when X1 is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is CR2aR2b;
or:
X' is CR2eR2t and X2 is CR2eR2d, and R2' and R2' together form a bond, and X3 is CR2aR2b;
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR Rze 21-;
RA is H, C1-C6alkyl, -C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
W1 is 0, S, N-RA, or C(R8a)(1e);
W2 is 0, S. N-RA, or C(10(10; provided that W1 and W2 are not both 0, or both S;
R2a R2b, R2c, R2d ¨2e, x and R2f are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl) and -C(=0)RB;
RE is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-
-11-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE arc independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is C1-C3alky1, or C1-C3fluoroa1kyl;
R4 is -NHR5, -N(R)2, -N(R5)3 or -OW;
each R5 is independently selected from H, Ci-C3alkyl, C1-C3haloalkyl, Ci-C3heteroalkyl and -CI-C3alkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NH127, -NHS(=0)2NHR7, -(C -C3 alkyl)-NHC(=0)R7, -(C -C3 alkyl)-C(=0)NHR5, -(C -C3alkyl)-NHS(=0)2R7, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(C1-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-C10heterocyc1oa1ky1, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from C -C6alkyl, CI-C6haloalkyl, CI -C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C1oheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C6alkyl-(substituted or unsubstituted C3-C [ocycloalkyl), -C
i-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -
RD and RE arc independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is C1-C3alky1, or C1-C3fluoroa1kyl;
R4 is -NHR5, -N(R)2, -N(R5)3 or -OW;
each R5 is independently selected from H, Ci-C3alkyl, C1-C3haloalkyl, Ci-C3heteroalkyl and -CI-C3alkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NH127, -NHS(=0)2NHR7, -(C -C3 alkyl)-NHC(=0)R7, -(C -C3 alkyl)-C(=0)NHR5, -(C -C3alkyl)-NHS(=0)2R7, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(C1-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-C10heterocyc1oa1ky1, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from C -C6alkyl, CI-C6haloalkyl, CI -C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C1oheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C6alkyl-(substituted or unsubstituted C3-C [ocycloalkyl), -C
i-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -
(012)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R8a, R8b, R8', and R8d are independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, C1-C6 alkoxy, Ci-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
R82 and R8d are as defined above, and R8b and R8' together form a bond;
or:
R8' and R8d are as defined above, and R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S. 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S. 0 and N;
or:
R8' and led are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8a and R8b are as defined above, and R8' and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, C1-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(Ci-C4alkyl)-OH, -NH(Ci-C4alkyl)-0 -(C1 -C4alkyl), -0(C -C4alkyl)-NH2; -0(C -C4alkyl)-NH-(C -C4alkyl), and -0(C -C4alky1)-N-(C1-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
[0009] In one aspect, provided herein are compounds having the structure of Formula C-XXI, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
p is 0, 1 or 2;
R8a, R8b, R8', and R8d are independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, C1-C6 alkoxy, Ci-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
R82 and R8d are as defined above, and R8b and R8' together form a bond;
or:
R8' and R8d are as defined above, and R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S. 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S. 0 and N;
or:
R8' and led are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8a and R8b are as defined above, and R8' and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, C1-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(Ci-C4alkyl)-OH, -NH(Ci-C4alkyl)-0 -(C1 -C4alkyl), -0(C -C4alkyl)-NH2; -0(C -C4alkyl)-NH-(C -C4alkyl), and -0(C -C4alky1)-N-(C1-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
[0009] In one aspect, provided herein are compounds having the structure of Formula C-XXI, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
-13-R2b _________________________________ R1 R25.\/ X2 R8b /N R8a HN
Formula C-XXI
wherein, W2 is 0, S, or C(R8e)(R8(I);
R1 is H, or Ci-C6alkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, Ci-C6alkyl, ¨C(=0)Ct-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a and R2b are independently selected from H, substituted or unsubstituted C1-C6alkyl, and ¨
C(=0)Fe;
RD is substituted or unsubstituted C1-C6alkyl, -C1-C6a1kyl-(substituted or unsubstituted C3-C6cycloalkyl), -CI-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C5heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is C1-C3alkyl, or Ci-C3fluoroalkyl;
each R5 is independently selected from H, Ci-C3alkyl, Ci-C3haloalkyl, Ci-C3heteroalkyl and -C1-C3alky1-(C3-05cycloalkyl);
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C ioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalky1, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)3-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or
Formula C-XXI
wherein, W2 is 0, S, or C(R8e)(R8(I);
R1 is H, or Ci-C6alkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, Ci-C6alkyl, ¨C(=0)Ct-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a and R2b are independently selected from H, substituted or unsubstituted C1-C6alkyl, and ¨
C(=0)Fe;
RD is substituted or unsubstituted C1-C6alkyl, -C1-C6a1kyl-(substituted or unsubstituted C3-C6cycloalkyl), -CI-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C5heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is C1-C3alkyl, or Ci-C3fluoroalkyl;
each R5 is independently selected from H, Ci-C3alkyl, Ci-C3haloalkyl, Ci-C3heteroalkyl and -C1-C3alky1-(C3-05cycloalkyl);
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C ioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalky1, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)3-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or
-14-unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroary1)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
RS a and Rgb are independently selected from H, Ci-C6alkyl, and C1-C6fluoroalkyl;
R8e and Rgd are independently selected from H, Ci-C6alkyl, and C1-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each le is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alky1)2, -C(=0)0H, -C(=0)NH2, -C(=0)C1-Cialkyl, -S(=0)2CH3, -NH(C -C4alkyl)-0H, -NH(C1-C4alkyl) -0 -(Ci-C4alkyl), -0 (Ci-C4alkyl)-NH2; -0(C -C4alky1)-NH-(Ci-C4alkyl), and -0(C -C4alky1)-N-(Ci -C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[0010] In one aspect, provided herein are compounds having the structure of Formula D-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
x2¨Xltw3 w2 wi Formula D-I
wherein, R1 is H, C3-C6cycloalkyl, ¨Ci-C6alkyl-(substituted or unsubstituted C2-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, ¨C1-C6a1kyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 is selected from N-RA, S, S(0) and S(0)2, then X2 is CR2eR2d, and X3 is CR2aR2b;
or when X1 is 0, then X2 is selected from CR2eR2d and N-RA, and X3 is CR2aR21%
or:
when X1 is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is CR2aR2b;
or:
X1 is CR2eR2f and X2 is CR2uR2d, and R2e and R2' together form a bond, and X3 is CR24R2b;
or:
p is 0, 1 or 2;
RS a and Rgb are independently selected from H, Ci-C6alkyl, and C1-C6fluoroalkyl;
R8e and Rgd are independently selected from H, Ci-C6alkyl, and C1-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each le is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alky1)2, -C(=0)0H, -C(=0)NH2, -C(=0)C1-Cialkyl, -S(=0)2CH3, -NH(C -C4alkyl)-0H, -NH(C1-C4alkyl) -0 -(Ci-C4alkyl), -0 (Ci-C4alkyl)-NH2; -0(C -C4alky1)-NH-(Ci-C4alkyl), and -0(C -C4alky1)-N-(Ci -C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[0010] In one aspect, provided herein are compounds having the structure of Formula D-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
x2¨Xltw3 w2 wi Formula D-I
wherein, R1 is H, C3-C6cycloalkyl, ¨Ci-C6alkyl-(substituted or unsubstituted C2-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, ¨C1-C6a1kyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 is selected from N-RA, S, S(0) and S(0)2, then X2 is CR2eR2d, and X3 is CR2aR2b;
or when X1 is 0, then X2 is selected from CR2eR2d and N-RA, and X3 is CR2aR21%
or:
when X1 is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is CR2aR2b;
or:
X1 is CR2eR2f and X2 is CR2uR2d, and R2e and R2' together form a bond, and X3 is CR24R2b;
or:
-15-X' and X3 are both CH2 and X2 is C=0, C=C(Rc)2, or C=NRc; where each RC is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-Csheterocycloa1kyl, substituted or unsubstituted awl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05hacrocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR2eR
2f;
W1 is 0, S, N-RA, or C(R8a)(R8b);
W2 is 0, S, N-RA, or C(R8e)(R8(I);
W3 is 0, S, N-RA, or C(R8e)(R8f); provided that the ring comprising WI, W2 and W3 does not comprise two adjacent oxygen atoms or sulfur atoms;
RA is H, Ci-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R1 is H, C1-C6alkyl, C3-C6cycloalkyl, ¨C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R2a R2b, R2e, R2d K-2e, and R2f are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted G2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alkyl-(substitutcd or unsubstituted heteroaryl) and ¨
C(=0)RB;
RB is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl,
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR2eR
2f;
W1 is 0, S, N-RA, or C(R8a)(R8b);
W2 is 0, S, N-RA, or C(R8e)(R8(I);
W3 is 0, S, N-RA, or C(R8e)(R8f); provided that the ring comprising WI, W2 and W3 does not comprise two adjacent oxygen atoms or sulfur atoms;
RA is H, Ci-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R1 is H, C1-C6alkyl, C3-C6cycloalkyl, ¨C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R2a R2b, R2e, R2d K-2e, and R2f are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted G2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alkyl-(substitutcd or unsubstituted heteroaryl) and ¨
C(=0)RB;
RB is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl,
-16-substituted or unsubstituted heteroaryl, -C1-C6a1kyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), (substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, (substituted or unsubstituted C3-C6cycloa1kyl), -Ci-C6a1kyl-(substituted or unsubstituted C2-Csheterocycloalkyl), -C[-Coalkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 is -NHR5, -N(1V)2, -N-(03 or -0R5;
each R' is independently selected from H, Ct-C3alkyl, C1-C3haloalkyl, Ci-C3heteroalkyl and -C1-C3alkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NH S (=0)2NHR7, -(C1 -C3 alkyl)-NHC (=0)127, -(C 1-C 3 alkyl)-C (=0)NHR5, -(C
-C 3 alkyl)-NHS(=0)2R7, -(Ci-C3alky1)-S(=0)2NHR7; -(Ci-C3alky1)-NHC(=0)NHR7, -(Ci-C3a1kyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Ci0heterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C ioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-Clocycloalkyl), (substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -Ct-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)1,-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, (substituted or unsubstituted C3-C6cycloa1kyl), -Ci-C6a1kyl-(substituted or unsubstituted C2-Csheterocycloalkyl), -C[-Coalkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 is -NHR5, -N(1V)2, -N-(03 or -0R5;
each R' is independently selected from H, Ct-C3alkyl, C1-C3haloalkyl, Ci-C3heteroalkyl and -C1-C3alkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NH S (=0)2NHR7, -(C1 -C3 alkyl)-NHC (=0)127, -(C 1-C 3 alkyl)-C (=0)NHR5, -(C
-C 3 alkyl)-NHS(=0)2R7, -(Ci-C3alky1)-S(=0)2NHR7; -(Ci-C3alky1)-NHC(=0)NHR7, -(Ci-C3a1kyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Ci0heterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C ioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-Clocycloalkyl), (substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -Ct-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)1,-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-
-17-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
Rga, Rgb, R8e, RSd, leand le are independently selected from H, C1-C6alkyl, C1-C6fluoroalkyl, C1-C6 alkoxy, C1-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
Rgd, Rgeand R8f are as defined above, and R8b and R8e together form a bond;
or:
R8a, le, R8d, and le- are as defined above, and lee and R8e together form a bond;
or:
R8', led, R8eand R8f are as defined above, and R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
lea, le, le, and ref are as defined above, and lee and R8e together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S. 0 and N;
or:
R8', R8d, R8eand R8f are as defined above, and R8a and R.gb together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
lea, le, leand le are as defined above, and R8e and le together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R82, R8b, R8c, and R8d are as defined above, and R8e and R8f together with the atoms to which they arc attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and
p is 0, 1 or 2;
Rga, Rgb, R8e, RSd, leand le are independently selected from H, C1-C6alkyl, C1-C6fluoroalkyl, C1-C6 alkoxy, C1-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
Rgd, Rgeand R8f are as defined above, and R8b and R8e together form a bond;
or:
R8a, le, R8d, and le- are as defined above, and lee and R8e together form a bond;
or:
R8', led, R8eand R8f are as defined above, and R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
lea, le, le, and ref are as defined above, and lee and R8e together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S. 0 and N;
or:
R8', R8d, R8eand R8f are as defined above, and R8a and R.gb together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
lea, le, leand le are as defined above, and R8e and le together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R82, R8b, R8c, and R8d are as defined above, and R8e and R8f together with the atoms to which they arc attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and
-18-each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, C1-C4 fluoroalkyl, C1-C4 alkoxy, Ci-C4fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alky1)2; -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(CI-C4alky1)-OH, -NH(C1-C4alkyl)-0-(C1-C4alkyl), -0(C1-C4alkyl)-NH2; -0(C1-C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alkyl)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[0011] In one aspect, provided herein are compounds having the structure of Formula D- XXII , pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
____________________________________ X al R1 twa R2b R2a 0 8 b NH R8a R5 0- -.NH
Formula D-XXII
wherein, w3 is 0, S, or C(R8e)(R8f);
RI is H, or Ci-C6alkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, C1-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a and R2b are independently selected from H, substituted or unsubstituted Ci-C6alkyl, and ¨
C(=O)RD;
RD is substituted or unsubstituted -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted CI-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is C1-C3alkyl, or C1-C3fluoroalkyl;
each R5 is independently selected from H, C1-C3alkyl, C1-C3haloalkyl, Ci-C3heteroalkyl and -C1-C3alkyl-(C3-05cycloalkyl);
[0011] In one aspect, provided herein are compounds having the structure of Formula D- XXII , pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
____________________________________ X al R1 twa R2b R2a 0 8 b NH R8a R5 0- -.NH
Formula D-XXII
wherein, w3 is 0, S, or C(R8e)(R8f);
RI is H, or Ci-C6alkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, C1-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a and R2b are independently selected from H, substituted or unsubstituted Ci-C6alkyl, and ¨
C(=O)RD;
RD is substituted or unsubstituted -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted CI-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is C1-C3alkyl, or C1-C3fluoroalkyl;
each R5 is independently selected from H, C1-C3alkyl, C1-C3haloalkyl, Ci-C3heteroalkyl and -C1-C3alkyl-(C3-05cycloalkyl);
-19-each R7 is independently selected from Ci-C6alky1, Ci-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted Ciohetcrocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1pcycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-Cipheterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
RS and Rgb are independently selected from H, Ci-C6alkyl and Ci-C6fluoroalkyl;
lee and Rgf are independently selected from H, Ci-C6alkyl and Ci-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, Ci-C4 fluoroalkoxy, -NH2, -NH(C1-C4alkyl), -NH(Ci-C4alky02, -C(=0)0H, -C(=0)NH2, -C(=0)Ci-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-OH, -NH(CI-C4alky1)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(C -C4alkyl)-NH-(C -C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C -C3 alkyl.
[0012] In another aspect, provided herein are compounds having the structure of Formula E-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
R w3 wl \-/
R3 ________________________ ( Formula E-I
wherein,
p is 0, 1 or 2;
RS and Rgb are independently selected from H, Ci-C6alkyl and Ci-C6fluoroalkyl;
lee and Rgf are independently selected from H, Ci-C6alkyl and Ci-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, Ci-C4 fluoroalkoxy, -NH2, -NH(C1-C4alkyl), -NH(Ci-C4alky02, -C(=0)0H, -C(=0)NH2, -C(=0)Ci-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-OH, -NH(CI-C4alky1)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(C -C4alkyl)-NH-(C -C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C -C3 alkyl.
[0012] In another aspect, provided herein are compounds having the structure of Formula E-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
R w3 wl \-/
R3 ________________________ ( Formula E-I
wherein,
-20-R1 is H, Ci-C6alkyl, C3-C6cycloalkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substitutcd or unsubstituted heteroaryl);
when X' is selected from N-RA, S, S(0) and S(0)2, then X2 is CR2cR-2(1, and X3 is CR2aR2b;
or when Xt is 0, then X2 is selected from CR2'R2d and N-RA, and X3 is CR2aR2b:
or:
when X1 is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is CR2aR2b;
or:
X' is CR2eR2t and X2 is CR2eR2d, and R2' and R2' together form a bond, and X3 is CR2aR2b;
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR Rze 2/-;
RA is H, C1-C6alky1, -C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
W1 is 0, S, N-RA, or C(R8d)(R8b);
W2 is 0, S. N-RA, or C(R8e)(R8d);
W3 is 0, S, N-R', or C(Rge)(1e); provided that the ring comprising W', W2 and W3 does not comprise two adjacent oxygen atoms or sulfur atoms;
R2a R2b, R2e, R2d K-2e, and R2f are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl) and -C(=0)RB;
RB is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl,
when X' is selected from N-RA, S, S(0) and S(0)2, then X2 is CR2cR-2(1, and X3 is CR2aR2b;
or when Xt is 0, then X2 is selected from CR2'R2d and N-RA, and X3 is CR2aR2b:
or:
when X1 is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is CR2aR2b;
or:
X' is CR2eR2t and X2 is CR2eR2d, and R2' and R2' together form a bond, and X3 is CR2aR2b;
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR Rze 2/-;
RA is H, C1-C6alky1, -C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
W1 is 0, S, N-RA, or C(R8d)(R8b);
W2 is 0, S. N-RA, or C(R8e)(R8d);
W3 is 0, S, N-R', or C(Rge)(1e); provided that the ring comprising W', W2 and W3 does not comprise two adjacent oxygen atoms or sulfur atoms;
R2a R2b, R2e, R2d K-2e, and R2f are independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl) and -C(=0)RB;
RB is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl,
-21-substituted or unsubstituted heteroaryl, -C1-C6a1kyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), (substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, (substituted or unsubstituted C3-C6cycloa1kyl), -Ci-C6a1kyl-(substituted or unsubstituted C2-Csheterocycloalkyl), -C[-Coalkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 is -NHR5, -N(1V)2, -N-(03 or -0R5;
each R' is independently selected from H, Ct-C3alkyl, C1-C3haloalkyl, Ci-C3heteroalkyl and -C1-C3alkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NH S (=0)2NHR7, -(C1 -C3 alkyl)-NHC (=0)127, -(C 1-C 3 alkyl)-C (=0)NHR5, -(C
-C 3 alkyl)-NHS(=0)2R7, -(Ci-C3alky1)-S(=0)2NHR7; -(Ci-C3alky1)-NHC(=0)NHR7, -(Ci-C3a1kyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Ci0heterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-Clocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -Ct-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)1,-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
Rga, Rgb, R8e, RSd, leand le are independently selected from H, C1-C6alkyl, C1-C6fluoroalkyl, C--C6 alkoxy, Ci-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
Rgd, Rgeand R8f are as defined above, and R8b and R8e together form a bond;
or:
R8a, le, R8d, and le- are as defined above, and lee and R8e together form a bond;
or:
R8', led, R8eand R8f are as defined above, and R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
lea, le, le, and ref are as defined above, and lee and R8e together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S. 0 and N;
or:
R8', R8d, R8eand R8f are as defined above, and R8a and R.gb together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
lea, le, leand le are as defined above, and R8e and le together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R82, R8b, R8c, and R8d are as defined above, and R8e and R8f together with the atoms to which they arc attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, Ci-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, Ci-C4 fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alkyl)2, -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(CI-C4alky1)-OH, -NH(C1-C4alkyl)-0-(C1-C4alkyl), -0(C1-C4alkyl)-NH2; -0(C1-C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[0013] In another aspect, provided herein are compounds having the structure of Formula E-XXI, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
õ
pp 2b 1R1 R2a v R8b 0 <N
R8a H 0 --;;;.\
Formula E-XXI
wherein, W13 is 0, S, or C(R8e)(R8f);
R1 is H, or C1-C6alkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, Ci-C6alkyl, ¨C(=0)Ct-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a and R2b are independently selected from H, substituted or unsubstituted C1-C6alkyl, and ¨
C(0)RD;
RD is substituted or unsubstituted Ci-C6alkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6a141-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
each R5 is independently selected from H, C1-C3alkyl, CI-C3ha1oa1ky1, C1-C3heteroalky1 and -C1-C3alkyl-(C3-05cycloalkyl);
each R7 is independently selected from Ci-C6alky1, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloa1kyl), (substituted or unsubstituted C2-C10heterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R and Rgb are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
RS and Rsf are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, heterospirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, CI-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, Ci-C4 fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alkyl)2, -C(=0)0H, -C(=0)NI-12, -C(=0)Ci-C3alkyl, -S(=0)2CH3, -NH(Ci-C4alkyl)-OH, -NH(Ct-C4alkyl)-0-(C1-C4alkyl), -0(CI-C4alky1)-N H2; -0(C -C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
[0014] In a further aspect, provided herein are compounds of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, and compositions comprising compounds of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, for treatment of cancer, inflammatory diseases and/or autoimmune diseases in an individual in need thereof.
[0015] In a further aspect, provided herein are compounds of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, and compositions comprising compounds of Formula A, Folinula B, Formula C, Formula D, Formula E, Formula F, or Folinula G, for inhibition of the activity of inhibitor of apoptosis proteins (IAPs) in an individual in need thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The novel features of the invention are set forth with particularity in the appended claims. A
better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0017] Figure 1 exemplifies the effects of compounds 16c, 17a, 17b, and 17c on MDA-MB-231 breast cancer cell survival.
DETAILED DESCRIPTION OF THE INVENTION
[0018] Aberrant and uncontrolled cell growth due to apoptosis suppression is a hallmark of cancer cells.
Cancer cells often display aberrant upregulation of pathways which inhibit apoptosis, allowing the cancer cells to proliferate. One such pathway which is upregulated in cancer cells is the inhibitor of apoptosis (TAP) pathway. The members of the TAP family are functionally and structurally related proteins, which inhibit apoptosis. IAPs share a Baculovirus TAP Repeat domain, each having one to three copies. Eight members of the TAP family have currently been identified, in both baculovirus and humans. Five human members of the TAP family include: XIAP, c-IAP1 (also, BIRC2), C-IAP2 (also, BIRC3), NAIP, and survivin. In certain instances, XIAP inhibits apoptosis by binding to and inhibiting the activity of caspase-9, caspase-3 and caspase 7.
[0019] Alterations in TAP proteins are found in many types of human cancer and are associated with chemoresistance, disease progression and poor prognosis. When the TAP pathway is upregulated, the TAP
proteins bind to and prevent initiator and effector caspases from cleaving downstream cellular proteins.
[0020] The proteolytic action of caspases is required to allow the cell death cascade to progress normally.
Accordingly, provided herein are compounds that bind the upregulated TAP
proteins. The compounds provided herein, in some embodiments, bind to IAPs and prevent them from suppressing caspase action, thereby allowing the cell death cascade to progress normally. In other words, provided herein are compounds that inhibit the action of TAP proteins, thereby inducing apoptosis in cells.
[0021] One protein implicated in binding with IAPs is SMAC. SMAC is a mitochondrial protein that negatively regulates apoptosis or programmed cell death. When a cell is primed for apoptosis by the final execution step of caspase activation, SMAC binds to TAP, which prevents TAP
from binding to, and deactivating caspases. Thus SMAC promotes apoptosis by activating caspases.
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, (substituted or unsubstituted C3-C6cycloa1kyl), -Ci-C6a1kyl-(substituted or unsubstituted C2-Csheterocycloalkyl), -C[-Coalkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 is -NHR5, -N(1V)2, -N-(03 or -0R5;
each R' is independently selected from H, Ct-C3alkyl, C1-C3haloalkyl, Ci-C3heteroalkyl and -C1-C3alkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NH S (=0)2NHR7, -(C1 -C3 alkyl)-NHC (=0)127, -(C 1-C 3 alkyl)-C (=0)NHR5, -(C
-C 3 alkyl)-NHS(=0)2R7, -(Ci-C3alky1)-S(=0)2NHR7; -(Ci-C3alky1)-NHC(=0)NHR7, -(Ci-C3a1kyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Ci0heterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-Clocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -Ct-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)1,-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
Rga, Rgb, R8e, RSd, leand le are independently selected from H, C1-C6alkyl, C1-C6fluoroalkyl, C--C6 alkoxy, Ci-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
Rgd, Rgeand R8f are as defined above, and R8b and R8e together form a bond;
or:
R8a, le, R8d, and le- are as defined above, and lee and R8e together form a bond;
or:
R8', led, R8eand R8f are as defined above, and R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
lea, le, le, and ref are as defined above, and lee and R8e together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S. 0 and N;
or:
R8', R8d, R8eand R8f are as defined above, and R8a and R.gb together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
lea, le, leand le are as defined above, and R8e and le together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R82, R8b, R8c, and R8d are as defined above, and R8e and R8f together with the atoms to which they arc attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, Ci-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, Ci-C4 fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alkyl)2, -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(CI-C4alky1)-OH, -NH(C1-C4alkyl)-0-(C1-C4alkyl), -0(C1-C4alkyl)-NH2; -0(C1-C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[0013] In another aspect, provided herein are compounds having the structure of Formula E-XXI, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
õ
pp 2b 1R1 R2a v R8b 0 <N
R8a H 0 --;;;.\
Formula E-XXI
wherein, W13 is 0, S, or C(R8e)(R8f);
R1 is H, or C1-C6alkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, Ci-C6alkyl, ¨C(=0)Ct-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a and R2b are independently selected from H, substituted or unsubstituted C1-C6alkyl, and ¨
C(0)RD;
RD is substituted or unsubstituted Ci-C6alkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6a141-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
each R5 is independently selected from H, C1-C3alkyl, CI-C3ha1oa1ky1, C1-C3heteroalky1 and -C1-C3alkyl-(C3-05cycloalkyl);
each R7 is independently selected from Ci-C6alky1, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloa1kyl), (substituted or unsubstituted C2-C10heterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R and Rgb are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
RS and Rsf are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, heterospirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, CI-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, Ci-C4 fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alkyl)2, -C(=0)0H, -C(=0)NI-12, -C(=0)Ci-C3alkyl, -S(=0)2CH3, -NH(Ci-C4alkyl)-OH, -NH(Ct-C4alkyl)-0-(C1-C4alkyl), -0(CI-C4alky1)-N H2; -0(C -C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
[0014] In a further aspect, provided herein are compounds of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, and compositions comprising compounds of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, for treatment of cancer, inflammatory diseases and/or autoimmune diseases in an individual in need thereof.
[0015] In a further aspect, provided herein are compounds of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, and compositions comprising compounds of Formula A, Folinula B, Formula C, Formula D, Formula E, Formula F, or Folinula G, for inhibition of the activity of inhibitor of apoptosis proteins (IAPs) in an individual in need thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The novel features of the invention are set forth with particularity in the appended claims. A
better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0017] Figure 1 exemplifies the effects of compounds 16c, 17a, 17b, and 17c on MDA-MB-231 breast cancer cell survival.
DETAILED DESCRIPTION OF THE INVENTION
[0018] Aberrant and uncontrolled cell growth due to apoptosis suppression is a hallmark of cancer cells.
Cancer cells often display aberrant upregulation of pathways which inhibit apoptosis, allowing the cancer cells to proliferate. One such pathway which is upregulated in cancer cells is the inhibitor of apoptosis (TAP) pathway. The members of the TAP family are functionally and structurally related proteins, which inhibit apoptosis. IAPs share a Baculovirus TAP Repeat domain, each having one to three copies. Eight members of the TAP family have currently been identified, in both baculovirus and humans. Five human members of the TAP family include: XIAP, c-IAP1 (also, BIRC2), C-IAP2 (also, BIRC3), NAIP, and survivin. In certain instances, XIAP inhibits apoptosis by binding to and inhibiting the activity of caspase-9, caspase-3 and caspase 7.
[0019] Alterations in TAP proteins are found in many types of human cancer and are associated with chemoresistance, disease progression and poor prognosis. When the TAP pathway is upregulated, the TAP
proteins bind to and prevent initiator and effector caspases from cleaving downstream cellular proteins.
[0020] The proteolytic action of caspases is required to allow the cell death cascade to progress normally.
Accordingly, provided herein are compounds that bind the upregulated TAP
proteins. The compounds provided herein, in some embodiments, bind to IAPs and prevent them from suppressing caspase action, thereby allowing the cell death cascade to progress normally. In other words, provided herein are compounds that inhibit the action of TAP proteins, thereby inducing apoptosis in cells.
[0021] One protein implicated in binding with IAPs is SMAC. SMAC is a mitochondrial protein that negatively regulates apoptosis or programmed cell death. When a cell is primed for apoptosis by the final execution step of caspase activation, SMAC binds to TAP, which prevents TAP
from binding to, and deactivating caspases. Thus SMAC promotes apoptosis by activating caspases.
[0022] In some embodiments, the compounds described herein are nonpeptidic SMAC mimetics and induce apoptosis (e.g., in cancer cells). In some embodiments, the compounds described herein are TAP
antagonists.
antagonists.
[0023] In certain instances, IAPs not only regulate caspases and apoptosis, but also modulate inflammatory signalling and immunity, mitogenic kinase signalling, proliferation and mitosis, as well as cell invasion and metastasis. Inhibitor of apoptosis (TAP) proteins have emerged as regulators of innate immune signaling downstream of Pattern Recognition Receptors (PRRs) such as Toll-like receptor 4 (TLR4), Nucleotide-Binding Oligomerization Domain 1 (NOD1) and NOD2 receptors, and Retinoic Acid-Inducible Gene (RIG)-I Receptor. In certain instances, Cellular Inhibitor of Apoptosis Protein-1 (cTAP1; also Baculoviral TAP Repeat Containing 2 or BIRC2), Cellular Inhibitor of Apoptosis Protein-2 (cIAP2; also, Baculoviral TAP Repeat Containing 3 or BIRC3), and X-linked Inhibitor of Apoptosis (XIAP) facilitate ubiquitin-dependent signaling activated by these PRRs and mediate activation of nuclear factor-kappa B (NF-KB) transcription factors as well as the MAP kinases p38 and JNK. Accordingly, the compounds described herein arc also useful in treatment of non-neoplastic diseases and/or inflammatory diseases and/or autoimmune diseases.
Definitions
Definitions
[0024] In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the invention may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments. Unless the context requires otherwise, throughout the specification and claims which follow, the word "comprise- and variations thereof, such as, "comprises" and "comprising" are to be construed in an open, inclusive sense, that is, as "including, but not limited to." Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention.
[0025] As used in this specification and the appended claims, the singular forms "a," "an," and "the"
include plural referents unless the content clearly dictates otherwise. It should also be noted that the term "or" is generally employed in its sense including "and/or" unless the content clearly dictates otherwise.
include plural referents unless the content clearly dictates otherwise. It should also be noted that the term "or" is generally employed in its sense including "and/or" unless the content clearly dictates otherwise.
[0026] The terms below, as used herein, have the following meanings, unless indicated otherwise:
[0027] "Amino" refers to the -NH2 radical.
[0028] "Cyano" or "nitrile" refers to the -CN radical.
[0029] "Hydroxy" or "hydroxyl" refers to the -OH radical.
[0030] "Nitro" refers to the -NO2 radical.
[0031] "Oxo" refers to the =0 substituent.
[0032] "Thioxo" refers to the =S substituent.
[0033] "Alkyl" refers to a straight or branched hydrocarbon chain radical, having from one to thirty carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 30 are included. An alkyl comprising up to 30 carbon atoms is refered to as a C1-C30 alkyl, likewise, for example, an alkyl comprising up to 12 carbon atoms is a C1-C17 alkyl.
Alkyls (and other moieties defined herein) comprising other numbers of carbon atoms are represented similarily. Alkyl groups include, but are not limited to, C1-C30 alkyl, C1-C20 alkyl, CI-C15 alkyl, CpCm alkyl, CI-Cs alkyl, C1-C6 alkyl, CI-CI alkyl, CI-C3 alkyl, C1-C2 alkyl, C2-C8 alkyl, C3-C8 alkyl and C4-C8 alkyl. Representative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, t-butyl, s-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, and the like. Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted as described below. "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group.
Alkyls (and other moieties defined herein) comprising other numbers of carbon atoms are represented similarily. Alkyl groups include, but are not limited to, C1-C30 alkyl, C1-C20 alkyl, CI-C15 alkyl, CpCm alkyl, CI-Cs alkyl, C1-C6 alkyl, CI-CI alkyl, CI-C3 alkyl, C1-C2 alkyl, C2-C8 alkyl, C3-C8 alkyl and C4-C8 alkyl. Representative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, t-butyl, s-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, and the like. Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted as described below. "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group.
[0034] "Alkoxy" refers to a radical of the formula -0R2 where R, is an alkyl radical as defined. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted as described below.
[0035] "Heteroalkylene" refers to an alkyl radical as described above where one or more carbon atoms of the alkyl is replaced with a 0, N or S atom. "Heteroalkylene" or "heteroalkylene chain" refers to a straight or branched divalent heteroalkyl chain linking the rest of the molecule to a radical group. Unless stated otherwise specifically in the specification, the heteroalkyl or heteroalkylene group may be optionally substituted as described below. Representative heteroalkyl groups include, but are not limited to -OCH2CH20Me, -OCH2CF2OCH2CH2NH2, or -OCH2CH2OCH2CH2OCH2CH2N(Me)2.
Representative heteroalkylene groups include, but are not limited to -OCH2CH20-, -OCH2CH2OCH2CH20-, or -OCH2CH2OCH2CH2OCH2CH20-.
Representative heteroalkylene groups include, but are not limited to -OCH2CH20-, -OCH2CH2OCH2CH20-, or -OCH2CH2OCH2CH2OCH2CH20-.
[0036] "Alkylamino" refers to a radical of the formula -NHR, or -NR,Ra where each R2 is, independently, an alkyl radical as defined above. Unless stated otherwise specifically in the specification, an alkylamino group may be optionally substituted as described below.
[0037] "Aryl" refers to a radical derived from a hydrocarbon ring system comprising hydrogen, 6 to 30 carbon atoms and at least one aromatic ring. The aryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems. Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indanc, indene, naphthalene, phenalene, phenanthrene, plciadene, pyrene, and triphenylene.
Unless stated otherwise specifically in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals that are optionally substituted.
Unless stated otherwise specifically in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals that are optionally substituted.
[0038] -Carboxy" refers to -CO2H. In some embodiments, carboxy moieties may be replaced with a "carboxylic acid bioisostere", which refers to a functional group or moiety that exhibits similar physical and/or chemical properties as a carboxylic acid moiety. A carboxylic acid bioisostere has similar biological properties to that of a carboxylic acid group. A compound with a carboxylic acid moiety can have the carboxylic acid moiety exchanged with a carboxylic acid bioisostere and have similar physical and/or biological properties when compared to the carboxylic acid-containing compound. For example, in one embodiment, a carboxylic acid bioisostere would ionize at physiological pH
to roughly the same extent as a carboxylic acid group. Examples of bioisosteres of a carboxylic acid include, but are not N = N =
ANOH N
A ,CN
s,N
H
limited to, OH
N I N
OH OH 0 and the like.
to roughly the same extent as a carboxylic acid group. Examples of bioisosteres of a carboxylic acid include, but are not N = N =
ANOH N
A ,CN
s,N
H
limited to, OH
N I N
OH OH 0 and the like.
[0039] "Cycloalkyl" refers to a stable, non-aromatic, monocyclic or polycyclic carbocyclic ring, which may include fused or bridged ring systems, which is saturated or unsaturated, and attached to the rest of the molecule by a single bond. Representative cycloalkyls include, but are not limited to, cycloaklyls having from three to fifteen carbon atoms, from three to ten carbon atoms, from three to eight carbon atoms, from three to six carbon atoms, from three to five carbon atoms, or three to four carbon atoms.
Monocyclic cycicoalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, and 7,7-dimethyl-bicyclo[2.2.1]heptanyl. Unless otherwise stated specifically in the specification, a cycloalkyl group may be optionally substituted. Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties:
>Nil, 0,0,0 ,O,C0,0,0,0,0,L01 Qi 1400 , and the like.
Monocyclic cycicoalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, and 7,7-dimethyl-bicyclo[2.2.1]heptanyl. Unless otherwise stated specifically in the specification, a cycloalkyl group may be optionally substituted. Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties:
>Nil, 0,0,0 ,O,C0,0,0,0,0,L01 Qi 1400 , and the like.
[0040] "Fused" refers to any ring structure described herein which is fused to an existing ring structure.
When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.
When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.
[0041] "Halo" or "halogen" refers to bromo, chloro, fluoro or iodo.
[0042] "Haloalkyr refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group may be optionally substituted.
[0043] -Perhalo" or -perfluoro" refers to a moiety in which each hydrogen atom has been replaced by a halo atom or fluorine atom, respectively.
[0044] "Heterocycly1" or "heterocyclic ring" or lietercycloalkyl" refers to a stable 3- to 24-membered non-aromatic ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 12-crown-4, 15-crown-5, 18-crown-6, 21-crown-7, aza-18-crown-6, diaza-18-crown-6, aza-21-crown-7, and diaza-21-crown-7. Unless stated otherwise specifically in the specification, a heterocyclyl group may be optionally substituted. Illustrative examples of heterocycloalkyl groups, also referred to as non-aromatic heterocycles, include:
(IS , N\
S
\D ci co)çN
N N , N-N
oioNileiN
o). 0 0, S, S, rs ro,) N/I
CC, 'and the like. The term heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides. Unless otherwise noted, heterocycloalkyls have from 2 to 10 carbons in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatonis) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring). Unless stated otherwise specifically in the specification, a heterocycloalkyl group may be optionally substituted.
(IS , N\
S
\D ci co)çN
N N , N-N
oioNileiN
o). 0 0, S, S, rs ro,) N/I
CC, 'and the like. The term heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides and the oligosaccharides. Unless otherwise noted, heterocycloalkyls have from 2 to 10 carbons in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatonis) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring). Unless stated otherwise specifically in the specification, a heterocycloalkyl group may be optionally substituted.
[0045] "Heteroaryl" refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur, and at least one aromatic ring. For purposes of this invention, the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, bcnzofuranyl, benzofuranonyl, benzothienyl (benzothiophcnyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl).
Unless stated otherwise specifically in the specification, a heteroaryl group may be optionally substituted.
Unless stated otherwise specifically in the specification, a heteroaryl group may be optionally substituted.
[0046] All the above groups may be either substituted or unsubstituted. The term -substituted" as used herein means any of the above groups (i.e., alkyl, alkylene, alkoxy, alkoxyalkyl, alkylcarbonyl, alkyloxycarbonyl,alkylamino, amidyl, amidinylalkyl, amidinylalkylcarbonyl, aminoalkyl, aryl, aralkyl, arylcarbonyl, aryloxycarbonyl, aralkylcarbonyl, aralkyloxycarbonyl, aryloxy, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, cycloalkyloxycarbonyl, guanidinylalkyl, guanidinylalkylcarbonyl, haloalkyl, heterocyclyl and/or heteroaryl), may be further functionalized wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atom substituent. Unless stated specifically in the specification, a substituted group may include one or more substituents selected from: oxo, nitrile, nitro, hydroxyl, thiooxy, alkyl, alkylene, alkoxy, alkoxyalkyl, alkylcarbonyl, alkyloxycarbonyl, aryl, aralkyl, arylcarbonyl, aryloxycarbonyl, aralkylcarbonyl, aralkyloxycarbonyl, aryloxy, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkylalkylcarbonyl, cycloalkyloxycarbonyl, heterocyclyl, heteroaryl, dialkylamines, arylamines, alkylarylamines, diarylamines, trialkylammonium (-N13), N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, triarylsilyl groups, perfluoroalkyl or perfluoroalkoxy, for example, trifluoromethyl or trifluoromethoxy. "Substituted" also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double-or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, "substituted" includes any of the above groups in which one or more hydrogen atoms are replaced with -NR,C(=0)NR,Rh, -NR,C(=0)0Rh, -NR,S02Rh, -0C(=0)NR,Rh, -0R,, -SR,, -SOR,, SO2Rg, OSO2Rg, S020R,, =NSO2R,, and -SO2NR,Rh.
"Substituted" also means any of the above groups in which one or more hydrogen atoms are replaced with -C(=0)R,, -C(=0)0R,, -CH2S02R,, -CH2SO2NR,Rh, -SH, -SR, or -SSR,. In the foregoing, R, and Rh are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl. In addition, each of the foregoing substituents may also be optionally substituted with one or more of the above substituents. Furthermore, any of the above groups may be substituted to include one or more internal oxygen or sulfur atoms. For example, an alkyl group may be substituted with one or more internal oxygen atoms to form an ether or polyether group. Similarily, an alkyl group may be substituted with one or more internal sulfur atoms to form a thioether, disulfide, etc.
Amidyl moieties may be substituted with up to 2 halo atoms, while other groups above may be substituted with one or more halo atoms. With the exception of alkyl groups, all other groups may also be substituted with amino or monoalklyamino. With the exception of alkyl and alkylcarbonyl groups, all other groups may also be substituted with guanidinyl or amidynyl. Optional substitutents for any of the above groups also include arylphosphoryl, for example -R0P(Ar)3 wherein Ra is an alkylene and Ar is aryl moiety, for example phenyl.
"Substituted" also means any of the above groups in which one or more hydrogen atoms are replaced with -C(=0)R,, -C(=0)0R,, -CH2S02R,, -CH2SO2NR,Rh, -SH, -SR, or -SSR,. In the foregoing, R, and Rh are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl. In addition, each of the foregoing substituents may also be optionally substituted with one or more of the above substituents. Furthermore, any of the above groups may be substituted to include one or more internal oxygen or sulfur atoms. For example, an alkyl group may be substituted with one or more internal oxygen atoms to form an ether or polyether group. Similarily, an alkyl group may be substituted with one or more internal sulfur atoms to form a thioether, disulfide, etc.
Amidyl moieties may be substituted with up to 2 halo atoms, while other groups above may be substituted with one or more halo atoms. With the exception of alkyl groups, all other groups may also be substituted with amino or monoalklyamino. With the exception of alkyl and alkylcarbonyl groups, all other groups may also be substituted with guanidinyl or amidynyl. Optional substitutents for any of the above groups also include arylphosphoryl, for example -R0P(Ar)3 wherein Ra is an alkylene and Ar is aryl moiety, for example phenyl.
[0047] An "effective amount" or "therapeutically effective amount" refers to an amount of a compound administered to a subject (e.g. a mammal, such as a human), either as a single dose or as part of a series of doses, which is effective to produce a desired therapeutic effect.
[0048] "Treatment" of a subject (e.g. a mammal, such as a human) includes any type of intervention used in an attempt to alter the natural course of the subject. In some embodiments, treatment includes administration of a pharmaceutical composition, subsequent to the initiation of a pathologic event or contact with an etiologic agent and includes stabilization of the condition (e.g., condition does not worsen, e.g., cancer does not metastasize and the like) or alleviation of the condition (e.g., reduction in tumor size, remission of cancer, absence of symptoms of autoimmune disease and the like).
In other embodiments, treatment also includes prophylactic treatment (e.g., administration of a composition described herein when an individual is suspected to be suffering from a condition described herein).
In other embodiments, treatment also includes prophylactic treatment (e.g., administration of a composition described herein when an individual is suspected to be suffering from a condition described herein).
[0049] As used herein, "subject", "individual" and "patient" are used interchangeably. None of the terms imply that a medical professional is required for the administration of the compounds disclosed herein.
[0050] A "tautomer" refers to a proton shift from one atom of a molecule to another atom of the same molecule. The compounds presented herein may exist as tautomers. Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In bonding arrangements whcrc tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Some examples of tautomeric interconversions include:
0 OH \IAA
H H
0 OH N H2 NH rrcf , NN
\ N H2 \ N H \N \ N
,sss, H ,rss r Nsis NN N H N¨ "N N H
Compounds Formula A ¨ six-Jive ring systems
0 OH \IAA
H H
0 OH N H2 NH rrcf , NN
\ N H2 \ N H \N \ N
,sss, H ,rss r Nsis NN N H N¨ "N N H
Compounds Formula A ¨ six-Jive ring systems
[0051] As used herein, Formula A includes compounds of Formula A-I, Formula A-II, Formula A-III-1, Formula A-III-2, Formula A-III-3, Formula A-IV, Formula A-V-1, Formula A-V-2, Formula A-V-3, Formula A-VI-1, Formula A-VI-2, Formula A-V1-3, Formula A-VIT-1 , Formula A-VII-2, Formula A-VII-3, Formula A-VIII, Formula A-IX-1, Formula A-IX-2, Formula A-X, Formula A-XI, Formula A-XII, Formula A-XIII, Formula A-XIV, Formula A-XV-1, Formula A-XV-2, Formula A-XV-3, Formula A-XV-4, Formula A-XVI-1, Formula A-XVI-2, Formula A-XVII, Formula A-XVIII, Formula A-XIX, Formula A-XX, and Formula A-XXI.
[0052] In one aspect, described herein is a compound of Formula A-I, or a pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, as described in the summary of the invention.
[0053] In one aspect, provided herein are compounds having the structure of Formula A-I, pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof:
_Xi Im2 R3rN
m Formula A-I
wherein, W1 is 0, S, N-RA, or C(R8a)(R8b);
W2 is 0, S, N-RA, or C(e)(Ied); provided that W1 and W2 are not both 0, or both S;
R1 is H, C1-C6alkyl, C3-C6cycloalkyl, ¨C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkYD, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 is 0, N-RA, S, S(0), or S(0)2, then X2 is C(R2aR2b);
or:
X1 is CR2cR2d and X2 is CR2a,-.x2b, and R2' and R2' together form a bond;
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring;
or:
X1is CH) and X2 is C=0, C=C(12c)2, or C=NRc; where each Rc is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), (substituted or unsubstituted aryl), or ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
RA is H, C1-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R22, R2b, R2c, ¨2d, tt are independently selected from H, substituted or unsubstituted substituted or unsubstituted CI-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substitutcd or unsubstituted C2-05heterocycloalkyl), -CI-C6a1kyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl) and -C(=0)RB;
RD is substituted or unsubstituted C1-C6alky1, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alky1-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted C i-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 is -NHR5, -N(R5)2, -N-(R5)3 or -0R5;
each fe is independently selected from H, C1-C3alkyl, C1-C3haloalkyl, C1-C3heteroa1kyl and -C1-C3alkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(Ci -C3 alkyl)-NHC(=0)127, -(C -C3 alkyl)-C(=0)NHR5, -(Ct -C
3 alkyl)-NHS(=0)2R7, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(C1-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Cioheterocycloalkyl, or substituted or unsubstitutcd hctcroaryl;
each R7 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C lohoterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloalkyl), (substituted or unsubstituted C2-Cioheterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alky1-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R8', le, Rk, and R8d are independently selected from H, Ci-C6alkyl, C1-C6fluoroa1kyl, C1-C6 alkoxy, C1-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
R8 and led are as defined above, and R8b and R8' together form a bond;
or:
Rsa and led are as defined above, and R81) and R8c together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8' and led are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or beterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
Rga and R81) are as defined above, and le and led together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, heterospirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, C1-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, Ci-C4 fluoroalkoxy, -NH2, -NH(C1-C4alkyl), -NH(Ci-C4alky02, -C(=0)0H, -C(=0)NH2, -C(=0)Ci-C3alkyl, -S(=0)2CF2, -NH(C1-C4alkyl)-OH, -NH(CI-C4alky1)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(CI-C4alky1)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
_Xi Im2 R3rN
m Formula A-I
wherein, W1 is 0, S, N-RA, or C(R8a)(R8b);
W2 is 0, S, N-RA, or C(e)(Ied); provided that W1 and W2 are not both 0, or both S;
R1 is H, C1-C6alkyl, C3-C6cycloalkyl, ¨C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkYD, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 is 0, N-RA, S, S(0), or S(0)2, then X2 is C(R2aR2b);
or:
X1 is CR2cR2d and X2 is CR2a,-.x2b, and R2' and R2' together form a bond;
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring;
or:
X1is CH) and X2 is C=0, C=C(12c)2, or C=NRc; where each Rc is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), (substituted or unsubstituted aryl), or ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
RA is H, C1-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R22, R2b, R2c, ¨2d, tt are independently selected from H, substituted or unsubstituted substituted or unsubstituted CI-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substitutcd or unsubstituted C2-05heterocycloalkyl), -CI-C6a1kyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl) and -C(=0)RB;
RD is substituted or unsubstituted C1-C6alky1, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alky1-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted C i-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 is -NHR5, -N(R5)2, -N-(R5)3 or -0R5;
each fe is independently selected from H, C1-C3alkyl, C1-C3haloalkyl, C1-C3heteroa1kyl and -C1-C3alkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(Ci -C3 alkyl)-NHC(=0)127, -(C -C3 alkyl)-C(=0)NHR5, -(Ct -C
3 alkyl)-NHS(=0)2R7, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(C1-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Cioheterocycloalkyl, or substituted or unsubstitutcd hctcroaryl;
each R7 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C lohoterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloalkyl), (substituted or unsubstituted C2-Cioheterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alky1-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R8', le, Rk, and R8d are independently selected from H, Ci-C6alkyl, C1-C6fluoroa1kyl, C1-C6 alkoxy, C1-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
R8 and led are as defined above, and R8b and R8' together form a bond;
or:
Rsa and led are as defined above, and R81) and R8c together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8' and led are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or beterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
Rga and R81) are as defined above, and le and led together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, heterospirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, C1-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, Ci-C4 fluoroalkoxy, -NH2, -NH(C1-C4alkyl), -NH(Ci-C4alky02, -C(=0)0H, -C(=0)NH2, -C(=0)Ci-C3alkyl, -S(=0)2CF2, -NH(C1-C4alkyl)-OH, -NH(CI-C4alky1)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(CI-C4alky1)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[0054] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, one group of compounds has the structure of Formula A-IL
R3 \
RU N
Formula A-IT
R3 \
RU N
Formula A-IT
[0055] Among the compounds of Formula A-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, one group of compounds that has the structure of Formula A-ill-1, Formula A-TIT-2 or Formula A-III-3:
R1 R8d R1 R8d x2µ)(1 R8c R8c y2 R3 ¨ R3 R8 b wl R4 U N Raa Formula A-III-1 Formula A-III-2 Ri 2 yXi v v µ,112 R3 's R8b /1\
Formula A-III-3.
R1 R8d R1 R8d x2µ)(1 R8c R8c y2 R3 ¨ R3 R8 b wl R4 U N Raa Formula A-III-1 Formula A-III-2 Ri 2 yXi v v µ,112 R3 's R8b /1\
Formula A-III-3.
[0056] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, one group of compounds that has the structure of Formula R1 R8d 2. Xi R8 c U R8a Formula A-III-1
[0057] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, one group of compounds has the structure of Formula A-IV:
Ri R3 X2 R8b N CR8 a Formula A-IV
Ri R3 X2 R8b N CR8 a Formula A-IV
[0058] Among the compounds of Formula A described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, or -S(=0)2NH-.
[0059] Among the compounds of Formula A described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, or -C(=0)NH-.
[0060] Among the compounds of Formula A described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R3 is C1-C3alkyl.
[0061] Among the compounds of Formula A described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R4 is¨NHR5, -N(R5)2, or -N(R5)3 ; and each R is independently selected from H, C1-C3alkyl, and -Ci-C3alkyl-(C3-05cycloalkyl).
[0062] Among the compounds of Formula A described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, or -C(=0)NH-;
R3 is C1-C3a1kyl;
R4 is¨NHR5, -N(R5)2, or -N(R5)3; and each R5 is independently selected from H, C1-C3alkyl, and -C1-C7alkyl-(C3-05cycloalkyl).
R3 is C1-C3a1kyl;
R4 is¨NHR5, -N(R5)2, or -N(R5)3; and each R5 is independently selected from H, C1-C3alkyl, and -C1-C7alkyl-(C3-05cycloalkyl).
[0063] Among the compounds of Formula A described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, A: is R3
[0064] Among the compounds of Formula A described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, - N
is - H
is - H
[0065] Among the compounds of Formula A described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring. Within this group of compounds are compounds wherein (R9)0-2 is H ;and q is 1, 2 or 3.
[0066] Among the compounds of Formula A described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof, is one group of compounds wherein R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring.
Within this group of compounds are compounds wherein H
R3 --/e4 is (R9)0-2 ; and q is 1, 2 or 3.
Within this group of compounds are compounds wherein H
R3 --/e4 is (R9)0-2 ; and q is 1, 2 or 3.
[0067] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula A-V-1, Formula A-V-2, or Formula A-V-3:
R2a R1 R2a Ri Rsd Rsc R2 b R3 R8b R3 N R8b R4 U N R4 U Rsa Formula A-V-1 Formula A-V-2 R2 b 0 0 R3 R 8b N
Formula A-V-3
R2a R1 R2a Ri Rsd Rsc R2 b R3 R8b R3 N R8b R4 U N R4 U Rsa Formula A-V-1 Formula A-V-2 R2 b 0 0 R3 R 8b N
Formula A-V-3
[0068] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula A-V-2:
2a R1 Rsd R
R2b,t0r, ROC
R3 R8b N
R4 U R8a Formula A-V-2
2a R1 Rsd R
R2b,t0r, ROC
R3 R8b N
R4 U R8a Formula A-V-2
[0069] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof, is one group of compounds having the structure of Formula A-VI-1, Formula A-VI-2, or Formula A-VI-3:
R2 a R1 R2a Ri R8d R2b SN R2btiSr... R8c R3 R 8b R3 N
R4 U --1/./.\\----R8 a R R8b4 U
R8a Formula A-VI-1 Formula A-VI-2 R2a R1 R2 b S 0 R3 R 8b õ N
R' U
Formula A-VI-3
R2 a R1 R2a Ri R8d R2b SN R2btiSr... R8c R3 R 8b R3 N
R4 U --1/./.\\----R8 a R R8b4 U
R8a Formula A-VI-1 Formula A-VI-2 R2a R1 R2 b S 0 R3 R 8b õ N
R' U
Formula A-VI-3
[0070] Among the compounds of Formula A-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula A-VH-1, Formula A-VII-2, or Formula A-VII-3:
0 0 1 0 0 Red IR.a R R2a R1 R2b Sw2 R21:t1S R8ci.
R3 R 8b R3 R8b Rt N N
R4 U R8a Formula A-VH-1 Formula A-VII-2 R20 0 -\\// R
R2 b S 0 R3 R8b N
Formula A-VII-3
0 0 1 0 0 Red IR.a R R2a R1 R2b Sw2 R21:t1S R8ci.
R3 R 8b R3 R8b Rt N N
R4 U R8a Formula A-VH-1 Formula A-VII-2 R20 0 -\\// R
R2 b S 0 R3 R8b N
Formula A-VII-3
[0071] Among the compounds of Formula A-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein X1 is N-RA.
[0072] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof, is one group of compounds having the structure of Formula A-VIII:
R3 -- R8b R4-1*-t \R8 a o R6 Formula A-VIII
R3 -- R8b R4-1*-t \R8 a o R6 Formula A-VIII
[0073] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula A-IX-1 or Formula A-IX-2:
R3 R8b R3 R8b R u N \--R8 a 4 Formula A-IX-1 Formula A-IX-2
R3 R8b R3 R8b R u N \--R8 a 4 Formula A-IX-1 Formula A-IX-2
[0074] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula A-X:
A
w2 R3 R8 b R- U
Formula A-X
wherein, ring A is a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, substituted or unsubstituted 5-10 membered aryl ring, or substituted or unsubstituted 5-10 membered heteroaryl ring.
A
w2 R3 R8 b R- U
Formula A-X
wherein, ring A is a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, substituted or unsubstituted 5-10 membered aryl ring, or substituted or unsubstituted 5-10 membered heteroaryl ring.
[0075] In some embodiments of Formula A-X, ring A is selected from indolyl, and phenyl.
[0076] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula A-XI:
x2-X1 N
R4 R 8a Formula A-XI
x2-X1 N
R4 R 8a Formula A-XI
[0077] In some embodiments of Formula A-XI, Rga and Rgb are independently selected from H and C -C3 alkyl.
[0078] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula A-XII:
, X1 Formula A-XII
, X1 Formula A-XII
[0079] Among the compounds of Formula A-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula A-XIII:
vz R3 's Formula A-XIII.
vz R3 's Formula A-XIII.
[0080] Within the group of compounds of Formula A are compounds wherein XI is 0, S or S(0)2, and X2 is CH).
[0081] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein Rgb and R8e together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N.
[0082] Within such a group of compounds are compounds of Formula A-I, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, having the structure of Formula A-XIV:
R3 x2, X1 0 (R9)03 U
Formula A-XIV
wherein ring B is an aryl or heteroaryl ring.
R3 x2, X1 0 (R9)03 U
Formula A-XIV
wherein ring B is an aryl or heteroaryl ring.
[0083] In some embodiments, ring B is an aryl. In some embodiments, ring B is phenyl. In some embodiments, ring B is a heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring or a bicyclic heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring. In some embodiments, ring B is a bicyclic heteroaryl ring. In some embodiments, ring B
is selected from phenyl, pyridinyl and thiophenyl. In some embodiments, ring B is selected from pyridinyl and thiophenyl.
is selected from phenyl, pyridinyl and thiophenyl. In some embodiments, ring B is selected from pyridinyl and thiophenyl.
[0084] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R82 and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N; or R8e and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N. Within such a group of compounds are compounds having the structure of Formula A-XV-1, Formula A-XV-2, Formula A-XV-3 or Formula A-XV-4:
,x1 R1 )1-4 R3 X- ) 3 X2 1,4 7 U U
Formula A-XV-1 Formula A-XV-2 x2. Xi R3 x2, Xi )1-3 Reit j)yN
Formula A-XV-3 Formula A-XV-4;
or Formula A-XVI-1 or Formula A-XVI-2:
N.,RA
Ri Ri , Xi , Xi t N LJ'jY.r\I
(RA R4 Formula A-XVI-1 Formula A-XVI-2;
wherein RA is H, C1-C3alkyl or ¨C(=0)Ci-C3alkyl.
,x1 R1 )1-4 R3 X- ) 3 X2 1,4 7 U U
Formula A-XV-1 Formula A-XV-2 x2. Xi R3 x2, Xi )1-3 Reit j)yN
Formula A-XV-3 Formula A-XV-4;
or Formula A-XVI-1 or Formula A-XVI-2:
N.,RA
Ri Ri , Xi , Xi t N LJ'jY.r\I
(RA R4 Formula A-XVI-1 Formula A-XVI-2;
wherein RA is H, C1-C3alkyl or ¨C(=0)Ci-C3alkyl.
[0085] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof, is one group of compounds wherein Rgb and lee together form a bond. Within such a group of compounds are compounds having the structure of Formula A-XVII:
R1 Fed R8a U N
Formula A-XVII.
R1 Fed R8a U N
Formula A-XVII.
[0086] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula A-XVIII:
X2 Th-VV2 R3 R8b t N
Formula A-XVIII
X2 Th-VV2 R3 R8b t N
Formula A-XVIII
[0087] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula A-XIX:
R3 R8b Formula A-XIX
R3 R8b Formula A-XIX
[0088] Among the compounds of Formula A-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula A-XX:
x2-XI E
R3 R8b RµljUN R8a Formula A-XX
x2-XI E
R3 R8b RµljUN R8a Formula A-XX
[0089] Among the compounds of Formula A are compounds having the structure of Formula A-XXI, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
R2b 1 R1 2a R8b N
R5 R8a Formula A-XXI
wherein, W2 is 0, S, or C(R8u)(R86);
R1 is H, or C1-C6alkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, Ci-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a, and R2b are independently selected from H, substituted or unsubstituted Ci-C6alkyl, and ¨
C(=0)RB;
R is substituted or unsubstituted Ci-C6alkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C
i-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C¨
05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
each R5 is independently selected from H, C1-C3a1kyl, C1-C3haloalkyl, C1-C3heteroalkyl and -C1-C3alkyl-(C3-C3cycloalkyl);
each R7 is independently selected from Ci-C6alkyl, C1-C6haloalkyl, C1-C6heteroalky1, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloa1kyl), -C1-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
Ria and Rib are independently selected from H, C1-C6alkyl, and C1-C6fluoroalkyl;
Ric and Rid are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-Caalkyl, C1-C4 fluoroalkyl, CI-Ca alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(C -Caalkyl), -NH(CI-C4alkyl)2, -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-0H, -NH(C1-C4alky1)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(CI-Caalkyl)-NH-(C1-Caalkyl), and -0(CI-C4alky1)-N-(C1-C4alkyl)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
R2b 1 R1 2a R8b N
R5 R8a Formula A-XXI
wherein, W2 is 0, S, or C(R8u)(R86);
R1 is H, or C1-C6alkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, Ci-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a, and R2b are independently selected from H, substituted or unsubstituted Ci-C6alkyl, and ¨
C(=0)RB;
R is substituted or unsubstituted Ci-C6alkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C
i-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C¨
05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
each R5 is independently selected from H, C1-C3a1kyl, C1-C3haloalkyl, C1-C3heteroalkyl and -C1-C3alkyl-(C3-C3cycloalkyl);
each R7 is independently selected from Ci-C6alkyl, C1-C6haloalkyl, C1-C6heteroalky1, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloa1kyl), -C1-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
Ria and Rib are independently selected from H, C1-C6alkyl, and C1-C6fluoroalkyl;
Ric and Rid are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-Caalkyl, C1-C4 fluoroalkyl, CI-Ca alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(C -Caalkyl), -NH(CI-C4alkyl)2, -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-0H, -NH(C1-C4alky1)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(CI-Caalkyl)-NH-(C1-Caalkyl), and -0(CI-C4alky1)-N-(C1-C4alkyl)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[0090] Among any of the compounds of Formula A described above and below, are compounds wherein, R2a, R21), R2c, R2d are independently selected from H, Ci-C3alkyl or -C(=0)12B; and RB is substituted or unsubstituted Ci-C6a1kyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), (substituted or unsubstituted aryl), or -Ci-C6alkyksubstituted or unsubstituted heteroaryl).
[0091] Among any of the compounds of Formula A described above and below, arc compounds wherein, R2a, R2b, R2c, K are independently selected from H, and Ci-C3alkyl.
[0092] Among any of the compounds of Formula A described above and below, are compounds wherein R1 is H or methyl.
[0093] Among any of the compounds of Formula A described above and below, are compounds wherein R1 is H.
[0094] Among any of the compounds of Formula A described above and below, are compounds wherein, R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0),,NHR7, -(Ci -C3 alkyl)-NHC(=0)127, -(C 1-C3 alkyl)-C(=0)NHR5, -(Ct -C 3 alkyl)-NHS (=0)2R7, -(C1 -C3 alkyl)-S (=0)2NHR7; -(C -C3 alkyl)-NHC(=0)NHR7, or -(C -C3 alkyl)-NHS(=0)2NH127.
[0095] Among any of the compounds of Formula A described above and below, are compounds wherein, R6 is substituted or unsubstituted C2-C10heterocycloalkyl, or substituted or unsubstituted heteroaryl.
[0096] Among any of the compounds of Formula A described above and below, are compounds wherein, R6 is a substituted or unsubstituted C2-C10heterocycloalkyl.
[0097] Among any of the compounds of Formula A described above and below, are compounds wherein, R6 is a substituted or unsubstituted heteroaryl.
[0098] Among any of the compounds of Formula A described above and below, are compounds wherein, R6 is -C(=0)NHR7, -S(=0)2NHR7,¨(Ci-C3alkyl)-C(=0)NH1V, or ¨(Ci-C3alkyl)-S(=0)2NHR7 .
[0099] Among any of the compounds of Formula A described above and below, are compounds wherein, R6 is -C(=0)NHR7, or -S(=0)2NHR7.
[00100] Among any of the compounds of Formula A described above and below, are compounds wherein R6 is ¨C(=0)NHIe.
[00101] Among any of the compounds of Formula A described above and below, are compounds wherein, each R7 is independently selected from a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C iocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C9-C1oheterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl),-(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl).
[00102] Among any of the compounds of Formula A described above and below, are compounds wherein, R7 is independently selected from a substituted or unsubstituted C3-C1ocycloalkyl, a substituted or unsubstituted C2-Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, and ¨(CH2)p-CH(substituted or unsubstituted ary1)9.
[00103] Among any of the compounds of Formula A described above and below, are compounds wherein, R7 is selected from N
N
vvvv Me N , N Me N -,ssc N N. Me css 10 -. \
/
N , / , N
Me , H .
N
vvvv Me N , N Me N -,ssc N N. Me css 10 -. \
/
N , / , N
Me , H .
[00104] Among any of the compounds of Formula A described above and below, are compounds wherein, W2 is C(R8c)(R8();
R1 is H;
X1 is 0;
R2a, R2b are independently selected from H, and C1-C3alky1;
R5 N 11.,,A ok.
.-H - N
R3 is a H =
, Rga, Rgb, R8c, R8d are independently selected from H and CI-C3alkyl.
R1 is H;
X1 is 0;
R2a, R2b are independently selected from H, and C1-C3alky1;
R5 N 11.,,A ok.
.-H - N
R3 is a H =
, Rga, Rgb, R8c, R8d are independently selected from H and CI-C3alkyl.
[00105] Any combination of the groups described above or below for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[00106] Among any of the compounds of Formula A described above and below, are compounds or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, selected from:
H H
...,..Ø, OM e 0 H j . H
Me,N¨ N..e.,.i.,N
.=. H
me 0 N = H
Me 0 1 _ N
u 1104 , , H H
=
00 =
H H
, Me N AN M
i .N M e , N ..).L.,I\-3, - - N
= H = H
Me 0 _ N Me 0 L.)_ N' u H H
, , H Fl 4.4õ.õ.Ø....E7.....> 0 444õ,õ..0,..t.......) Me , 1\1=01,,N H
- H .=. H N .s=
Me 0 _ m N e 0 u H 0 H , and , H
4,......õ..-0 :
,.HN it = H
Me 0 N
0 H .
H H
...,..Ø, OM e 0 H j . H
Me,N¨ N..e.,.i.,N
.=. H
me 0 N = H
Me 0 1 _ N
u 1104 , , H H
=
00 =
H H
, Me N AN M
i .N M e , N ..).L.,I\-3, - - N
= H = H
Me 0 _ N Me 0 L.)_ N' u H H
, , H Fl 4.4õ.õ.Ø....E7.....> 0 444õ,õ..0,..t.......) Me , 1\1=01,,N H
- H .=. H N .s=
Me 0 _ m N e 0 u H 0 H , and , H
4,......õ..-0 :
,.HN it = H
Me 0 N
0 H .
[00107] A pharmaceutical composition comprising a compound of Formula A
described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, and a pharmaceutically acceptable carrier.
Formula B - Seven-Five ring systems
described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, and a pharmaceutically acceptable carrier.
Formula B - Seven-Five ring systems
[00108] As used herein, Formula B includes compounds of Formula B-I, Folinula B-II, Formula B-III-1, Formula B-III-2, Formula B-I11-3, Formula B-IV, Formula B-V-1, Formula B-V-2, Formula B-V-3, Formula B-VI-1, Formula B-VI-2, Formula B-VI-3, Formula B-VH-1, Formula B-VII-2, Formula B-VII-3, Formula B-VIII-1, Formula B-VIII-2, Formula B-VIII-3, Formula B-TX-1, Formula B-IX-2, Formula B-X, Formula B-XI-1, Formula B-XI-2, Formula B-XI1, Formula B-XIII, Formula B-XIV, Formula B-XV, Formula B-XVI-1, Formula B-XVI-2, Formula B-XVI-3, Formula B-XVI-4, Formula B-XVII-1, Formula B-XVIT-2, Formula B-XVIII, Formula B-XIX, Formula B-XX, Formula B-XXI, and Formula B-XXII.
[00109] In one aspect, described herein is a compound of Formula B-I, or a pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, as described in the summary of the invention.
[00110] In another aspect, provided herein are compounds having the structure of Formula B-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
x2-Xl\f_ w2 wl Formula B-I
wherein, R1 is H, Ci-C6alkyl, C3-C6cycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalltyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 is selected from N-RA, S, S(0) and S(0)2, then X2 is cR2c--It2d, and X3 is CR2aR21);
or when Xf is 0, then X2 is selected from CR2c'-'It2d and N-RA, and X3 is CR2aR2b or:
when Xf is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is cR2aR2b;
or:
)(1 is ceR2rand .x2 is cR2c-It2d, and R2e and R2e together form a bond, and X3 is CR2aR2b;
or:
X1 and X3 are both CH2 and X2 is C=0, C=C(102, or C=NRc; where each Rc is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6eycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C5heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR2eR21;
RA is H, C1-C6alkyl, ¨C(=0)C1-C6a1kyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
W1 is 0, S, N-RA, or C(R8a)(R8b);
W2 is 0, S, N-RA, or C(R8c)(1e); provided that W1 and W2 are not both 0, or both S;
R22 R2b, R2c, R2d R2C, and R2f are independently selected from H, substituted or unsubstituted C6alkyl, substituted or unsubstitutcd C1-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl) and ¨
C(=0)RB;
RB is substituted or unsubstituted CI-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyksubstituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1 -C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨CI-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is C1-C3alkyl, or C1-C3fluoroalkyl;
R4 is -NHR5, -N(R5)2, -N(R5)3 or -0R5;
each R5 is independently selected from H, C1-C3a1kyl, C1-C3haloalkyl, C1-C3heteroa1kyl and -C 1 -C3 alkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(C1 -C3 alkyl)-NHC(=0)R7, -(C 1-C3 alkyl)-C(=0)NHR5, -(Ct -C
3 alkyl)-NHS(=0)21e, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(Ci-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Cioheterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C1ohetcrocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6a1kyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R8b, R8', and R8d are independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, C1-C6 alkoxy, C1-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
RS a and led are as defined above, and R8b and R8' together form a bond;
or:
R8a and R8d are as defined above, and R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8' and led are as defined above, and R" and R8b together with the atoms to which they arc attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R and R" are as defined above, and le and R" together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, C1-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, Ci-C4fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alkyl)2, -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-OH, -NH(C1-C4alky1)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH7; -0(Ci-C4alkyl)-NH-(Ci-C4alkyl), and -0(Ci-C4alkyl)-N-(Ci-C4alky02, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
x2-Xl\f_ w2 wl Formula B-I
wherein, R1 is H, Ci-C6alkyl, C3-C6cycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalltyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 is selected from N-RA, S, S(0) and S(0)2, then X2 is cR2c--It2d, and X3 is CR2aR21);
or when Xf is 0, then X2 is selected from CR2c'-'It2d and N-RA, and X3 is CR2aR2b or:
when Xf is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is cR2aR2b;
or:
)(1 is ceR2rand .x2 is cR2c-It2d, and R2e and R2e together form a bond, and X3 is CR2aR2b;
or:
X1 and X3 are both CH2 and X2 is C=0, C=C(102, or C=NRc; where each Rc is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6eycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C5heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR2eR21;
RA is H, C1-C6alkyl, ¨C(=0)C1-C6a1kyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
W1 is 0, S, N-RA, or C(R8a)(R8b);
W2 is 0, S, N-RA, or C(R8c)(1e); provided that W1 and W2 are not both 0, or both S;
R22 R2b, R2c, R2d R2C, and R2f are independently selected from H, substituted or unsubstituted C6alkyl, substituted or unsubstitutcd C1-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl) and ¨
C(=0)RB;
RB is substituted or unsubstituted CI-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyksubstituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1 -C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨CI-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is C1-C3alkyl, or C1-C3fluoroalkyl;
R4 is -NHR5, -N(R5)2, -N(R5)3 or -0R5;
each R5 is independently selected from H, C1-C3a1kyl, C1-C3haloalkyl, C1-C3heteroa1kyl and -C 1 -C3 alkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(C1 -C3 alkyl)-NHC(=0)R7, -(C 1-C3 alkyl)-C(=0)NHR5, -(Ct -C
3 alkyl)-NHS(=0)21e, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(Ci-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Cioheterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C1ohetcrocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6a1kyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R8b, R8', and R8d are independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, C1-C6 alkoxy, C1-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
RS a and led are as defined above, and R8b and R8' together form a bond;
or:
R8a and R8d are as defined above, and R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8' and led are as defined above, and R" and R8b together with the atoms to which they arc attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R and R" are as defined above, and le and R" together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, C1-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, Ci-C4fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alkyl)2, -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-OH, -NH(C1-C4alky1)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH7; -0(Ci-C4alkyl)-NH-(Ci-C4alkyl), and -0(Ci-C4alkyl)-N-(Ci-C4alky02, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[00111] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-IT:
x3 wl Formula B-II.
x3 wl Formula B-II.
[00112] Among the compounds of Formula B-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-III-1, Formula B-III-2 or Formula B-III-3:
X2¨X1 I Rsc w2 X R8b X <R8b R3 R8a R3 R8a 4)----"U
Formula B-111-1 Formula B-III-2 R1 Red X2_X I R8 X3 wi Formula B-III-3.
X2¨X1 I Rsc w2 X R8b X <R8b R3 R8a R3 R8a 4)----"U
Formula B-111-1 Formula B-III-2 R1 Red X2_X I R8 X3 wi Formula B-III-3.
[00113] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-III- 1 :
R1 Rsd X2_XJ R8c R8b R3 R8a Formula B-111-1
R1 Rsd X2_XJ R8c R8b R3 R8a Formula B-111-1
[00114] Among the compounds of Formula B-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Fonnula B-TV:
R3 R8a Formula B-W.
R3 R8a Formula B-W.
[00115] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, or -S(=0)2NH-.
[00116] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, or -C(=0)NH-.
[00117] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R3 is Ci-C3alkyl.
[00118] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R4 is¨NHR5, -N(R5)2, or -N (R5)3; and each Rs is independently selected from H, Ci-C3a1kyl, and -C1-C3alkyl-(C3-05cycloalkyl).
[00119] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, or -C(=0)NH-;
R3 is Ci-C3alkyl;
R4 is¨NHR5, -N(R5)2, or -N(R5)3; and each Rs is independently selected from H, C1-C3alkyl, and -Ci-C3alkyl-(C3-05cycloalkyl).
R3 is Ci-C3alkyl;
R4 is¨NHR5, -N(R5)2, or -N(R5)3; and each Rs is independently selected from H, C1-C3alkyl, and -Ci-C3alkyl-(C3-05cycloalkyl).
[00120] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, is R3
[00121] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, N Nook is = H
[00122] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring.
[00123] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, (R9/0-2 R3 cHrYEA..
is H ;and q is 1, 2 or 3.
is H ;and q is 1, 2 or 3.
[00124] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring.
[00125] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, N µ22( -.1(.4 q R4 "1.0 is (R9)2 'and q is 1, 2 or 3.
[00126] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stercoisomer thereof, is one group of compounds wherein, X1 is selected from N-RA, S, S(0) and S(0)2; and X2 is CH2.
[00127] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-V-1, Formula B-V-2, or Formula B-V-3:
R2c R2 R2d R1 R2d R1 R8d _________________________ S \\(_____ S Rsc R2b w2 R2.
R2a ..,ixR8b R2a R8b R3 N R4 R6 R4 R8a R3 N R8a )-----U )------U
Formula B-V-1 Formula B-V-2 UL2c i_ _ __________________________________ S \____ R2b R2a ..,,.....c)<R8b N R8a )---Formula B-V-3
R2c R2 R2d R1 R2d R1 R8d _________________________ S \\(_____ S Rsc R2b w2 R2.
R2a ..,ixR8b R2a R8b R3 N R4 R6 R4 R8a R3 N R8a )-----U )------U
Formula B-V-1 Formula B-V-2 UL2c i_ _ __________________________________ S \____ R2b R2a ..,,.....c)<R8b N R8a )---Formula B-V-3
[00128] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-VI-1, Formula B-V1-2, Formula B-V1-3:
R2c 0 0 R2c 0 , R2d __________________ µv/ R w2 R2. 1 R2d \v/u R8d R2b S \(______ SRi R8c R2a ..õ...._<R8b R22 R8b R3 N(, R8a R3 N R82 )-----U /\-----U
Formula B-VI-1 Formula B-VI-2 R2c 0 0 R2d \\/, R1 ____________________________________ o R2b {____ R3 \N R8 a /\----"U
Formula B-VI-3
R2c 0 0 R2c 0 , R2d __________________ µv/ R w2 R2. 1 R2d \v/u R8d R2b S \(______ SRi R8c R2a ..õ...._<R8b R22 R8b R3 N(, R8a R3 N R82 )-----U /\-----U
Formula B-VI-1 Formula B-VI-2 R2c 0 0 R2d \\/, R1 ____________________________________ o R2b {____ R3 \N R8 a /\----"U
Formula B-VI-3
[00129] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-VII-1, Formula B-VII-2 or Formula B-VII-3 R2c R2c R2d R1 R2d R1 R8d R2b ______________________ 0 \\(______w2 R2. 0 R8c R2a ..........cx R8 b R22 R8b R3 N R8a R3 N R82 )---- U )-----U
Formula B-VII-1 Formula B-VII-2 R 2c R2d ________________________________________ 0 \f____ R2b R2a ..,......< R8 b R3 N R8 a )----U
Formula B-VII-3
Formula B-VII-1 Formula B-VII-2 R 2c R2d ________________________________________ 0 \f____ R2b R2a ..,......< R8 b R3 N R8 a )----U
Formula B-VII-3
[00130] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stercoisomer thereof, is one group of compounds having the structure of Formula B-V-2, Formula B-VI-2, or Formula B-VII-2:
R2C R2 C0 , R2d R1 R8d R2d \vj Ri R8d R2. R2 S R8c S R8c .
R22 R8b R22 R8b R3 N R8a R3 N R8a )-----U )---U
Formula B-V-2 Formula B-VI-2 R2c R2d R1 R8d 0 Rsc a R2a R8b R3 N R8a /\---U
Formula B-VII-2
R2C R2 C0 , R2d R1 R8d R2d \vj Ri R8d R2. R2 S R8c S R8c .
R22 R8b R22 R8b R3 N R8a R3 N R8a )-----U )---U
Formula B-V-2 Formula B-VI-2 R2c R2d R1 R8d 0 Rsc a R2a R8b R3 N R8a /\---U
Formula B-VII-2
[00131] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-VIII-1, Formula B-VIII-2, or Formula B-VIII-3:
R \ RA\
R1 R1 R8d R3 N R8a R3 N R8a )---"U )-----"U
Formula B-VIII-1 Formula B-VIII-2 RA
\
RNN------ \(....._ R22 <IR8b R3 Rsa )----U)----..\\"N
Formula B-VIII-3
R \ RA\
R1 R1 R8d R3 N R8a R3 N R8a )---"U )-----"U
Formula B-VIII-1 Formula B-VIII-2 RA
\
RNN------ \(....._ R22 <IR8b R3 Rsa )----U)----..\\"N
Formula B-VIII-3
[00132] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein X1 is CH2; and X2 is selected from 0, N-RA, S, S(0), and S(0)2.
[00133] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-a-1 or Formula B-IX-2:
R2r R2d R2b -- R2b R3 N R8a R3 N R8a )-----L1 )------U
Formula B-IX-1 Formula B-IX-2
R2r R2d R2b -- R2b R3 N R8a R3 N R8a )-----L1 )------U
Formula B-IX-1 Formula B-IX-2
[00134] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-X:
w2 R3 R8a R4 a R6 Fomula B-X
w2 R3 R8a R4 a R6 Fomula B-X
[00135] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-XT-1 or Formula B-XI-2:
R2r R2e R22 w2 R2b R3 R82 R$
R8a Formula B-XI-1 Formula B-XI-2 wherein, ring A is a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, substituted or unsubstituted 5-10 membered aryl ring, or substituted or unsubstituted 5-10 membered heteroaryl ring.
R2r R2e R22 w2 R2b R3 R82 R$
R8a Formula B-XI-1 Formula B-XI-2 wherein, ring A is a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, substituted or unsubstituted 5-10 membered aryl ring, or substituted or unsubstituted 5-10 membered heteroaryl ring.
[00136] Within such a group of compounds are compounds wherein ring A is selected from indolyl and phenyl.
[00137] Among the compounds of Formula B-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-XT-1:
[00138] Among the compounds of Formula B-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Fomula B-XII:
b R22 R8b R3 R8a Formula B-XII
b R22 R8b R3 R8a Formula B-XII
[00139] Within such a group of compounds are compounds wherein Rga and R8b are independently selected from H and CI-C3alkyl.
[00140] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-XIII:
v2 vi Ri R2b --ix R2a Formula B-XIII
v2 vi Ri R2b --ix R2a Formula B-XIII
[00141] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-XTV:
R2b R2a N
Formula B-XIV
R2b R2a N
Formula B-XIV
[00142] Within the group of compounds of Formula B-XII, B-XIII and B-XIV are compounds wherein XI
is 0, S or S(0)2, and X2 is CH2.
is 0, S or S(0)2, and X2 is CH2.
[00143] Within the group of compounds of Formula B-XII, B-XIII and B-XIV are compounds wherein XI
is 0, and X2 is N-RA.
is 0, and X2 is N-RA.
[00144] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein X1 is 0, S or S(0)7, and X2 is CH2;
or X1 is N-RA and X2 is C=0 or CH);
or X1 and X2 are C and are members of a fused substituted or unsubstituted a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted membered heteroaryl ring;
RA is H, CI-Coalkyl, or ¨C(=0)CI-C6alkyl.
or X1 is N-RA and X2 is C=0 or CH);
or X1 and X2 are C and are members of a fused substituted or unsubstituted a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted membered heteroaryl ring;
RA is H, CI-Coalkyl, or ¨C(=0)CI-C6alkyl.
[00145] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8b and We together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N.
[00146] Within such a group of compounds arc compounds having the structure of Formula B-XV:
X2¨X = R1 (R9)0-3 Formula B- XV
wherein ring B is an aryl or heteroaryl ring.
X2¨X = R1 (R9)0-3 Formula B- XV
wherein ring B is an aryl or heteroaryl ring.
[00147] In some embodiments, ring B is an aryl. In some embodiments, ring B is phenyl. In some embodiments, ring B is a heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring or a bicyclic heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring. In some embodiments, ring B is a bicyclic heteroaryl ring. In some embodiments, ring B
is selected from phenyl, pyridinyl and thiophenyl. In some embodiments, ring B is selected from pyridinyl and thiophenyl.
is selected from phenyl, pyridinyl and thiophenyl. In some embodiments, ring B is selected from pyridinyl and thiophenyl.
[00148] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8 and le together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N or R8c and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N.
[00149] Within such a group arc compounds having the structure of Formula B-XVI-1, Formula B-XVI-2, Formula B-XVI-3, or Formula B-XVI-4:
RI RI
X2¨X1 X2¨X1 )1-4 X3 )1-4 X3 U
Formula B-XV1-1 Formula B-XVI-2 x2¨xi Ri R1 X2¨X ' )1-3 Formula B-XVI-3 Formula B-XV1-4;
or having the structure of Formula B-XVII-1 or Formula B-XVII-2:
)1-3 Formula B-XVII-1 Formula B-XVII-2 wherein RA is H, Ci-C3alkyl or ¨C(=0)C i-C3alkyl.
RI RI
X2¨X1 X2¨X1 )1-4 X3 )1-4 X3 U
Formula B-XV1-1 Formula B-XVI-2 x2¨xi Ri R1 X2¨X ' )1-3 Formula B-XVI-3 Formula B-XV1-4;
or having the structure of Formula B-XVII-1 or Formula B-XVII-2:
)1-3 Formula B-XVII-1 Formula B-XVII-2 wherein RA is H, Ci-C3alkyl or ¨C(=0)C i-C3alkyl.
[00150] Among the compounds of Formula B-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8b and R8c together form a bond.
[00151] Within such a group are compounds having the structure of Formula B-XVIII:
R1 R8d X2¨X1 X3 R8a Formula B-XVIII.
R1 R8d X2¨X1 X3 R8a Formula B-XVIII.
[00152] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-XIX:
Ri x2¨X1 =
R8a Formula B-XIX.
Ri x2¨X1 =
R8a Formula B-XIX.
[00153] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-XX:
X2¨X1 =
Formula B-XX.
X2¨X1 =
Formula B-XX.
[00154] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula B-XXI:
X2¨X1 =
Formula B-XX1.
X2¨X1 =
Formula B-XX1.
[00155] In another aspect, provided herein are compounds having the structure of Formula B-XXII, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
R2b R8b R2a 0N R8a N H
Formula B-XX11 wherein, W2 is 0, S, or R1 is H, or C1-C6alkyl;
XI is 0, N-RA, S, S(0), or S(0)2;
RA is H, C1-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R22 and R21) are independently selected from H, substituted or unsubstituted Ci-C6alkyl, and ¨
C(=0)RD;
RD is substituted or unsubstituted C1-C6alkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C[-Coalkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or CI-C3fluoroalkyl;
each R5 is independently selected from H, C1-C3alkyl, CI-C3ha1oa1ky1, C1-C3heteroalky1 and -C1-C3alkyl-(C3-05cycloalkyl);
each le is independently selected from Ci-C6alky1, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloa1kyl), -C1-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R and Rgb are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
R8c and led are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, CI-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alkyl)2, -C(=0)0H, -C(=0)NH2, -C(=0)Ci-C3alkyl, -S(=0)2CH3, -NH(Ci-C4alkyl)-OH, -NH(Ct-C4alkyl)-0-(C1-C4alkyl), -0(CI-C4alky1)-NH2; -0(CI-C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or CI -C3alkyl.
R2b R8b R2a 0N R8a N H
Formula B-XX11 wherein, W2 is 0, S, or R1 is H, or C1-C6alkyl;
XI is 0, N-RA, S, S(0), or S(0)2;
RA is H, C1-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R22 and R21) are independently selected from H, substituted or unsubstituted Ci-C6alkyl, and ¨
C(=0)RD;
RD is substituted or unsubstituted C1-C6alkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C[-Coalkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or CI-C3fluoroalkyl;
each R5 is independently selected from H, C1-C3alkyl, CI-C3ha1oa1ky1, C1-C3heteroalky1 and -C1-C3alkyl-(C3-05cycloalkyl);
each le is independently selected from Ci-C6alky1, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloa1kyl), -C1-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R and Rgb are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
R8c and led are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, CI-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-C4alkyl)2, -C(=0)0H, -C(=0)NH2, -C(=0)Ci-C3alkyl, -S(=0)2CH3, -NH(Ci-C4alkyl)-OH, -NH(Ct-C4alkyl)-0-(C1-C4alkyl), -0(CI-C4alky1)-NH2; -0(CI-C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or CI -C3alkyl.
[00156] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R2a, R2b R2e, R2d, R2e, and K2f are independently selected from H, C1-C3alkyl and -C(=0)RB; and le is substituted or unsubstituted Ci-C6alkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl).
[00157] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racematc or stereoisomer thereof, is one group of compounds wherein R2a, R2b R2c, R2d, R2e, and R2f are independently H or Ci-C3 alkyl.
[00158] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racematc or stereoisomer thereof, is one group of compounds wherein R1 is H or methyl.
[00159] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R1 is H.
[00160] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is ¨NHC(=0)R7, -C(=0)NHR7, ¨NHS(=0)2R7, -S(=0)2NHR7; ¨NHC(=0)NHR7, -NHS(=0)2NHR7, ¨(Ci-C3alkyl)-NHC(=0)R7, ¨(C1-C3alky1)-C(=0)NHR5, ¨(C1-C3a1kyl)-NHS(=0)2R7, ¨(Ci-C3alkyl)-S(=0)2NHR7; ¨(Ci-C3alkyl)-NHC(=0)NHR7, or ¨(Ci-C3alkyl)-NHS(=0)2NHR7.
[00161] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is substituted or unsubstituted G-Cioheterocycloalkyl, or substituted or unsubstituted heteroaryl.
[00162] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted C2-C10heterocycloalkyl.
[00163] Among the compounds of Formula B described above or below, or pharmaceutically acceptable saltõV-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted heteroaryl.
[00164] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NHR7, -S(=0)2NHR7,¨(Ci-C3alkyl)-C(=0)NHRs, or ¨(Ci-C3alkyl)-S(=0)2NHR7 .
[00165] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NHR7, or -S(=0)2NHR7.
[00166] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R6 is ¨C(=0)NHR7.
[00167] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, each R7 is independently selected from a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C2-Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyksubstituted or unsubstituted C3-C iocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C7-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH?)p-CH(substituted or unsubstituted aryl) ,-(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl).
[00168] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R7 is independently selected from a substituted or unsubstituted C3-Cipcycloalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, and ¨(CH2)p-CH(substituted or unsubstituted aryl)2.
[00169] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R7 is selected from \.. 0 .7.,;_N1 0 N
I
N
I
Me ;s5' .., Vcc 'I Me -., -- .- N
, , , , N -csss N NN. Me y si \
/
.. N , / , N
Me , H .
I
N
I
Me ;s5' .., Vcc 'I Me -., -- .- N
, , , , N -csss N NN. Me y si \
/
.. N , / , N
Me , H .
[00170] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, W2 is C(R8e)(e);
R1 is H;
R2a, R2b are independently selected from H, and C1-C3alkyl;
"ez- H
A
R3 is : H =
z R8a, R8b, R8e, R8d are independently selected from H and Ci-C3alkyl.
R1 is H;
R2a, R2b are independently selected from H, and C1-C3alkyl;
"ez- H
A
R3 is : H =
z R8a, R8b, R8e, R8d are independently selected from H and Ci-C3alkyl.
[00171] Any combination of the groups described above or below for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[00172] Among the compounds of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, are compounds selected from:
c 01::! H c..._..\c,1--- ,. 0 H j\---N
-TI /N :. H 0 N
Me /vie l-J H , Me -.111e 0 H
, H H
c N
/N :. 0 Me - 0 H , Me Me 0 N
Me H , NH
, H H
Hi\--N .= Hi\--N .
/N , H 0 0 h1 H 0 N
Me - Me Me 0 , H
Me , H H
(0 -0 c)s ,N , H CI ce¨N
Mel Me e ' 0 H , Me fvi ¨
, H H H
/1\I
, H
Me i/ie 0 H ,Me/ M
..;
e , H H
H
ro,_\
-Nr\I
/N , H 0 0 Hmi Me - ert 0 0 Me "iiie , 1/ie H
, (-) 0 H._...., ii L , S I-1, c....S.(viem 0 N 0 cli Hi\---N s. H"-N ==
, 0 0 hi N¨" H 0 0 1_1 Me/ -;
Me iiie Me , , H
S._.....
0\\ cNi .....? 0 C , [IjAH7 eMe H
Boc ,11.--(-11 0 )2--N`. \N
-F1µ 1 )--Ni=
Me' i-vie 0 H Me' me 0 H
, H
(-0 7 o,P
µs,l_____ o O c_lcri--.)- , iiii\--NN
, . H 0 0 NH
H j\---N ' Md Me 0 -.-1\1µ
'NI , H 0 H
Me Me = , OH
HO
H
H
H
O N 7 Me MAIM
Hi-N(,.Nria N . ---=
kJ 0 Me' Me Hj\N N
Mai N . H 0 n Ns le .... H
, Me Me , OH OH
H
OH
H H
: Me 7 Me MAI MAI:
111.
Hi\---N WAIL
õ Ns lir , Ns* 0 ..., H 1/4., H
Me' Me , Me' Me , HO
H
:0 H H H
__..,,.7 7 Me MAim MAI:-Wir Hi\---N Wail Hi-N
lir N . H 0 N
Me s. 0 0 H Me 0 H
Me Me , ,and H
OH
H
7 Me O N
Hi\---N Hlir illaltri %-, Me' Me
c 01::! H c..._..\c,1--- ,. 0 H j\---N
-TI /N :. H 0 N
Me /vie l-J H , Me -.111e 0 H
, H H
c N
/N :. 0 Me - 0 H , Me Me 0 N
Me H , NH
, H H
Hi\--N .= Hi\--N .
/N , H 0 0 h1 H 0 N
Me - Me Me 0 , H
Me , H H
(0 -0 c)s ,N , H CI ce¨N
Mel Me e ' 0 H , Me fvi ¨
, H H H
/1\I
, H
Me i/ie 0 H ,Me/ M
..;
e , H H
H
ro,_\
-Nr\I
/N , H 0 0 Hmi Me - ert 0 0 Me "iiie , 1/ie H
, (-) 0 H._...., ii L , S I-1, c....S.(viem 0 N 0 cli Hi\---N s. H"-N ==
, 0 0 hi N¨" H 0 0 1_1 Me/ -;
Me iiie Me , , H
S._.....
0\\ cNi .....? 0 C , [IjAH7 eMe H
Boc ,11.--(-11 0 )2--N`. \N
-F1µ 1 )--Ni=
Me' i-vie 0 H Me' me 0 H
, H
(-0 7 o,P
µs,l_____ o O c_lcri--.)- , iiii\--NN
, . H 0 0 NH
H j\---N ' Md Me 0 -.-1\1µ
'NI , H 0 H
Me Me = , OH
HO
H
H
H
O N 7 Me MAIM
Hi-N(,.Nria N . ---=
kJ 0 Me' Me Hj\N N
Mai N . H 0 n Ns le .... H
, Me Me , OH OH
H
OH
H H
: Me 7 Me MAI MAI:
111.
Hi\---N WAIL
õ Ns lir , Ns* 0 ..., H 1/4., H
Me' Me , Me' Me , HO
H
:0 H H H
__..,,.7 7 Me MAim MAI:-Wir Hi\---N Wail Hi-N
lir N . H 0 N
Me s. 0 0 H Me 0 H
Me Me , ,and H
OH
H
7 Me O N
Hi\---N Hlir illaltri %-, Me' Me
[00173] In some embodiments, a compound of Formula B described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof, is t\-11 H
0\\
1-111-7-HN 0 0 HINIµ.
:-Me -Me
0\\
1-111-7-HN 0 0 HINIµ.
:-Me -Me
[00174] Also provided herein are pharmaceutical compositions comprising a compound of Formula B
described above, or pharmaceutically acceptable salt, IV-oxide, racemate or stereoisomer thereof, and a pharmaceutically acceptable carrier.
Formula C -Eight-five ring systems
described above, or pharmaceutically acceptable salt, IV-oxide, racemate or stereoisomer thereof, and a pharmaceutically acceptable carrier.
Formula C -Eight-five ring systems
[00175] As used herein, Formula C includes compounds of Formula C-I, Formula C-II, Formula C-III-1, Formula C-III-2, Formula C-III-3, Formula C-IV, Formula C-V-1, Formula C-V-2, Formula C-V-3, Formula C-VI-1, Formula C-VI-2, Formula C-VI-3, Formula C-VII-1, Formula C-VII-2, Formula C-VII-3, Formula C-VIII-1, Formula C-VIII-2, Formula C-VIII-3, Formula C-IX-1, Formula C-IX-2, Formula C-X-1, Formula C-X-2, Formula C-XI, Formula C-XII, Formula C-XIII, Formula C-XIV, Formula C-XV-1, Formula C-XV-2, Formula C-XV-3, Formula C-XV-4, Formula C-XVI-1, Formula C-XVI-2, Formula C-XVII, Formula C-XVIII, Formula C-XIX, Formula C-XX, and Formula C-XXI.
[00176] In one aspect, described herein is a compound of Formula C-I, or a pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, as described in the summary of the invention.
[00177] In another aspect, provided herein are compounds having the structure of Formula C-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
y2-x1 R
\õ,W2 wi U ____________________________________ 0 R3 _________________________ ( Formula C-1 wherein, R1 is H, C1-C6alkyl, C3-C6cycloalkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X' is selected from N-RA, S, S(0) and S(0)2, then X2 is cR2c-.-.K 2d, and X3 is cR2,,R2b;
Or when XI is 0, then X2 is selected from CR2eR2d and N-RA, and X3 is CR22R2b;
or:
when X1 is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is cR2aR2b;
or:
X1 is CR2eR2f and X2 is CR2eR2d, and R2' and R2' together form a bond, and X3 is CR2aR2b;
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring;, and X3 is CR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X' is CR2eR
2t;
RA is H, Ci-C6alkyl, ¨C(=0)Ct-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
W' is 0, S, N-R', or C(R8d)(R8b);
W2 is 0, S, N-RA, or CH-0(e); provided that W1 and W2 are not both 0, or both S;
R2a R2b, R2c, R2d R2e, and ¨2 f x are independently selected from H, substituted or unsubstituted CI-C6alkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heteroeycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl) and ¨
C(=0)RD;
RD is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalky1, substituted or unsubstituted C2-05heteroeycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alky(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), ¨CI -C6alkyl-(substituted or unsubstituted heteroaryl) or ¨
NRDRD;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C9' C5heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3a1kyl, or CI-C3fluoroalky1;
R4 is -NHR5, -N(R5)2, -N(R5)3 or -0R5;
each R5 is independently selected from H, C1-C3a1kyl, CI-C3haloalkyl, Ci-C3heteroalkyl and -CI-C3a1kyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(C1 -C3 alkyl)-NHC(=0)127, -(C 1-C3 alkyl)-C(=0)NHR5, -(Ct -C
3 alkyl)-NHS(=0)2R7, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(C1-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-C10heterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted hctcroaryl, -C1-C6alkyl-(substituted or unsubstitutcd C3-Ciocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -CI-C6alkyl-(substituted or unsubstituted aryl), -C1-C6a1kyksubstituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)1,-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R8a, Rn, R8c, and led are independently selected from H, Ci-C6alky1, C1-C6fluoroa1kyl, C1-C6 alkoxy, Ci-C6heteroa1kyl, and substituted or unsubstituted aryl;
or:
R8a and R8d are as defined above, and R8b and R8e together form a bond;
or:
R8a and R8d are as defined above, and leb and R8e together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 hetcroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8e and R8d are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8a and leb are as defined above, and lee and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH,-SH, (C=0), CN, Ci-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-OH, -NH(C1-C4alky1)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(CI-C4alky1)-NH-(CI-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or CI-C3alkyl.
y2-x1 R
\õ,W2 wi U ____________________________________ 0 R3 _________________________ ( Formula C-1 wherein, R1 is H, C1-C6alkyl, C3-C6cycloalkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X' is selected from N-RA, S, S(0) and S(0)2, then X2 is cR2c-.-.K 2d, and X3 is cR2,,R2b;
Or when XI is 0, then X2 is selected from CR2eR2d and N-RA, and X3 is CR22R2b;
or:
when X1 is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is cR2aR2b;
or:
X1 is CR2eR2f and X2 is CR2eR2d, and R2' and R2' together form a bond, and X3 is CR2aR2b;
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring;, and X3 is CR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X' is CR2eR
2t;
RA is H, Ci-C6alkyl, ¨C(=0)Ct-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
W' is 0, S, N-R', or C(R8d)(R8b);
W2 is 0, S, N-RA, or CH-0(e); provided that W1 and W2 are not both 0, or both S;
R2a R2b, R2c, R2d R2e, and ¨2 f x are independently selected from H, substituted or unsubstituted CI-C6alkyl, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heteroeycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl) and ¨
C(=0)RD;
RD is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalky1, substituted or unsubstituted C2-05heteroeycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alky(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), ¨CI -C6alkyl-(substituted or unsubstituted heteroaryl) or ¨
NRDRD;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C9' C5heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3a1kyl, or CI-C3fluoroalky1;
R4 is -NHR5, -N(R5)2, -N(R5)3 or -0R5;
each R5 is independently selected from H, C1-C3a1kyl, CI-C3haloalkyl, Ci-C3heteroalkyl and -CI-C3a1kyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(C1 -C3 alkyl)-NHC(=0)127, -(C 1-C3 alkyl)-C(=0)NHR5, -(Ct -C
3 alkyl)-NHS(=0)2R7, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(C1-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-C10heterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted hctcroaryl, -C1-C6alkyl-(substituted or unsubstitutcd C3-Ciocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -CI-C6alkyl-(substituted or unsubstituted aryl), -C1-C6a1kyksubstituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)1,-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R8a, Rn, R8c, and led are independently selected from H, Ci-C6alky1, C1-C6fluoroa1kyl, C1-C6 alkoxy, Ci-C6heteroa1kyl, and substituted or unsubstituted aryl;
or:
R8a and R8d are as defined above, and R8b and R8e together form a bond;
or:
R8a and R8d are as defined above, and leb and R8e together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 hetcroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8e and R8d are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8a and leb are as defined above, and lee and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH,-SH, (C=0), CN, Ci-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-OH, -NH(C1-C4alky1)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(CI-C4alky1)-NH-(CI-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or CI-C3alkyl.
[00178] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-11:
X2¨X1 RWi ______________________________ U 0 Formula C-H.
X2¨X1 RWi ______________________________ U 0 Formula C-H.
[00179] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-III-1, Formula C-III-2 or Formula C-III-3:
R8(21 X2¨
v2_ xl K R8c X1 Ri r's X3 Rx3 R8a R R8a _______________ U 0 U 0 Formula C-ITT-1 Formula C-HT-2 R8d wl _____________________________ U 0 Formula C-III-3.
R8(21 X2¨
v2_ xl K R8c X1 Ri r's X3 Rx3 R8a R R8a _______________ U 0 U 0 Formula C-ITT-1 Formula C-HT-2 R8d wl _____________________________ U 0 Formula C-III-3.
[00180] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-III-1:
R8d / X2¨ X1 R8c X3 R8b R8a R3 (N
_________________________ U 0 Formula C-III-1
R8d / X2¨ X1 R8c X3 R8b R8a R3 (N
_________________________ U 0 Formula C-III-1
[00181] Among the compounds of Formula C-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-IV:
X2¨X1 R1 X3 Reb Rea ________________________________ U 0 Formula C-1V
X2¨X1 R1 X3 Reb Rea ________________________________ U 0 Formula C-1V
[00182] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, or -S(=0)2NH-.
[00183] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, or -C(=0)NH-.
1001841 Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R3 is Ci-C3alkyl.
[00185] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R4 is¨NHR5, -N(R5)2, or -1\r(R5)3; and each R5 is independently selected from H, Ci-C3alkyl, and -CI-C3alkyl-(C3-05cycloalkyl).
[00186] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, or -C(=0)NH-;
R3 is C1-C3alkyl;
R4 is¨NHR5, -N(R5)2, or -1\r(R5)3; and each R5 is independently selected from H, Ci-C3alkyl, and -CI-C3alkyl-(C3-05cycloalkyl).
[00187] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R4 is R3 [00188] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, N
= N
R4 U is H
[00189] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring.
[00190] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, (R9)o-2 ,/=-===.
is H and q is 1, 2 or 3.
[00191] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein le is bonded to a nitrogen atom of U to form a substituted or unsubstitutcd 5-7 membered ring.
[00192] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, N
/1-4q R4 s (R9)0-2 ; and q is 1, 2 or 3.
[00193] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, X1 is selected from N-RA, S. 5(0) and S(0)2; and X' is CH2.
[00194] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-V-1 or Formula C-V-2 or Formula C-V-3:
R2' R2c R2d R1 R2d R1 R8d Rsc R2t, R2' R2a2 R8b R2a R 8b R8a Formula C-V-1 Formula C-V-2 R2c R R2d _____________________________ 2b R1 R2a S
/N R8a _______________________________ U 0 Formula C-V-3 [00195] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-VI-1 or Formula C-VI-2 or Formula C-VI-3:
R2c 0 R2c 0 R2d \ \//0 R2d I If? 1 R8d 8c R2b S R1 R2b s R R
R2a Rs: R2a R8b Rsa ) ______________________ U 0 ) __ U 0 Formula C-VI- 1 Formula C-VI-2 Rai \,O/
R2b R2a ..........\><R8b /N R8a R3 \\ R8 ) __ U 0 Formula C-VI-3 [00196] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable saltõV-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-VII-1 or Formula C-VII-2 or Formula C-VII-3:
R2c R2c R2d R2b R2d R8d R8c R2b 0.µ R1 7 0 R1 R2a R2a R8b /N Rsa /N Rsa ) ______________________ U 0 ) __ U 0 Formula C-VII-1 Formula C-VII-2 R2c R2d R2b ..........\><R8b /N R8a ) __ U 0 Formula C-VII-3 [00197] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable saltõV-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-VIII-1 or Formula C-VIII-2 or Formula C-VIII-3:
R2c RA R2c RA
/
R2b R2d i\j/ R1 R2b R2d Red N R1 R8c \--W2 R2a R8b R2a R8b ) _____________ U 0 ) __ U 0 Formula C-VIII-1 Formula C-VIII-2 R2c RA
R2d /
R2b R2a \,,---0 .......,\><R8b /N Oa ) ____________________________ U 0 Formula C-VIII-3 [00198] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds haying the structure of Formula C-V-2 or Formula C-VI-2 or Formula C-VII-2 or Formula C-VIII-2:
R2c R2c R2d R2d RO R8d R2b R2b S/ Ri R8c S R1 R8dR8c R2a R8b R2a R8b /N R8a /N R8a ) _____________ U 0 ) __ U 0 Formula C-V-2 Formula C-VI-2 R2c R2c RA
R2d R8d R2d / Red R2' 0 R1 R8c R2b N R1 R8c R2a R8b R2a R8b N R8a /N R8a ) _____________ U 0 ) __ U 0 Formula C-V11-2 Formula C-V111-2 [00199] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein X1 is CH2; and X2 is selected from 0, N-RA, S, S(0), and S(0)2.
[00200] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof; is one group of compounds having the structure of Formula C-IX-1 or Formula C-IX-2:
R2d R21 R8d __________________ R1 R8c R2a R1 Rac R2b R2b R8b R8b R8a Raa Formula C-IX-1 Formula C-IX-2 [00201] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-X-1 or Formula C-X-2:
A R2e R2f R2b w2 W2 RBb <R8b R8a R8a ______________ U 0 U 0 Formula C-X-1 Formula C-X-2 wherein ring A is a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, substituted or unsubstituted 5-10 membered aryl ring, or substituted or unsubstituted 5-10 membered heteroaryl ring.
[00202] Within such a group of compounds are compounds wherein ring A is selected from indolyl and phenyl.
[00203] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof; is one group of compounds having the structure of Formula C-XI:
2b 2_x1 Ri A/X
R a F Rai) R8a R3 (N
Formula C-XI
[00204] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-XII:
2b Rfax2_xi R1 R3 __ > _____ 0 Formula C-XII
[00205] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-XIII:
2b Rf)(2¨x1 R1 _______________________________ U 0 Formula C-XTTI
[00206] Among the compounds of Formula C-XI, Formula C-XII and Formula is one group of compounds wherein X' is 0, S or S(0)2, and X2 is CH2.
[00207] Among the compounds of Formula C-XI, Formula C-Xii and Formula C-XIII, is one group of compounds wherein X1 is N-RA, and X2 CH2.
[00208] Among the compounds is one group of compounds wherein R2a, R2F, R2c, R2d, R2e, and R2f are independently H or C1-C3 alkyl; and R1 is H or methyl. Among the compounds is one group of compounds wherein RI is H.
[00209] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N.
[00210] Within such a group of compounds are compounds having the structure of Formula C-XIV:
X2¨Xi R1 (R9)0-3 x3 __________________________ U 0 Formula C- XIV
where ring B is an aryl or heteroaryl ring.
[00211] In some embodiments, ring B is an aryl. In some embodiments, ring B is phenyl. In some embodiments, ring B is a heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring or a bicyclic heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring. In some embodiments, ring B is a bicyclic heteroaryl ring. In some embodiments, ring B
is selected from phenyl, pyridinyl and thiophenyl. In some embodiments, ring B is selected from pyridinyl and thiophenyl.
[00212] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N; or R8c and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N.
[00213] Within such a group of compounds are compoundds having the structure of Formula C-XV-1, Formula C-XV-2, Formula C-XV-3, or Formula C-XV-4:
y2- x1 R1 /'µ y2 -xl Ri )1-4 x3 )1-4 R3 R __ U
Formula C-XV-1 Formula C-XV-2 X2 X1 R1 x2¨x1 R1 R a )1-3 3 (N
_________________ U 0 U 0 Formula C-XV-3 Formula C-XV-4 or having the structure of Formula C-XVI-1 or Formula C-XVI-2:
RA
X2¨X1 Ri y2 ¨x1 W
)1-3 N
Formula C-XVI-1 Formula C-XVI-2 wherein RA is H, Ci-C3alky1 or ¨C(=0)Ci-C3alkyl.
[00214] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein Rgb and le together form a bond.
[00215] Within such a group of compounds are compounds having the structure of Formula C-XVII:
R1 Rsd fx2¨xi X3 Rsa Formula C-XVII
[00216] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-XVIII:
X2¨X1 R1 /
X3 R8b 8a _____________________________ U 0 Formula C-XVIII
[00217] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof; is one group of compounds having the structure of Formula C-XIX:
x2¨x1 R1 /
X3 R8b /N R8a Formula C-XIX
[00218] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-XX:
y2¨ x1 R1 /'s R8a Formula C-XX
[00219] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-XXI, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
R22 R8b /N R8a HN
Formula C-XXI
wherein, W2 is 0, S, or C(R8e)(R8(I);
R' is H, or Ci-Coalkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, Ci-C6alkyl, -C(=0)C1-C6a1kyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a and R2b are independently selected from H, substituted or unsubstituted Ci-C6alkyl, and -C(=O)RD;
RD is substituted or unsubstituted -Ci-C6alkyl-(substituted or unsubstituted C6cycloa1kyl), -Ci-C6alky1-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alky1-(substituted or unsubstituted aryl), -C1-C6a1kyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted CI-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alky1, or C1-C3fluoroa1kyl;
each R' is independently selected from H, Ct-C3alkyl, C1-C3haloa1kyl, Ci-C3heteroalky1 and -CI-C3alky1-(C3-05cycloalkyl);
each R7 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C1ohetcrocycloa1kyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -C1-C6alky1-(substituted or unsubstituted aryl), -C1-C6a1kyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
RS 'T and leb are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
Rg and led are independently selected from H, C1-C6alkyl, and C1-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, C1-C4alkyl, C1-C4 fluoro alkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(CI-C4alkyl), -NH(Ci-C4alky1)2, -C(=0)0H, -C(=O)N H,, -C(=0)C 1-C3alkyl, -S(=0)2C111, -N H(C -C4alkyl)-OH, -81--NH(C1-C4alkyl) -0 -(Ci-C4alkyl), - 0 (C -C4alkyl)-NH2; -0(C -C4alkyl)-NH-(C 1 -C4alkyl), and -0(C -C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached folin a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
[00220] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R2a, R2b R2c, R2d, R2e, and K-21 are independently selected from H, Ci-C3alkyl and -C(=0)RB; and RB is substituted or unsubstituted Ci-C6alkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyksubstituted or unsubstituted heteroaryl).
[00221] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R2a, R2b R2c, R2d, R2e, and R21 are independently H or Ci-C3 alkyl.
[00222] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R1 is H or methyl.
[00223] Among the compounds of Formula C described above or below, or pharmaceutically acceptable saltõAr-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R1 is H.
[00224] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is ¨NHC(=0)R7, -C(=0)NHR7, ¨NHS(=0)2R7, -S(=0)4\THR7; ¨NHC(=0)NHR7, -NH S (=0)2NHR7, ¨(C1 -C3 alkyl)-NHC(=0)R7, ¨(C 1-C3 alkyl)-C(=0)NHR5, ¨(Ct -C
3 alkyl)-NHS(=0)2R7, ¨(Ci-C3alkyl)-S(=0)2NHR7; ¨(Ci-C3alkyl)-NHC(=0)NHR7, or ¨(Ci-C3alkyl)-NHS(=0)2NHR7.
[00225] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is substituted or unsubstituted C2-C10heterocycloalkyl, or substituted or unsubstituted heteroaryl.
[00226] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted C2-Cioheterocycloalkyl.
[00227] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted heteroaryl.
[00228] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NHR7, -S(=0)2NHR7,¨(Ci-C3alkyl)-C(-0)NFIR', or ¨(Ci-C3alkyl)-S(=0)2NHR7 .
[00229] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NHR7, or -S(=0)2NHR7.
[00230] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R6 is ¨C(=0)NHR7.
[00231] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, each R7 is independently selected from a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C iocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted G-Cioheterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2-(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl).
[00232] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racematc or stereoisomer thereof, is one group of compounds wherein, R7 is independently selected from a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C2-Cipheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, and ¨(CH2)p-CH(substituted or unsubstituted ary1)2.
[00233] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R7 is selected from ,,N
N
tt1/4 I
Me 's555 0 .., -. N 11101 I
-- ,'-' ,-, , N
N N Me, , Me , , I
,z, i Nõ. Me 'csss 0 \
/
N
, H .
[00234] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, W2 is C(R8u)(R8();
R1 is H;
¨2a, K R21' are independently selected from H, and C1-C3alkyl;
R5 N 1\1-,)L, ook R3 is ' H =
z lea, Rgb, Rge, Rgd are independently selected from H and C1-C3alkyl.
[00235] Any combination of the groups described above or below for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[00236] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racematc or stereoisomer thereof, arc compounds selected from:
0 ,c¨NNHH 0 4c¨NNH
,TIJI.-.. ,1-1 11 INH
Me : IF1 N Me N
Me 0 Me 0 HT" HN
, , Me 'y Me0 oc'NNN,,,H 0 H 0 ----\N-Ac NpH
õNJ.
Me - N Me - N
Me 0 f Me 0 HN HN"' ',and I.
[00237] Also provided herein are pharmaceutical composition comprising a compound of Formula C, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof, and a pharmaceutically acceptable carrier.
Formula D -Seven-six ring systems [00238] As used herein, Formula D includes compounds of Formula D-I, Formula D-II, Foimula D-II-1, Formula D-II-2, Formula D-II-3, Formula D-III, Formula D-IV, Formula D-V-1, Formula D-V-2, Formula D-V-3, Formula D-VI-1, Formula D-VI-2, Formula D-VI-3, Formula D-VII-1, Formula D-VII-2, Formula D-VII-3, Formula D-VIII-1, Formula D-VIII-2, Formula D-VIII-3, Formula D-IX-1, Formula D-IX-2, Formula D-X, Formula D-XI-1, Formula D-X1-2, Formula D-X11-1, Formula D-X11-2, Formula D-XIII, Formula D-XIV, Formula D-XV, Formula D-XVI-1, Formula D-XVI-2, Formula D-XVI-3, Formula D-XVI-4, Formula D-XVII-1, Formula D-XVII-2, Formula D-XVIII-1, Formula D-XVIII-2, Formula D-XIX, Formula D-XX, Formula D-XXI and Formula D-XXII.
[00239] In one aspect, described herein is a compound of Formula D-I, or a pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, as described in the summary of the invention.
[00240] A compound having the structure of Formula D-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
x2-Xltw3 '\vv2 wi Formula D-I
wherein, R1 is H, Ci-C6alkyl, C3-C6cycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalltyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 is selected from N-RA, S, S(0) and S(0)2, then X2 is cR2c--It2d, and X3 is CR2aR21);
or when Xt is 0, then X2 is selected from CR2c'-'2d X and N-RA, and X3 is CR2aR2b or:
when Xt is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is cR2aR2b;
or:
.x1 is ceRzrand .x2 is cR2c-2d, and R2e and R2e together form a bond, and X3 is CR2aR2b;
or:
X1 and X3 are both CH2 and X2 is C=0, C=C(Rc)2, or C=NRc; where each Rc is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1 -C6alkyl-(substituted or unsubstituted C2-C5heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR2eR21;
W1 is 0, S, N-RA, or C(Rga)(R8b);
W2 is 0, S, N-R', or C(R8c)(R8d);
W3 is 0, S, N-RA, or C(R8e)(R8f); provided that the ring comprising V, W2 and W3 does not comprise two adjacent oxygen atoms or sulfur atoms;
RA is H, Ci-C6alkyl, ¨C(=0)Ct-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted hetcroaryl;
R2a R2b, R2c, R2d R2e, and ¨ x 2f are independently selected from H, substituted or unsubstituted C1-C6alky1, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05beterocycloalkyl), (substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl) and ¨
C(=0)RB;
RB is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), (substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE arc independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, i-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-C5heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 is -NHR5, -N(R)2, -N-(03 or -OR5;
each R5 is independently selected from H, Ci-C3alkyl, C1-C3haloalkyl, Ci-C3heteroalkyl and -C1-C3alkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(Ci -C3 alkyl)-NHC(=0)127, -(C -C3 alkyl)-C(=0)NHR% -(Ct -C3 alkyl)-NHS(=0)2R7, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(Ci-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-C10heterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from CI-C6a1kyl, Ci-C6haloalkyl, C1-C6hctcroalky1, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C loheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C10cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
Rsb, R8c, K-8d, R8eand R8f are independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, C1-C6 alkoxy, CI-C6hcteroalkyl, and substituted or unsubstitutcd aryl;
or:
R8a, R8d, R8eand R8f are as defined above, and R8b and R8e together form a bond;
or:
Rga, Rgb, led, and lef are as defined above, and R8' and R8' together form a bond;
or:
R8a, R8d, R8eand R8f are as defined above, and R8b and R8s together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
lea, Rgb, and ref are as defined above, and le' and le together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S. 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S. 0 and N;
or:
R8', R8d, R8eand R8f are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
lea, le, leand fef are as defined above, and R8' and led together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8a, WI', R8', and R8d are as defined above, and R8e and R8f together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, Ci-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-Caalkyl),), -C(=0)0H, -C(=0)NF17, -C(=0)Ci-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-0H, -NH(CI-C4alkyl)-0-(Ci-C4alkyl), -0 (C -C4alky1)-NF-17 ; -0(C -C4alkyl)-NH-(C -C4alkyl), and -0(C -C4alkyl)-N-(Ci -C4alkyl) ), or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[00241] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-II:
-w2 yR3 w1 Formula D-11 [00242] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-II-1, Formula D-11-2, or Formula D-II-3:
R8f R R8e X2--X1 w3 Red 3 R w2 Xee X3 R3 =R86 R3 N ylcR86 R8a R8a Formula D-I1-1 Formula D41-2 R8f X2¨X1 R8e Rsci X3 R8c R3 wl R' 0 R6 Formula D-II-3 [00243] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-III:
R8f R R8e X2--X1 R8d X3 flR8C
R3 R8b R8a Formula D-III
[00244] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-IV:
X2--X ' 0 R8d R8a Formula D-IV
[00245] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, or -S(=0)2NH-.
[00246] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, or -C(=0)NH-.
[00247] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R3 is C1-C3alkyl.
[00248] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R4 is¨NHR5, -N(R5)2, or -N(R5)3; and each R is independently selected from H, Ct-C3alkyl, and -Ci-C3alkyl-(C3-05cycloalkyl).
[00249] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(-0)-, or -C(=0)NH-;
R3 is C1-C3alkyl;
R4 is¨NHR5, -N(R5)2, or -N(R5)3; and each R5 is independently selected from H, Ci-C3alkyl, and -Ci-C3alkyl-(C3-05cycloalkyl).
[00250] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, ,.N )22-' R4) is R3 [00251] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, - N
is - H
[00252] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring.
[00253] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, (R9)0-2 R4j.0 is H ;and q is 1, 2 or 3.
[00254] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein le is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring.
[00255] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, H
N
N:2a N.
is (R9)0-2 ; and q is 1, 2 or 3.
[00256] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, X1 is selected from N-RA, S, S(0) and S(0)2; and X2 is CH2.
[00257] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-V-1, Formula D-V-2, or Formula D-V-3:
R2 R2c Rd R1 R2d R1 R8fR8e R2a _______________ S.\w3 R2bw2 R2* R8d Sjç
R2a R8c R8a Formula D-V-1 Formula D-V-2 R 2 c Rai R1 R2b d ll ......õ......
R22 ________________________________________ R8c R3 N ........õ..õ..\----R8b R4)-----U R8a Formula D-V-3 [00258] Among the compounds of Formula D4 described above or below, or pharmaceutically acceptable saltõV-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-VI-1, Formula D-VI-2, Formula D-VI-3:
R2c 00 R2 00 8f R2d \\ / Ri R2d \\// R1 R R8 R2be S Sw3 "===...w2 R2. R8d R2a I R2a R8c R3 N ,..,w1 R3 N--\-----R86 )---U )----U R8a Formula D-VI- 1 Formula D-VI-2 R2d \\// R1 S to N.,1._,t 2b ¨8d R
R2a R8c )---1.1 R8a Formula D-VI-3 [00259] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-VII-1, Formula D-VII-2 or Formula D-VII-3 R2c R2 R2d , R1 R2d r, R1 R81R8e L.,tw3 L., Rsd R2 b R2 o R2 ______________ w2 a I R2a R8c R3 N W I R3 N,.......\----R8b )-----11 /\----U R82 Formula D-VII-1 Formula D-VII-2 R2c R2d R2b R8c1 8c R8a R4 oR6 Formula D-VII-3 [00260] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-V-2, Formula D-VI-2, or Formula D-VII-2:
R8f R2d R R8e R2d \\// R1 R8e R2a R8c R2a R8c R3 N.çR8bR3 Rsa Raa Formula D-V-2 Formula D-VI-2 R2d R1 R8f R8e R2b R8d R2a R8c Rsa Formula D-VII-2 [00261] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group wherein R1 is H
or methyl; R2a, R2b R2c, R2d, R2e, and R2f are independently H or C 1-C3 alkyl; R8a, R81) R8c, R8d, R8e, and R8f are independently H or Ci-C3 alkyl.
[00262] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group wherein R1 is H.
[00263] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-VIII-1, Formula D-VITT-2, or Formula D-VTII-3:
RA R\ R8f _ R1 R1 \ R8e N----U R2a R2(,.
\ w \.
I R2a R8c \./W1 R3 N.....N...........õ\--R8b )-----U )-----U R8a Formula D-VIII-1 Formula D-VIII-2 RA
R2b N¨uto Rsd -......_ R22 R8c R3 N .....N.......õõ.7_Rsb )---U R82 Formula D-VIII-3 [00264] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein X1 is CH2; and X2 is selected from 0, N-RA, S, S(0), and S(0)2.
[00265] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-IX-1 or Formula D-IX-2:
R2d R2f __________________________ F.1 R1 R2 wa I
N- w 1 R3 N w 1 \/
)----U )-----U Y
Formula D-IX-1 Formula D-IX-2 [00266] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stercoisomer thereof, is one group of compounds having the structure of Formula D-X:
W&w2 I
R4 0 wl N \/
)-----U
Formula D-X
[00267] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-XI-1 or Formula D-XI-2:
R2e R2f R2b W3 w2 A WN3 w2 R2a Formula D-XI-1 Formula D-XI-2 wherein, ring A is a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, substituted or unsubstituted 5-10 membered aryl ring, or substituted or unsubstituted 5-10 membered heteroaryl ring.
[00268] Within this group of compounds are compounds wherein ring A is selected from indolyl and phenyl.
[00269] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, raccmate or stereoisomer thereof, is one group of compounds having the structure of Formula D-XII-1 or Formula D-XII-2:
X2¨X1 R8d R2b X2¨X1 R2a R8c R2a R3 Rab R3 R8b R8a R8a Formula D-XII-1 Formula D-XII-2 [00270] Within such a group of compounds wherein Rsa and R8b are independently selected from H and C1-C3alkyl.
[00271] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-XIII:
R2b XX
R2a Formula D-XIII
[00272] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-X1V:
R2b R2a Formula D-XIV
[00273] Among the compounds of Formula D-XII, Formula D-XIII and Formula D-XIV
are compounds wherein X[ is 0, S or S(0)2, and X2 is CH).
[00274] Among the compounds of Formula D-XII, Formula D-X111 and Formula D-XIV
are compounds wherein X' is 0, and X2 is N-RA.
[00275] Among the compounds of Formula D-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein leb and lee together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N.
[00276] Within such a group of compounds are compounds having the structure of Formula D-XV:
(R9)3 Formula D-XV
wherein ring B is an aryl or heteroaryl ring.
[00277] In some embodiments, ring B is an aryl. In some embodiments, ring B is phenyl. In some embodiments, ring B is a heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring or a bicyclic heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring. In some embodiments, ring B is a bicyclic heteroaryl ring. In some embodiments, ring B
is selected from phenyl, pyridinyl and thiophenyl. In some embodiments, ring B is selected from pyridinyl and thiophenyl.
[00278] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8 and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N or R8' and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N.
[00279] Within such a group of compounds arc compounds having the structure of Formula D-XVI-1, Formula D-XVI-2, Formula D-XVI-3, or Formula D-XVI-4:
W i W
X2¨X1 x2¨X ' )1-4 )-----U )----U R6 0 0 Formula D-XVI-1 Formula D-XVI-2 x2¨X1 X2¨X1 / 2 / /SJ)1-3 )¨sstJ 1-3 )-----"U 2 , Formula D-XV1-3 Formula D-XV1-4;
or compounds having the structure of Formula D-XVII-1 or Formula D-XVII-2:
,- RA
i R1 R1 N
X2¨X ' X2¨X1 X3 )2 X3 >,........_µN b }
)2 )-----U
/
Formula D-XVII-1 Formula D-XVII-2 wherein RA is H, C1-C3alky1 or ¨C(=0)Ci-C3a1kyl.
[00280] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8b and R8c together form a bond.
[00281] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8e and lee together form a bond.
[00282] Within such a group of compounds are compounds having the structure of Formula D-XVIII-1 or Formula D-XVIII-2:
R8f X2 ¨X
x2¨X R1 Red R8d R8a R3 N
Formula D-XVIII-1 Formula D-XVIII-2.
[00283] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stercoisomer thereof, is one group of compounds having the structure of Formula D-XIX:
X2--X1 w3 w2 Ry_.3 7NyWal Formula D-XIX
[00284] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-XX:
X2¨X1 Th Formula D-XX
[00285] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-XXI:
X2--X1 .= 0 Formula D-XXI
[00286] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-XXII, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
__________________________________ Xal R1 tW3 R2b p 8b 0 =
R8a Formula D-XXII
wherein, W3 is 0, S, or C(R8e)(R85;
R1 is H, or Ci-C6alkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, CI -C6alkyl, ¨C(=0)CI-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R24. and R2b are independently selected from H, substituted or unsubstituted C1-C6alkyl, and ¨
C(=0)RB;
RE is substituted or unsubstituted Ci-C6alkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is C1-C3a1kyl, or C1-C3fluoroalkyl;
each R' is independently selected from H, C1-C3alkyl, C1-C3haloalkyl, C1-C3heteroalkyl and -C1-C3a1kyl-(C3-05cycloa1kyl);
each le is independently selected from CI -C6alkyl, C1-C6haloalkyl, CI -Coheteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C1oheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C10cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH)),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R82 and R8b are independently selected from H, Ci-C6alkyl and Ci-C6fluoroalkyl;
R8e and fef are independently selected from H, C1-C6alkyl and C1-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, CI-C4alkyl, C1-C4 fluoro alkyl, C1-C4 alkoxy, fluoroalkoxy, -NH2, -NH(C -NH(C i-C4 alkyl) ,, -C(=0)0H, -C(=0)N112, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-OH, -NH(C1-C4alkyl)-0 -(C 1 -C4alkyl), -0 (C -C4alkyl)-NF17; -0(C -C4alkyl)-NH-(C -C4alkyl), and -0(C -C4alkyl)-N-(Ci-C4alkyl)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[00287] Among the compounds of Formula D described above or below, or pharmaceutically acceptable saltõV-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R2a, R2b R2c, R2d, R2e, and K2f are independently selected from H, C1-C3alkyl and -C(=0)RB; and RB is substituted or unsubstituted Ci-C6alkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6a1kyl-(substituted or unsubstituted heteroaryl).
[00288] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R2a, R2b R2e, R2d, R2c, and R2f are independently H or C1-C3 alkyl.
[00289] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, le, le le, led, lee, and le are independently selected from H, Ci-C3alkyl and -C(=0)RB; and RB is substituted or unsubstituted C1-C6alkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyksubstituted or unsubstituted heteroaryl).
[00290] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein lea, le lee, led, lee, and R8f are independently H or Ci-C3 [00291] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R1 is H or methyl.
[00292] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racematc or stereoisomer thereof, is one group of compounds wherein R1 is H.
[00293] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is ¨NHC(=0)R7, -C(=0)NHR7, ¨NHS(=0)2R7, -S(=0)2NHR7; ¨NHC(=0)NHR7, -NH S (=0)2NHR7, ¨(C1-C3alkyl)-NHC(=0)R7, ¨(CI-C3alkyl)-C(=0)NHR5, ¨(C1-C3alkyl)-NHS(=0)2R7, ¨(Ci-C3alkyl)-S(=0)2NHR7; ¨(Ci-C3alkyl)-NHC(=0)NHR7, or ¨(Ci-C3alkyl)-NHS(=0)2NHR7.
[00294] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is substituted or unsubstituted C2-Cl11heterocyc1oa1ky1, or substituted or unsubstituted heteroaryl.
[00295] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted C2-Cipheterocycloalkyl.
[00296] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted heteroaryl.
[00297] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NHR7, -S(=0)2NHR7,¨(Ci-C3alkyl)-C(=0)NHle, or ¨(Ci-C3alkyl)-S(=0)2NHR7.
[00298] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NHR7, or -S(=0)2NHR7 [00299] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R6 is ¨C(=0)NH127.
[00300] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, each R7 is independently selected from a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C2-C1oheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C iocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C,-Cipheterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2-(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl).
[00301] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R7 is independently selected from a substituted or unsubstituted CI-Ciocycloalkyl, a substituted or unsubstituted C2-C10heterocycloa1kyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, and ¨(CH2)p-CH(substituted or unsubstituted aryl)).
[00302] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R7 is selected from µ tt,4_1\1 410, , , ,..1\1 sit ',No..
I
, , N , ----N
<cc \
I
Me .. .. N
, -- , , , N , N N M e Me , , Me y 0 \
N / I
N
, H .
[00303] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, W3 is C(R8e)(1e);
R1 is H;
R2a, R2b are independently selected from H, and CI-C3alkyl;
INI,T.I.NX. 0 H
, H
R3 is - H
z , Rga, le, lee, le are independently selected from H and Ci-C3alkyl.
[00304] Any combination of the groups described above or below for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[00305] Any combination of the groups described above for the various variables is contemplated herein.
Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[00306] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is a compound of structure:
s 1=1 / H o'er [00307] Also provided herein are pharmaceutical composition comprising a compound of Formula D or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, and a pharmaceutically acceptable carrier.
Formula E -Eight-six ring systems [00308] As used herein, Formula E includes compounds of Formula E-I, Formula E-II, Formula E-II-1, Formula E-II-2, Formula E-II-3, Formula E-III, Formula E-IV, Formula E-V-1, Formula E-V-2, Formula E-V-3, Formula E-VI-1, Formula E-VI-2, Formula E-VI-3, Formula E-VII-1, Formula E-VII-2, Formula E-VII-3, Formula E-VIII-1, Formula E-VIII-2, Formula E-VIII-3, Formula E-IX-1, Formula E-IX-2, Formula E-X-1, Formula E-X-2, Formula E-XI-1, Formula E-XI-2, Formula E-XII, Foimula E-XIII, Formula E-XIV, Formula E-XV-1, Formula E-XV-2, Formula E-XV-3, Formula E-XV-4, Formula E-XV1-1, Formula E-XVI-2, Formula E-XVII-1, Formula E-XVII-2, Formula E-XVIII, Formula E-XIX, Formula E-XX, and Formula E-XXI.
[00309] In one aspect, described herein is a compound of Formula E-I, or a pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, as described in the summary of the invention.
[00310] In another aspect, provided herein are compounds having the structure of Formula E-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
y2_xi IA 3 7's X3 w2 R3 ________________________ ( Formula E-I
wherein, R' is H, Ci-C6alkyl, C3-C6cycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X' is selected from N-R", S, S(0) and S(0)2, then X2 is cR2c-x 2d, and X' is cR2aR2n;
or 1 R2cR2d A 3 when X i 2s 0, then X is selected from C and N-R, and X i 2a s CRR2b;
or:
when X1 is CH), then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is CR2aR2b;
or:
X1 is CR2eR2f and X2 is CR2eR2d, and R2' and R2' together form a bond, and X3 is CR2aR2b;
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR24R2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR21121;
RA is H, C1-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
W1 is 0, S, N-RA, or C(R8a)(Rgb);
W2 is 0, S, N-RA, or C(R8')(R8(f);
W3 is 0, S, N-RA, or C(R8e)(R8f); provided that the ring comprising W1, W2 and W3 does not comprise two adjacent oxygen atoms or sulfur atoms;
R2a R2b, R2e, R2d ¨2e, x and R2f are independently selected from H, substituted or unsubstituted C1-C6alky1, substituted or unsubstituted C1-C6beteroalkyl, substituted or unsubstituted C3-Cocycloalkyl, substituted or unsubstituted C7-C4leterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨CI -C6alkyl-(substituted or unsubstituted heteroaryl) and ¨
RB is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted CI-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NT(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or CI-C3fluoroalkyl;
R4 is -NHR5, -N(R5)2, -N(R5)3 or -0R5;
each R5 is independently selected from H, C1-C3a1kyl, C1-C3haloalkyl, C1-C3heteroalkyl and -C1-elalkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(C1 -C3 alkyl)-NHC(=0)R7, -(C 1-C3 alkyl)-C(=0)NHR5, -(C1 -C
3 alkyl)-NHS(=0)2R7, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(C1-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Cioheterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-C1ocycloalkyl, a substituted or unsubstituted C oheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)5-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0,1 or 2;
Rga, Rgb, R8c, X-8d, Rgeand Rgf are independently selected from H, Ci-C6alkyl, C1-C6fluoroalkyl, C--C6 alkoxy, Ci-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
Rga, Rgd, Rgeand Rgf are as defined above, and Rgb and fee together form a bond;
or:
Rga, Rgb, led, and R8f are as defined above, and lee and Rge together form a bond;
or:
Rga, K¨ 8d, Rgeand R8f are as defined above, and Rgb and Rge together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
Rga, Rgb, led, and Rgf are as defined above, and Rs' and Rge together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
8d, R8ealld R8f are as defined above, and R82 and Rgb together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
Rs', Rgb, Rgeand Rgf are as defined above, and Rge and Rgd together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
Rga, Rgb, R8c, and led are as defined above, and lee and R8f together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S. 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, C1-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(C1-C4alkyl), -NH(Ci-C4alky1)2, -C(=0)0H, -C(=0)NH2, -C(=0)Ci-C3alkyl, -S(=0)2CH2, -NH(Ci-C4alkyl)-OH, -NH(C1-C4alkyl)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(C1-C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
[00311] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-II:
RI
X2¨ I
X \/W
X3 w2 Formula E-II
[00312] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-II-1, Formula E-II-2, or Formula E-II-3:
R81 R8e RI W
X2¨ XI Red \-21\1\/3 Rsc X3 w2 ___________________________ Rab R3 (Nj\¨R813 R3 _________________________ Y\R8a R8a ___________ U 0 U 0 Formula E-II-1 Formula E-II-2 D8f e A
X3 _________________________________________ R8c ____________________________ U 0 Formula E-11-3 [00313] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-III:
Rae X2¨ X'11 R8d X3 ___________ R8c Ns.\\ _______________________________________ R8b R3 R8a ____________________________ U 0 Formula E-III
[00314] Among the compounds of Formula Elf described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-IV:
X2¨ X1 R1 Red X3 ____________________________________________ R8c R3 (N
Formula E-TV
[00315] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, or -S(=0)2NH-.
[00316] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, or -C(=0)NH-.
[00317] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof, is one group of compounds wherein, R3 is Ci-Clalkyl.
[00318] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R4 is¨NHR% -N(R5)2, or -1\14(125)3; and each R5 is independently selected from H, C1-C3alkyl, arid -C1-C7a1kyl-(C3-05cycloalkyl).
[00319] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R3 N )2( R4 U)22. is R3 [00320] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R4/I\ N
is H
z [00321] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring.
[00322] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, (R9)0-2 N
is H ;and q is 1, 2 or 3.
[00323] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein le is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring.
[00324] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, ,\-/-14q is (R9)0-2 ;and (1 is 1, 2 or 3.
[00325] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, X1 is selected from N-RA, S, S(0) and S(0)2; and X2 is CH2.
[00326] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-V-1 or Formula E-V-2 or Formula E-V-3:
R2 R2c R 2d R2d R8f 8e R1 R1 R 8d R2b R2b R 2a _______________________ sW3 _____________________________________________________________ R8 c /NW
1 z N ..,,,,=\ R85 ...,.,...
) ___________________________ U 0 R6 ) __ U 0 Formula E-V-1 Formula E-V-2 R2c R2d R21 R8d R2a sR1 \ION.
______________________________________________ R8 N ____________________________________________ R85 R3 I µR8a ) __ U 0 Formula E-V-3 [00327] Among the compounds of Formula E-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-VI-1 or Formula E-VT-2 or Formula E-VI-3:
R 2d R2c 0 0 R2d "2C
0 0 R8f R8e R2 b ISIII\2N R1 R2b µSµ11 R1 R8d '.w2 R2a ______________ R8c I
/NW 1 zN,.õ..,.,\ Rap \\ R6 R8a ) ________________________ U 0 R6 ) __ U 0 Formula E-VI-1 Formula E-VI-2 R2d 00 R2c R2b 11/ R1 R8d \.,.Ø,i R2a _____________ Rsc ____________________________________________ R8b /N
R3 R8a ) __ U 0 Formula E-VI-3 [00328] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable saltõN-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-VII-1 or Formula E-VII-2 or Formula E-VII-3:
02c R2 c R ge R 2d RI R8f R2 b 0 R1 R2b 0 FXREsd R2a \.-'w3 w2 R 2a _____________ R8c I
/N
,. d __________________________ R8b -.-vv R3 R3 ____ ''N --y R6 -NR8a ) ____________ u 0 R6 ) __ U 0 Formula E-VII-1 Formula E-VII-2 R2c R2d R2b Rld R22 R8c z N R 8b R3 R6 R8a ) __ U 0 Formula E-VII-3 [003291Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-VIII-1 or Formula E-VIII-2 or Formula E-VIII-3:
R2c A R2c RA pp8f R2d R R2d / ' s R 8e R2b N/ Ri\A& w2 R2b N K/R8d R2a R2a _________________ R8 c I
, .,1 _________________________ R8b /N vv,...
R3 R3 ,NYNR8a ) ___________ U 0 R6 ) __ U 0 Formula E-VIII-3 Formula E-VIII-3 R2 c RA
R2d R2b N/ Rld \\......õ,=0 R2a R8 /N _________________________________________ R8b R3 R6 Rsa ) __ U 0 Formula E-VIII-3 [003301Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein X1 is CIF; and X2 is selected from 0, N-RA, S, S(0), and S(0)2.
[00331] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stercoisomer thereof; is one group of compounds having the structure of Formula E-IX-1 or Formula E-IX-2:
R2d R2f R20 3 R2a R1 b R2bW2 w2 /N wi wi _________________ u 0 u 0 Formula E-IX-1 Formula E-IX-2 [00332] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-X-1 or Formula E-X-2:
A R2e R2f R2a R1A R1 R2b W3 w w2 2 Formula E-X-1 Formula E-X-2 wherein ring A is a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, substituted or unsubstituted 5-10 membered aryl ring, or substituted or unsubstituted 5-10 membered heteroaryl ring.
[00333] Within such a group of compounds are compounds wherein ring A is selected from indolyl and phenyl.
[00334] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-XI or Formula E-XI-2:
X2¨X1 R8d X2¨X1 X3 __________ Rsc X3 _______________________________ R8b /N R8b R3 \(N
Rsa R3 \ R8 a Formula E-XI-1 Formula E-XI-2 [00335] Among the compounds of Formula &I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-XIT:
x2¨x1 R1 _______________________________ U 0 Formula E-XII
[00336] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-XIII:
x3 N
Formula E-XIII
[00337] Within the group of compounds of Formula E-XI, Formula E-XII and Formula E-XIII are compounds wherein X1 is 0, S or S(0)2, and X2 is CH2.
[00338] Within the group of compounds of Formula E-XI, Formula E-XII and Formula E-XIII are compounds wherein X1 is N-RA, and X2 CH,.
[00339] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein Rs') and Rgc together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N.
[00340] Within such a group of compounds are compounds having the structure of Formula E-XIV:
y2¨x1 /¨
X3 (R9)0-3 /N
__________________________ U 0 Formula E- XIV
where ring B is an aryl or heteroaryl ring.
[00341] In some embodiments, ring B is an aryl. In some embodiments, ring B is phenyl. In some embodiments, ring B is a heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring or a bicyclic heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring. In some embodiments, ring B is a bicyclic heteroaryl ring. In some embodiments, ring B
is selected from phenyl, pyridinyl and thiophenyl. In some embodiments, ring B is selected from pyridinyl and thiophenyl.
[00342] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8d and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N; or R8e and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N.
[00343] Within this group are compounds having the structure of Formula E-XV-1, Formula E-XV-2, Formula E-XV-3, or Formula E-XV-4:
y2¨x1 R1 x2 ¨xl Ri )1-4 )2 /N /N
)1-4 Formula E-XV-1 Formula E-XV-2 X3 X3 ) y2_x1 R1 x2¨xl R1 /'s 1-3 2 )2 /N
________________ U 0 U 0 Formula E-XV-3 Formula E-XV-4;
or Formula E-XVI-1 or Formula E-XVI-2:
,RA
x2¨x1 R1 D1 IN
x2_xl )1-3 )2 N
R ____________________________________________ U
Formula E-XVI-1 Formula E-XVI-2 wherein RA is H, Ci-C3alkyl or ¨C(=0)Ci-C3alkyl.
[00344] Among the compounds of Formula E-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein e and le together form a bond.
[00345] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein e and e together form a bond.
[00346] Within this group are compounds having the structure of Formula E-XVII-1 or Formula E-XVII-2:
R1 R8f X2¨X1 X2¨X1 7R8c \/R8d R3 R3 R8a _____________ U 0 U 0 Formula E-XV11-1 Formula E-XV11-2.
[00347] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-XV1H:
X2¨X1 R1 3 X3 w2 w1 R3 __________________________________ Ny u 0 R6 Formula E-XVIII
[00348] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-XIX:
x2-x1 R1 ______________________________ U 0 R6 Formula E-XIX
[00349] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-XX:
x2-x1 R1 ______________________________ U 0 R6 Formula E-XX
[00350] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure Formula E-XXI, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
R2b 1R1 X
R2a _____________________________________ NR
sb 0 <
HN
Formula E-XX1 wherein, w3 is 0, S, or C(R8e)(R8f);
R1 is H, or C1-C6alkyl;
X' is 0, N-RA, S, S(0), or S(0)2;
RA is H, C1-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a and R2b are independently selected from H, substituted or unsubstituted Ci-C6alkyl, and -C(0)RD;
RD is substituted or unsubstituted Ci-C6alkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
each R5 is independently selected from H, Ci-C3alkyl, C1-C3haloalkyl, Ci-C3heteroalkyl and -CI-C3alkyl-(C3-05cycloalkyl);
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C10heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -CI-C6alkyl-(substituted or unsubstituted C3-Ciocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
Rga and Rgb are independently selected from H, C1-C6alkyl, and CI-C6fluoroalkyl;
R8e and Rare independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-Caalkyl, Ci-C4 fluoroalkyl, C1-C4 alkoxy, CI-Ca fluoroalkoxy, -NH2, -NH(CI-Caalkyl), -NH(Ci-C4alky1)2, -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-OH, -NH(C1-C4alkyl)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(C -C4alkyl)-NH-(C -C4alkyl), and -0(C -C4alkyl)-N-(C1-C4alkyl)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[00351] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R22, R2b R2c, R2d, R2e, and R2' are independently selected from H, Ci-C;alkyl and -C(=O)RE; and RE is substituted or unsubstituted C1-C6alky1, -C1-C6alkyl-(substituted or unsubstituted C5-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨Ci-C6alkyksubstituted or unsubstituted heteroaryl).
[00352] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R2', R2b R2e, R2d, R2e, and R2f are independently H or Ci-C3 alkyl.
[00353] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein 12' is H or methyl.
[00354] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein 121 is H.
[00355] Among the compounds of Formula E described above or below, or pharmaceutically acceptable saltõN-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is ¨NHC(=0)127, -C(=0)NH127, ¨NHS(=0)2127, -S(=0)2NHR7; ¨NHC(=0)NH127, -NH S (=0)2NHR7, ¨(C1-C3alkyl)-NHC(=0)127, ¨(C -C3alkyl)-C(=0)NHR5, ¨(C1-C
3alkyl)-NH S (=0)2127, ¨(C -C3alkyl)-S (=0)2NHR7; ¨(C i-C3alkyl)-NHC(=0)NH127, or ¨(Ci-C3alkyl)-NHS(=0)2NH127.
[00356] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is substituted or unsubstituted C2-C10heterocyc1oa1ky1, or substituted or unsubstituted heteroaryl.
[00357] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted C2-C1oheterocycloalkyl.
[00358] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted heteroaryl.
[00359] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NHI27, -S(=0)2NH127,¨(CI-C3alkyl)-C(=0)NH125, or ¨(Ci-C3alkyl)-S(=0)2NH127.
[00360] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NH127, or -S(=0)3NHR7.
[003611Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R6 is ¨C(=0)NHR7.
[00362] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, each R7 is independently selected from a substituted or unsubstituted Cl-Ciocycloalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyksubstituted or unsubstituted C3-C iocycloalkyl), -C i-C6alkyl-(substituted or unsubstituted C,-C
wheterocycloalkyl, -CI -C6alkyl-(substituted or unsubstituted aryl), -C1 -C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2-(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl).
[00363] Among the compounds of Formula E described above or below, or pharmaceutically acceptable saltõ AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R7 is independently selected from a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C2-Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, and ¨(CH2)p-CH(substituted or unsubstituted aryl)).
[00364] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R7 is selected from N
:32z µ31t.
Me Csss 110 N , N Me NV, 'csss Me srisc , Me , and H .
[00365] Also provided herein are pharmaceutical compositions comprising a compound of Formula E, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, and a pharmaceutically acceptable carrier.
[00366] Also contemplated within the scope of embodiments described herein are dimeric compounds. In one aspect, provided herein are compounds of Formula F:
Formula F
wherein Z1 and Z2 are compounds selected from any one of Formula A, Formula B, Formula C, Formula D or Formula E described above or below; and L is a bridge between the compounds such that a compound of Formula F is a dimeric compound. In some embodiments, L is a bond (e.g., a bond between two aryl groups of Z1 and Z2. In some embodiments, L is a disulfide linkage.
In some embodiments, L is an ether, amide or ester linkage. In some embodiments, L is a cycle (e.g., a cyclopropyl ring, a pyrrolidine ring, a phenyl ring). In some embodiments, a compound of Formula F is selected from:
11111µ
Me H
Ss-S H 0 Me- Me Me Me 0 [00367] Also contemplated within the scope of embodiments described herein are trimeric compounds. In one aspect, provided herein are compounds of Formula G:
= Z3 Z-7 ss , Formula G
wherein Z1 and Z2 and Z3 are compounds selected from any one of Formula A, Formula B, Formula C, Formula D or Formula E described above or below; and 1.õ1 and L2 are a bridges between the compounds such that a compound of Formula G is a trimeric compound. In some embodiments, L1 and L2 are independently selected from a bond (e.g., a bond between two aryl groups of Z1 and Z2 or Z3), a disulfide linkage, an ether, amide or ester linkage and the like.
[00368] Any combination of the groups described above or below for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
Methods [00369] Provided herein are methods of treating a hyperproliferative disorder in an individual in need thereof comprising administration of a therapeutically effective amount of a compound of any one Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G, to the individual in need thereof.
[00370] In some of such embodiments, the hyperproliferative disorder is cancer or an autoimmune disease.
[00371] In some of such embodiments, the autoimmune disease is hemolytic anemia, autoimmune hepatitis, Berger's disease or IgA nephropathy, celiac sprue, chronic fatigue syndrome, Crohn's disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, or vitiligo.
[00372] Also provided herein are methods of treating cancer in an individual in need thereof comprising administration of a therapeutically effective amount of a compound of any one of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G,to the individual in need thereof.
[00373] In some embodiments, the cancer is an epithelial cancer, a carcinoma, a neoplasm, a sarcoma, a chondrosarcoma, a blastoma, a cancer of the central nervous system, or a haematological cancer. In some embodiments, the cancer is an epithelial cancer or a carcinoma. In sonic embodiments, the cancer is a neoplasm or a sarcoma or a chondrosarcoma or a blastoma or a cancer of the central nervous system. In some embodiments, the cancer is a haematological cancer.
[00374] Also provided herein are methods of treating a disease associated with angiogenesis in an individual in need thereof comprising administration of a therapeutically effective amount of a compound of any one of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F
or Formula G, to the individual in need thereof.
[00375] In some embodiments the disease associated with angiogenesis is macular degeneration, rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, sclerodeinia or hypertrophic scarring.
[00376] Also provided herein are methods of inhibiting the activity of inhibitor of apoptosis (IAP) proteins in an individual in need thereof comprising administration of a therapeutically effective amount of a compound of any one of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G, to the individual in need thereof [003771In some embodiments, the TAP protein is XIAP, cIAP-1, clAP-2, ML-IAP, survivin, NAIP, apollon, or ILP2.
1003781 Also provided herein are methods of inducing apoptosis in a cell comprising contacting the cell with a therapeutically effective amount of a compound of any one of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G. In some of such embodiments the compound of any one of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G, binds a XIAP BIR3 domain, thus antagonizing the action of IAPs.
Synthesis of Compounds [00379] In some embodiments, the synthesis of compounds described herein are accomplished using means described in the chemical literature, using the methods described herein, or by a combination thereof. In addition, solvents, temperatures and other reaction conditions presented herein may vary.
[00380] In other embodiments, the starting materials and reagents used for the synthesis of the compounds described herein are synthesized or are obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, FischerScientific (Fischer Chemicals), and AcrosOrganics.
1003811 In further embodiments, the compounds described herein, and other related compounds having different substituents are synthesized using techniques and materials described herein as well as those that are recognized in the field, such as described, for example, in Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4th Ed., (Wiley 1992); Carey and Sundberg, Advanced Organic Chemistry 4th Ed., Vols. A
and B (Plenum 2000, 2001), and Green and Wuts, Protective Groups in Organic Synthesis jrd Ed., (Wiley 1999). General methods for the preparation of compounds as disclosed herein may be derived from reactions and the reactions may be modified by the use of appropriate reagents and conditions, for the introduction of the various moieties found in the formulae as provided herein. As a guide the following synthetic methods may be utilized.
Formation of Covalent Linkages by Reaction of an Electrophile with a Nucleophile [00382] The compounds described herein can be modified using various electrophiles and/or nucleophiles to form new functional groups or substituents. Table IA entitled "Examples of Covalent Linkages and Precursors Thereof' lists selected non-limiting examples of covalent linkages and precursor functional groups which yield the covalent linkages. Table IA may be used as guidance toward the variety of electrophiles and nucleophiles combinations available that provide covalent linkages. Precursor functional groups are shown as electrophilic groups and nucleophilic groups.
Table 1: Examples of Covalent Linkages and Precursors Thereof Covalent Linkage Product Electrophile Nucleophile Carboxamides Activated esters amines/anilines Carboxamides acyl azides amines/anilines Carboxamides acyl halides amines/anilines Esters acyl halides alcohols/phenols Esters acyl nitrites alcohols/phenols Carboxamides acyl nitrites amines/anilines Imines Aldehydes amines/anilines Alkyl amines alkyl halides amines/anilines Esters alkyl halides carboxylic acids Thioethers alkyl halides Thiols Ethers alkyl halides alcohols/phenols Thioethers alkyl sulfonates Thiols Esters Anhydrides alcohols/phenols Carboxamides Anhydrides amines/anilines Thiophenols aryl halides Thiols Aryl amines aryl halides Amines Thioethers Azindines Thiols Carboxamides carboxylic acids amines/anilines Esters carboxylic acids Alcohols hydrazines Hydrazides carboxylic acids N-acylureas or Anhydrides carbodiimides carboxylic acids Esters diazoalkancs carboxylic acids Thioethers Epoxides Thiols Thioethers haloacetamides Thiols Ureas Isocyanates amines/anilines Urethanes 1socyanates alcohols/phenols Thioureas isothiocyanates amines/anilines Thioethers Maleimides Thiols Alkyl amines sulfonate esters amines/anilines hioethers sulfonate esters Thiols Sulfonamides sulfonyl halides amines/anilines Sul fonate esters sulfonyl halides phenols/alcohols Use of Protecting Groups [00383] In the reactions described, it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, in order to avoid their unwanted participation in reactions. Protecting groups are used to block some or all of the reactive moieties and prevent such groups from participating in chemical reactions until the protective group is removed. It is preferred that each protective group be removable by a different means. Protective groups that are cleaved under totally disparate reaction conditions fulfill the requirement of differential removal.
[00384] Protective groups can be removed by acid, base, reducing conditions (such as, for example, hydrogenolysis), and/or oxidative conditions. Groups such as trityl, dimethoxytrityl, acetal and t-butyldimethylsily1 are acid labile and may be used to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected with Cbz groups, which are removable by hydrogenolysis, and Fmoc groups, which are base labile. Carboxylic acid and hydroxy reactive moieties may be blocked with base labile groups such as, but not limited to, methyl, ethyl, and acetyl in the presence of amines blocked with acid labile groups such as t-butyl carbamate or with carbamates that are both acid and base stable but hydrolytically removable.
1003851 Carboxylic acid and hydroxy reactive moieties may also be blocked with hydrolytically removable protective groups such as the benzyl group, while amine groups capable of hydrogen bonding with acids may be blocked with base labile groups such as Fmoc. Carboxylic acid reactive moieties may be protected by conversion to simple ester compounds as exemplified herein, which include conversion to alkyl esters, or they may be blocked with oxidatively-removable protective groups such as 2,4-dimethoxybenzyl, while co-existing amino groups may be blocked with fluoride labile silyl carbamates.
1003861 Allyl blocking groups are useful in then presence of acid- and base-protecting groups since the former are stable and can be subsequently removed by metal or pi-acid catalysts. For example, an allyl-blocked carboxylic acid can be deprotected with a Pd -catalyzed reaction in the presence of acid labile t-butyl carbamate or base-labile acetate amine protecting groups. Yet another form of protecting group is a resin to which a compound or intermediate may be attached. As long as the residue is attached to the resin, that functional group is blocked and cannot react. Once released from the resin, the functional group is available to react.
1003871 Typically blocking/protecting groups may be selected from:
1-13,=-\ H3C5 / SSIC
(C6H5)3C--/
Me Et allyl 1-11C0 Bn PMB trityl t-butyl B) c/ 0 \
(CH3)3C--'hr\ HiC0 jLss5S 0)LsSSS H,C CH, 0 (H3C)3C..,S1,, Cbz Hoc acetyl alloc TBDMS
Fmoc 1003881 Other protecting groups, plus a detailed description of techniques applicable to the creation of protecting groups and their removal are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994.
Synthesis of compounds of Formula A
1003891 In some embodiments, a compound of Formula A-I is synthesized as shown below in Scheme 1 and in the Chemistry Examples section:
Scheme 1 Me0 ) \ HO Me MO e yoc o 1,11,\EI:i----yoc OH o flr Me0 o_/ ___________________________________ ,..
,Nljt, N
,N.,)L. OH ¨ ¨ [tW, 80 C - N
R5 - N n R5 -=4 H /R7 1-2 20 mi 1-1 30% 1 TFA
R7 (2 steps) 25 C
/
+
_ ///N
H
C 0 :
1-4 0 I'D
H
rAV'YN R7 = H /
Formula A-I
[00390] Starting with a compound of Formula 1-1, a four component Ugi reaction provides a compound of Formula 1-2, which is then cyclized and deprotected to provide a compound of Formula A-I.
[00391] In a further embodiment, compounds of Formula A-I are synthesized starting with compound 1-6 as shown in Scheme 2 below:
Scheme 2 yoc OR284,1/4_,OH Me0 412a Me0 Me H
Rza 0 :
meo)D CF3CH2OH yoc 0 TEA
_,.. H 0 25 C me' NYLNifyi Me . N Tr õIN.,-A, I-13_ 0¨
E/le H 0 11W, 80 C Me _- N
R7 ,R7 1-2 20 min fVle H 0 H 0 1-6 \ , N
- + 0 - ,.., H
CI\I¨R7 NH3 1-7 Formula A-I
[00392] Table 1-1 shows data for certain compounds of Formula A-I.
Table 1-1 Yield XIAP BIR1/2 XIAP BIR3 Product R28 R2 (2 steps) K1(0) K1 (LM) 7a H 11 . 30% C B
7b H -1 IF CI 69% C B
H
7c ,,,, 67% C A
Me 79%. C A
7d õ 0 Me 63% C B
7e All IC% .
Me 46% C B
7f KEY: A = <25 micromolar; B > 25 and < 50 micromolar; C >50 micromolar [00393] Other compounds that are useful for the Ugi reaction shown above or below include and are not limited to:
OH 2- c-e.,,,OH Hi Boc OM ) 0 CI N+ N+
1 , me.NJI,N,OH
e-NIT,,OH 6s-ri .-.- H II BocHN
me 0 SCPh3 + IP ) Me0 . Me0 BocHN
r,OH Me0 MeCb<Me -+N
0¨ 0¨ Me -C- OMe LJ
0 OMe OH
HO OH
BocHN( OH OH
OHBocHN
BocHN 0 0 BocHN OH
0 0 .
Synthesis of compounds of Formula B
[00394] In some embodiments, a compound of Formula B-I is synthesized as shown below in Scheme 3:
Scheme 3 X
) e0 X
(,kile0 Me y I:I
M
BocHNOH ) __________________ _) CF3CH2OH
H TFA
Me0 JAW, 80 C BocHNIIir N ,, NR7 25 C H2N N /R7 20 min ¨ H
NH3 CEN ¨R7 2-2 0 H
1-3 1-4 Boc-N-Me-Ala-OH
HOBT, EDC, NMM
THF, 23 C
Y 1:1 Y LI H
%.....7 . TEA Nc, .--?
Boc, R7 Boo, N--)LN IR7 -,...
Me' i\-õe 0 H Me i Me 0 H w Me 0 ---H
Formula B-I
[00395] Starting with a compound of Formula 2-1, a four component Ugi reaction provides a compound of Formula 2-2. X is a protected thiol, or protected hydroxyl, or N-RA as described herein. The compound of Formula 2-2 is cyclized and a reaction with a protected alaninc provides a compound of Formula B-I as a mixture of diastereomers. The mixture of diastereomers is separated by silica gel chromatography to provide a compound of Formula B-I having the structure 2-4.
Where Y is S, the sulfur atom is optionally oxidized.
[00396] Table 2-1 and below and Figure 1 show certain data for compounds of Formula B:
Table 2-1 Yield XIAP BIR1/2 XIAP BIR3 ML-IAP
Product Y R1 (4 steps) K1 ( M) Ki ( M) Ki (uM) 16a 0 õle 44% C A A
s¶:?Z 110 16b 0 36% A A -X
47% C A A
16c S
=":;. IP
ND C A A
16d 0 41% C B -16e 0 N 0 \
KEY: A = < 25 micromolar; B > 25 and <50 micromolar; C >50 micromolar [0039711n an alternative embodiment, compounds of Formula B-XV are synthesized according to Scheme 4 shown below.
Scheme 4 X
) Me() ---, , H ---,, Y
BocHNoe.r0H ) Me0 B) Steps of Scheme 2 B ') N
NH3 CI\I¨R7 Me/
Me 0 H
Formula B-XV
[00398] Starting with a compound of Formula 2-1, a four component Ugi reaction comprising a compound of Formula 3-1 followed by cylization and a reaction with a protected alaninc as shown in Scheme 3 provides a compound of Formula B-XV. Table 2-2 below shows certain data for compounds of Formula B-XV:
Table 2-2 Yield XIAP BIR1/2 XIAP BIR3 ML-IAP
Product Structure (4 steps) Ki (.iM) Ki (pM) Ki (pM) H
0 c , 17a 43% C A A
N
Me e M
17b 49% A A A
1\1 -- H 0 N
Me/
Me H
c.._.S 1.....__1,414 60% A A A
0 N..
17c MeeH 0 M
KEY: A = <25 micromolar; B > 25 and < 50 micromolar; C >50 micromolar [003991 It will be understood that the reactions shown in Schemes 1-4 above are illustrative and arc also applicable to synthesis of compounds of Formula C, Formula D and Formula E, and such disclosure is contemplated within the scope of embodiments described herein. Synthesis of compounds of Formula C, Formula D and Formula E is shown in further detail in the Chemistry Examples section.
Administration and Pharmaceutical Composition [00400] In general, the compounds of this invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities.
Therapeutically effective amounts of compounds of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G may range from about 0.01 to about 500 mg per kg patient body weight per day, which can be administered in single or multiple doses.
Preferably, the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to about 250 mg/kg per day, about 0.05 to about 100 mg/kg per day, or about 0.1 to about 50 mg/kg per day. Within this range the dosage can be about 0.05 to about 0.5, about 0.5 to about 5 or about 5 to about 50 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing about 1.0 to about 1000 milligrams of the active ingredient, particularly about 1.0, 5.0, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient. The actual amount of the compound of this invention, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound being utilized, the route and form of administration, and other factors.
[00401] In general, compounds of this invention will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., intranasal, suppository, intrapulmonaary), or parenteral (e.g., intramuscular, intravenous, intrathecal, or intraperitoneal) administration. The preferred manner of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
[00402] The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No.
4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 um in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No.
5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
[00403] The compositions are comprised of in general, a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G. Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
[00404] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.
[00405] Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.
[00406] Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 20th ed., 2000).
[00407] The level of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F
or Formula G based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80 wt %.
[00408] The compounds of the present invention may be used in combination with one or more other drugs in the treatment of diseases or conditions for which compounds of the present invention or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone. Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound of the present invention is preferred. However, the combination therapy may also include therapies in which the compound of the present invention and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of the present invention and the other active ingredients may be used in lower doses than when each is used singly.
[00409] Accordingly, the pharmaceutical compositions of the present invention also include those that contain one or more other active ingredients, in addition to a compound of the present invention.
[00410] The above combinations include combinations of a compound of the present invention not only with one other active compound, but also with two or more other active compounds. Likewise, compounds of the present invention may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which compounds of the present invention are useful. Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred. Accordingly, the pharmaceutical compositions of the present invention also include those that also contain one or more other active ingredients, in addition to a compound of the present invention. The weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
[00411] In the case wherein the patient's status does improve, upon the doctor's discretion the administration of a compound described herein is optionally given continuously; alternatively, the dose of drug being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a "drug holiday"). The length of the drug holiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. The dose reduction during a drug holiday includes from 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
[00412] Once improvement of the patient's conditions has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In some embodiments, patients require intermittent treatment on a long-term basis upon any recurrence of symptoms.
Combination therapy [00413] In some cases, a compound described herein is administered in combination with a second anti-cancer agent. Examples of anti-cancer agents for use in combination with a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G include inhibitors of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; mTOR
inhibitors; and antibodies (e.g., rituxan).
[00414] Other anti-cancer agents that can be employed in combination with a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Fornmla G include Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin;
acodazole hydrochloride;
acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide;
amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine;
azetepa; azotomycin; batimastat;
benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate;
bizelesin; bleomycin sulfate;
brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone;
caracemide; carbetimer; carboplatin;
carmustinc; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil;
cirolcmycin; cladribinc;
crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine;
dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin;
doxorubicin hydrochloride;
droloxifene; droloxifene citrate; dromostanolonc propionate; duazomycin;
edatrexate; cflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole;
esorubicin hydrochloride; estramustine; estramustine phosphate sodium;
etanidazole; etoposide; etoposide phosphate; ctoprinc; fadrozolc hydrochloride; fazarabinc; fenrctinidc;
floxtuidinc; fludarabinc phosphate;
fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine;
gemcitabine hydrochloride;
hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleulin II
(including recombinant interleukin 11, or r1L2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl; interferon alfa-n3;
interferon beta-1a; interferon gamma-1 b; iproplatin; irinotecan hydrochloride; lanreotide acetate;
letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium;
lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride;
megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metopiine;
meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin;
mitomycin; mitosper;
mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole;
nogalamycin; ormaplatin;
oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate;
perfosfamide; pipobroman;
piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin;
prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride;
pyrazofurin; riboprine;
rogletimide; safingol; safingol hydrochloride; semustine; simtrazene;
sparfosate sodium; sparsomycin;
spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin;
streptozocin; sulofenur;
talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride;
temoporfin; teniposide; teroxirone;
testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine;
toremifene citrate; trestolone acetate; triciribinc phosphate; trimetrexatc; trimetrexate glucuronate;
triptorclin; tubulozolc hydrochloride;
uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate;
vincristine sulfate; vindesine;
vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate;
vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin;
zorubicin hydrochloride.
[00415] Other anti-cancer agents that can be employed in combination with a compound of Formula A, Fonnula B, Formula C, Formula D, Formula E, Formula F or Formula G include: 20-epi-1, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene;
adecypenol; adozelesin;
aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine;
aminolevulinic acid;
amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D;
antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1;
antiandrogen, pro static carcinoma;
antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine;
atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3;
azasetron; azatoxin; azatyrosine;
baccatin III derivatives; balanol; batimastat; BCRIABL antagonists;
benzochlorins; benzoylstaurosporine;
beta lactam derivatives; beta-alethinc; betaclamycin B; bctulinic acid; bFGF
inhibitor; bicalutamidc;
bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin;
breflate; bropirimine; budotitane;
buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives;
canarypox IL-2;
capecitabinc; carboxamide-amino-triazolc; carboxyamidotriazolc; CaRest M3;
CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS);
castanospermine; cecropin B; cetrorelix;
chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine;
clomifene analogues;
clotrimazole; collismycin A; collismycin B; combrctastatin A4; combretastatin analogue; conagenin;
crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives;
curacin A;
cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate;
cytolytic factor; cytostatin;
dacliximab; decitabinc; dchydrodidemnin B; deslorclin; dexamethasone;
dexifosfamidc; dcxrazoxanc;
dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin;
diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene;
dronabinol; duocarmycin SA;
ebselen; ecomustine; edelfosine; edrecolomab; eflomithine; elemene; emitefur;
epirubicin; epristeride;
estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole;
etoposide phosphate;
exemestane; fadrozole; fazarabine; fenretinide; filgrastim; fmasteride;
flavopiridol; flezelastine;
fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex;
formestane; fostriecin;
fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix;
gelatinase inhibitors;
gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin;
ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat;
imidazoacridones; imiquimod;
immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor;
interferon agonists; interferons;
interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact;
irsogladine; isobengazole;
isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N
triacetate; lanreotide;
leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorclin; levamisole;
liarozole; linear polyaminc analogue; lipophilic disaccharide peptide; lipophilic platinum compounds;
lissoclinamide 7; lobaplatin;
lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine;
lurtotecan; lutetium texaphyrin;
lysofylline; lytic peptides; maitansine; mannostatin A; marimastat;
masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone;
meterelin; methioninase;
metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim;
mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol;
multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B;
mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin;
nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim;
nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators;
nitroxide antioxidant;
nitrullyn; 06-benzylguanine; octreotide; okicenone; oligonucleotides;
onapristone; ondansetron;
ondansctron; oracin; oral cytokinc inducer; ormaplatin; osaterone;
oxaliplatin; oxaunomycin; palauaminc;
palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin;
pazelliptine; pegaspargase;
peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron;
perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatasc inhibitors; picibanil;
pilocarpine hydrochloride;
pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex;
platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin;
prednisone; propyl bis-acridonc; prostaglandin J2; protcasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine;
pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists; raltitrexcd; ramosctron; ras farnesyl protein transferasc inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated;
rhenium Re 186 etidronate;
rhizoxin; ribozymes; R11 retinamide; rogletimide; rohitukine; romurtide;
roquinimex; rubiginone Bl;
ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine;
senescence derived 1; sense oligonucleotides; signal transduction inhibitors;
signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane;
sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D;
spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor;
stem-cell division inhibitors;
stipiamide; stromelysin inhibitors; sulfinosine; sup eractive vasoactive intestinal peptide antagonist;
suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine;
tamoxifen methiodide;
tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium;
telomerase inhibitors; temoporfin;
temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine;
thiocoraline; thrombopoietin;
thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist;
thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride;
topsentin; toremifene; totipotent stem cell factor; translation inhibitors; trctinoin; triacctyluridinc;
triciribine; trimarexate; triptorclin;
tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC
inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists;
vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin;
vinorelbine; vinxaltine;
vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.
[00416] Yet other anticancer agents that can be employed in combination with a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G include alkylating agents, antimetabolites, natural products, or hormones, e.g., nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, etc.), or triazenes (decarbazine, etc.). Examples of antimetabolites include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
[00417] Examples of natural products useful in combination with a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G include but are not limited to vinca alkaloids (e.g., vinblastin, vincristinc), cpipodophyllotoxins (e.g., ctoposidc), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon alpha).
[00418] Examples of alkylating agents that can be employed in combination a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G include, but are not limited to, nitrogen mustards (e.g., mcchloroethamine, cyclophosphamidc, chlorambucil, mclphalan, etc.), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes (dccarbazinc, etc.). Examples of antimctabolitcs include, but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxuridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin.
[00419] Examples of hormones and antagonists useful in combination a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G include, but are not limited to, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), gonadotropin releasing hormone analog (e.g., leuprolide). Other agents that can be used in the methods and compositions described herein for the treatment or prevention of cancer include platinum coordination complexes (e.g., cisplatin, carboblatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide).
[00420] Examples of anti-cancer agents which act by arresting cells in the G2-M phases due to stabilized microtubules and which can be used in combination with an irreversible EGFR
tyrosine kinasc inhibitor compound include without limitation the following marketed drugs and drugs in development: Erbulozole (also known as R-55104), Dolastatin 10 (also known as DLS-10 and NSC-376128), Mivobulin isethionate (also known as C1-980), Vincristine, N SC-639829, Discodermolide (also known as NVP-XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtins (such as Altorhyrtin A
and Altorhyrtin C), Spongistatins (such as Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (also known as LU-103793 and NSC-D-669356), Epothilones (such as Epothilone A, Epothilone B, Epothilone C (also known as desoxyepothilone A or dEpoA), Epothilone D (also referred to as KOS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B (also known as BMS-310705), 21-hydroxyepothilone D (also known as Desoxyepothilone F and dEpoF), 26-fluoroepothilone), Auristatin PE (also known as NSC-654663), Soblidotin (also known as TZT-1027), LS-4559-P (Pharmacia, also known as LS-4577), LS-4578 (Pharmacia, also known as LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), (Aventis), Vincristinc sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, also known as WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, also known as ILX-651 and LU-223651), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko), 1DN -5005 (lndena), Cryptophycin 52 (also known as LY-355703), AC-7739 (Ajinomoto, also known as AVE-8063A and CS-39.HC1), AC-7700 (Ajinomoto, also known as AVE-8062, AVE-8062A, CS-39-L-Ser.HC1, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (also known as NSC-106969), T-138067 (Tularik, also known as T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, also known as DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin Al (also known as BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijian tide B.
Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, also known as SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU
(CytoskeletonlMt. Sinai School of Medicine, also known as MF-191), TMPN
(Arizona State University), Vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, Inanocine (also known as NSC-698666), 3-1AABE (Cytoskeleton/Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, also known as T-900607), RPR-115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, Isoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (also known as NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, also known as D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (also known as SPA-110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi).
[00421] In some cases, a compound described herein (e.g., a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G) is administered in combination with INF-alpha and/or INF-related apoptosis-inducing ligand (TRAIL). TRAIL shows homology to other members of the TNF-alpha family of proteins. In some cases, a compound described herein (e.g., a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G) is administered in combination with a INF-alpha modulator and/or a INF-alpha analogue (e.g., lenalidomide, revlimid, CC-5013; CC-4047, ACTIMID. Tthalidomide and the like). In some cases, a compound described herein (e.g., a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G) is administered in combination with an adjuvant, hormone therapy, immunotherapy or any combination thereof.
Methods of Use [00422] Disclosed herein, in certain embodiments, are methods of inhibiting the activity of an inhibitor of apoptosis (IAP) protein in an individual in need thereof comprising administering a therapeutically effective amount of a compound disclosed herein to the individual. In some embodiments, the TAP protein is XIAP, cIAP-1, cIAP-2, ML-IAP, survivin, NAIP, apollon, ILP2, or any combinations thereof.
[00423] In some embodiments, inhibiting the activity of an TAP protein induces apoptosis in a plurality of cells. In some embodiments, the cells are cancerous cells. In some embodiments, the cancer is a sarcoma, carcinoma, blastoma, myeloma, leukemia, lymphoma, or combinations thereof In some embodiments, the cancer is a skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, uterine cancer, pancreatic cancer, liver cancer, or any combinations thereof In some embodiments, the cancer is acute myelogenous leukemia (AML). In some embodiments, the cancer is renal cell carcinoma.
In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer.
In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is gastric carcinoma. In some embodiments, the cancer is esophageal squamous cell carcinoma. In some embodiments, the cancer is a lung cancer. In some embodiments, the lung cancer is non-small cell lung carcinoma or small cell lung cancer. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is breast cancer.
[00424] In some embodiments, inhibiting the activity of an IAP protein treats a hyperproliferative disorder. In some embodiments, the hyperproliferative disorder is a cancer or an autoimmune disease. In some embodiments, the autoimmune disease is hemolytic anemia, autoimmune hepatitis, Berger's disease or IgA nephropathy, celiac sprue, chronic fatigue syndrome, Crohn's disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, or vitiligo. In some embodiments, the cancer is a sarcoma, carcinoma, blastoma, myeloma, leukemia, lymphoma, or combinations thereof In some embodiments, the cancer is a skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, uterine cancer, pancreatic cancer, liver cancer, or any combinations thereof. In some embodiments, the cancer is acute myelogenous leukemia (AML). In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is gastric carcinoma. In some embodiments, the cancer is esophageal squamous cell carcinoma. In some embodiments, the cancer is a lung cancer. In some embodiments, the lung cancer is non-small cell lung carcinoma or small cell lung cancer. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is breast cancer.
[00425] Disclosed herein, in certain embodiments, are methods of treating a cancer in an individual in need thereof comprising administering a therapeutically effective amount of a compound disclosed herein to the individual. In some embodiments, the cancer is a sarcoma, carcinoma, blastoma, myeloma, leukemia, lymphoma, or combinations thereof In some embodiments, the cancer is a skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, uterine cancer, pancreatic cancer, liver cancer, or any combinations thereof. In some embodiments, the cancer is acute myelogenous leukemia (AML). In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer.
In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is gastric carcinoma. In some embodiments, the cancer is esophageal squamous cell carcinoma.
In some embodiments, the cancer is a lung cancer. In some embodiments, the lung cancer is non-small cell lung carcinoma or small cell lung cancer. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is breast cancer.
[00426] Disclosed herein, in certain embodiments, are methods of treating a disease associated with unwanted angiogenesis in an individual in need thereof comprising administering a therapeutically effective amount of a compound disclosed herein to the individual. In some embodiments, the disease associated with unwanted angiogenesis is macular degeneration, rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, scleroderma or hypertrophic scarring. In some embodiments, the disease associated with unwanted angiogenesis is a cancer. In some embodiments, the cancer is a sarcoma, carcinoma, blastoma, myeloma, leukemia, lymphoma, or combinations thereof. In some embodiments, the cancer is a skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, uterine cancer, pancreatic cancer, liver cancer, or any combinations thereof In some embodiments, the cancer is acute myelogenous leukemia (AML). In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer.
In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is gastric carcinoma. In some embodiments, the cancer is esophageal squamous cell carcinoma.
In some embodiments, the cancer is a lung cancer. In some embodiments, the lung cancer is non-small cell lung carcinoma or small cell lung cancer. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is breast cancer.
CHEMISTRY EXAMPLES
[00427] The following examples are intended to illustrate but not limit the disclosed embodiments. All solvents were used as purchased from commercial sources or dried over 4A
molecular sieves prior to use in the case of moisture sensitive reactions. Reactions conducted under microwave irradiation were performed in a CEM Discover microwave reactor using either CEM 10 inL reaction vessels or a ChemGlass heavy wall pressure vessel (100 mL, 38 mm x 190 mm). Reaction progress was monitored by reverse-phase HPLC and/or thin-layer chromatography (TLC). High resolution mass spectrometry was performed using ESI-TOFMS, ELMS (reference: perfluorokerosene) and APCI-MS.
TLC was performed using silica gel 60 F254 pre-coated plates (0.25 mm). Flash chromatography was performed using silica gel (32-63 lam particle size) or aluminum oxide (activated, basic, ¨150 mesh size). All products were purified to homogeneity by TLC analysis (single spot, unless stated otherwise), using a UV lamp and/or iodine and/or CAM or basic KMnat for detection purposes. NMR spectra were recorded on 400 MHz and 500 MHz spectrometers at ambient temperature. 1H and 13C NMR chemical shifts are reported as 6 using residual solvent as an internal standard; CDCI3: 7.26, 77.16 ppm; CD3OD: 3.31, 49.00 ppm; DMSO-d6: 2.50, 39.52 ppm, CD3CN: 1.94 (1H), 1.32 (13C) ppm. Abbreviations used: alanine (Ala), 1-hydroxybenzotriazole (HOBT), N-methylmorpholine (NMM), N-(3-dimethylaminopropy1)-N'-ethylcarbodiimide (EDC), palladium on carbon (Pd-C), dichloromethane (DCM), diethyl ether (Et20), ethyl acetate (Et0Ac), 2,2,2-trifluoroethanol (TFE), methanol (Me0H), homoserine (HSer), tetrahydrofuran (THF), trifluoroacetic acid (TFA), diisobutylaluminum hydride (DIBAL).
1004281 Example 1: Preparation of (S)-benzyl 3-(benzyloxy)-2-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)propanoate.
OBn Boc,Me-Ala, NMM OBn HOBT, EDC .. Boc 0 _7c =
H2N Xy0Bn __________________________________ Nj-L OBn THE, 23 C Me' N
= H
o Me 0 95%
1004291 To a solution of the serine derivative (1.74 g, 3.80 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (773 mg, 3.80 mmol, 1.0 equiv), HOBT=xH20 (641 mg, 4.18 mmol, 1.1 equiv) and NMM (1.25 mL, 11.4 mmol, 3 equiv) in THF (45 mL) at 0 C was added EDC=HC1 (766 mg, 3.99 mmol, 1.05 equiv). After 30 min the cold bath was removed. The solution stirred for 14 h and then was quenched with saturated aqueous NaHCO3 (50 mL), extracted with ethyl acetate (2 x 40 mL), dried over sodium sulfate and then concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (5:1->4:1-43:1 hexanes/Et0Ac) to yield the product (1.70 g, 95%). itf= 0.20 (5:1 hexanes/Et0Ac). NMR (400 MHz, CDCI3) 6: 7.34-7.27 (m, 8H), 7.19 (dd, 2H, J= 2.0, 8.0 Hz), 5.18 (q, 2H, J= 12.0 Hz), 4.79-4.74 (m, 1H), 4.45 (q, 2H, J= 12.0 Hz), 3.89 (dd, 1H, J= 3.2, 9.6 Hz), 3.66 (dd, 1H, J= 3.2, 9.6 Hz), 2.75 (s, 3H), 1.45 (s, 9H), 1.34 (t, 3H, J= 7.2 Hz);
13C NMR (100 MHz, CDC13) 6: 171.6, 170.0, 137.5, 135.4, 128.7, 128.5, 128.5, 128.3, 127.9, 127.7, 73.4, 69.8, 67.4, 52.9, 30.0, 28.4, 13.9; HRMS calcd for C26H34N206Na: 493.23091, found 493.23211.
[00430] Example 2: Preparation of (S)-2-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)-3-hydroxypropanoic acid.
OBn OH
Boc o Pd-C, H2 Boc 0 )1'sN Me0H, 23 C N OH
o H
Me H 0 57%
1004311 To a solution of benzyl ester (1.70 g, 3.61 mmol, 1.0 equiv) in methanol (25 mL) was added 10 wt%
Pd-C (100 mg). A balloon of H2 was applied for 16 h, then the mixture was filtered through Celite" with DCM and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (1:1 hexanes/Et0Ac¨>100% DCM-->5% Me0H/DCM) to yield the product (591 mg, 57%). NMR
(400 MHz, CD30D) 6: 4.41 (t, 1H, J = 3.6 Hz), 3.91 (dd, 1H, J = 4.4, 10.8 Hz), 3.83 (dd, 1H, J = 4.0, 11.2 Hz), 3.35-3.34 (m, 1H), 2.86 (s, 3H), 1.47 (s, 9H), 1.38 (d, 3H, J= 6.8 Hz);
"C NMR (100 MHz, CD3CN) 6: 207.9, 173.1, 172.4, 81.0, 62.6, 55.4, 30.9, 28.5. HRMS calcd for Ci2H22N206Na: 313.1370, found 313.1371.
[00432] Example 3: Preparation of (2S,3R)-benzyl 3-(benzyloxy)-24(S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)butanoate.
Me. _..0Bn Boc,Me-Ala, NMM Me, ,OBn ¨
HOBT, EDC Boc 0 se.y.0Bn ____ THF, 23 C u 1411 0 Me¨ 0 57%
[00433] Same procedure as Example 1 using threonine derivative (4.65 g, 11.9 mmol, 1.0 equiv), Boc-AT-Me-Ala-OH (2.43 g, 11.9 mmol, 1.0 equiv), HOBT=xH20 (2.19 g, 14.3 mmol, 1.1 equiv), NMM (3.94 mL, 35.8 mmol, 3 equiv) and EDC=HC1 (2.75 g, 14.3 mmol, 1.05 equiv) in THF
(100 mL). The resultant oil was purified by flash chromatography on silica gel (5:1¨>4:12:1 hexanes/Et0Ac) to yield the product (3.32 g, 57%). Rf= 0.26 (5:1 hexanes/ethyl acetate). Ili NMR (400 MHz, CDC13) 6: 7.31-7.25 (m, 8H), 7.17-7.15 (m, 2H), 5.14 (d, 1H, J= 6.0 Hz), 5.06 (d, 1H, J= 6.0 Hz), 4.67 (dd, 1H, 2.4, 9.2 Hz), 4.48 (d, 1H, J= 12.0 Hz), 4.27 (d, 1H, J= 12.0 Hz),4.15 (qd, 1H, J= 2.0, 6.0 Hz), 2.79 (s, 3H), 1.60 (s, 1H), 1.42 (s, 9H), 1.35 (d, 3H, J= 7.2 Hz), 1.16 (d, 3H, 6.4 Hz); "C NMR
(100 MHz, CDC13) 6:
172.2, 170.4, 135.5, 128.7, 128.7, 128.5, 128.5, 128.5, 128.4, 127.8, 127.8, 74.3, 70.9, 67.3, 56.8, 28.4, 16.4. HRMS calcd for C27H36N206Na: 507.2466, found 507.2468.
[00434] Example 4: Preparation of (25,3R)-24(S)-24(tert-butoxycarbonyl)(methyl)amino)propanamido)-3-hydroxybutanoic acid.
Me, ,OBn Me OH
Boc 0 ¨ Pd-C, H2 Boc 0 N
0Bn OH
Me0H, 23 C Me N
H
Me 0 Me 0 97%
[00435] Same procedure as Example 2 using benzyl ester (3.306 g, 6.82 mmol, 1.0 equiv) and 10 wt% Pd-C (150 mg) in methanol (50 mL). The resultant oil was sufficiently pure as a crude product (2.01 g, 97%).
NMR (400 MHz, CD30D) 6: 7.44 (bs, 1H), 4.70 (bs, 1H), 4.40-4.36 (m, 1H), 4.33 (dd, 1H, J= 2.8, 6.4 Hz), 2.87 (s, 3H), 1.48 (s, 9H), 1.39 (d, 3H, J= 7.2 Hz), 1.18 (d, 3H, J= 6.4 Hz); "C NMR (100 MHz, CD30D) 6: 174.7, 173.7, 157.5, 81.9, 68.2, 59.0, 55.7, 30.9, 28.6, 20.7, 14.9.
HRMS calcd for C 13H24N206Na: 327.15266, found 327.15236.
[00436] Example 5: 4,4-Dimcthoxybutanal.
Me0 Me0 DIBAL
DCM, -78 C Me0 93%
[00437] To a solution of nitrile (1.2 g, 9.29 mmol, 1.0 equiv) in DCM (75 mL) at -78 C under N2 was added 1.1 M DIBAL in cyclohexane (23.23 mL, 10.2 mmol, 1.1 equiv). After 3 hat -78 C, the mixture was slowly warmed to r.t. and quenched with sat. aq. NH4C1 (25 mL) and Rochelle salt (25 mL).
Reaction progress was monitored by TLC (vanillin stain). After stirring for 1 h, the mixture was extracted with DCM (3 x 20 mL). The organics were then washed with brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo to yield a colorless, relatively volatile liquid product (1.14 g, 93%) which was sufficiently pure to use without further purification. The analytical data match those previously reported:
Gricsbaum, K.; Jung, I. C.; Mertens, H. J. Org. Chem. 1990, 55, 6024.
[00438] Example 6: 4,4-Dimethoxy-2,2-dimethylbutanenitrile.
Me0 Me0 LDA, Mel ) /
Me0 Me0 <Me DCM, -78 C Me 87%
[00439] To a solution of diisopropylamine (4.77 mL, 34.1 mmol, 2.2 equiv) in THF (50 mL) at -10 C
under N2 was added 1.5 M n-BuLi in hexanes (22.7 mL, 34.1 mmol, 2.2 equiv).
After 30 min the mixture was cooled to -78 C and a solution of nitrile (2.0 g, 15.5 mmol, 1.0 equiv) in THF (10 mL) was added.
After 1 h iodomethane (2.12 mL, 34.1 mmol, 2.2 equiv) was added. The mixture was slowly warmed to 0 C and kept there for 14 h, at which time it was quenched with sat. aq. NH4C1 (40 mL) and extracted with Et0Ac (3 x 20 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (5:1->3:1 hexanesiEt0Ac) to yield the product (2.105 g, 87%) as a yellow oil. Rf= 0.49 (3:1 hexanes/Et0Ac). 1H NMR
(400 MHz, CDC11) 6:
4.60 (t, 1H, J= 5.6 Hz), 3.37 (s, 6H), 1.83 (d, 2H, J= 4.4 Hz), 1.39 (s, 6H);
13C NMR (100 MHz, CDC13) 6: 124.7, 102.4, 53.3, 43.0, 30.0, 27.5 [00440] Example 7: Preparation of 4,4-dimethoxy-2,2-dimethylbutanal.
Me0 Me0 ) Me0 <Me Me0 __ e DIBAL
= M
Me DCM, -78 C Me O-N
46%
[00441] Same procedure as Example 5 using the nitrile derivative (500 mg, 3.18 mmol, 1.0 equiv) in DCM (25 mL) and 1.1 M DIBAL in cyclohexane (3.18 mL, 10.2 mmol, 1.1 equiv).
The resultant oil was purified by flash chromatography on silica gel (9:1 hexanes/Et0Ac) to yield the product (232 mg, 46%) as a colorless, relatively volatile oil. Rf= 0.39 (7:1 hexanes/Et0Ac).
[00442] Example 8: Preparation of 2-(diethoxymethyl)benzaldehyde.
Et0 n-BuLi Et0 Et0 THE, -78 C. Et0 Br then DMF 0-quant.
[00443] To a solution of aryl bromide (1.94 g, 7.49 mmol, 1.0 equiv) in THF
(20 mL) at -78 C under N2 was added 1.5 M n-BuLi in hexanes (7.49 mL, 11.2 mmol, 1.5 equiv). After 30 min DMF (869 L, 11.2 mmol, 1.5 equiv) was added. The mixture was slowly warmed to r.t. over 4 h, at which time it was quenched with sat. aq. NH4C1 (40 mL) and extracted with Et0Ac (3 x 20 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (95:4:1 hexanes/Et0Ac/Et3N) to yield the product (2.105 g, 87%) as a yellow oil. Rf= 0.46 (3:1 hexanes/Et0Ac). The analytical data match those previously reported:
Ueda, M.; Kawai, S.;
Hayashi, M.; Naito, T.; Miyata., 0. J. Org. Chem. 2010, 75, 914.
[004441Example 9: N-(Naphthalen-l-yl)formamide.
NH2 EtOCHO H. NH
LHMDS
THF, 85 C ftjj 64%
[00445] To a mixture of 1-naphthylamine (6.0 g, 41.9 mmol, 1.0 cquiv) and ethyl formate (6.74 mL, 83.8 mmol, 2 equiv) in THF (200 mL) was added 1 M LHMDS in THF (75.4 mL, 75.4 mmol, 1.8 equiv). The mixture was heated to 85 C for 14 11 and then concentrated. The resulting solid was filtered and rinsed with hexanes to yield the product. The filtrate was concentrated and the filtration procedure was repeated for a second batch of product to yield overall the product (3.05 g, 64%) as a brown solid and a 2:1 mixture of rotational isomers. R1= 0.10 (5:1 hexanes/ethyl acetate). 1H NMR (400 MHz, CDC13) 6: 8.65-8.61 (m, 2H), 8.45 (bs, 1H), 8.04-7.99 (m, 2H), 7.92-7.85 (m, 2H), 7.80 (d, 1H, ./= 8.4 Hz), 7.73 (d, 1H, ./= 8.0 Hz), 7.63-7.51 (m, 3H), 7.50-7.44 (m, 2H), 7.32 (d, 1H, J= 7.6 Hz); 13C NMR
(100 MHz, CDC13) 6:
164.1, 159.7, 134.4, 134.2, 132.2, 131.1, 129.0, 128.7, 127.9, 127.2, 127.2, 127.2, 127.0, 126.7, 126.4, 126.3, 125.9, 125.7, 121.4, 121.0, 120.5, 119.3. HRMS calcd for C11H9N0:
171.0679, found 171.0681.
[00446] Example 10: Preparation of 1-isocyanonaphthalene.
HA NH N-POCI3, E13N
DCM, 0 C
79%
[00447] To a solution of formamide derivative (1.048 g, 6.12 mmol, 1.0 equiv) in DCM (20 mL) at 0 C
was added Et3N (4.33 mL, 31.2 mmol, 5.1 equiv) followed by phosphorus oxychloride (841 uL, 9.18 mmol, 1.5 equiv). The mixture was warmed to 23 'V and stirred for 2 h, at which time it was poured into a mixture of saturated NaHCO3 (40 mL) and 1 M NaOH (20 mL) and extracted with DCM (3 x 20 mL).
The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (1:1 hexanes/DCM) to yield the product (740 mg, 79%) as a brown oil which was stored at 0 C. Rf= 0.72 (3:1 hexanes/Et0Ac). [FT NMR (400 MHz, CDC13) 6: 8.19 (d, 1H, J= 8.4 Hz), 7.90 (d, 2H, J= 8.0 Hz), 7.68 (t, 1H, J= 7.6 Hz), 7.61 (t, 2H, J=
7.2 Hz), 7.45 (td, 1H, J=
2.4, 8.4 Hz); [3C NMR (100 MHz, CDC13) 6: 167.3, 133.7, 129.9, 128.5, 128.2, 128.1, 127.6, 125.1, 124.7, 123.1. HRMS calcd for CiiHgN: 154.06513, found 154.06671.
[00448] Example 11: Preparation of N-benzhydrylformamide.
iLj EtOCHO 0 H
70%
[00449]A mixture of benzhydrylamine (4.0 g, 21.8 mmol, 1.0 equiv) and ethyl formate (2.0 mL, 24.9 mmol, 1.14 equiv) was heated to 75 C for 14 b. Ethyl acetate was added and the mixture was triturated by sonication, then filtered and rinsed with Et20 to yield the product (3.24g, 70%) as a white solid. The compound exists as a mixture of rotational isomers. Rf= 0.29 (3:1 hexanes/Et0Ac). 'H NMR (400 MHz, CDC13) 6: 8.15 (s, 1H), 7.34-7.19 (m, 10H), 6.69 (d, 1H, J = 6.0 Hz), 6.27 (d, 1H, J = 8.4 Hz); 13C NMR
(100 MHz, CDC13) 6: 160.4, 141.0, 128.8, 127.7, 127.5, 55.7. HRMS calcd for C14Ht4N0: 212.10699, found 212.100748.
[00450] Example 12: Preparation of (isocyanomethylene)dibenzene.
0 POCI3, Et3 N
H N
DCM, 0 C +N
93%
[00451] To a solution of formamide derivative (1.727 g, 8.17 mmol, 1.0 equiv) in DCM (35 mL) at 0 C
was added Et3N (5.79 mL, 41.7 mmol, 5.1 equiv) followed by phosphorus oxychloride (1.12 mL, 12.3 mmol, 1.5 equiv). The mixture was warmed to 23 C and stirred for 18 h, at which time it was poured into a mixture of saturated NaHCO3 (50 mL) and 1 M NaOH (20 mL) and extracted with DCM (3 x 30 mL).
The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (DCM->5:1 DCM/Et0Ac) to yield the product (1.467 g, 93%) as an orange solid which was stored at 0 C. Rf= 0.73 (7:1 hexanes/Et0Ac). 1H NMR
(400 MHz, CDC13) 6:
7.41-7.33 (m, 10H), 5.92 (s, 1H); 13C NMR (100 MHz, CDC13) 6: 158.5, 137.7, 129.1, 128.6, 126.7, 77.2, 62.1. HRMS calcd for C14H11NNa: 216.07837, found 216.07971.
[00452] Example 13: Preparation of (R)-N-(1,2,3,4-tetrahydronaphthalen-l-yl)formamide.
EtOCHOiii 11111J T
63%
[00453[A mixture of (R)-(-)-1,2,3,4-tetrahydro-l-naphthylamine (10.0 g, 67.9 mmol, 1 equiv) and ethyl formate (6.23 mL, 77.4 mmol, 1.14 equiv) was heated to 80 C for 14 h. Hexanes was added and the mixture was triturated by sonication, then filtered and rinsed with hexanes to yield the product (7.44 g, 63%) as a tan solid. Rf= 0.22 (3:1 hexanes/Et0Ac). NMR (400 MHz, CDC13) 6:
8.23 (s, 1H), 7.29-7.25 (m, 1H), 7.23-7.16 (m, 2H), 7.13-7.08 (m, 1H), 5.82 (bs, 1H), 5.28 (dd, 1H, J= 5.2, 14.0 Hz), 2.85-2.73 (m, 2H), 2.15-2.03 (m, 1H), 1.88-1.81 (m, 3H); 13C NMR (100 MHz, CDC13) 6: 160.5, 137.7, 136.1, 129.4, 128.8, 127.6, 126.5, 46.4, 30.3, 29.3, 20Ø HRMS calcd for C111-113NONa: 198.0889, found 198.0890.
[00454] Example 14: Preparation of (R)-1-isocyano-1,2,3,4-tetrahydronaphthalene.
III
HANH N+
r-Lõ, nai 3, ciGni DCM, 0 C
69%
[00455] To a solution of formamide derivative (2.85 g, 16.3 mmol, 1.0 equiv) in DCM (40 mL) at 0 C
was added Et3N (11.51 mL, 82.9 mmol, 5.1 equiv) followed by phosphorus oxychloride (2.23 mL, 24.4 mmol, 1.5 equiv). The mixture was warmed to 23 C and stirred for 2 h, at which time it was poured into saturated NaHCO3 (200 mL) and extracted with DCM (2 x 100 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (3:1->1 :1 hexanes/DCM) to yield the product (1.76 g, 69%) as a brown oil which was stored at 0 C. It1= 0.59 (5:1 hexanes/Et0Ac). Ifi NMR (400 MHz, CDC13) 6: 7.45-7.43 (m, 1H), 7.26-7.23 (m, 2H), 7.14-7.11 (m, 1H), 4.83 (app. s, 1H), 2.92-2.84 (m, 1H), 2.80-2.72 (m, 1H), 2.18-2.12 (m, 2H), 2.11-2.01 (m, 1H), 1.87-1.78 (m, 1H); '3C NMR (100 MHz, CDC13) 6: 155.2, 136.5, 132.1, 129.5,128.6, 128.6, 126.7, 52.6, 30.7, 28.6, 19.4. HRMS calcd for CiiHi2N: 158.0964, found 158.0966.
[00456] Example 15: Preparation of 1-(2,2-dimethoxyethyl)-2-isocyanobenzene.
, Me OMe OMe [00457] The isocyanide was prepared according to the established literature procedure; see Gilley, C. B.;
Buller, M. J.; Kobayashi, Y. Org. Lett. 2007, 9, 3631.
[00458] Example 16: General synthetic scheme for the preparation of 6,5-heterobicyclic compounds described below:
Boc 0 R2a,¨ ,OH MeO\
R2a 0 e 0 Me - NIIIM=r HM 0_) a-b A
- H
Me Me N1(13 Me 0 N
NH3 CA\J--R7 0 H
a) CF3CH2OH, JAW, 80 C; b) TFA, DCM, 23 C
[00459] Example 17: Preparation of (3S,8aS)-N-benzy1-3-((S)-2-(methylamino)propanamido)-4-oxohexahydro-2H-pyrrolo[2,1-b][1,3]oxazine-6-carboxamide.
Me0 OH meo)D OMe HO Me TFA
Boc 0 fy CF3CH2OH DCM 0 7 0- _______________________ Boc 0 jyH õ 0 MeNOH
Ark 23.c N
pW, 80 C- MeN
Ae H 0 NH3 20 min = H
Me 0 N
0 H IFP 30% Re H 0 NO
(2 steps) [00460] A mixture of carboxylic acid (93 mg, 0.320 mmol, 1.0 equiv), aldehyde (44 mg, 0.336 mmol, 1.05 equiv), benzyl isocyanide (38 mg, 0.320 mmol, 1.0 equiv) and 7 M ammonia in Me0H (92 pt, 0.641 mmol, 2.0 equiv) in TFE (3 mL) was stirred under microwave iffadiation at a set temperature of 80 C for 20 min. The mixture was then transferred to a round bottom flask and concentrated in vacuo, then 1 M
NaOH (15 mL) was added and the mixture was extracted with DCM (3 x 7 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was combined with TFA (147 1.92 mmol, 6 equiv) in DCM (5 mL) and stiffed at 23 C for 14 h. The mixture was concentrated in vacuo and purified by flash chromatography on basic alumina (3:1 hexanesiEt0Ac¨>DCM-97%
Me0H/DCM) to yield the product as a 1:1 diastereomixture of the the free base (36 mg, 30%
over 2 steps). Some of the material was further purified by preparative scale HPLC for use in biological assays. 11-I NMR (400 MHz, CD30D) 6: 8.51 (bs, 1H), 7.33-7.28 (m, 8H), 7.26-7.21 (m, 2H), 5.23 (t, 1H, =
5.2 Hz), 5.16 (dd, I H, = 5.2, 8.4 Hz), 4.68 (dd, 1H, J = 3.2, 6.4 Hz), 4.61-4.56 (m, 2H), 4.48 (d, 1H, 1= 15.2 Hz), 4.42-4.33 (m, 4H), 4.28 (dd, 1H, J= 6.4, 11.6 Hz), 4.24 (dd, 1H, J= 6.0, 11.6 Hz), 4.01 (dd, 1H, J= 3.2, 11.6 Hz), 3.92 (dd, 1H, J= 3.2, 11.6 Hz), 3.69 (q, 2H, J= 6.8 Hz), 2.61 (s, 3H), 2.60 (s, 3H), 2.41-2.29 (m, 2H), 2.26-2.16 (m, 2H), 1.94-1.82 (m, 2H), 1.49 (d, 3H, J= 7.2 Hz), 1.47 (d, 3H, 1= 7.2 Hz); 13C NMR (100 MHz, CD30D) 6: 173.6, 173.4, 167.9, 167.1, 139.7, 139.7, 129.5, 129.5, 128.4, 128.4, 128.2, 128.2, 91.1, 90.9, 71.7, 70.8, 60.7, 59.8, 58.8, 44.2, 44.0, 32.3, 32.2, 32.2, 31.2, 27.2, 26.7, 16.8, 16.7. HRMS calcd for C19H27N404: 375.2027, found 375.2028.
[00461] Example 18: Preparation of (3S,8a5)-N-(4-chloropheny1)-3-((S)-2-(methylamino)propanamido)-4-oxohexahydro-2H-pyrrolo[2,1-b][1,3]oxazine-6-carboxamide.
Me0 OH Me TFA
me ElBoc 0 m.o)D CF3CH2OH _ c e0 CI DCM
=
¨ H
W, so Me c N 23 C dit CI
Ae 0 NH3... CI 120 min H 0 N
(2 steps) A H
me 0 N
-csN
[00462] Same procedure as Example 17 with carboxylic acid (105 mg, 0.362 mmol, 1.0 equiv), aldehyde (50 mg, 0.380 mmol, 1.05 equiv), isocyanide (50 mg, 0.362 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(103 litL, 0.723 mmol, 2.0 equiv) in TFE (3 mL). The resultant oil was combined with TFA (166 !at, 2.17 mmol, 6 equiv) in DCM (5 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and purified by flash chromatography on basic alumina (3:1 hexanes/Et0Ac-9DCM-97%
Me0H/DCM) to yield the product as a 1:1 diastereomixture of the free base (98 mg, 69% over 2 steps). 1H NMR (400 MHz, CDC13) 6: 8.53 (bs, I H), 7.58 (d, 2H, J= 3.2 Hz), 7.57 (d, 2H, = 3.6 Hz), 7.32 (d, 2H, J= 2.0 Hz), 7.30 (d, 2H, J = 3.6 Hz), 5.29 (dd, 1H, J = 5.2, 7.2 Hz), 5.21 (dd, 1H, J =
4.8, 6.8 Hz), 4.71-4.68 (m, 2H), 4.66-4.63 (m, 1H), 4.49 (d, 1H, J = 8.8 Hz), 4.31 (dd, 1H, J= 6.8, 11.6 Hz), 4.26 (dd, 1H, J= 6.4, 11.6 Hz), 4.01 (dd, 1H, J= 2.8, 11.6 Hz), 3.94 (dd, 1H, J= 2.8, 11.6 Hz), 3.62 (q, 1H, J= 6.8 Hz), 3.60 (q, 1H, J= 6.8 Hz), 2.56 (s, 6H), 2.47-2.35 (m, 2H), 2.30-2.25 (m, 2H), 2.13-2.07 (m, 2H), 2.02-1.87 (m, 2H), 1.45 (d, 3H, J= 7.2 Hz), 1.43 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CDC13) 6:
171.8, 171.6, 167.8, 167.3, 138.5, 138.2, 130.5, 130.3, 129.8, 129.8, 122.8, 122.5, 91.0, 90.9, 71.4, 70.9, 61.1, 60.3, 59.0, 32.6, 32.6, 32.3, 31.3, 27.1, 26.7, 17.2, 17Ø HRMS calcd for ClgH24C1N404:
395.1481, found 395.1479.
[00463] Example 19: Preparation of (3S,8a5)-3-((S)-2-(methylamino)propanamido)-4-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)hexahydro-2H-pyrrolo[2,1-b][1,3]oxazine-6-carboxamide.
Me0 OH ) Z
Me oe 0=) CF3CH2OH 0 Me0q3..
Bo OH Me DTLAm 0 w Me' OH
Ae H 0 NH3 p (268m0i 23 C e e H 0 110 Me 0 N
0 H Mr 67% u H
(2 steps) [00464] Same procedure as Example 17 with carboxylic acid (97 mg, 0.334 mmol, 1.0 equiv), aldehyde (46 mg, 0.351 mmol, 1.05 equiv), isocyanide (53 mg, 0.334 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(97 L, 0.668 mmol, 2.0 equiv) in TFE (3 mL). The resultant oil was combined with TFA (177 uL, 1.55 mmol, 6 equiv) in DCM (5 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and purified by flash chromatography on basic alumina (3:1 hexanesiEt0Ac-9DCM-97%
McOH/DCM) to yield the product as the free base (72 mg, 67% over 2 steps). Some of the material was further purified by preparative scale HPLC for use in biological assays. 'H NMR (400 MHz, CDC13) 6: 8.51 (s, 1H), 7.40-7.36 (m, 1H), 7.17-7.06 (m, 7H), 5.24 (dd, 1H, J= 4.8, 6.4 Hz), 5.17 (dd, 1H, J= 4.8, 8.0 Hz), 5.10-5.04 (m, 2H), 4.66-4.62 (m, 2H), 4.57 (t, J= 8.0 Hz), 4.35 (d, 1H, J= 7.6 Hz), 4.27 (dd, 1H, J= 6.4, 11.6 Hz), 4.24 (dd, 1H, J= 6.0, 12.0 Hz), 3.76-3.65 (m, 2H), 2.87-2.72 (m, 4H), 2.63 (s, 3H), 2.61 (s, 3H), 2.43-2.31 (m, 2H), 2.28-2.17 (1n, 2H), 2.05-1.88 (m, 7H), 1.86-1.74 (m, 5H), 1.52 (d, 3H, J= 7.2 Hz), 1.49 (d, 3H, J= 7.2 Hz); l'C NMR (100 MHz, CDC13) 6: 206.6, 172.9, 172.8, 171.7, 167.7, 167.0, 138.7, 138.5, 137.6, 137.6, 130.1, 129.9, 129.7, 129.3, 128.2, 128.1, 127.2, 127.2, 127.1, 91.1, 91.0, 71.6, 70.9, 60.8, 59.8, 58.9, 58.8, 58.8, 32.3, 32.3, 32.2, 31.3, 31.3, 31.2, 30.2, 30.2, 27.2, 26.8, 21.8, 21.5, 16.8, 16.7.
HRMS calcd for C22H3oN404Na: 437.21593, found 437.20535.
[00465] Example 20: Preparation of (2R,3S,8aS)-2-methy1-34(S)-2-(methylamino)propanamido)-4-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-y1)hexahydro-2H-pyrrolo[2,1-b][1,3]oxazine-6-carboxamide.
Me0 Me OH
Boc 0 Me0)-) Me0 Me TFA
111., OH ¨ Boc (r DCM 0Me 0 w Me' IFAry e Ae 0 NH3 RW, me N 1111, 23 C N =
7 20 min H 0 Ke Me 0 I 0 H ND
[00466] Same procedure as Example 17 with carboxylic acid (85 mg, 0.279 mmol, 1.0 equiv), aldehyde (39 mg, 0.293 mmol, 1.05 equiv), isocyanide (44 mg, 0.279 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(80 L, 0.559 mmol, 2.0 cquiv) in TFE (3 mL). The resultant oil was combined with TFA (128 _L, 1.67 mmol, 6 equiv) in DCM (5 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and purified by flash chromatography on basic alumina (3:1 hexanes/Et0Ac¨>DCM-97%
Me0H/DCM) to yield the product as a slightly impure free base (94 mg, yield not calculated). Some of the material was further purified by preparative scale HPLC for use in biological assays. 1H
NMR (400 MHz, DMSO-d6) 6:8.28 (d, 1H, J= 8.8 Hz), 8.26 (d, 1H, J= 8.8 Hz), 8.24 (s, 2H), 8.18 (d, 1H, J= 8.8 Hz), 8.00 (d, 1H, J
= 8.8 Hz), 7.28 (d, 1H, J= 7.2 Hz), 7.16-7.06 (in, 6H), 5.25 (t, 1H, J= 5.6 Hz), 5.20 (dd, 1H, .1= 5.2, 7.6 Hz), 4.99-4.92 (m, 2H), 4.60 (dd, 1H, J= 5.6, 8.4 Hz), 4.50 (dd, 1H, J= 5.2, 8.4 Hz), 4.46 (t, 1H, J= 7.2 Hz), 4.34-4.27 (m, 2H), 4.24 (t, 2H, J= 8.4 Hz), 3.13 (q, 1H, J= 6.8 Hz), 3.09 (q, 1H, J= 6.8 Hz), 2.76-2.70 (m, 3H), 2.24 (s, 3H), 2.22 (s, 3H), 1.93-1.80 (m, 6H), 1.80-1.60 (m, 6H), 1.17 (d, 3H, J= 6.8 Hz), 1.15 (d, 3H, J= 6.8 Hz), 1.07 (d, 3H, J= 6.4 Hz), 1.00 (d, 3H, J= 6.4 Hz); 13C
NMR (100 MHz, DMSO-d6) 6: 174.1, 170.3, 169.9, 165.7, 165.2, 137.6, 137.4, 137.0, 136.9, 128.7, 128.5, 128.3, 127.7, 126.7, 126.6, 125.8, 125.7, 99.5, 87.7, 87.6, 73.4, 72.6, 59.2, 58.8, 58.7, 57.9, 50.5, 50.3, 46.6, 46.5, 34.0, 33.7, 30.7, 30.0, 29.9, 28.8, 28.8, 26.0, 25.7, 20.5, 18.9, 18.7, 16.5. HRMS calcd for C231-132N404Na:
451.23158, found 451.23286.
[00467] Example 21: Preparation of (2R,3S,8aS)-2-methy1-3-((S)-2-(methylamino)propanamido)-N-(naphthalen-1-y1)-4-oxohexahydro-2H-pyrrolo[2,1-b][1,3]oxazine-6-carboxamide.
Me0 Me OH
Boc 0 Me )D
0¨ CF3CH2OH Boc MeO OMe TFA
DCM
ONle 13, me, N NoThrOH
C W, 80 C* Me N 63 H
23 % C nie-NNe-yN 111 Me H 0 NH3 + 20 min Me H 0 Me H 0 N
0 El 0 H
(2 steps) [00468] Same procedure as Example 17 with carboxylic acid (100 mg, 0.328 mmol, 1.0 equiv), aldehyde (46 mg, 0.344 mmol, 1.05 equiv), isocyanide (50 mg, 0.328 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(94 uL, 0.657 mmol, 2.0 equiv) in TFE (3 mL). The resultant oil was combined with TFA (151 uL, 1.97 mmol, 6 equiv) in DCM (5 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and purified by flash chromatography on basic alumina (1:1 hexanes/Et0Ac¨>DCM-97%
Me0H/DCM) to yield the product as the free base (88 mg, 63% over 2 steps). Some of the material was further purified by preparative scale HPLC for use in biological assays. 1H NMR (400 MHz, CD30D) 6: 8.53 (bs, 1H), 8.13-8.09 (m, 1H), 8.05 (d, 1H, J= 6.8 Hz), 7.92-7.87 (m, 2H), 7.81 (t, 2H, J= 6.4 Hz), 7.56-7.46 (m, 8H), 5.29 (dd, 1H, J= 5.2, 8.0 Hz), 5.21 (dd, 1H, J= 4.8, 8.4 Hz), 4.83 (t, 1H, J=
8.4 Hz), 4.71-4.67 (m, 2H), 4.62 (d, 1H, J = 4.0 Hz), 4.36-4.24 (m, 2H), 3.70 (q, 1H, I = 6.8 Hz), 3.65 (q, 1H, J = 6.8 Hz), 2.59 (s, 3H), 2.52 (s, 3H), 2.42-2.32 (m, 2H), 2.31-2.18 (m, 2H), 2.16-2.02 (m, 2H), 1.96-1.85 (m, 1H), 1.50 (d, 3H, J= 6.8 Hz), 1.38 (d, 3H, J= 7.2 Hz), 1.24 (t, 6H, J= 6.8 Hz); '3C NMR (100 MHz, CD30D) 6: 173.3, 173.2, 172.7, 172.4, 168.3, 167.5, 135.7, 135.7, 134.0, 133.7, 130.6, 130.6, 129.3, 129.2, 128.2, 128.1, 127.5, 127.4, 127.3, 127.2, 126.4, 126.4, 124.6, 124.3, 124.1, 123.8, 91.0, 90.9, 76.3, 75.7, 60.6, 59.5, 59.1, 58.9, 52.8, 52.5, 32.6, 32.4, 32.2, 31.2, 26.7, 26.2, 17.3, 17.2, 16.7.
HRMS calcd for C23H29N404:
425.2183, found 425.2181.
[00469] Example 22: Preparation of (2R,3S,8a5)-N-benzhydry1-2-methy1-3-((S)-2-(methylamino)propanamido)-4-oxohexahydro-2H-pyrrolo[2,1-b][1,3]oxazine-6-carboxamide.
Me0 )-) 0 Me0 Me 20:.)IMe OH Me0 ,NX,y0H 0_ CF3CH2OH TFA Me 0 nW, 80 C Me' N DCM
Me H 0 NH3 H Me . N
20 min Me 0 N 23 C H
0 Me 0 H N
u H
46%
(2 steps) [00470] Same procedure as Example 17 with carboxylic acid (105 mg, 0.345 mmol, 1.0 equiv), aldehyde (47 mg, 0.362 mmol, 1.05 cquiv), isocyanidc (67 mg, 0.345 mmol, 1.0 cquiv) and 7 M ammonia in McOH
(99 uL, 0.690 mmol, 2.0 equiv) in TFE (3 mL). The resultant oil was combined with TFA (159 pt, 2.07 mmol, 6 equiv) in DCM (5 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and purified by flash chromatography on basic alumina (1:1 hexanesiEt0Ac-9DCM-97%
Me0H/DCM) to yield the product as the free base (73 mg, 46% over 2 steps). IFINMR (400 MHz, CD30D) 6: 7.38-7.18 (m, 20H), 6.17 (s, 1H), 6.15 (s, 1H), 5.21 (dd, 1H, J = 5.2, 8.0 Hz), 5.13 (dd, 1H, J = 4.8, 8.8 Hz), 4.66 (t, 1H, J= 7.6 Hz), 4.62 (d, 1H, J= 4.4 Hz), 4.56 (d, 1H, J= 4.4 Hz), 4.47 (d, 1H, J= 8.4 Hz), 4.28 (dd, 1H, = 4.4, 6.4 Hz), 4.22 (dd, 1H, J= 4.4, 6.4 Hz), 3.25 (q, 1H, J= 6.8 Hz), 3.21 (q, 1Hõ/ = 6.8 Hz), 2.36 (s, 3H), 2.30 (s, 3H), 2.39-2.25 (m, 2H), 2.19-2.12 (m, 2H), 2.06-1.86 (m, 4H), 1.85-1.79 (m, 2H), 1.31 (d, 3H, J= 6.8 Hz), 1.26 (d, 3H, J= 7.2 Hz), 1.20 (d, 3H, J= 6.4 Hz), 1.18 (d, 3H, J= 6.4 Hz); '3C NMR
(100 MHz, CD30D) 6: 176.8, 176.6, 173.0, 172.7, 168.0, 167.6, 143.0, 142.8, 142.6, 142.6, 129.7, 129.6, 129.5, 129.4, 128.9, 128.8, 128.7, 128.6, 128.5, 128.5, 128.3, 128.1, 90.7, 90.6, 76.3, 75.5, 60.4, 60.3, 60.0, 59.2, 58.5, 58.4, 52.5, 52.2, 34.2, 34.1, 32.1, 31.1, 29.5, 26.7, 26.1, 19.2, 19.1, 16.8, 16.7. HRMS
calcd for C26H32N404Na: 487.23158, found 487.23308.
[00471J Example 23: General synthetic scheme for the preparation of 7,5-heterobicyclic Smac peptidomimetics.
X
)1-2 me0 X
¨).-BocHN Me0 B `) 1-2 0 0¨ R1 Ri Bo c (S)- WR 7 -+ 0 N /N---!)LH 0 NH3 CNI H Me--R7 'N'Ae H
12 B> d B
R1,R7 Bock (R) R1 R7 /1\1 H 0 N /F\I H 0 0 N
Me Klie 0 H Me icne a) CF3CH2OH, W, 80 C; b) TFA, DCM, 23 C;
c) Boc-N-Me-Ala-OH, EDC, NMM, HOBT, THF, 23 C; d) TFA, DCM
[004721 Example 24: Preparation of (4S,9aS)-4-amino-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)octahydropyrrolo[2,1-b][1,31oxazepine-7-carboxamide.
OH Me0 BocHN Xr Me0)D
OH 0¨ CF3CH2OH
C- ____________________ ' OH
me0\13.0Me H
N __________________________________________________ ' ti 0 Hi BocHN DCM H,N---\(:(-0 1 al f 20 min 0 Ns 35 TFA C - 0 , N *
[00473] A mixture of Boc-N-HSer-OH (318 mg, 1.45 mmol, 1.0 equiv), aldehyde (201 mg, 1.52 mmol, 1.05 equiv), isocyanide (228 mg, 1.45 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(414 uL, 2.90 mmol, 2.0 equiv) in TFE (5 mL) was stirred under microwave irradiation at a set temperature of 80 C for 20 min. The mixture was then transferred to a round bottom flask and concentrated in vacuo, then 1 M
NaOH (15 inL) was added and the mixture was extracted with DCM (3 x 7 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was combined with TFA (834 L, 10.9 mmol, 8 equiv) in DCM (5 mL) and stirred at 35 C for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[004741 Example 25: Preparation of tert-butyl methyl((2S)-1-oxo-1-(((4S,9aS)-5-oxo-7-(((R)-1,2,3,4-tetrahydronaphthalen- 1-yl)carbamoyl)octahydropyrrolo [2,1 -b] [1,3] oxazep in-4 -y1) amino)propan-2-yl)carbamate.
(01:1 01;1 H
Boc,Me-Ala, HOBT, EDC 0 0 _________________________ 1.- Boc Boo, \\__N
=
H2N¨e% Ali* NMM, THF, 23 C m ;N-1?-1 0 NI N----7 *
IP Me' l'. µ... H
4..., H Me Me 44% combined (3 steps) [00475] To a solution of amine (622 mg, 1.36 mmol, 1.0 equiv), Boc-N-Me-Ala-OH
(276 mg, 1.36 mmol, 1.0 equiv), HOBT=xH20 (229 mg, 1.50 mmol, 1.1 equiv) and NMM (598 uL, 5.44 mmol, 4 equiv) in THF
(15 mL) at 0 C was added EDC-1-1C1 (274 mg, 1.43 mmol, 1.05 equiv). After 30 mm the cold bath was removed. The solution stirred for 14 h and then was quenched with saturated aqueous NaHCO3 (25 mL), extracted with ethyl acetate (2 x 20 mL), dried over sodium sulfate and then concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (2:1¨>1:1¨>1:3 hexanes/Et0Ac) to yield, after 3 steps, partially separated diastereomers S-isomer (30 mg, 4%, -3:1 d.r.) and R-isomer (40 mg, 5%, -3:1 d.r.), along with unseparated R+S isomers (267 mg, 35%). Data for S-isomer: Rf= 0.40 (1:3 hexanes/Et0Ac). 1H NMR (400 MHz, CDC13) 6: 7.23-7.05 (m, 4H), 6.84 (d, 1H, J=
8.0 Hz), 5.22 (t, 1H, J= 6.4 Hz), 5.18-5.08 (m, 1H), 4.69 (dd, 1H, ./= 5.6, 10.8 Hz), 4.62 (d, 1H, ./= 7.6 Hz), 4.13-4.03 (m, 1H), 3.95 (q, 1H, J= 12.8 Hz), 2.75 (s, 3H), 2.80-2.74 (m, 1H), 2.47-2.37 (m, 1H), 2.17-1.89 (m, 4H), 1.88-1.69 (m, 5H), 1.43 (s, 9H), 1.32 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 171.4, 169.9, 169.8, 137.6, 137.3, 136.9, 136.7, 129.3, 129.2, 128.6, 128.3, 27.4, 127.3, 126.4, 126.2, 90.3, 90.0, 70.7, 70.6, 61.1, 60.6, 53.1, 52.6, 47.7, 47.7, 33.3, 32.7, 32.5, 30.2, 30.1, 29.8, 29.3, 29.3, 28.4, 28.4, 25.9, 20.5, 20.1. Data for R-isomer: Rf= 0.55 (1:3 hexanes/Et0Ac). 11-INMR (400 MHz, CDC13) 6: 7.24-7.11 (m, 4H), 7.11-7.05 (m, 1H), 6.69 (bs, 1H), 5.21 (d, 1H, J= 5.6 Hz), 5.10 (q, 1H, J= 6.8 Hz), 4.75 (dd, 1H, J-7.6, 11.6 Hz), 4.55 (d, 1H, J= 8.0 Hz), 4.47 (t, 1H, 1= 8.8 Hz), 4.01 (d, 1H, J= 12.8 Hz), 3.97 (t, 1H, J=
12.4 Hz), 2.82-2.75 (m, 2H), 2.77 (s, 3H), 2.45-2.33 (m, 1H), 2.32-2.24 (m, 1H), 2.24-2.13 (m, 2H), 2.06-E93 (m, 3H), 1.84-1.76 (m, 2H), 1.74-1.64 (m, 5H), 1.45 (s, 9H), 1.34 (d, 3H, J= 6.8 Hz); 13C NMR (100 MHz, CDC13) 6: 172.1, 171.0, 169.8, 137.6, 136.7, 129.3, 128.6, 127.4, 126.4, 90.0, 70.6, 66.0, 61.2, 53.2, 47.8, 33.3, 32.7, 30.2, 29.3, 28.5, 25.8, 20.2, 14Ø HRMS calcd for C281-140N406: 551.2840, found 551.2838.
[00476] Example 26: Preparation of (4S,7S,9aS)-4-((S)-2-(methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-l-yl)octahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide.
TFA -DCM
N N H 0 Ny Me' tvi e 0 H Me' Le 0 H
quant.
[00477] To a solution of carbamate (30 mg, 0.057 mmol, 1 equiv, ¨7:3 d.r.) in DCM (2 mL) was added TFA (35 .1., 0.454 mmol, 8 equiv). After stirring for 20 h at 23 C, the solution was concentrated. The product was eluted through a short plug (-400 mg) of Silicyle TMA-chloride ion exchange resin with Me0H to yield product=HC1 (26 mg, quantitative) as the major diastereomer (-7:3). 1H NMR (400 MHz, CD30D) 6:7.38-7.35 (m, 1H), 7.15-7.06 (m, 3H), 5.41-5.38 (m, 1H), 5.09-5.03 (m, 1H), 4.42 (t, 1H, J=
6.4 Hz), 4.15 (dt, 1H, J= 2.8, 12.8 Hz), 4.04-3.96 (m, 1H), 3.95-3.89 (m, 1H), 2.86-2.71 (m, 2H), 2.67 (s, 3H), 2.32-2.25 (m, 1H), 2.12 (q, 2H, J= 7.2 Hz), 2.06-1.96 (m, 2H), 1.94-1.85 (m, 1H), 1.85-1.74 (m, 2H), 1.58 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CD30D) 6: 173.4, 172.7, 172.7, 172.2, 169.6, 169.3, 138.6, 138.5, 137.8, 137.7, 130.0, 130.0, 129.6, 129.2, 128.2, 128.1, 127.1, 91.0, 71.3, 71.2, 62.4, 62.4, 58.4, 58.3, 54.4, 54.2, 34.0, 33.6, 33.3, 33.2, 31.8, 31.3, 31.2, 30.2, 30.2, 28.2, 28.0, 21.7, 21.6, 16.4, 16.4.
HRMS calcd for C231-133N404: 429.2496, found 429.2495.
[00478] Example 27: Preparation of (4S,9aS)-4-amino-N-(naphthalen-l-y1)-5-oxooctahydropyffolo [2,1-b][1,3]oxazepine-7-carboxamide.
OH Me BocHN0 Hc9 OH
me0\01f4.
H TFA
____________________________________________________ y IN + N
0 W, 80 DCM C BocHN 7NCI
ti H 0 H
[00479] Same procedure as Example 24 with Boc-N-HSer-OH (150 mg, 0.684 mmol, 1.0 equiv), aldehyde (95 mg, 0.718 mmol, 1.05 equiv), isocyanide (105 mg, 0.684 mmol, 1.0 equiv) and 7 M ammonia in Me0H (195 tiL, 1.37 mmol, 2.0 equiv) in TFE (4 mL). The resultant oil was combined with TFA (314 [IL, 4.10 mmol, 6 equiv) in DCM (5 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00480] Example 28: Preparation of tert-butyl methyl((2S)-1-(((4S,9aS)-7-(naphthalen-l-ylcarbamoy1)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepin-4-yl)amino)-1-oxopropan-2-yl)carbamate.
01:1 0 t1 Boc,Me-Ala, HOBT, EDC 0 0 __________________________ Boc H2NCR NMM, THF, 23 C 0 N
H Me Me 36% combined (3 steps) [00481] Same procedure as Example 25 above using amine derivative (209 mg, 0.615 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (125 mg, 0.615 mmol, 1.0 equiv), HOBT-xH20 (104 mg, 0.677 mmol, 1.1 equiv), NMM (338 !IL, 3.08 mmol, 5 equiv [to soak up xs TFA]) and EDC=HC1 (124 mg, 0.646 mmol, 1.05 equiv) in THF (10 mL). The resultant oil was purified by flash chromatography on silica gel (2:11:1¨>1:3 hexanes/Et0Ac) to yield, after 3 steps, S-isomer (43 mg, 12%, ¨6:1 d.r.) and R-isomer (37 mg, 10%, ¨6:1 d.r.), along with unseparated mixture (49 mg, 14%). Data for S-isomer: Rf= 0.33 (1:3 hexanes/Et0Ac). 1H NMR (400 MHz, CDC13) J: 9.11 (s, 111), 8.10 (d, 1H, J= 7.6 Hz), 7.98 (d, 1H, J=
8.8 Hz), 7.86 (d, 1H, J= 8.0 Hz), 7.67 (d, 1H, J= 8.4 Hz), 7.56-7.44 (m, 3H), 7.32 (s, 1H), 5.33 (t, 1H, J
= 6.4 Hz), 4.90 (d, 1H, J= 6.4 Hz), 4.81 (dd, 1H, 5.2, 10.4 Hz), 4.19 (dt, 1H, J= 2.8, 12.8 Hz), 4.07-3.98 (m, 1H), 2.78 (s, 3H), 2.59-2.46 (m, 2H), 2.32-2.21 (m, 1H), 2.01-1.91 (m, 3H), 1.85-1.74 (m, 1H), 1.44 (s, 9H), 1.36 (d, 3H, J= 6.8 Hz); 13C NMR (100 MHz, CDC13) : 172.1, 171.4, 169.1, 168.5, 134.1, 132.7, 128.9, 126.6, 126.5, 126.0, 125.9, 125.5, 120.7, 119.8, 90.7, 70.8, 61.2, 52.8, 32.8, 32.6, 30.2, 28.5, 28.4, 25.6. Data for R-isomer: Ri= 0.42 (1:3 hexanes/Et0Ac). 1H NMR (400 MHz, CDC13) 6: 9.47 (s, 1H), 8.03 (d, 1H, J= 7.2 Hz), 7.94 (d, 1H, J= 7.6 Hz), 7.82 (d, 1H, J= 7.6 Hz), 7.63 (d, 1H, J= 8.0 Hz), 7.55 (s, 1H), 7.50-7.40 (m, 2H), 7.31 (s, 1H), 5.21 (s, 1H), 4.96 (d, 1H, J=
7.6 Hz), 4.85-4.78 (m, 1H), 4.43 (t, 1H, J= 8.8 Hz), 4.14 (d, 1H, J= 12.8 Hz), 3.99 (t, 1H, J= 12.0 Hz), 2.79 (s, 3H), 2.61-2.53 (m, 1H), 2.26-2.14 (m, 1H), 2.11-1.97 (m, 2H), 1.90-1.78 (m, 1H), 1.46 (s, 9H), 1.34 (d, 3H, J= 7.2 Hz); 13C
NMR (100 MHz, CDC13) 6: 175.0, 173.3, 172.4, 168.5, 134.1, 132.8, 128.7, 126.5, 126.1, 125.8, 125.4, 121.0, 119.5, 90.3, 70.6, 65.9, 61.6, 53.2, 49.2, 33.6, 32.5, 30.3, 30.3, 28.5, 28.5, 28.4, 24.6. HRMS calcd for C2g1-136N406Na: 547.25271, found 547.25362.
[00482] Example 29: Preparation of (4S,7S,9aS)-4-((S)-2-(methylamino)propanamido)-N-(naphthalen-1-y1)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide.
H H
O TFA
o( _s(r1- ¨
DCM o Boc, .....)\_.
N - H 0 N ,N H 0 N
MetµAe 0 H Me t'= 0 H
quant. Me [00483] To a solution of carbamate (12 mg, 0.023 mmol, 1 equiv, -6:1 d.r.) in DCM (1 mL) was added TFA (14 pL, 0.183 mmol, 8 equiv). After stirring for 20 h at 23 C, the solution was concentrated to yield product=TFA (12 mg, quantitative) as the major diastereomer. 1H NMR (400 MHz, CD30D) 6: 8.12-8.08 (m, 1H), 7.92-7.88 (m, 1H), 7.79 (d, 1H, J= 8.4 Hz), 7.67 (dd, 1H, J = 1.2, 7.2 Hz), 7.56-7.45 (m, 3H), 5.48 (q, 1H, J= 2.8 Hz), 4.99 (d, 1H, J= 12.0 Hz), 4.75 (t, 2H, J= 6.8 Hz), 4.21 (dt, 1H, J= 2.8, 12.4 Hz), 4.10-4.00 (m, 1H), 3.96-3.87 (m, 1H), 2.68 (s, 3H), 2.44-2.29 (m, 2H), 2.22-2.07 (m, 2H), 1.83 (dd, 1H, J= 2.0, 14.4 Hz), 1.60 (d, 3H, J= 6.8 Hz); 13C NMR (100 MHz, CD30D) 6:
172.9, 172.5õ 169.7, 135.7, 134.0, 129.9, 127.3, 127.2, 126.5, 123.5, 91.1, 71.4, 62.8, 58.4, 54.3, 49.0, 33.8, 33.4, 31.8, 28.1, 16.4. HRMS calcd for C23H28N404Na: 447.20028, found 447.20189.
[00484] Example 30: Preparation of (4S,9aS)-4-amino-7-(1H-indole-1-carbonyl)hexahydropyrrolo[2,1-b][1,3]oxazepin-5(2H)-one.
OH Me0 BocHN Xr Me0) OH 0=) CF3CH2OH OH
Me0 OMe N =20 min 113..
(0.
0 + s ...,,,,.. C BocHN TFA
DCM
NH3 cS 0 N 23 C H2N
OH)0 ¨OMe OMe OMe OMe [00485] Same procedure as Example 24 with Boc-N-HSer-OH (313 mg, 1.43 mmol, 1.0 equiv), aldehyde (198 mg, 1.50 mmol, 1.05 equiv), isocyanide (273 mg, 1.43 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(408 uL, 2.85 mmol, 2.0 equiv) in TFE (5 mL). The resultant oil was combined with TFA (1.09 mL, 14.3 mmol, 10 equiv) in DCM (5 nit) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00486]Example 31: Preparation of tert-Butyl ((2S)-14(4S,9aS)-7-(1H-indole-1-carbony1)-5-oxooctahydropyrrolo[2,1-b] [1,31 oxazepin-4 -yl)amino)-1-oxopropan-2-y1)(methyl)carbamate.
H H
0 s .1.õ-\
0 s Boc,Me-Ala, :
HOBT, EDC 0 cN---1 N ow... Boc 1110 NMM, THF, 23 C B 14--/ 1101 H2Nr13-0 N MI k. H 0 N
0 ¨ MI Is H 0 ----N
0 ¨
0 ¨ Me Me 41% combined (3 steps) [00487] Same procedure as Example 25 above using crude amine (611 mg, 1.43 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (291 mg, 1.43 mmol, 1.0 equiv), HOBT=xH20 (241 mg, 1.57 mmol, 1.1 equiv), NMM (786 [IL, 7.15 mmol, 5 equiv [to soak up xs TFA]) and EDC=HCI (288 mg, 1.50 mmol, 1.05 equiv) in THF (15 mL). The resultant oil was purified by flash chromatography on silica gel (2:1 1:11:4 hexanes/Et0Ac) to yield, after 3 steps, S-isomer (150 mg, 21%) and R-isomer (144 mg, 20%). Data for S-isomer: Rf= 0.27 (1:3 hexanes/Et0Ac). H NMR (400 MHz, CDC13) 6: 8.51 (d, 1H, J= 8.4 Hz), 7.57 (d, 1H, J= 8.0 Hz), 7.50 (d, 1H, J= 4.0 Hz), 7.35 (t, 1H, J= 8.4 Hz), 7.28 (t, 1H, J= 7.6 Hz), 7.16 (s, 1H), 6.69 (d, 1H, J= 3.6 Hz), 5.35 (dd, 1H, J= 3.6, 6.4 Hz), 5.28 (dd, 1H, .1=4.8, 8.0 Hz), 4.80 (dd, 1H, J= 6.0, 10.8 Hz), 4.75-4.65 (m, 1H), 4.31 (dt, 1H, J= 3.2, 12.8 Hz), 4.12 (q, 1H, J= 7.2 Hz), 4.05 (t, 1H, J= 13.2 Hz), 2.76 (s, 3H), 2.44-2.31 (m, 2H), 2.30-2.19 (m, 2H), 2.05-1.98 (m, 2H), 1.42 (s, 9H), 1.34 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 171.1, 170.8, 168.8, 135.9, 130.2, 125.3, 124.0, 124.0, 120.8, 117.0, 110.0, 89.7, 80.6, 80.6, 77.2, 70.8, 64.3, 60.4, 59.7, 53.0, 32.6, 30.3, 28.3, 28.3, 28.3, 27.2, 21Ø Data for R-isomer: Rf= 0.50 (1:3 hexanes/Et0Ac). 1H NMR (400 MHz, CDC13) 6: 8.38 (s, 1H), 7.57 (d, 1H, J= 7.6 Hz), 7.49 (d, 1H, J= 4.0 Hz), 7.35 (t, 1H, J= 7.2 Hz), 7.28 (d, 1H, J= 7.6 Hz), 7.18 (s, 1H), 6.71 (d, 1H, J= 3.6 Hz), 5.44-5.39 (iii, 2H), 4.88 (dd, 1H, J= 5.6, 11.2 Hz), 4.75-4.69 (m, 1H), 4.47(t, 2H, J= 8.8 Hz), 4.31-4.24 (m, 1H), 4.17 (dt, 1H, J= 3.2, 12.8 Hz), 4.13-4.04(m, 1H), 3.72-3.66 (m, 1H), 3.56-3.48 (m, 1H), 2.79 (s, 3H), 2.66-2.54 (m, 1H), 2.37 (sept, 1H, J= 6.8 Hz), 2.21-2.06 (m, 4H), 1.81 (qd, 1H, J= 3.6, 14.0 Hz), 1.67-1.58 (m, 1H), 1.43 (s, 9H), 1.33 (d, 3H, J= 7.2 Hz); 13C NMR
(100 MHz, CDC13) 6: 172.3, 171.1, 168.7, 135.8, 130.2, 125.4, 124.1, 123.8, 121.0, 116.7, 110.3, 89.6, 70.7, 65.8, 60.0, 53.0, 49.1, 33.1, 32.2, 30.4, 28.4, 28.4, 28.4, 26.9. HRMS
calcd for C26H34N406Na:
521.2371, found 521.2372.
[00488] Example 32: Preparation of (S)-N-445,7S,9a5)-7-(1H-indole-1-earbonyl)-oxooetahydropyrrolo[2,1-b][1,3]oxazepin-4-y1)-2-(methylamino)propanamide.
0 17=1 0 1:1 TFA
IN' DCM
Boc N
0 n 0 Me Me' Me' quant. Me [00489] Same procedure as Example 29 above using carbamate (52 mg, 0.104 mmol, 1 equiv) and TFA
(64 uL, 0.834 mmol, 8 equiv) in DCM (2 mL). After stirring for 20 h at 23 C, the solution was concentrated to yield product-TFA (53 mg, quantitative) as a single diastereomer. 'H NMR (400 MHz, CD30D) 6: 8.39 (d, 1H, J= 8.0 Hz), 7.84 (d, 1H, J= 4.0 Hz), 7.58 (d, 1H, J=
7.2 Hz), 7.33-7.24 (m, 2H), 6.73 (d, 1H, J= 4.0 Hz), 5.50-5.46 (m, 1H), 5.34 (t, 1H, J= 6.8 Hz), 4.26 (dt, 1H, J= 3.2, 12.4 Hz), 4.10-4.02 (m, 1H), 3.92-3.84 (m, 2H), 2.65 (s, 3H), 2.28 (qd, 1H, J= 3.6, 12.4 Hz), 2.19-2.05 (m, 2H), 1.86 (d, 1H, J= 14.0 Hz), 1.55 (dd, 2H, J= 4.0, 7.2 Hz), 1.50 (d, 3H, J= 7.2 Hz); 13C
NMR (100 MHz, CD30D) 6: 172.2, 171.0, 169.6, 137.2, 131.9, 126.0, 126.0, 125.0, 122.0, 117.4, 110.7, 90.9, 71.4, 61.5, 58.3, 54.4, 49.0, 33.7, 33.2, 31.7, 28.3, 16.3. HRMS calcd for C2IF126N404Na: 421.18463, found 421.18593.
[00490] Example 33: Preparation of (S)-N-((4S,7R,9aS)-7-(1H-Indole-1-carbony1)-oxooctahydropyrrolo[2,1-b][1,3]oxazepin-4-y1)-2-(methylamino)propanamide.
H H
DCM
0 ¨... 0 c...\(L?' 010 23 C FN1-}11 0 so---N ¨
Me' '-'= ...., -- Me l' Me quant. Me [00491] Same procedure as Example 29 above using carbamate (51 mg, 0.102 mmol, 1 equiv) and TFA
(117 L, 1.02 mmol, 10 equiv) in DCM (2 mL). After stirring for 20 hat 23 C, the solution was concentrated to yield product-TFA (52 mg, quantitative) as a single diastereomer. Ili NMR (400 MHz, CDC13) 6: 8.34 (d, 1H, J= 8.0 Hz), 7.85 (d, 1H, J= 4.0 Hz), 7.59 (d, 1H, J=
6.8 Hz), 7.34-7.24 (m, 2H), 6.75 (d, 1H, J= 4.0 Hz), 5.57-5.53 (m, 2H), 5.09 (dd, 1H, 1=2.0, 11.2 Hz), 4.67 (dd, 1H, J= 9.2, 10.8 Hz), 4.46 (td, 1H, J= 1.6, 8.8 Hz), 4.35-4.27 (m, 1H), 4.19 (dt, 1H, J= 2.8, 12.4 Hz), 4.12-4.04 (m, 1H), 3.90 (t, 2H, J= 6.8 Hz), 3.74-3.66 (m, 1H), 2.68 (s, 3H), 2.62-2.53 (m, 2H), 2.39-2.27 (m, 2H), 2.07 (dd, 2H, J= 7.2, 13.2 Hz), 1.93-1.87 (m, 1H), 1.55 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CD30D) 6:
176.8, 172.5, 171.1, 170.4, 169.4, 137.1, 131.9, 126.1, 125.9, 125.1, 122.0, 117.4, 111.0, 90.9, 71.3, 67.2, 61.5, 58.4, 58.2, 54.3, 50.2, 34.1, 33.2, 31.8, 31.8, 29.2, 27.9, 16.3, 16.2.
HRMS calcd for C2iH27N404:
399.2027, found 399.2028.
[00492] Example 34: Preparation of (45,75,9a5)-4-amino-5-oxo-N#R)-1,2,3,4-tetrahydronaphthalen-1-yl)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide.
STrt Me0 BocHN 1)).(2 Me0) OH 0=) CF3CH2OH STrt meo C\1).1 H TFA
_,.. S I:I
N
0 AW, 80 C BocHN 60 C
H2NCorNi N +
T 20 min 0 NI
[00493] Same procedure as Example 24 with Boc-N-HCys(Trt)-OH (665 mg, 1.39 mmol, 1.0 equiv), aldehyde (193 mg, 1.46 mmol, 1.05 equiv), isocyanide (219 mg, 1.39 mmol, 1.0 equiv) and 7 M ammonia in Me0H (398 !IL, 2.78 mmol, 2.0 equiv) in TFE (5 mL). The resultant oil was combined with TFA (1.07 mL, 13.9 mmol, 10 equiv) in DCM (5 mL) and stirred at 60 C for 6 h. The mixture was concentrated in vacuo, then partially purified (trityl byproduct removed and more polar product(s) collected) by flash chromatography on basic alumina (3:1 hexanes/Et0Ac¨*DCM¨>7% Me0H/DCM) to yield semi-pure product.
[00494] Example 35: Preparation of tert-Butyl methyl((2S)-1-oxo-1-(44S,9aS)-5-oxo-7-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)octahydropyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)propan-2-yl)carbamate.
rs s 1:1 S
Boc,Me-Ala, 1111 HOBT, EDC
___________________________ Boc 0 Boc 0 0 N * NMM, THF, 23 C /iµi¨/-111 0 n Ns.10 Me Hi 0 r., F110=117 H Me t H Me H
Me 47% combined (3 steps) [00495] Same procedure as Example 25 above using crude amine (658 mg, 1.39 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (282 mg, 1.39 mmol, 1.0 equiv), HOBT=xH20 (234 mg, 1.39 mmol, 1.1 equiv), NMM (917 !AL, 8.34 mmol, 6 equiv [to soak up xs TEA]) and EDC=HC1 (280 mg, 1.46 mmol, 1.05 equiv) in THF (18 mL). The resultant oil was purified by flash chromatography on silica gel (1:1¨>1:21:3 hexanes/Et0Ac) to yield, after 3 steps, S-isomer (121 mg, 16%, ¨3:1 d.r.) and R-isomer (100 mg, 13%, ¨3:1 d.r.) along with unseparated mixture (136 mg, 18%). Data for S-isomer:
R1= 0.27 (1:3 hexancs/Et0Ac). 1H NMR (400 MHz, CDCI3) 6: 7.32 (d, 1H, J= 7.6 Hz), 7.25-7.21 (m, 1H), 7.16-7.04 (m, 4H), 5.17 (q, 1H, J= 7.2 Hz), 5.08 (t, 1H, J= 7.2 Hz), 4.74 (d, 1H, J= 8.0 Hz), 4.53 (dd, 1H, J= 6.0, 10.8 Hz), 3.35-3.22 (m, 1H), 2.76 (s, 3H), 2.63-2.46 (m, 1H), 2.20 (d, 1H, J=
12.8 Hz), 2.12-1.98 (m, 2H), 1.92-1.71 (m, 5H), 1.59 (q, 1H, J= 12.4 Hz), 1.43 (s, 9H), 1.31 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 171.3, 169.6, 169.3, 137.3, 129.2, 129.1, 128.8, 127.2, 126.1, 62.3, 61.8, 52.8, 47.6, 33.0, 32.1, 30.4, 30.2, 29.3, 28.4, 28.4, 26.5, 20.5. Data for R-isomer: Rf= 0.44 (1:3 hexanes/Et0Ac). 1H NMR
(400 MHz, CDC13) 6: 7.22-7.12 (m, 4H), 7.09-7.04 (m, 1H), 6.62 (bs, 1H), 5.28 (d, 1H, J= 7.6 Hz), 5.09 (d, 1H, J= 6.4 Hz), 4.66-4.56 (m, 2H), 3.32 (t, 1 H, J= 12.0 Hz), 2.87-2.68 (m, 3H), 2.75 (s, 3H), 2.35-2.19 (m, 3H), 2.08-1.96 (m, 2H), 1.85-1.69 (m, 5H), 1.45 (s, 9H), 1.29 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 170.9, 169.6, 137.6, 136.6, 129.3, 128.6, 127.4, 126.3, 63.8, 61.3, 53.5, 47.7, 33.7, 31.7, 30.1, 29.3, 28.5, 28.4, 20.1. HRMS calcd for C28H401\1403SNa: 567.26116, found 567.26151.
[00496] Example 36: Preparation of (45,7S,9a5)-4-((S)-2-(methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide.
S S
TFA
DCM
Bog, C\I\ ¨11o. 0 Qi H M
H 0 Ni 0 N't Me' Le H e 0 H
quant.
[00497] Same procedure as Example 24 using carbamate (90 mg, 0.165 mmol, 1 equiv, ¨3:1 d.r.) and TFA
(126 [IL, 1.65 mmol, 10 equiv) in DCM (4 InL). After stirring for 20 hat 32 C, the solution was concentrated. The product was eluted through a short plug (-500 mg) of Silicyle TMA-chloride ion exchange resin with Me0H to yield product=HC1 (79 mg, quantitative) as the major diastereomer.
NMR (400 MHz, CD30D) 6: 7.39-7.34 (m, 1H), 7.17-7.05 (m, 4H), 5.46-5.39 (m, 1H), 5.07 (t, 1H, J=
6.8 Hz), 4.77 (dd, 1H, J = 2.0, 11.2 Hz), 4.57 (dd, 1H, J = 5.2, 7.6 Hz), 3.94-3.87(m, 1H), 3.29-3.21 (m, 1H), 3.02 (ddd, 1H, J = 2.8, 6.0, 14.4 Hz), 2.82-2.75 (m, 2H), 2.66 (s, 3H), 2.60-2.49 (m, 1H), 2.25-2.17 (m, 2H), 2.15-2.09 (m, 1H), 2.05-1.95 (m, 2H), 1.95-1.74 (m, 4H), 1.53 (d, 3H, J= 7.2 Hz); 13C NMR
(100 MHz, CD30D) 6: 172.3, 171.9, 169.5, 138.7, 138.5, 137.6, 137.3, 130.2, 130.0, 129.9, 129.5, 128.4, 128.3, 127.2, 127.1, 63.9, 63.4, 63.1, 58.4, 58.3, 55.1, 54.2, 54.1, 34.1, 33.3, 31.8, 31.8, 31.3, 31.0, 30.1, 30.1, 28.8, 28.5, 21.5, 21.1, 16.4, 16.3. HRMS calcd for C23H33N403S:
445.2268, found 445.2267.
[00498] Example 37: Preparation of (4S,7R,9aS)-4-((S)-2-(methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-l-yl)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide.
H H
S E
TFA
DCM
N H 0 0 Ne Mel H
quant. Me [00499] Same procedure as Example 24 using carbamate (24 mg, 0.0441 mmol, 1 equiv, ¨3:1 dr.) and TFA (34 [IL, 0.441 mmol, 10 equiv) in DCM (2 mL). After stirring for 20 h at 32 C, the solution was concentrated. The product was eluted through a short plug (-500 mg) of Silicyle TMA-chloride ion exchange resin with Me0H to yield product=HC1 (21 mg, quantitative) as the major diastereomer. 1H
NMR (400 MHz, CD30D) 6: 7.16-7.08 (m, 4H), 5.51 (d, 1H, J= 7.2 Hz), 5.08-5.03 (m, 1H), 4.83 (s, 1H), 4.57 (d, 1H, J= 8.8 Hz), 3.93 (q, 1H, J= 7.2 Hz), 3.37-3.34 (m, 1H), 2.90 (ddd, 1H, J= 2.8, 5.6, 12.0 Hz), 2.82-2.75 (m, 2H), 2.66 (s, 3H), 2.60-2.50 (m, 1H), 2.49-2.39 (m, 2H), 2.26-2.19 (m, 1H), 2.10-1.89 (m, 6H), 1.86-1.74 (m, 4H), 1.46 (d, 3H, J= 6.8 Hz); 13C NMR (100 MHz, CD30D) 6: 173.3, 172.3, 169.0, 138.7, 137.8, 130.0, 129.8, 129.2, 128.7, 128.1, 127.1, 64.6, 62.4, 58.3, 54.6, 53.8, 34.2, 33.7, 32.1, 31.8, 31.2, 30.3, 29.6, 21.7, 16.4. HRMS calcd for C23H33N403S: 445.2268, found 445.2267.
[00500] Example 38: Preparation of (4S,11bS)-4-amino-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-y1)-2,3,4,5,7,11b-hexahydro 41,3 ] oxazepino [2,3-a] is oindo le-7-carb oxamide.
OH Me0 .
BocHN XrMe0 OH
Me0 Me H
N TFA
,.. H
cN
0 RI+ ON, 80 C BocHN DCM
20 min 0 Nr. 23 C 0 Ni NH3 se, 0 H 0 H
[00501] Same procedure as Example 24 with Boc-N-HSer-OH (175 mg, 0.800 mmol, 1.0 cquiv), aldehyde (144 mg, 0.800 mmol, 1.0 equiv), isocyanide (126 mg, 0.800 mmol, 1.0 equiv) and 7 M ammonia in Me0H (229 L, 1.60 mmol, 2.0 equiv) in TFE (4 mL). The resultant oil was combined with TFA (490 !IL, 6.40 mmol, 8 equiv) in DCM (3 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00502] Example 39: Preparation of tert-Butyl methyl((2S)-1-oxo-1-(((4S,11bS)-5-oxo-7-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoy1)-2,3,4,5,7,11b-hexahydro- [1,3] oxazepino [2,3-a]is oindo1-4-yflamino)propan-2-Acarbamate.
E
0 s Boc,Me-Ala, 0 HOBT, EDC 0 c......1c1V
H2NC H Boo NMM, THF, 23 C Me N 0ri H
H Me 43%
(3 steps) [00503] Same procedure as Example 25 using crude amine (323 mg, 0.640 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (130 mg, 0.640 mmol, 1.0 equiv), HOBT=xH20 (108 mg, 0.704 mmol, 1.1 equiv), NMM (281 nt, 2.56 mmol, 4 equiv) and EDC=HC1 (129 mg, 0.672 mmol, 1.05 equiv) in THF
(12 mL). The resultant oil was purified by flash chromatography on silica gel (3:1¨>1:11:2 hexanes/Et0Ac) to yield, after 3 steps, the unseparated diastercomixture (200 mg, 43%). By NMR, one of the diastereomers seems to exist as a pair of rotational isomers. R1= 0.18 (1:1 hexanes/Et0Ac). 1H NMR (400 MHz, CDC13) 6: 7.56 (d, 1H, J= 7.6 Hz), 7.47 (q, 1H, J= 4.4 Hz), 7.44-7.39 (m, 5H), 7.38-7.34 (m, 1H), 7.32-7.27 (m, 1H), 7.18-7.14 (m, 3H), 7.10-7.06 (m, 1H), 7.03 (d, 1H, J= 7.2 Hz), 6.90 (d, 1H, J= 7.2 Hz), 6.74 (d, 1H, J= 7.6 Hz), 6.44-6.36 (m, 3H), 6.21 (s, 1H), 5.50 (bs, 2H), 5.17-5.10 (m, 1H), 5.03 (dd, 1H, J = 8.0, 14.4 Hz), 4.88-4.80 (m, 2H), 4.72-4.66 (m, 1H), 4.44 (td, 2H, J= 8.8 Hz), 4.31-4.15 (m, 5H), 2.80 (s, 3H), 2.79 (s, 3H), 2.77 (s, 3H), 2.71 (t, 4H, J= 6.4 Hz), 2.22-2.08 (m, 3H), 2.06-1.98 (m, 2H), 1.86-1.73 (m, 5H), 1.71-1.61 (m, 2H), 1.48 (s, 9H), 1.46 (s, 9H), 1.35 (d, 3H, J= 7.2 Hz), 1.34 (d, 3H, J= 7.2 Hz), 1.33 (d, 3H, J=
7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 175.0, 172.4, 170.5, 168.3, 168.1, 137.7, 137.2, 136.8, 136.5, 136.5, 135.9, 135.7, 135.7, 135.2, 130.7, 130.5, 129.4, 129.3, 129.0, 128.7, 127.8, 127.4, 127.2, 126.4, 126.2, 125.0, 125.0, 122.9, 122.3, 122.3, 92.0, 91.5, 71.4, 71.4, 66.7, 66.5, 65.9, 53.3, 52.8, 49.2, 47.9, 47.7, 30.3, 29.3, 29.2, 28.5, 28.4, 28.4, 20.4, 20.2. HRMS calcd for C32H41N406Na: 599.28401, found 599.28561.
[00504] Example 40: Preparation of (4S,11bS)-4-((S)-2-(Methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1 -y1)-2,3,4,5,7,11b-hexahydro-[1,3] oxazepino [2,3-a] iso indole-7-carboxamide.
Bo 0 1:1 DCM
c 28 C
iq¨)Lri M e' e 0 H quant. Me' Le 0 0 H
[00505] Same procedure as Example 29 using carbamate (38 mg, 0.066 mmol, 1 equiv) and TFA (40 !AL, 0.527 mmol, 8 equiv) in DCM (2 mL). After stirring for 20 h at 28 C, the solution was concentrated to yield product=TFA (38 mg, quantitative) as a 1:1 diastereomixture. Data for the 1:1 diastereomixture: 11-1 NMR (400 MHz, CD:30D) 6: 7.53-7.45 (m, 7H), 7.39-7.35 (m, 1H), 7.26(d, 1H, ./
= 7.2 Hz), 7.16-7.07(d, 2H, J= 2.0 Hz), 6.53 (d, 1H, J= 1.6 Hz), 6.47 (s, 1H), 5.57 (d, 1H, J= 1.6 Hz), 5.47 (s, 1H), 5.11-5.03 (m, 3H), 4.66 (dd, 1H, J= 9.2, 11.2Hz), 4.46 (td, 1H, J= 2.0, 9.2 Hz), 4.35-4.27 (m, 4H), 3.97 (q, 1H, J=
6.8 Hz), 3.88 (q, 1H, J= 7.2 Hz), 2.89-2.74 (m, 3H), 2.70 (s, 3H), 2.69 (s, 3H), 2.62-2.54 (m, 1H), 2.33 (II, 1H, J= 1.6, 10.8 Hz), 2.02-1.92 (m, 6H), 1.85-1.76 (m, 3H), 1.62 (d, 3H, J= 7.2 Hz), 1.55 (d, 3H, J=
7.2 Hz), 1.54 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CD30D) 6:176.8, 172.2, 172.0, 171.0, 170.5, 170.4, 169.7, 169.2, 162.8, 162.4, 138.7, 138.6, 138.5, 138.4, 137.7, 137.5, 136.9, 136.6, 131.3, 131.3, 130.3, 130.2, 130.1, 130.0, 129.7, 129.5, 128.2, 128.2, 127.1, 126.3, 123.2, 123.2, 101.3, 93.2, 92.4, 72.1, 72.0, 67.3, 67.2, 66.9, 58.4, 58.4, 58.2, 54.6, 54.4, 50.2, 34.2, 33.5, 31.8, 31.8, 31.4, 31.0, 30.2, 30.2, 29.2, 21.6, 21.4, 16.4, 16.4, 16.2. HRMS calcd for C27H33N404: 477.2496, found 477.2493.
[00506]Example 41: Preparation of (45,9a5)-4-Amino-8,8-dimethy1-5-oxo-N#R)-1,2,3,4-tetrahydronaphthalen-1-y1)octahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide.
OH Me0 BocH N Lir. WO) _)< Me OH
OH 0- -e CF3CH2OH
C - -0.
Me0\1 Me Role H
N I 0 c W, 80 C BocHN TFA
Mem[t DCM
20 min 0 Ni 30 C 0 N
[00507] Same procedure as Example 24 with Boc-N-HSer-OH (157 mg, 0.718 mmol, 1.0 equiv), aldehyde (144 mg, 0.718 mmol, 1.0 equiv), isocyanide (113 mg, 0.718 mmol, 1.0 equiv) and 7 M ammonia in Me0H (205 L, 1.44 mmol, 2.0 equiv) in TFE (4 mL). The resultant oil was combined with TFA (473 ilL, 7.18 mmol, 10 equiv) in DCM (4 mL) and stirred at 30 C for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00508]Example 42: tert-Butyl ((5)-1-4(45,75,9aS)-8,8-dimethy1-5-oxo-7-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)octahydropyrrolo[2,1-b][1,3]oxazepin-4-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate.
H 0 tl 0 lil me c Boc,Me-Ala, (07.24_ (N)-1?-mdik HOBT, EDC
Boc 0 cP I*
H2N 4,1111/0 NMM, THF, 23 C ro ,N"----CH 0 0 NI 11110 0 n N e H e H
.../ H Me Me 49% combined (3 steps) [00509] Same procedure as Example 25 using crude amine (270 mg, 0.555 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (113 mg, 0.555 mmol, 1.0 equiv), HOBT-xH20 (93 mg, 0.610 mmol, 1.1 equiv), NMM (366 ilL, 3.33 mmol, 6 equiv [to soak up xs TFA]) and EDC=HC1 (112 mg, 0.582 mmol, 1.05 equiv) in THF (10 mL). The resultant oil was purified by flash chromatography on silica gel (3:1 1:11:3 hexanes/Et0Ac) to yield, after 3 steps, S-isomer (29 mg, 7%, >10:1 d.r.) along with unseparated mixture (168 mg, 42%). Data for S-isomer: Rf= 0.30 (1:1 hexanes/Et0Ac). 1HNMR (400 MHz, CDC13) 6: 7.29-7.25 (m, 2H), 7.17-7.12(m, 2H), 7.09-7.05 (m, 1H), 6.72 (d, 1H, J = 8.0 Hz), 5.24(t, 1H, J = 5.6 Hz), 5.16 (dd, 1H, J= 5.6, 6.8 Hz), 4.70 (dd, 1H, J= 5.6, 11.2 Hz), 4.16 (s, 1H), 4.05-3.98 (m, 1H), 3.93 (q, 1H, J= 12.4 Hz), 2.79 (s, 3H), 2.78-2.73 (in, 2H), 2.19 (dd, 1H, J= 6.8, 14.0 Hz), 2.06-1.96 (m, 2H), 1.88 (dd, 1H, J = 6.0, 14.0 Hz), 1.87-1.69 (m, 5H), 1.66-1.60(m, 1H), 1.47(s, 9H), 1.34(d, 3H, J = 7.2 Hz), 1.18 (s, 3H), 1.07 (s, 3H); 13C NMR (100 MHz, CDC13) 6: 170.7, 168.8, 137.3, 136.7, 136.6, 129.2, 128.9, 127.4, 126.4, 89.3, 89.2, 70.9, 70.7, 52.6, 47.5, 46.1, 39.6, 30.2, 29.7, 29.2, 28.5, 28.4, 23.8, 21.2, 19.9, 14.3, 14Ø Data for R-isomer: Rf= 0.39 (1:3 hexanes/Et0Ac). HRMS calcd for C301-144N406Na:
579.3153, found 579.3155.
[00510] Example 43: Preparation of (4S,7S,9aS)-8,8-Dimethy1-44(S)-2-(methylamino)propanamido)-5-oxo-N4R)-1,2,3,4-tetrahydronaphthalen-l-yl)octahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide.
H H
DCM
quant. NI¨)LHN 0 Ns.
Mel V H Mel t`= 0 H
Me Me [00511] Same procedure as Example 29 using carbamate (25 mg, 0.045 mmol, 1 equiv, 8:3 d.r.) and TEA
(35 L, 0.449 mmol, 10 equiv) in DCM (1 mL). After stirring for 20 h at 33 C, the solution was concentrated to yield product-TFA (25 mg, quantitative) as the major diastereomer. 1H NMR (400 MHz, CD30D) 6: 8.15 (d, 1H, J= 8.4 Hz), 7.32 (d, 1H, J= 6.4 Hz), 7.17-7.07 (m, 3H), 5.44 (t, 1H, J= 6.4 Hz), 5.10 (q, 1H, J= 6.8 Hz), 4.14 (dt, 1H, J= 3.2, 12.0 Hz), 4.08 (s, 1H), 3.99-3.91 (m, 2H), 2.80 (p, 2H, J =
6.0 Hz), 2.68 (s, 3H), 2.20 (dd, 1H, J= 6.4, 13.2 Hz), 2.08-1.96 (m, 3H), 1.89-1.77 (m, 4H), 1.58 (d, 3H, J
= 7.2 Hz); 13C NMR (100 MHz, CD30D) 6: 172.2, 171.5, 169.6, 138.5, 137.6, 130.1, 129.7, 128.3, 127.1, 117.5, 114.6, 90.5, 71.7, 71.3, 58.4, 54.2, 47.0, 40.1, 33.2, 31.8, 31.4, 30.1, 29.3, 24.2, 21.4, 16.3. HRMS
calcd for C25H3N404: 457.2809, found 457.2811.
[00512] Example 44: Preparation of (4S,7S,9aS)-4-Amino-8,8-dimethy1-5-oxo-N4R)-1,2,3,4-tetrahydronaphthalen-1-y1)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide.
STrt Me0 Me0) N i"
0C- =-)<MeMe STrt _...
OH
Me0 Me rt e H S 1:1 m BocHX
TFA cl---re N
BocHN N DCM
38 C H2N . 20 min i %., ..., H
[005131 Same procedure as Example 24 with Boc-N-HCys(Trt)-OH (500 mg, 1.05 mmol, 1.0 equiv), aldehyde (176 mg, 1.10 mmol, 1.05 equiv), isocyanide (165 mg, 1.05 mmol, 1.0 equiv) and 7 M ammonia in Me0H (299 tit, 2.09 mmol, 2.0 equiv) in TFE (5 mL). The resultant oil was combined with TFA (804 uL, 10.5 mmol, 10 equiv) in DCM (5 mL) and stirred at 38 C for 141-1. The mixture was concentrated in vacuo, then partially purified (trityl byproduct removed and more polar product(s) collected) by flash chromatography on basic alumina (3:1 hexanes/Et0Ac¨>DCM¨>7% Me0H/DCM) to yield semi-pure product.
[005141 Example 45: Preparation of tert-butyl a2S)-1-4(45,9a5)-8,8-dimethyl-5-oxo-7-4(R)-1,2,3,4-tetrahydronaphthalen-1-y1)carbamoyl)octahydropyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate.
s mp S E S
Boc,Me-Ala, Me HOBT, EDC 0 N \r-DI-N
H2NP? = _____ BOR Boo, 0 * NMM, THF, 23 *C "H 0 No' H 0 -141 Me Me 60% combined (3 steps) [005151 Same procedure as Example 25 using amine (387 mg, 0.998 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (202 mg, 0.998 mmol, 1.0 equiv), HOBT=xH20 (168 mg, 1.10 mmol, 1.1 equiv), NMM (329 !AL, 2.99 mmol, 3 equiv) and EDC=HC1 (201 mg, 1.05 mmol, 1.05 equiv) in THF (10 mL). The resultant oil was purified by flash chromatography on silica gel (3:1¨>1:1¨>1:3 hexanes/Et0Ac) to yield, after 3 steps, 5-isomer (12 mg, 2%) and R-isomer (47 mg, 8%), along with unseparated mixture (300 mg, 50%) and unreacted Boc-protected starting material (59 mg, 12%) left over from the previous reaction. Data for diastereomixture: 1H NMR (400 MHz, CD30D) 6: 7.32-7.28 (m, 1H), 7.18-7.11 (m, 6H), 7.10-7.06 (m, 2H), 5.49 (d, 1H, = 9.2 Hz), 5.41 (q, 1H, = 8.0 Hz), 5.09 (t, 1H, = 6.0 Hz), 5.03 (t, 1H, .1= 6.0 Hz), 5.03 (t, 1H, J= 12.0 Hz), 4.69-4.57 (m, 4H), 4.24 (d, 1H, J= 12.4 Hz), 4.19-4.16 (m, 1H), 3.31 (d, 2H, J
= 2.0 Hz), 3.29-3.21 (m, 2H), 2.86 (s, 6H), 2.81 (s, 3H), 2.80-2.75 (m, 2H), 2.68-2.56 (m, 1H), 2.31-2.20 (m, 3H), 2.02-1.75 (m, 13H), 1.48 (s, 18H), 1.37 (d, 3H, .I= 7.6 Hz), 1.32 (d, 3H, .1= 7.2 Hz), 1.15 (s, 3H), 1.13 (s, 3H); 13C NMR (100 MHz, CD30D) 6: 172.7, 171.8, 171.4, 138.8, 138.5, 137.4, 137.4, 130.2, 130.1, 130.0, 130.0, 129.8, 129.8, 128.5, 128.3, 128.2, 127.2, 73.3, 73.3, 63.9, 61.9, 61.7, 54.8, 54.2, 54.1, 47.6, 47.2, 40.9, 40.9, 40.8, 33.8, 33.2, 32.2, 31.3, 31.2, 31.1, 30.8, 30.2, 30.1, 28.7, 28.7, 28.7, 25.3, 23.9, 21.3, 21Ø Data for S-isomer: Rf= 0.24 (1:1 hexanes/Et0Ac). Data for R-isomer: Rf = 0.38 (1:1 hexanes/Et0Ac). 1H NMR (400 MHz, CDC13) 6: 7.34-7.29 (m, 1H), 7.20-7.12 (m, 3H), 7.08 (d, 1H, J=
7.2 Hz), 6.00 (d, 1H, J= 8.8 Hz), 5.33 (d, 1H, J= 8.8 Hz), 5.14-5.07 (m, 1H), 4.57-4.47 (m, 1H), 4.06-4.02 (in, 1H), 3.28 (t, 1H, J= 12.8 Hz), 2.85-2.79 (m, 2H), 2.76 (s, 3H), 2.34-2.26 (m, 1H), 2.01-1.90 (in, 2H), 1.87-1.73 (m, 6H), 1.47 (s, 9H), 1.35 (s, 3H), 1.30 (d, 3H, J= 7.2 Hz), 1.25-1.20 (m, 1H), 1.15 (s, 3H); 13C NMR (100 MHz, CDC13) 6: 171.5, 170.6, 170.6, 169.3, 137.9, 136.3, 129.4, 129.1, 129.0, 127.5, 126.3, 73.0, 62.8, 53.9, 47.8, 46.5, 39.9, 39.8, 33.3, 32.7, 30.6, 30.1, 29.3, 28.5, 28.5, 24.6, 19.8. HRMS
calcd for C30f144N4055: 595.2925, found 595.2922.
[00516] Example 46: Preparation of (4S,9aS)-8,8-dimethy1-4-((S)-2-(methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-l-y1)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide.
TFA S 1:1 DCM Mzi Boc, N
1.1 0 Me' H
Me quant. Me [00517] Same procedure as Example 24 using carbamate (62 mg, 0.108 mmol, 1 equiv) and TFA (66 L, 0.866 mmol, 8 equiv) in DCM (3 mL). After stirring for 20 h at 38 C, the solution was concentrated.
The product was eluted through a short plug (-500 mg) of Silicyle TMA-chloride ion exchange resin with Me0H to yield product=HC1 (54 mg, quantitative) as a 1:1 diastereomixture. 1H NMR (400 MHz, CD30D) 6: 7.34-7.27 (m, 2H), 7.18-7.06 (m, 7H), 5.54-5.45 (m, 1H), 5.41 (t, 1H, J= 8.0 Hz), 5.11-5.06 (m, 1H), 5.06-5.01 (m, 1H), 4.77-4.71 (m, 2H), 4.23 (s, 1H), 4.16 (s, 1H), 3.97-3.89 (m, 2H) 3.29-3.19 (m, 2H), 2.93-2.84 (m, 2H), 2.78 (dd, 4H, J= 6.4, 12.8 Hz), 2.68 (s, 6H), 2.32-2.21 (m, 3H), 2.01-1.75 (m, 12H), 1.55 (d, 3H, J= 7.2 Hz), 1.54-1.50 (m, 2H), 1.47 (d, 3H, J= 6.8 Hz), 1.40-1.37 (m, 2H), 1.16 (s, 6H), 1.14 (s, 3H), 1.13 (s, 3H); i3C NMR (100 MHz, CD30D) 6: 172.4, 172.3, 171.8, 171.4, 169.3, 168.9, 138.8, 138.5, 137.4, 137.4, 130.1, 130.1, 129.8, 128.3, 127.1, 127.0, 73.4, 63.8, 61.8, 58.3, 55.1, 54.4, 40.9, 40.9, 40.7, 33.6, 32.1, 31.8, 31.7, 31.3, 31.1, 30.9, 30.2, 30.1, 28.7, 23.9, 21.3, 21.0, 16.3, 16.2.
HRMS calcd for C25H371\14035: 473.2581, found 473.2579.
[00518] Example 47: Preparation of (4S,7S,9aS)-4-((S)-2-((tert-Butoxycarbonyl)(methyl)amino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxylic acid.
c NaOH, H20 0 = c__1(1ri Boc Me0H, 23 C Boc 'NJ [1 0 'Nil 0 OH
Mel 0 ¨ 0 Me 75% Me/ Me [00519] To a solution of amide (142 mg,-0.285 mmol, 1.0 equiv) in Me0H (6 mL) was added 1M NaOH
(1 mL). After stirring for 3 h, the methanol was removed in vacuo. Then Et0Ac (10 mL) and 1 M NaOH
(8 mL) were added and an extraction was performed, with the organic layer being discarded. The aqueous layer was acidified with 3M HCl to pH < 2 and then extracted with DCM (3 x 5 mL). The organics were dried over sodium sulfate, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (1:3 hexanes/Et0Ac-9DCM-95% Me0H/DCM) to yield the product as a colorless oil (85 mg, 75%). Rf= 0.17 (7% Me0H/DCM). 11-1 NMR (400 MHz, CDC13) 6: 7.30 (bs, 1H), 5.22 (m, 1H), 4.77 (t, 1H, J= 8.0 Hz), 4.52-4.46 (m, 1H), 4.14 (d, 1H, J= 12.8 Hz), 3.95 (t, 1H, J= 12.0 Hz), 2.78 (s, 3H), 2.32-2.18 (m, 2H), 2.13-2.02 (m, 2H), 2.00-1.85 (m, 2H), 1.44 (s, 9H), 1.33 (d, 3H, J=
7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 171.5, 171.5, 156.2, 156.1, 89.8, 80.8, 80.7, 70.7, 59.7, 52.9, 32.7, 30.4, 30.4, 28.4, 28.4, 26.5, 26.5, 14.2. HRMS calcd for C181-129N307Na:
422.18977, found 422.19015.
[00520] Example 48: Preparation of tert-butyl ((S)-14(4S,7S,9aS)-74(R)-chroman-4-ylcarbamoy1)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepin-4-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate.
c _____________________________________ =
Bos N--)11 0 HOBT, EDC
0H NMM, THF, 23 C 0Bos H 0 *
Me Le Me H
880/ Me [00521] To a solution of carboxylic acid (50 mg, 0.125 mmol, 1.0 equiv), (R)-chroman-4-ylamine-HC1 (23 mg, 0.125 mmol, 1.0 equiv), HOBT=xH20 (21 mg, 0.138 mmol, 1.1 equiv) and NMM
(41 L, 0.376 mmol, 3 equiv) in THF (5 mL) at 0 C was added EDC=HC1 (25 mg, 0.131 mmol, 1.05 equiv). After 30 min the cold bath was removed. The solution stirred for 14 h and then was quenched with saturated aqueous NaHCO3 (15 mL), extracted with ethyl acetate (2 x 10 mL), dried over sodium sulfate and then concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (1:3 hexanes/Et0Ac) to yield the product (58 mg, 88%). Rf= 0.11 (1:2 hexanes/Et0Ac). 'H NMR (400 MHz, CDC13) 6: 7.16-7.10 (m, 3H), 6.91 (d, 1H, J= 7.2 Hz), 6.86-6.77 (m, 2H), 5.22 (t, 1H, J= 6.0 Hz), 5.12 (q, 1H, J= 6.8 Hz), 4.68 (dd, 1H, J= 6.0, 11.2 Hz), 4.59 (d, 1H, J= 7.2 Hz), 4.22 (td, 1H, J= 2.8, 7.2 Hz), 4.15-4.08 (m, 1H), 4.06-4.01 (m, 1H), 3.92 (t, 1H, J= 12.4 Hz), 2.74 (s, 3H), 2.41-2.37 (m, 2H), 2.25-2.17 (m, 1H), 2.16-2.07 (m, 1H), 2.02 (dd, 1H, J= 2.8, 7.2 Hz), 1.95-1.84 (m, 2H), 1.61-1.45 (m, 1H), 1.42 (s, 9H), 1.31 (d, 3H, J = 7.2 Hz); 13C NMR (100 MHz, CDC13) 6:
171.5, 170.1, 155.0, 129.3, 128.9, 122.3, 120.7, 117.2, 90.2, 77.2, 70.6, 63.6, 60.5, 52.6, 43.8, 32.7, 32.5, 30.2, 29.0, 28.4, 25.9.
HRMS calcd for C271-138N407Na: 553.26327, found 553.26399.
[00522J Example 49: Preparation of (4S,7S,9aS)-N-((R)-chroman-4-y1)-4-((S)-2-(methylamino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide.
0 1:1 01:1 TFA
0 c 0 DCM
Me Bos 0 -11 0 Ni 110, 32 C
Me N4' p 0 H
Me quant. oe [00523] To a solution of carbamate (58 mg, 0.109 mmol, 1 equiv) in DCM (2 mL) was added TFA (83 nL, 1.09 mmol, 10 equiv). After stirring for 20 h at 32 C, the solution was concentrated. The product was eluted through a short plug (-500 mg) of Silicyle TMA-chloride ion exchange resin with Me0H to yield product=HC1 (51 mg, quantitative). 11-I NMR (400 MHz, CD30D) 6: 7.33 (d, 1H, J= 7.6 Hz), 7.13 (t, 1H, J= 8.4 Hz), 6.86 (t, 1H, J= 7.2 Hz), 6.76 (d, 1H, J= 8.0 Hz), 5.39 (dd, 1H, J= 3.6, 6.8 Hz), 5.08 (t, 1H, J= 6.0 Hz), 4.40 (d, 1H, J= 6.8 Hz), 4.26-4.12 (m, 3H), 4.03-3.89 (m, 2H), 2.67 (s, 3H), 2.33-2.24 (m, 1H), 2.14-1.97 (m, 6H), 1.81 (dd, 1H, J= 2.0, 14.0 Hz), 1.58 (d, 3H, J=
6.8 Hz); 13C NMR (100 MHz, CD30D) 6: 172.9, 172.2, 169.6, 156.4, 130.5, 130.0, 123.5, 121.6, 117.8, 91.0, 71.3, 64.6, 62.3, 58.4, 54.2, 49.0, 44.9, 33.6, 33.3, 31.8, 30.2, 28.0, 16.4. HRMS calcd for C22H3IN405: 431.2289, found 431.2286.
[00524] Example 50: Preparation of (4S,7R,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxylic acid.
0Nr_e_NE
NaOH, H20 0 110 _________________ 0 c IL/
BojN c Me0H, 23 C Boc 0 ¨ 'Nil] 0 so,¨OH
MI 1/4/le 26% Me' Me [00525] To a solution of amide (105 mg, 0.211 mmol, 1.0 equiv) in Me0H (4 mL) was added 1M NaOH
(1 mL). After stirring for 3 h, the methanol was removed in vacuo. HPLC
analysis of the crude reaction mixture revealed that the R-isomer didn't react as cleanly as the S-isomer (Example 47). Then DCM (10 mL) and 1 M NaOH (8 mL) were added and an extraction was performed, with the organic layer being discarded. The aqueous layer was acidified with 3M HC1 to pH < 2 and then extracted with DCM (3 x 5 mL). The organics were dried over sodium sulfate, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (1:3 hexanes/Et0Ac¨>DCM¨>5%
Me0H/DCM) to yield the product as a colorless oil (22 mg, 26%). Rf= 0.14 (7% Me0H/DCM). 1H
NMR (400 MHz, CDC13) 6: 5.25 (d, 1H, J= 6.8 Hz), 4.83 (dd, 1H, J= 5.6, 9.6 Hz), 4.65 (d, 1H, J= 8.8 Hz), 4.14-4.09 (m, 1H), 4.0 (t, 1H, *7= 12.0 Hz), 2.79 (s, 3H), 2.41-2.31 (m, 1H), 2.27-2.11 (m, 2H), 2.06-1.96 (m, 1H), 1.78 (qd, 1H, J= 3.6, 12.0 Hz), 1.46 (s, 9H), 1.33 (d, 3H, J= 7.6 Hz); 13C NMR (100 MHz, CDC13) 6: 173.9, 172.0, 171.3, 89.6, 80.9, 70.7, 60.6, 59.8, 53.1, 33.0, 32.5, 30.5, 28.5, 26.1, 21.2, 14.3, 14.1. HRMS calcd for C18H29N307Na: 422.18977, found 422.19015.
[00526] Example 51: Preparation of tert-butyl ((5)-14(4S,7R,9a5)-7-((R)-chroman-4-ylcarbamoy1)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepin-4-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate.
H214" 110 0 c 0 Boc HOBT, EDC Boc, NMM, THF, 23 C
N H 0 *
Me "Lie Me Lie H
33%
[00527] To a solution of carboxylic acid (21 mg, 0.0053 mmol, 1.0 equiv), (R)-chroman-4-ylamine=HC1 (10 mg, 0.0053 mmol, 1.0 equiv), HOBT=xH20 (9 mg, 0.0058 mmol, 1.1 equiv) and NMM (17 L, 0.0158 mmol, 3 equiv) in THF (3 mL) at 0 C was added EDC=HC1 (11 mg, 0.0055 mmol, 1.05 equiv).
After 30 min the cold bath was removed. The solution stirred for 14 h and then was quenched with saturated aqueous NaHCO3 (10 mL), extracted with ethyl acetate (2 x 10 mL), dried over sodium sulfate and then concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (1:1¨>1:3 hexanes/Et0Ac) to yield the product (9 mg, 33%). 1H NMR (400 MHz, CDC13) 6: 7.20-7.12 (m, 3H), 6.89 (t, 1H, J= 7.6 Hz), 6.82 (d, 1H, J= 8.4 Hz), 5.23-5.19 (m, 1H), 5.12-5.05 (m, 1H), 4.79-4.71 (m, 1H), 4.55 (d, 1H, J= 8.0 Hz), 4.26-4.19 (m, 1H), 4.15-4.06 (m, 2H), 3.97 (t, 1H, J= 12.0 Hz), 2.77 (s, 3H), 2.39-2.26 (m, 1H), 2.24-2.13 (m, 2H), 2.07-2.00 (m, 1H), 1.99-1.91 (m, 2H), 1.80-1.70 (m, 2H), 1.44 (s, 9H), 1.34 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 172.3, 171.1, 169.9, 155.2, 129.4, 129.3, 122.0, 120.9, 117.3, 90.1, 70.6, 63.4, 61.1, 53.1, 43.8, 33.4, 32.7, 32.1, 29.8, 29.1, 28.5, 25.6, 22.8, 14.3. HRMS calcd for C27H38N407Na: 553.26327, found 553.26399.
[005281 Example 52: Preparation of (4S,7R,9aS)-N-((R)-chroman-4-y1)-4-((S)-2-(methylamino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide.
0 cPN 0 DCM
0 c 0 Boc H N
,N H 0 /7--N1 Mei Lie 0 H Me 0 H
quant. Me [00529] To a solution of carbamate (58 mg, 0.109 mmol, 1 equiv) in DCM (2 mL) was added TEA (83 [a., 1.09 mmol, 10 equiv). After stirring for 20 h at 32 C, the solution was concentrated to yield product=TFA (51 mg, quantitative). 1H NMR (400 MHz, CD30D) 6: 8.43 (d, 1H, J=
8.0 Hz), 7.15-7.09 (m, 2H), 6.85 (t, 1H, J= 8.0 Hz), 6.78-6.73 (m, 1H), 5.40 (d, 2Hõ./= 5.6 Hz), 5.10-5.04 (in, 1H), 4.99 (dd, 1H, J= 2.4, 11.2 Hz), 4.53 (d, 1H, J= 9.2 Hz), 4.21 (t, 2H, J= 5.2 Hz), 4.14 (dt, 1H, J= 3.2, 13.2 Hz), 4.05-3.96 (m, 1H), 3.91 (q, 1H, J= 7.2 Hz), 2.67 (s, 3H), 2.44-2.31 (m, 1H), 2.30-2.18 (m, 1H), 2.16-2.07 (m, 1H), 2.04-1.95 (m, 3H), 1.93-1.81 (m, 2H), 1.52 (d, 3H, J= 6.8 Hz); 13C
NMR (100 MHz, CD30D) 6:
173.5, 172.7, 169.3, 156.5, 130.2, 129.9, 123.5, 121.6, 117.9, 91.1, 71.2, 64.6, 62.3, 58.3, 54.4, 44.9, 34.0, 33.3, 31.8, 30.1, 28.2, 16.4. HRMS calcd for C22H30N405Na: 453.21084, found 453.21280.
[005301 Example 53: Preparation of (S)-ethyl 2-((S)-2-(((benzyloxy)carbonyl)(methyl)amino)propanamido)-3-(1H-indo1-3-yepropanoate.
44Ik Cbz,Me-Ala, NMM
NH HOBT, EDC NH
?bz 0 THF, r.t.
OEt H2N Me OEt 'N
0 rieH
[00531] To a solution of tryptophan derivative (600 mg, 2.23 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (530 mg, 2.23 mmol, 1.0 equiv), HOBT=xH20 (376 mg, 2.46 mmol, 1.1 equiv) and NMM
(736 iL, 6.70 mmol, 3 equiv) in THF (15 mL) at 0 C was added EDC=HC1 (449 mg, 2.34 mmol, 1.05 equiv). After 30 min the cold bath was removed. The solution was stirred for 14 h and then quenched with saturated aqueous NaHCO3 (20 mL), extracted with ethyl acetate (2 x 20 mL), dried over sodium sulfate and then concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (3:11:1 hexanes/Et0Ac) to yield the product (790 mg, 79%). LCMS calcd for M+H: 452.22, found 452.22.
[00532] Example 54: Preparation of (S)-24(S)-2-(((benzyloxy)carbonyl)(methyl)amino)propanamido)-3-(1H-indol-3-yl)propanoic acid (88).
=I.
NH Li0H, H20 NH
Cbz 0 Cbz 0 L THF, r.t. I
OEt OH
Me" '-j.(N
AeH 0 rieH
[00533] To a solution of ester (790 mg, 1.75 mmol, 1.0 equiv) in THE (12 mL) and H20 (3 inL) was added LiOH (84 mg, 3.50 mmol, 2 equiv). After stirring for 3 h, Et20 (10 mL) and 1 M NaOH (8 mL) were added and an extraction was performed, with the organic layer being discarded. The aqueous layer was acidified with 3M HC1 to pH < 2 and then extracted with DCM (3 x 8 mL).
The combined organics were dried over sodium sulfate, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (DCM-95% Me0H/DCM) to yield the product as a colorless oil (574 mg, 78%). LCMS calcd for M+H: 424.19, found 424.18.
[00534] Example 55: Preparation of benzyl ((2S)-1-(42S)-14(5,5-dimethoxy-1-oxo-1-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)amino)pentan-2-yllamino)-3-(1H-indol-3-y1)-1-oxopropan-2-y1)amino)-1-oxopropan-2-y1)(methyl)carbamate.
440 Me0 NH HN 41t LI
Cbz 0 Me0) Me Me OH 0¨ CF3CH2OH
Cbz 0 C-Me H 0 N+ ON, 80 C!).LN
20 min = H
H
[00535] A mixture of carboxylic acid (104 mg, 0.246 mmol, 1.0 equiv), aldehyde (34 mg, 0.258 mmol, 1.0 equiv), isocyanide (39 mg, 0.246 mmol, 1.0 equiv) and 7 M ammonia in Me0H (70 litL, 0.491 mmol, 2.0 equiv) in TFE (3 mL) was stirred under microwave irradiation at a set temperature of 80 C for 20 min.
The mixture was then transferred to a round bottom flask and concentrated in vacuo, then 1 M NaOH (15 mL) was added and the mixture was extracted with DCM (3 x 7 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was used without further purification in the next step. LCMS calcd for M+H: 712.37, found 712.34.
[005361 Example 56: Preparation of benzyl methyk(S)-1-oxo-1-4(35,65,12bR)-5-oxo-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoy1)-1,2,3,5,6,7,12,12b-octahydropyrrolo[1',2':1,2]azepino[3,4-b]indol-6-yl)amino)propan-2-yecarbamate.
HN
NH NH
Me0 Me H
Cbz 0 TFA 7 -me H
j4N1 DCM1 0 N 0 N
rtiA e H 0 n 40 121 Ns. 10 H u H H
Me' Le mw Le [00537] To a solution of dimethyl acetal (166 mg, 0.233 mmol, 1 equiv) in DCM
(4 mL) was added TFA
(143 litL, 1.87 mmol, 8 equiv). After stirring for 20 h at 23 C, the solution was concentrated and then purified by flash chromatography on silica gel (1:1¨>1:2 hexanes/Et0Ac) to yield S-isomer (18 mg, 11%), R-isomer (38 mg, 24%) and a mixture of the two isomers (10 mg, 6%). LCMS calcd for M+H: 648.32, found 648.30.
[005381 Example 57: Preparation of (3S,6S,12bR)-64(S)-2-(methylamino)propanamido)-5-oxo-NAR)-1,2,3,4-tetrahydronaphthalen-l-y1)-1,2,3,5,6,7,12,12b-octahydropyrrolo[1',2':1,2]azepino[3,4-b]indole-3-carboxamide.
NH NH
7 Pd-C, H2 Me0H 0 Cbz Me 0 Nµ
0 H e' lkie -Me [00539] To a solution of carbamate (16 mg, 0.0247 mmol, 1.0 equiv) in methanol (4 mL) was added 10 wt% Pd-C (5 mg). A balloon of H2 was applied for 16 h, then the mixture was filtered through Celite with DCM and concentrated in vacuo. The resultant oil was purified by preparative scale HPLC to yield the product (6 mg, 43%). LCMS calcd for M+H: 514.28, found 514.28.
[005401 Example 58: Preparation of tert-butyl ((S)-1-(((4S,7S,9aS)-1,1-dioxido-5-oxo-7-(((R)-1,2,3,4-tetrahydronaphthalen- 1-yl)carbamoyl)octahydropyffolo [2,1 -b] [1,3 ]
thiazepin-4-yl)amino)-1-oxoprop an-2-yl)(methyl)carbamate.
r mCPBA
0 k-}' =
15 c,N j---ri>----t5Ap, -5 CC Bocisii,\10 0 Nal* Bo -N
Me' Le 0 H
67% overall Me/ Le Mel Me [00541] To a solution of sulfide (48 fig, 0.0881 mmol, 1.0 equiv) in DCM (4 mL) at -5 C was added mCPBA (75% purity, 45 mg, 0.194, 2.2 equiv). After 10 minutes the cold bath was removed and the reaction stirred at 23 C for 3 h, then concentrated. The crude product was purified by flash chromatography on silica gel (3:11:11:2 hexanes/Et0Ac) to yield S-isomer (15 mg, 21%) and R-isomer (32 mg, 46%). LCMS calcd for M+H: 577.27, found 577.29.
[00542] Example 59: Preparation of (4S,7S,9aS)-44(S)-2-(methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-l-y1)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 1,1-dioxide.
0,p ,4 1;1 TFA 0 0 DCM
HcoN3N4 Boc 23 C
v H quant. N H 0 0 [1 Me, Le me' Le [00543] To a solution of carbamate (15 mg, 0.026 mmol, 1 equiv) in DCM (2 mL) was added TEA (16 IAL, 0.208 mmol, 8 equiv). After stirring for 20 h at 32 C, the solution was concentrated to yield product=TFA (15 mg, quantitative). LCMS calcd for M+H: 477.22, found 477.23.
[00544] Example 60: Preparation of N,N'-(disulfanediylbis(2,1-phenylene))diformamide.
DMSO; OHC-N
H S-S H
H2N 14111 Ac20, HCO2H
SH THF, -20 C N-CHO
[00545] The disulfide was prepared according to the established literature procedure; see Hyvl, J., Srogl, J.
Eur. Org. Chem. 2010, 2849-2851.
[00546] Example 61: Preparation of 1,2-bis(2-isocyanophenyl)disulfane.
OHC-N POCI3, Et3N
N
H S-s H
-"s- õC_ N
DCM, 0 C C -CHO N.
46%
[00547] To a solution of formamide (2.41 g, 7.92 mmol, 1.0 equiv) in DCM (40 mL) at 0 C was added Et3N (5.60 mL, 40.4 mmol, 5.1 equiv) followed by phosphorus oxychloride (1.09 mL, 11.9 mmol, 1.5 equiv). The mixture was warmed to 23 C and stirred for 2 h, at which time it was poured into saturated NaHCO3 (200 mL) and extracted with DCM (2 x 100 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (5:1 hexanes/Et0Ac) to yield the product (980 mg, 46%) which was stored at 0 C.
It1= 0.38 (5:1 hexanes/Et0Ac). LCMS calcd for M+H: 269.02, found 269.01.
[00548] Example 62: Preparation of (4S,41S,9aS,9a'S)-N,N'-(disulfanediylbis(2,1-phenylene))bis(4-amino-8,8-dimethy1-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide).
Me0 OH OHme0\7eme 0 ti Me Meth<Me N TFA fit 0_ BocHNLIjy BocHNOH CF3CH2OH 0 N H2 N
DCM õ N
NH3 o 41, eW, 80 C 0 H S-s H 0 40 C H S-S H 0 110 e OH
j:3IH2 * N
Me R4e m 110 meo M A o [00549] Same procedure as Example 24 with Boc-N-HSer-OH (159 mg, 0.725 mmol, 2.0 equiv), aldehyde (122 mg, 0.762 mmol, 2.1 equiv), isocyanide (97 mg, 0.363 mmol, 1.0 cquiv) and 7 M ammonia in McOH
(207 uL, 1.45 mmol, 4.0 equiv) in TFE (5 mL). The resultant oil was combined with TFA (302 pt, 3.95 mmol, 16 equiv) in DCM (5 mL) and stirred at 40 C for 14 h. The mixture was concentrated in vacuo, then partially purified by flash chromatography on basic alumina (3:1 hexanes/Et0AcDCM¨>7%
Me0H/DCM), to yield semi-pure product. LCMS calcd for M+H: 697.28, found 697.28.
[00550] Example 63: Preparation of (S,45,4'S,9a5,9a'S)-N,N'-(disulfanediylbis(2,1-phenylene))bis(8,8-dimethy1-44(S)-2-(methylamino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide).
0 MrcA
Boc,Me-Ala, HOBT, EDC
0 c N..)..1 0 N
M!. Me 0 õ H S- H NMM, THE, 23 *C Me/ -Me 0 H S-s H 0 ..
N.
s 0 =
M/t Ni.i2 boc N
Me Mec-L, [00551] Same procedure as Example 25 using bis-amine (69 mg, 0.099 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (40 mg, 0.198 mmol, 2.0 equiv), HOBT=xH20 (33 mg, 0.218 mmol, 2.2 equiv), NMM (65 uL, 0.594 mmol, 6 equiv) and EDC=HC1 (40 mg, 0.208 mmol, 2.1 equiv) in THF (5 mL). The resultant oil was purified by flash chromatography on silica gel (3:1¨>1:1¨>1:3 hexanes/Et0Ac) to yield the product (32 mg, overall yield not determined). LCMS calcd for M+H: 1067.49, found 1067.60.
[00552J Example 64: Preparation of methyl (S,4S,4'S,9aS,9a'S)-N,N'-(disulfanediylbis(2,1-phenylene))bis(8,8-dimethy1-4-((S)-2-(methylamino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide) o o Boc TFA
NilMe md .1vie H S- 111PS H 0 Hr: .õMe DCM md rvie 0 H S-s H 0 H NIMe N,-ILC!_r(-10c 23 CC
14/VrC¨H
Me Me 0 Me m I:1 A 0 [00553] To a solution of carbamate (10 mg, 9.37 iamol, 1 equiv) in DCM (2 mL) was added TFA (7 pi-, 93.7 pinol, 10 equiv). The mixture was stirred for 16 h, then concentrated in vacuo to give the product=TFA (9.5 mg, 95%). LCMS calcd for [M+ CF3CO2H]/2 + Na: 570.18, found 570.25.
[005541 Example 65: Preparation of (4S,10aS)-4-amino-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)octahydro-2H-pyrido[2,1-b][1,3]thiazepine-7-carboxamide.
OMe STrt OMe Me0) oime BocHNXrOH
CO
0 e BocHN DCM H2N1 )11114 NH3 itiW, 100 C
0 0 NI. ip [00555] A mixture of Boc-N-HCys(Trt)-OH (250 mg, 0.523 mmol, 1.0 equiv), aldehyde (80 mg, 0.550 mmol, 1.05 equiv), isocyanide (82 mg, 0.523 mmol, 1.0 equiv) and 7 M ammonia in Me0H (150 pL, 1.05 mmol, 2.0 equiv) in TFE (4 mL) was stirred under microwave irradiation at a set temperature of 100 C
for 20 min. The mixture was then transferred to a round bottom flask and concentrated in vacuo, then 1 M
NaOH (15 mL) was added and the mixture was extracted with DCM (3 x 7 mL). The combined organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was combined with TFA
(401 5.23 mmol, 10 equiv) in DCM (5 mL) and stirred at 55 C for 14 h. The mixture was concentrated in vacuo, then partially purified by flash chromatography on basic alumina (3:1 hexanes/Et0Ac¨*DCM¨>7% Me0H/DCM), to yield semi-pure product. LCMS calcd for M+H: 374.19, found 374.21.
[005561 Example 66: Preparation of tert-butyl methy142S)-1-oxo-1-(((4S,10aS)-5-oxo-7-(((R)-1,2,3,4-tetrahydronaphthalen-1-y1)carbamoyl)octahydro-2H-pyrido[2,1-b][1,3]thiazepin-4-yl)amino)propan-2-y1)carbamate.
S 7 Boc,Me-Ala, NMM S
HOBT, EDC
Cs\ NW-2 Boc 0 , THF, r.t.
Me/ ive [00557] Same procedure as Example 25 using amine (156 mg, 0.418 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (85 mg, 0.418 mmol, 1.0 equiv), HOBTAH20 (70 mg, 0.459 mmol, 1.1 equiv), NMM (138 pL, 1.25 mmol, 3 equiv) and EDC=HC1 (84 mg, 0.439 mmol, 1.05 equiv) in THF (6 mL). The resultant oil was purified by flash chromatography on silica gel (3:1¨>2:1¨>1:1¨>1:3 hexanes/Et0Ac) to yield, after 3 steps, the product (102 mg, 43% overall). LCMS calcd for M+H: 559.30, found 559.32.
[00558] Example 67: Preparation of (4S,10aS)-4-((S)-2-(methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-y0octahydro-2H-pyrido[2,1-b][1,3]thiazepine-7-carboxamide.
S S
TFA
Boc DCM
Me Me H
[00559] To a solution of carbamate (41 mg, 0.0734 mmol, 1 cquiv) in DCM (2 mL) was added TFA (56 uL, 0.734 mmol, 10 equiv). The mixture was stirred for 16 h, then concentrated in vacuo to give the product=TFA (42 mg, quantitative). LCMS calcd for M+H: 459.24, found 459.28.
[00560] Example 68: Preparation of tert-butyl ((6S,9aS)-5-oxo-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)hexahydro-2H-oxazolo[2,3-b][1,3]oxazepin-6-yl)carbamate.
C-} gi+ OH 0 1:1 HO
7 (Me0)3CH
BocHN 40H
NH3 H CF3CH2OH Ts0H+120 BocHN< PhH, 80 C BocHN
W, 80 C 0 u H
[00561] A mixture of Boc-N-HSer-OH (150 mg, 0.684 mmol, 1.0 equiv), glycolaldehyde dimer (41 mg, 0.342 mmol, 0.5 equiv), isocyanide (108 mg, 0.684 mmol, 1.0 equiv) and 7 M
ammonia in Me0H (293 uL, 2.05 mmol, 3.0 equiv) in TFE (4 mL) was stirred under microwave irradiation at a set temperature of 80 C for 20 min. The mixture was then transferred to a round bottom flask and concentrated in vacuo, then 1 M NaOH (15 mL) was added and the mixture was extracted with DCM (3 x 7 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was combined with trimethyl orthoformate (89 uL, 0.808 mmol, 2 equiv) and Ts01-1.1-120 (23 mg, 0.121 mmol, 0.3 equiv) in PhH (5 mL) and stirred at 90 C for 10 h. The mixture was concentrated in vacuo and the crude product will be processed as described in preceding examples. LCMS calcd for M+H:
446.23, found 446.23.
[005621 Example 69: Preparation of (6S,11bR)-6-amino-10-hydroxy-2,2-dimethy1-5-oxo-NAR)-1,2,3,4-tetrahydronaphthalen-l-y1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo[1,2-a]azepine-3-carboxamide.
Me0 OH
HO
Me Me0)D< HO Me BocHN Me0 Me 0¨ CF3CH2OH
EyM TFA
OH H2N N : Mem _ BocH N C-pW, 80 C DCM
0 IN+ ,== 0 N
0 es Ns111 lip H
[00563] Same procedure as Example 24 with Boc-Tyr-OH (346 mg, 1.23 mmol, 1.0 equiv), aldehyde (197 mg, 1.23 mmol, 1.0 equiv), isocyanide (193 mg, 1.23 mmol, 1.0 equiv) and 7 M
ammonia in Me0H (351 IAL, 2.46 mmol, 2.0 cquiv) in TFE (4 mL). The resultant oil was combined with TFA (575 ILL, 7.51 mmol, 8 equiv) in DCM (5 mL) and stirred at 35 'V for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[005641Example 70: Preparation of tert-butyl ((2S)-1 -(((6S,11bR)-10-hydroxy-2,2-dimethy1-5-oxo-3 -(((R)-1,2,3,4-tetrahydronaphthalen-1 -yl)carb amoy1)-2,3 ,5,6,7,11b-hexahy dro-1H-b enzo [c] pyrro lo [1,2-a] azepin-6-yl)amino)-1 -oxoprop an-2-y1)(methyl)carb amatc.
OH
OH
Boc,Me-Ala, Me HOBT, EDC
Me MAI;
111, NMM, THF, 23 C Boc (:)\\N
11.
0H Mel Me [00565] Same procedure as Example 25 using crude amine (406 mg, 0.939 mmol, 1.0 equiv), Boc-IV-Me-Ala-OH (191 mg, 0.939 mmol, 1.0 equiv), HOBT-xH20 (158 mg, 1.03 mmol, 1.1 equiv), NMM (310 !IL, 2.82 mmol, 3 equiv and EDC=HC1 (189 mg, 0.986 mmol, 1.05 equiv) in THE (10 mL). The resultant oil was purified by flash chromatography on silica gel (3:1¨>1:1¨>1:3 hexanes/Et0Ac with <5% DCM in all eluant to dissolve) to yield, after 3 steps the unseparated diastereomixture (250 mg, slightly impure).
LCMS calcd for M+H: 619.35, found 619.16.
[005661 Example 71: Preparation of (6S,11bR)-10-hydroxy-2,2-dimethy1-64(S)-2-(methylamino)propanamido)-5-oxo-N#R)-1,2,3,4-tetrahydronaphthalen-1 -y1)-2,3,5,6,7,11 b-hexahydro-1H-benzo [c] pyrrolo [1,2 -a] azepine-3 -carboxamide.
OH OH
H H
7 Me TFA 7 Me MAiik Mak:-Boc\N 0 Ns", 0 H N , H 0 0 HN'lli0 Me Me Mei Me [00567] To a solution of carbamate (47 mg, 0.0760 mmol, 1 equiv) in DCM (2 mL) was added TFA (47 [AL, 0.608 mmol, 8 equiv). The mixture was stirred for 16 h at 40 C, then concentrated in vacuo to give the product=TFA (42 mg, quantitative). The product was purified by reverse phase HPLC. LCMS calcd for M+H: 519.30, found 519.07.
[00568] Example 72: Preparation of (4S,9aR)-4-amino-8,8-dimethy1-2,5-dioxo-N#R)-1,2,3,4-tetrahydronaphthalen-1-ylioctahydro-lH-pyrrolo[1,2-a][1,3]diazepine-7-carboxamide.
Me0 NH2 ) M 0 Me0 NH, eo 0 _)<õ,,e . e CF3CH2OH ),.y.
OH 0¨ m _,.. fs-A OMe FT TFA
¨.- 0 H H
,...12,\..clie m -N
BocHN c BocHN N 4111 s' DCM H2N 0 ,..., Ns 110 OOP
[00569] Same procedure as Example 24 with Boc-Asn-OH (290 mg, 1.25 mmol, 1.0 equiv), aldehyde (200 mg, 1.25 mmol, 1.0 equiv), isocyanide (196 mg, 1.25 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(357 L, 2.50mmol, 2.0 equiv) in TFE (4 mL). The resultant oil was combined with TFA (635 L, 8.30 mmol, 8 equiv) in DCM (5 mL) and stirred at 35 'V for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00570] Example 73: Preparation of tert-butyl ((2S)-1-(44S,9aR)-8,8-dimethy1-2,5-dioxo-7-(((R)-1,2,3,4-tetrahydronaphthalen-l-y1)carbamoylioctahydro-1H-pyrrolo[1,2-a][1,3]diazepin-4-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate.
0 H H Boc,Me-Ala, ..,,,,le .....,\,,õõ1õ,....õ. m,õõ,:
m HOBT, EDC
111.
N Boc MIP NM M, THE, 23 C 1 ....)\---N
Ns' 4104 H2N 0 N.' ....., H
0 H Me Me [00571] Same procedure as Example 25 using crude amine (398 mg, 1.03 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (210 mg, 1.03 mmol, 1.0 equiv), HOBT=xH20 (174 mg, 1.14 mmol, 1.1 equiv), NMM (341 !AL, 3.11 mmol, 3 cquiv and EDC-FIC1 (208 mg, 1.09 mmol, 1.05 cquiv) in THF (10 mL). The resultant oil was purified by flash chromatography on silica gel (1:1-+1:3 hexanes/Et0Ac-->DCM-*3:1 DCMJEt0Ac--> Et0Ac) to yield, after 3 steps the unseparated diastereomixture (300 mg, slightly impure).
LCMS calcd for M+H: 570.33, found 570.14.
[00572]Example 74: Preparation of (4S,9aR)-8,8-dimethy1-44(S)-2-(methylamino)propanamido)-2,5-dioxo-NAR)-1,2,3,4-tetrahydronaphthalen-1-yl)octahydro-1H-pyrrolo[1,2-a][1,3]diazepine-7-carboxamide.
MAIL:
µ
0 TFA 0 N 11, Boc H 0 0 3Docomc ,1 0 0 md -riAe Me Ivie [00573] To a solution of carbamate (58 mg, 0.102 mmol, 1 equiv) in DCM (2 mL) was added TFA (62 fiL, 0.814 mmol, 8 equiv). The mixture was stirred for 16 h at 23 C, then concentrated in vacuo to give the product=TFA, which was purified by reverse phase HPLC to give 17 mg of a polar isomer and 7 mg of a less polar isomer. LCMS calcd for M+H: 470.28, found 470.36.
[00574]Example 75: Preparation of (6S,11bR)-6-amino-9-hydroxy-2,2-dimethy1-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-l-y1)-2,3,5,6,7,11b-hexahydro-1H-benzo [c] pyrro lo[1,2-a] azepine-3 -c arboxamide and (6 S,11bR)-6-amino-11-hydroxy-2,2-dimethy1-5 -ox o-N-((R)-1,2,3,4-tetrahydronaphthalen-l-y1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo[1,2-a]azepine-3-carboxamide.
OH
Me0 OH
Me0) \(Me meo OMe 0=7 'Me CF3CH2OH
NH3 BocHN
FyM DCM TFA :
uW
BocHN , 80 C N
JICJIJ two isomers: R1 or R2 = OH
other substituent = H
[00575] Same procedure as Example 24 with Boc-m-Tyr-OH (306 mg, 1.09 mmol, 1.0 equiv), aldehyde (192 mg, 1.20 mmol, 1.0 equiv), isocyanide (171 mg, 1.09 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(311 p.L, 2.18 mmol, 2.0 equiv) in TFE (4 mL). The resultant oil was combined with TFA (625 viL, 8.16 mmol, 8 cquiv) in DCM (5 mL) and stirred at 23 'V for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00576]Example 76: Preparation of tert-butyl ((2S)-1-(46S,11bR)-9-hydroxy-2,2-dimethy1-5-oxo-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-y1)carbamoy1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo [1,2-azepin -6-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate and tert-butyl ((2S)-1-(((6S,11bR)- l 1-hydroxy-2,2-dimethy1-5-oxo-3-4(R)-1,2,3,4-tetrahydronaphthalen-1-yllcarbamoy1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo[1,2-a]azepin-6-yllamino)-1-oxopropan-2-y1)(methyl)carbamate.
Boc,Me-Ala, HOBT, EDC
7 Me : Me MA, ___________ 11. MA
111. 404 Boc W NMM, THF, 23 C
0 AS' H2N Nt' 'Nil 0 0 Els. w Me/
ivie two isomers: al or R2 = OH
two isomers: R1 or R2 = OH
other substituent = H other substituent = H
[00577] Same procedure as Example 25 using crude amine (442 mg, 1.02 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (207 mg, 1.02 mmol, 1.0 equiv), HOBT=xH20 (172 mg, 1.12 mmol, 1.1 equiv), NMM (337 [IL, 3.06 mmol, 3 equiv and EDC-FIC1 (205 mg, 1.07 mmol, 1.05 cquiv) in THF (10 mL). The resultant oil was purified by flash chromatography on silica gel (3:1-+1:1-+1:3 hexanes/Et0Ac¨>7% Me0H/DCM, all eluant with <5% DCM to dissolve) to yield, after 3 steps three product-containing fractions (most polar:
253 mg, medium polarity: 112 mg, least polar: 92 mg). LCMS calcd for M+H:
619.35, found 619.45.
[00578] Example 77: Preparation of (6S,11bR)-9-hydroxy-2,2-dimethy1-64(S)-2-(methylamino)propanamido)-5-oxo-N#R)-1,2,3,4-tetrahydronaphthalen-l-y1)-2,3,5,6,7,11b-hexabydro-1H-benzo[c]pyrrolo[1,2-a]azepine-3-carboxamide and (6S,11bR)-11-hydroxy-2,2-dimethy1-64(S)-2-(methylamino)propanamido)-5-oxo-N#R)-1,2,3,4-tetrahydronaphthalen-1-y1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo[1,2-a]azepine-3-carboxamide.
: Me TEA : Me MA MAIL:
BoR .11110 30 C
0 n N H 0 0 Nµ
H
Me 'Me Me/ Me two isomers: R1 or R2 = OH two isomers: R1 or R2 = OH
other substituent = H other substituent = H
[00579] Each fraction of Example 77 was run separately. To a solution of carbamate (253 mg most polar isomer, 112 mg medium polarity isomer, 92 mg least polar isomer) in DCM (2 nit) was added TFA (250, 111, 91 L, respectively, 8 equiv). The mixture was stiffed for 16 h at 40 C, then concentrated in vacuo to give the product=TFA, which was purified by reverse phase HPLC to give 151 mg of the most polar isomer, 55 mg of the medium polarity isomer and 19 mg of the least polar isomer. LCMS calcd for M+H:
519.30, found 519.41.
[00580] Example 78: Preparation of two regioisomers: (6S,11bR)-6-amino-9,10-dihydroxy-2,2-dimethy1-5-oxo-N#R)-1,2,3,4-tetrahydronaphthalen-1-y1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo[1,2-a]azepine-3-carboxamide and (6S,11bR)-6-amino-10,11-dihydroxy-2,2-dimethy1-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-y1)-2,3,5,6,7,11b-hexahydro-1H-benzo [c] pyrro lo [1,2-a] azepine-3 -c arboxamide.
OH Me0 HO Me OH R1 OH
BocHN
Me0) aiki D<Me HO R2 Me W, 80 C Ns 0 Meme TFA : Me B ocHN
N
W
DCM
NH3 Op 0 ' 'PH H2N 0 0 FIN'r alk two isomers: R1 or R2 = OH
other substituent = H
[00581] Same procedure as Example 24 with Boc-3,4-dihydroxy-L-phenylalanine (288 mg, 0.967 mmol, 1.0 equiv), aldehyde (155 mg, 0.967 mmol, 1.0 equiv), isocyanide (152 mg, 0.967 mmol, 1.0 equiv) and 7 M ammonia in Me0H (276 uL, 1.93 mmol, 2.0 equiv) in TFE (4 mL). The resultant oil was combined with TFA (369 uL, 4.82 mmol, 8 equiv) in DCM (5 mL) and stirred at 35 C for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00582] Example 79: Preparation of two regioisomers: tert-butyl ((2S)-1-(((6S,11bR)-9,10-dihydroxy-2,2-dimethy1-5-oxo-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yOcarbamoy1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo[1,2-a]azepin-6-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate and tert-butyl ((2S)-1-(((6S,11bR)-10,11-dihydroxy-2,2-dimethy1-5-oxo-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-y1)carbamoy1)-2,3,5,6,7,11b-hexahydro-1H-benzo [c]pyrrolo [1,2-a] azepin-6-yl)ami no)-1 -oxopropan-2-yl)(methyl)carbamate.
OH RI OH
Boo, Me-Ala, 7 Me HOBT, EDC 7 Me Mak ThI 111.
NMM, THF, 23 C Boc0 N
Me two isomers: R1 or R2 = OH two isomers: R1 or R2 = OH
other substituent = H other substituent = H
[00583] Same procedure as Example 25 using crude amine (339 mg, 0.602 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (122 mg, 0.602 mmol, 1.0 equiv), HOBT=xH20 (101 mg, 0.662 mmol, 1.1 equiv), NMM (198 uL, 1.80 mmol, 3 equiv and EDC=HC1 (121 mg, 0.632 mmol, 1.05 equiv) in THF (10 mL). The resultant oil was not purified (to avoid degradation) and used crude in the next step.
LCMS calcd for M+H: 635.34, found 635.16.
[00584] Example 80: Preparation of two regioisomers: (6S,11bR)-9,10-dihydroxy-2,2-dimethy1-64(S)-2-(methylamino)propanamido)-5-oxo-N#R)-1,2,3,4-tetrahy dronaphthalen-1 -y1)-2,3,5,6,7,11b-hexahydro-1H-benzo [c] pyrrolo [1,2 -a] azepine-3 -carboxamide and (6 S,11bR)-10,11 -dihydroxy-2,2-dimethy1-64(S)-2-(methylamino)prop anamido)-5-oxo-N-( (R)-1,2,3,4-tetrahydronaphthalen-1 -y1)-2,3,5,6,7,11b-hexahydro-1H-benzo [c]pyrrolo [1,2 -a] azepine-3 -carboxamide.
w OH
OH OH
7 Me M;- TFA OH
7 Me : Me 0 Maltz-Boc N0 N API* DCM
111. 0 Mel Me N. H 00 N l f Fr two isomers: W or R2 = OH Me ' me Me :me other substituent = H
[00585] To a solution of carbamate (54 mg, 0.00851 mmol, 1 equiv) in DCM (2 mL) was added TFA (52 !AL, 0.681 mmol, 8 equiv). The mixture was stirred for 16 h at 25 C, then concentrated in vacuo to give the product=TFA, which was purified by reverse phase HPLC to give 3.7 mg of a more polar isomer and 7 mg of a less polar isomer. LCMS calcd for M+H: 535.29, found 535.17.
BIOLOGY EXAMPLES
[00586] Example B-1: 5000 PPC-1 cells were plated and grown overnight.
Compounds were plated and 4 hrs later, TRAIL was added to half of the plate while RPMI was added to the other half of the plate as a control. Plates were return to the incubator for 24 hrs. Plates were removed from the incubator and placed on the bench for 30 mm and then 25 uL of Cell Titer Glo were added per well. Plates were placed on a rocker and then read on a luminometer. 5000 MDA-MB-231 cells were plated per well. Compound was added and 4 hrs later, TRAIL was added at 5 ng/mL.; RPMI was added for a minus TRAIL control.
Plates were incubated an additional 24 hrs, removed to the bench for 30 min.
and then 25 uL of cell titer glo was added per well. Plates were placed on a rocker and read on a luminometer. Data were fit using PRISM.
[00587] Table B-1 below shows assay data for certain compounds described herein.
Table B-1 Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFa) 16 (WO (I1M) Ki LD50 LD50 LD50 (11M) (11M) (11M) (11-1M) o Me N N'N
Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFc,t) Ki (I-1M) (j1M) Ki LD50 LD50 LD50 (j1,M) (W) (I-1M) (1-1M) AcHNO,,N H
N-N .
r,o .
H 0 OMe MeAl N)'Irli Me H 0 N
H ' 4 C B ' o .
ti 0 OMe Me-IN--)LeCiri s Me H 0 N
H ' 5 ' C B ' o , mErki jc I -1N----..
Me H- X
N *
o r o meNort:IN----.
Me H 0 0 HN *
0 OMe H
me,Isl,N1,1(1% 111 Me H 0 N
0 H . . . .
o 3... CI
me,N,....No=N 140 m H
e 8 , N
=-= H
H
me,Islj-LNI,r el Me H 0 N'' IP
ome o , H II
me,N,...,,N 1111 X).ri me H 0 N,s, .,r,0 , ti 0me Me' N --/- Nr-i Me H 0 N
H3-_N-c( =
N _ H Me 0 Nis 1p -me 0 H
Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFc,t) 160-im) (j-1.m) Ki LD50 LD50 (j1,M) (" (" (1-1M) 0 F=1 o 13 A A
Q.--rsil-1 NI
Me' me 0 -n H
0 ti 0 14 C A A
NQI---Hi\---Me' - %-= H
Me H Me 0 15 C B
:
me, : r.i.rN
Me 0 N
H sjj NHH
roe,N,,,,Ncp Me 0 H
HI*"
Mel 17 A A
t--""Nci - H
Me 0 0p HN
Me 18 C B
0yMe0 --õH
meN=cp ' H N
Me 0 of HN
Me 19 C B
Oymeo ,c-NN:-L,Ei 0 Nj=L
Me' = N N ' Me H 0 HN
Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFc,t) Ki 0-1M) (j1M) Ki LD50 LD50 LD50 (PM (" (1-1,M) (1-1M) 0 NjEr H
, Me _ Nj N H ()N Ala ., me 0 41k.
MII;LA_e N p - H
Me 0 HN,"
0H 22 C B z ,õ.....,\_ 0 ck....) 0 H
NI---2\--HN 0 -})--N
0 ¨
Me fvie rot! 23 C B
o L-Ncµrfj--i_ 0 , _ H 0 N
0 _ Me fvie s li 0 24 C A A A A A
c11"-- 0 Hi---N
Me ,NI - H 0 Ns. .
-me - H
6:1 dr. 25 A A 0 11;1 0 )%;----H N
Mel .- N
Me 00 >10:1 dr. c 0 H Me 26 A A A A A A
0 i-=s1-1-M
L)LN
. OH [I' Me, Me 0 H
N--.)---N me' 0 NAlp :- 0 H
Me Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFc,t) Ki 0-1M) (j1M) Ki LD50 LD50 LD50 (PM) (" (1-1,M) (1-1M) H)------e._ flp N¨' H 0 N\
Me' Ivie 0 H
(--N,I.Th:
N0-3 -N-----el. 1110 . H 00 rf Me' me NH
H
-- _ O N
H. j\---N
N . H 0 n Nµ ir ... H
Me/ -Me NH
H
O N
IIIL-H j-N
N . H 0 Ns ir M6,me O o , o N
H\--NCI-.._ s=
N¨' H 0 0 iti 111#
MI itAe 3:1 d.r. 33 C A A A A
HiLO Nccr-= ilk Me irvie 0 0 H
>8:1 d.r. 34 C A A A A
Hi\---N N
Me, Me 0 H
H 35 slem A A A A A
c;r Hi\--N , N . H 0 0 if Me' iidie 3:1 d.r.
Me "i-Ae 0 0 --N H
Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFc,t) Ki (1-LM) (j1M) Ki LD50 LD50 LD50 (PM) (" (" (Jim) o,9 37 C A
'S .17I
j N H 0 0 ill IP
Me/ .Me Os? 38 C B
'SNr__Ej 0 cN....)- =
H j-N
Me/ 11e cPN , 0 H
N . H 0 ,' 110 Me,--t Me o H
rosLmT4 40 A A
11- )C04;;R:.
kid iA. --sH 00 H Me' ,A.
fIcs'i -..-,..
0 cN illi Me/ _ N H uci rw'illp 'me H
cN
H j\--N
md Me H r0 7 i\---NNNI;:j, N H 0 nin Me .iiie Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFc,t) Ki 0-1M) (j1M) Ki LD50 LD50 LD50 (PM) (" (P,M) (1-1M) : Me MAI
111, N H 0 Ns Me/ 'ftle OH
OH
Me MAI;
!IP
N . H 0 Ns H
Me -me / Me Mak !IF
N H 0 Ns H
Mei me N Me mAik:
11.
N H 0 Ns H
Me/ -me : 0 Me MAIL, !IP
H j¨N
= H
Me me OH
: Me 111, H
Me/ me KEY: A = <25 micromolar; B > 25 and < 50 micromolar; C >50 micromolar Example B-2: Clinical trial for Leukemia [00588] Study Type: Interventional [00589] Endpoint Classification: Safety/Efficacy Study [00590] Intervention Model: Single Group Assignment [00591] Masking: Open Label [00592] Primary Purpose: Treatment Purpose [00593] The purpose of this study is to determine how well a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, works to treat relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia in blastic phase.
Intervention [00594] Patients are administered 35 mg/kg of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, by IV infusion, once every two weeks for 14 weeks.
Outcome Measures [00595] The primary outcome measure is the patient's response to a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, as first-line treatment in patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia in blastic phase.
[00596] The secondary outcome measure is (a) to evaluate the side-effects of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof; (b) the efficacy of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, on relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia in blastic phase;
and (c) to evaluate quality of life in patients following treatment.
Detailed Description [00597] Patients will be given a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, intravenously once, every two weeks for 14 weeks. Prior to each injection of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, a physical exam, blood work and assessment of any side effects will be performed. Every 5 weeks the patient's cancer will be re-evaluated to determine whether the treatment is working. Participation in this study will last at least 14 weeks, however patients may remain on the study as long as there is no disease progression, and they are able to tolerate the study drug without severe side effects.
Eligibility [00598] Ages Eligible for Study: 18 Years and older [00599] Genders Eligible for Study: Male or female
1001841 Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R3 is Ci-C3alkyl.
[00185] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R4 is¨NHR5, -N(R5)2, or -1\r(R5)3; and each R5 is independently selected from H, Ci-C3alkyl, and -CI-C3alkyl-(C3-05cycloalkyl).
[00186] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, or -C(=0)NH-;
R3 is C1-C3alkyl;
R4 is¨NHR5, -N(R5)2, or -1\r(R5)3; and each R5 is independently selected from H, Ci-C3alkyl, and -CI-C3alkyl-(C3-05cycloalkyl).
[00187] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R4 is R3 [00188] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, N
= N
R4 U is H
[00189] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring.
[00190] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, (R9)o-2 ,/=-===.
is H and q is 1, 2 or 3.
[00191] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein le is bonded to a nitrogen atom of U to form a substituted or unsubstitutcd 5-7 membered ring.
[00192] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, N
/1-4q R4 s (R9)0-2 ; and q is 1, 2 or 3.
[00193] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, X1 is selected from N-RA, S. 5(0) and S(0)2; and X' is CH2.
[00194] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-V-1 or Formula C-V-2 or Formula C-V-3:
R2' R2c R2d R1 R2d R1 R8d Rsc R2t, R2' R2a2 R8b R2a R 8b R8a Formula C-V-1 Formula C-V-2 R2c R R2d _____________________________ 2b R1 R2a S
/N R8a _______________________________ U 0 Formula C-V-3 [00195] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-VI-1 or Formula C-VI-2 or Formula C-VI-3:
R2c 0 R2c 0 R2d \ \//0 R2d I If? 1 R8d 8c R2b S R1 R2b s R R
R2a Rs: R2a R8b Rsa ) ______________________ U 0 ) __ U 0 Formula C-VI- 1 Formula C-VI-2 Rai \,O/
R2b R2a ..........\><R8b /N R8a R3 \\ R8 ) __ U 0 Formula C-VI-3 [00196] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable saltõV-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-VII-1 or Formula C-VII-2 or Formula C-VII-3:
R2c R2c R2d R2b R2d R8d R8c R2b 0.µ R1 7 0 R1 R2a R2a R8b /N Rsa /N Rsa ) ______________________ U 0 ) __ U 0 Formula C-VII-1 Formula C-VII-2 R2c R2d R2b ..........\><R8b /N R8a ) __ U 0 Formula C-VII-3 [00197] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable saltõV-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-VIII-1 or Formula C-VIII-2 or Formula C-VIII-3:
R2c RA R2c RA
/
R2b R2d i\j/ R1 R2b R2d Red N R1 R8c \--W2 R2a R8b R2a R8b ) _____________ U 0 ) __ U 0 Formula C-VIII-1 Formula C-VIII-2 R2c RA
R2d /
R2b R2a \,,---0 .......,\><R8b /N Oa ) ____________________________ U 0 Formula C-VIII-3 [00198] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds haying the structure of Formula C-V-2 or Formula C-VI-2 or Formula C-VII-2 or Formula C-VIII-2:
R2c R2c R2d R2d RO R8d R2b R2b S/ Ri R8c S R1 R8dR8c R2a R8b R2a R8b /N R8a /N R8a ) _____________ U 0 ) __ U 0 Formula C-V-2 Formula C-VI-2 R2c R2c RA
R2d R8d R2d / Red R2' 0 R1 R8c R2b N R1 R8c R2a R8b R2a R8b N R8a /N R8a ) _____________ U 0 ) __ U 0 Formula C-V11-2 Formula C-V111-2 [00199] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein X1 is CH2; and X2 is selected from 0, N-RA, S, S(0), and S(0)2.
[00200] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof; is one group of compounds having the structure of Formula C-IX-1 or Formula C-IX-2:
R2d R21 R8d __________________ R1 R8c R2a R1 Rac R2b R2b R8b R8b R8a Raa Formula C-IX-1 Formula C-IX-2 [00201] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-X-1 or Formula C-X-2:
A R2e R2f R2b w2 W2 RBb <R8b R8a R8a ______________ U 0 U 0 Formula C-X-1 Formula C-X-2 wherein ring A is a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, substituted or unsubstituted 5-10 membered aryl ring, or substituted or unsubstituted 5-10 membered heteroaryl ring.
[00202] Within such a group of compounds are compounds wherein ring A is selected from indolyl and phenyl.
[00203] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof; is one group of compounds having the structure of Formula C-XI:
2b 2_x1 Ri A/X
R a F Rai) R8a R3 (N
Formula C-XI
[00204] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-XII:
2b Rfax2_xi R1 R3 __ > _____ 0 Formula C-XII
[00205] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-XIII:
2b Rf)(2¨x1 R1 _______________________________ U 0 Formula C-XTTI
[00206] Among the compounds of Formula C-XI, Formula C-XII and Formula is one group of compounds wherein X' is 0, S or S(0)2, and X2 is CH2.
[00207] Among the compounds of Formula C-XI, Formula C-Xii and Formula C-XIII, is one group of compounds wherein X1 is N-RA, and X2 CH2.
[00208] Among the compounds is one group of compounds wherein R2a, R2F, R2c, R2d, R2e, and R2f are independently H or C1-C3 alkyl; and R1 is H or methyl. Among the compounds is one group of compounds wherein RI is H.
[00209] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8b and R8' together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N.
[00210] Within such a group of compounds are compounds having the structure of Formula C-XIV:
X2¨Xi R1 (R9)0-3 x3 __________________________ U 0 Formula C- XIV
where ring B is an aryl or heteroaryl ring.
[00211] In some embodiments, ring B is an aryl. In some embodiments, ring B is phenyl. In some embodiments, ring B is a heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring or a bicyclic heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring. In some embodiments, ring B is a bicyclic heteroaryl ring. In some embodiments, ring B
is selected from phenyl, pyridinyl and thiophenyl. In some embodiments, ring B is selected from pyridinyl and thiophenyl.
[00212] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N; or R8c and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N.
[00213] Within such a group of compounds are compoundds having the structure of Formula C-XV-1, Formula C-XV-2, Formula C-XV-3, or Formula C-XV-4:
y2- x1 R1 /'µ y2 -xl Ri )1-4 x3 )1-4 R3 R __ U
Formula C-XV-1 Formula C-XV-2 X2 X1 R1 x2¨x1 R1 R a )1-3 3 (N
_________________ U 0 U 0 Formula C-XV-3 Formula C-XV-4 or having the structure of Formula C-XVI-1 or Formula C-XVI-2:
RA
X2¨X1 Ri y2 ¨x1 W
)1-3 N
Formula C-XVI-1 Formula C-XVI-2 wherein RA is H, Ci-C3alky1 or ¨C(=0)Ci-C3alkyl.
[00214] Among the compounds of Formula C-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein Rgb and le together form a bond.
[00215] Within such a group of compounds are compounds having the structure of Formula C-XVII:
R1 Rsd fx2¨xi X3 Rsa Formula C-XVII
[00216] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-XVIII:
X2¨X1 R1 /
X3 R8b 8a _____________________________ U 0 Formula C-XVIII
[00217] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof; is one group of compounds having the structure of Formula C-XIX:
x2¨x1 R1 /
X3 R8b /N R8a Formula C-XIX
[00218] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-XX:
y2¨ x1 R1 /'s R8a Formula C-XX
[00219] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula C-XXI, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
R22 R8b /N R8a HN
Formula C-XXI
wherein, W2 is 0, S, or C(R8e)(R8(I);
R' is H, or Ci-Coalkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, Ci-C6alkyl, -C(=0)C1-C6a1kyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a and R2b are independently selected from H, substituted or unsubstituted Ci-C6alkyl, and -C(=O)RD;
RD is substituted or unsubstituted -Ci-C6alkyl-(substituted or unsubstituted C6cycloa1kyl), -Ci-C6alky1-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alky1-(substituted or unsubstituted aryl), -C1-C6a1kyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted CI-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alky1, or C1-C3fluoroa1kyl;
each R' is independently selected from H, Ct-C3alkyl, C1-C3haloa1kyl, Ci-C3heteroalky1 and -CI-C3alky1-(C3-05cycloalkyl);
each R7 is independently selected from C1-C6alkyl, C1-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C1ohetcrocycloa1kyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -C1-C6alky1-(substituted or unsubstituted aryl), -C1-C6a1kyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
RS 'T and leb are independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
Rg and led are independently selected from H, C1-C6alkyl, and C1-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, C1-C4alkyl, C1-C4 fluoro alkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(CI-C4alkyl), -NH(Ci-C4alky1)2, -C(=0)0H, -C(=O)N H,, -C(=0)C 1-C3alkyl, -S(=0)2C111, -N H(C -C4alkyl)-OH, -81--NH(C1-C4alkyl) -0 -(Ci-C4alkyl), - 0 (C -C4alkyl)-NH2; -0(C -C4alkyl)-NH-(C 1 -C4alkyl), and -0(C -C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached folin a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
[00220] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R2a, R2b R2c, R2d, R2e, and K-21 are independently selected from H, Ci-C3alkyl and -C(=0)RB; and RB is substituted or unsubstituted Ci-C6alkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyksubstituted or unsubstituted heteroaryl).
[00221] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R2a, R2b R2c, R2d, R2e, and R21 are independently H or Ci-C3 alkyl.
[00222] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R1 is H or methyl.
[00223] Among the compounds of Formula C described above or below, or pharmaceutically acceptable saltõAr-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R1 is H.
[00224] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is ¨NHC(=0)R7, -C(=0)NHR7, ¨NHS(=0)2R7, -S(=0)4\THR7; ¨NHC(=0)NHR7, -NH S (=0)2NHR7, ¨(C1 -C3 alkyl)-NHC(=0)R7, ¨(C 1-C3 alkyl)-C(=0)NHR5, ¨(Ct -C
3 alkyl)-NHS(=0)2R7, ¨(Ci-C3alkyl)-S(=0)2NHR7; ¨(Ci-C3alkyl)-NHC(=0)NHR7, or ¨(Ci-C3alkyl)-NHS(=0)2NHR7.
[00225] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is substituted or unsubstituted C2-C10heterocycloalkyl, or substituted or unsubstituted heteroaryl.
[00226] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted C2-Cioheterocycloalkyl.
[00227] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted heteroaryl.
[00228] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NHR7, -S(=0)2NHR7,¨(Ci-C3alkyl)-C(-0)NFIR', or ¨(Ci-C3alkyl)-S(=0)2NHR7 .
[00229] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NHR7, or -S(=0)2NHR7.
[00230] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R6 is ¨C(=0)NHR7.
[00231] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, each R7 is independently selected from a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C iocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted G-Cioheterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2-(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl).
[00232] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racematc or stereoisomer thereof, is one group of compounds wherein, R7 is independently selected from a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C2-Cipheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, and ¨(CH2)p-CH(substituted or unsubstituted ary1)2.
[00233] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R7 is selected from ,,N
N
tt1/4 I
Me 's555 0 .., -. N 11101 I
-- ,'-' ,-, , N
N N Me, , Me , , I
,z, i Nõ. Me 'csss 0 \
/
N
, H .
[00234] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, W2 is C(R8u)(R8();
R1 is H;
¨2a, K R21' are independently selected from H, and C1-C3alkyl;
R5 N 1\1-,)L, ook R3 is ' H =
z lea, Rgb, Rge, Rgd are independently selected from H and C1-C3alkyl.
[00235] Any combination of the groups described above or below for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[00236] Among the compounds of Formula C described above or below, or pharmaceutically acceptable salt, N-oxide, racematc or stereoisomer thereof, arc compounds selected from:
0 ,c¨NNHH 0 4c¨NNH
,TIJI.-.. ,1-1 11 INH
Me : IF1 N Me N
Me 0 Me 0 HT" HN
, , Me 'y Me0 oc'NNN,,,H 0 H 0 ----\N-Ac NpH
õNJ.
Me - N Me - N
Me 0 f Me 0 HN HN"' ',and I.
[00237] Also provided herein are pharmaceutical composition comprising a compound of Formula C, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof, and a pharmaceutically acceptable carrier.
Formula D -Seven-six ring systems [00238] As used herein, Formula D includes compounds of Formula D-I, Formula D-II, Foimula D-II-1, Formula D-II-2, Formula D-II-3, Formula D-III, Formula D-IV, Formula D-V-1, Formula D-V-2, Formula D-V-3, Formula D-VI-1, Formula D-VI-2, Formula D-VI-3, Formula D-VII-1, Formula D-VII-2, Formula D-VII-3, Formula D-VIII-1, Formula D-VIII-2, Formula D-VIII-3, Formula D-IX-1, Formula D-IX-2, Formula D-X, Formula D-XI-1, Formula D-X1-2, Formula D-X11-1, Formula D-X11-2, Formula D-XIII, Formula D-XIV, Formula D-XV, Formula D-XVI-1, Formula D-XVI-2, Formula D-XVI-3, Formula D-XVI-4, Formula D-XVII-1, Formula D-XVII-2, Formula D-XVIII-1, Formula D-XVIII-2, Formula D-XIX, Formula D-XX, Formula D-XXI and Formula D-XXII.
[00239] In one aspect, described herein is a compound of Formula D-I, or a pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, as described in the summary of the invention.
[00240] A compound having the structure of Formula D-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
x2-Xltw3 '\vv2 wi Formula D-I
wherein, R1 is H, Ci-C6alkyl, C3-C6cycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalltyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
when X1 is selected from N-RA, S, S(0) and S(0)2, then X2 is cR2c--It2d, and X3 is CR2aR21);
or when Xt is 0, then X2 is selected from CR2c'-'2d X and N-RA, and X3 is CR2aR2b or:
when Xt is CH2, then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is cR2aR2b;
or:
.x1 is ceRzrand .x2 is cR2c-2d, and R2e and R2e together form a bond, and X3 is CR2aR2b;
or:
X1 and X3 are both CH2 and X2 is C=0, C=C(Rc)2, or C=NRc; where each Rc is independently selected from H, -CN, -OH, alkoxy, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1 -C6alkyl-(substituted or unsubstituted C2-C5heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR2aR2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR2eR21;
W1 is 0, S, N-RA, or C(Rga)(R8b);
W2 is 0, S, N-R', or C(R8c)(R8d);
W3 is 0, S, N-RA, or C(R8e)(R8f); provided that the ring comprising V, W2 and W3 does not comprise two adjacent oxygen atoms or sulfur atoms;
RA is H, Ci-C6alkyl, ¨C(=0)Ct-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted hetcroaryl;
R2a R2b, R2c, R2d R2e, and ¨ x 2f are independently selected from H, substituted or unsubstituted C1-C6alky1, substituted or unsubstituted Ci-C6heteroalkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05beterocycloalkyl), (substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl) and ¨
C(=0)RB;
RB is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), (substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE arc independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, i-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-C5heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
R4 is -NHR5, -N(R)2, -N-(03 or -OR5;
each R5 is independently selected from H, Ci-C3alkyl, C1-C3haloalkyl, Ci-C3heteroalkyl and -C1-C3alkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(Ci -C3 alkyl)-NHC(=0)127, -(C -C3 alkyl)-C(=0)NHR% -(Ct -C3 alkyl)-NHS(=0)2R7, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(Ci-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-C10heterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from CI-C6a1kyl, Ci-C6haloalkyl, C1-C6hctcroalky1, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C loheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C10cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
Rsb, R8c, K-8d, R8eand R8f are independently selected from H, Ci-C6alkyl, Ci-C6fluoroalkyl, C1-C6 alkoxy, CI-C6hcteroalkyl, and substituted or unsubstitutcd aryl;
or:
R8a, R8d, R8eand R8f are as defined above, and R8b and R8e together form a bond;
or:
Rga, Rgb, led, and lef are as defined above, and R8' and R8' together form a bond;
or:
R8a, R8d, R8eand R8f are as defined above, and R8b and R8s together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
lea, Rgb, and ref are as defined above, and le' and le together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S. 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S. 0 and N;
or:
R8', R8d, R8eand R8f are as defined above, and R8a and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
lea, le, leand fef are as defined above, and R8' and led together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8a, WI', R8', and R8d are as defined above, and R8e and R8f together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, Ci-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C fluoroalkoxy, -NH2, -NH(Ci-C4alkyl), -NH(Ci-Caalkyl),), -C(=0)0H, -C(=0)NF17, -C(=0)Ci-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-0H, -NH(CI-C4alkyl)-0-(Ci-C4alkyl), -0 (C -C4alky1)-NF-17 ; -0(C -C4alkyl)-NH-(C -C4alkyl), and -0(C -C4alkyl)-N-(Ci -C4alkyl) ), or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[00241] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-II:
-w2 yR3 w1 Formula D-11 [00242] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-II-1, Formula D-11-2, or Formula D-II-3:
R8f R R8e X2--X1 w3 Red 3 R w2 Xee X3 R3 =R86 R3 N ylcR86 R8a R8a Formula D-I1-1 Formula D41-2 R8f X2¨X1 R8e Rsci X3 R8c R3 wl R' 0 R6 Formula D-II-3 [00243] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-III:
R8f R R8e X2--X1 R8d X3 flR8C
R3 R8b R8a Formula D-III
[00244] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-IV:
X2--X ' 0 R8d R8a Formula D-IV
[00245] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, or -S(=0)2NH-.
[00246] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, or -C(=0)NH-.
[00247] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R3 is C1-C3alkyl.
[00248] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R4 is¨NHR5, -N(R5)2, or -N(R5)3; and each R is independently selected from H, Ct-C3alkyl, and -Ci-C3alkyl-(C3-05cycloalkyl).
[00249] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(-0)-, or -C(=0)NH-;
R3 is C1-C3alkyl;
R4 is¨NHR5, -N(R5)2, or -N(R5)3; and each R5 is independently selected from H, Ci-C3alkyl, and -Ci-C3alkyl-(C3-05cycloalkyl).
[00250] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, ,.N )22-' R4) is R3 [00251] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, - N
is - H
[00252] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring.
[00253] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, (R9)0-2 R4j.0 is H ;and q is 1, 2 or 3.
[00254] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein le is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring.
[00255] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, H
N
N:2a N.
is (R9)0-2 ; and q is 1, 2 or 3.
[00256] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, X1 is selected from N-RA, S, S(0) and S(0)2; and X2 is CH2.
[00257] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-V-1, Formula D-V-2, or Formula D-V-3:
R2 R2c Rd R1 R2d R1 R8fR8e R2a _______________ S.\w3 R2bw2 R2* R8d Sjç
R2a R8c R8a Formula D-V-1 Formula D-V-2 R 2 c Rai R1 R2b d ll ......õ......
R22 ________________________________________ R8c R3 N ........õ..õ..\----R8b R4)-----U R8a Formula D-V-3 [00258] Among the compounds of Formula D4 described above or below, or pharmaceutically acceptable saltõV-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-VI-1, Formula D-VI-2, Formula D-VI-3:
R2c 00 R2 00 8f R2d \\ / Ri R2d \\// R1 R R8 R2be S Sw3 "===...w2 R2. R8d R2a I R2a R8c R3 N ,..,w1 R3 N--\-----R86 )---U )----U R8a Formula D-VI- 1 Formula D-VI-2 R2d \\// R1 S to N.,1._,t 2b ¨8d R
R2a R8c )---1.1 R8a Formula D-VI-3 [00259] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-VII-1, Formula D-VII-2 or Formula D-VII-3 R2c R2 R2d , R1 R2d r, R1 R81R8e L.,tw3 L., Rsd R2 b R2 o R2 ______________ w2 a I R2a R8c R3 N W I R3 N,.......\----R8b )-----11 /\----U R82 Formula D-VII-1 Formula D-VII-2 R2c R2d R2b R8c1 8c R8a R4 oR6 Formula D-VII-3 [00260] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-V-2, Formula D-VI-2, or Formula D-VII-2:
R8f R2d R R8e R2d \\// R1 R8e R2a R8c R2a R8c R3 N.çR8bR3 Rsa Raa Formula D-V-2 Formula D-VI-2 R2d R1 R8f R8e R2b R8d R2a R8c Rsa Formula D-VII-2 [00261] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group wherein R1 is H
or methyl; R2a, R2b R2c, R2d, R2e, and R2f are independently H or C 1-C3 alkyl; R8a, R81) R8c, R8d, R8e, and R8f are independently H or Ci-C3 alkyl.
[00262] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group wherein R1 is H.
[00263] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-VIII-1, Formula D-VITT-2, or Formula D-VTII-3:
RA R\ R8f _ R1 R1 \ R8e N----U R2a R2(,.
\ w \.
I R2a R8c \./W1 R3 N.....N...........õ\--R8b )-----U )-----U R8a Formula D-VIII-1 Formula D-VIII-2 RA
R2b N¨uto Rsd -......_ R22 R8c R3 N .....N.......õõ.7_Rsb )---U R82 Formula D-VIII-3 [00264] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein X1 is CH2; and X2 is selected from 0, N-RA, S, S(0), and S(0)2.
[00265] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-IX-1 or Formula D-IX-2:
R2d R2f __________________________ F.1 R1 R2 wa I
N- w 1 R3 N w 1 \/
)----U )-----U Y
Formula D-IX-1 Formula D-IX-2 [00266] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stercoisomer thereof, is one group of compounds having the structure of Formula D-X:
W&w2 I
R4 0 wl N \/
)-----U
Formula D-X
[00267] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-XI-1 or Formula D-XI-2:
R2e R2f R2b W3 w2 A WN3 w2 R2a Formula D-XI-1 Formula D-XI-2 wherein, ring A is a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, substituted or unsubstituted 5-10 membered aryl ring, or substituted or unsubstituted 5-10 membered heteroaryl ring.
[00268] Within this group of compounds are compounds wherein ring A is selected from indolyl and phenyl.
[00269] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, raccmate or stereoisomer thereof, is one group of compounds having the structure of Formula D-XII-1 or Formula D-XII-2:
X2¨X1 R8d R2b X2¨X1 R2a R8c R2a R3 Rab R3 R8b R8a R8a Formula D-XII-1 Formula D-XII-2 [00270] Within such a group of compounds wherein Rsa and R8b are independently selected from H and C1-C3alkyl.
[00271] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-XIII:
R2b XX
R2a Formula D-XIII
[00272] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-X1V:
R2b R2a Formula D-XIV
[00273] Among the compounds of Formula D-XII, Formula D-XIII and Formula D-XIV
are compounds wherein X[ is 0, S or S(0)2, and X2 is CH).
[00274] Among the compounds of Formula D-XII, Formula D-X111 and Formula D-XIV
are compounds wherein X' is 0, and X2 is N-RA.
[00275] Among the compounds of Formula D-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein leb and lee together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N.
[00276] Within such a group of compounds are compounds having the structure of Formula D-XV:
(R9)3 Formula D-XV
wherein ring B is an aryl or heteroaryl ring.
[00277] In some embodiments, ring B is an aryl. In some embodiments, ring B is phenyl. In some embodiments, ring B is a heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring or a bicyclic heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring. In some embodiments, ring B is a bicyclic heteroaryl ring. In some embodiments, ring B
is selected from phenyl, pyridinyl and thiophenyl. In some embodiments, ring B is selected from pyridinyl and thiophenyl.
[00278] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8 and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N or R8' and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N.
[00279] Within such a group of compounds arc compounds having the structure of Formula D-XVI-1, Formula D-XVI-2, Formula D-XVI-3, or Formula D-XVI-4:
W i W
X2¨X1 x2¨X ' )1-4 )-----U )----U R6 0 0 Formula D-XVI-1 Formula D-XVI-2 x2¨X1 X2¨X1 / 2 / /SJ)1-3 )¨sstJ 1-3 )-----"U 2 , Formula D-XV1-3 Formula D-XV1-4;
or compounds having the structure of Formula D-XVII-1 or Formula D-XVII-2:
,- RA
i R1 R1 N
X2¨X ' X2¨X1 X3 )2 X3 >,........_µN b }
)2 )-----U
/
Formula D-XVII-1 Formula D-XVII-2 wherein RA is H, C1-C3alky1 or ¨C(=0)Ci-C3a1kyl.
[00280] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8b and R8c together form a bond.
[00281] Among the compounds of Formula D-I described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8e and lee together form a bond.
[00282] Within such a group of compounds are compounds having the structure of Formula D-XVIII-1 or Formula D-XVIII-2:
R8f X2 ¨X
x2¨X R1 Red R8d R8a R3 N
Formula D-XVIII-1 Formula D-XVIII-2.
[00283] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stercoisomer thereof, is one group of compounds having the structure of Formula D-XIX:
X2--X1 w3 w2 Ry_.3 7NyWal Formula D-XIX
[00284] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-XX:
X2¨X1 Th Formula D-XX
[00285] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-XXI:
X2--X1 .= 0 Formula D-XXI
[00286] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula D-XXII, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
__________________________________ Xal R1 tW3 R2b p 8b 0 =
R8a Formula D-XXII
wherein, W3 is 0, S, or C(R8e)(R85;
R1 is H, or Ci-C6alkyl;
X1 is 0, N-RA, S, S(0), or S(0)2;
RA is H, CI -C6alkyl, ¨C(=0)CI-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R24. and R2b are independently selected from H, substituted or unsubstituted C1-C6alkyl, and ¨
C(=0)RB;
RE is substituted or unsubstituted Ci-C6alkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is C1-C3a1kyl, or C1-C3fluoroalkyl;
each R' is independently selected from H, C1-C3alkyl, C1-C3haloalkyl, C1-C3heteroalkyl and -C1-C3a1kyl-(C3-05cycloa1kyl);
each le is independently selected from CI -C6alkyl, C1-C6haloalkyl, CI -Coheteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C1oheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C10cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH)),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
R82 and R8b are independently selected from H, Ci-C6alkyl and Ci-C6fluoroalkyl;
R8e and fef are independently selected from H, C1-C6alkyl and C1-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, CI-C4alkyl, C1-C4 fluoro alkyl, C1-C4 alkoxy, fluoroalkoxy, -NH2, -NH(C -NH(C i-C4 alkyl) ,, -C(=0)0H, -C(=0)N112, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-OH, -NH(C1-C4alkyl)-0 -(C 1 -C4alkyl), -0 (C -C4alkyl)-NF17; -0(C -C4alkyl)-NH-(C -C4alkyl), and -0(C -C4alkyl)-N-(Ci-C4alkyl)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[00287] Among the compounds of Formula D described above or below, or pharmaceutically acceptable saltõV-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R2a, R2b R2c, R2d, R2e, and K2f are independently selected from H, C1-C3alkyl and -C(=0)RB; and RB is substituted or unsubstituted Ci-C6alkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6a1kyl-(substituted or unsubstituted heteroaryl).
[00288] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R2a, R2b R2e, R2d, R2c, and R2f are independently H or C1-C3 alkyl.
[00289] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, le, le le, led, lee, and le are independently selected from H, Ci-C3alkyl and -C(=0)RB; and RB is substituted or unsubstituted C1-C6alkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyksubstituted or unsubstituted heteroaryl).
[00290] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein lea, le lee, led, lee, and R8f are independently H or Ci-C3 [00291] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R1 is H or methyl.
[00292] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racematc or stereoisomer thereof, is one group of compounds wherein R1 is H.
[00293] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is ¨NHC(=0)R7, -C(=0)NHR7, ¨NHS(=0)2R7, -S(=0)2NHR7; ¨NHC(=0)NHR7, -NH S (=0)2NHR7, ¨(C1-C3alkyl)-NHC(=0)R7, ¨(CI-C3alkyl)-C(=0)NHR5, ¨(C1-C3alkyl)-NHS(=0)2R7, ¨(Ci-C3alkyl)-S(=0)2NHR7; ¨(Ci-C3alkyl)-NHC(=0)NHR7, or ¨(Ci-C3alkyl)-NHS(=0)2NHR7.
[00294] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is substituted or unsubstituted C2-Cl11heterocyc1oa1ky1, or substituted or unsubstituted heteroaryl.
[00295] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted C2-Cipheterocycloalkyl.
[00296] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted heteroaryl.
[00297] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NHR7, -S(=0)2NHR7,¨(Ci-C3alkyl)-C(=0)NHle, or ¨(Ci-C3alkyl)-S(=0)2NHR7.
[00298] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NHR7, or -S(=0)2NHR7 [00299] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R6 is ¨C(=0)NH127.
[00300] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, each R7 is independently selected from a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C2-C1oheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C iocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C,-Cipheterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2-(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl).
[00301] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R7 is independently selected from a substituted or unsubstituted CI-Ciocycloalkyl, a substituted or unsubstituted C2-C10heterocycloa1kyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, and ¨(CH2)p-CH(substituted or unsubstituted aryl)).
[00302] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R7 is selected from µ tt,4_1\1 410, , , ,..1\1 sit ',No..
I
, , N , ----N
<cc \
I
Me .. .. N
, -- , , , N , N N M e Me , , Me y 0 \
N / I
N
, H .
[00303] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, W3 is C(R8e)(1e);
R1 is H;
R2a, R2b are independently selected from H, and CI-C3alkyl;
INI,T.I.NX. 0 H
, H
R3 is - H
z , Rga, le, lee, le are independently selected from H and Ci-C3alkyl.
[00304] Any combination of the groups described above or below for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[00305] Any combination of the groups described above for the various variables is contemplated herein.
Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
[00306] Among the compounds of Formula D described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is a compound of structure:
s 1=1 / H o'er [00307] Also provided herein are pharmaceutical composition comprising a compound of Formula D or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, and a pharmaceutically acceptable carrier.
Formula E -Eight-six ring systems [00308] As used herein, Formula E includes compounds of Formula E-I, Formula E-II, Formula E-II-1, Formula E-II-2, Formula E-II-3, Formula E-III, Formula E-IV, Formula E-V-1, Formula E-V-2, Formula E-V-3, Formula E-VI-1, Formula E-VI-2, Formula E-VI-3, Formula E-VII-1, Formula E-VII-2, Formula E-VII-3, Formula E-VIII-1, Formula E-VIII-2, Formula E-VIII-3, Formula E-IX-1, Formula E-IX-2, Formula E-X-1, Formula E-X-2, Formula E-XI-1, Formula E-XI-2, Formula E-XII, Foimula E-XIII, Formula E-XIV, Formula E-XV-1, Formula E-XV-2, Formula E-XV-3, Formula E-XV-4, Formula E-XV1-1, Formula E-XVI-2, Formula E-XVII-1, Formula E-XVII-2, Formula E-XVIII, Formula E-XIX, Formula E-XX, and Formula E-XXI.
[00309] In one aspect, described herein is a compound of Formula E-I, or a pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, as described in the summary of the invention.
[00310] In another aspect, provided herein are compounds having the structure of Formula E-I, pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
y2_xi IA 3 7's X3 w2 R3 ________________________ ( Formula E-I
wherein, R' is H, Ci-C6alkyl, C3-C6cycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
when X' is selected from N-R", S, S(0) and S(0)2, then X2 is cR2c-x 2d, and X' is cR2aR2n;
or 1 R2cR2d A 3 when X i 2s 0, then X is selected from C and N-R, and X i 2a s CRR2b;
or:
when X1 is CH), then X2 is selected from 0, N-RA, S, S(0), and S(0)2, and X3 is CR2aR2b;
or:
X1 is CR2eR2f and X2 is CR2eR2d, and R2' and R2' together form a bond, and X3 is CR2aR2b;
or:
X1 and X2 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X3 is CR24R2b;
or:
X2 and X3 are independently selected from C and N, and are members of a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, a fused substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, a fused substituted or unsubstituted 5-10 membered aryl ring, or a fused substituted or unsubstituted 5-10 membered heteroaryl ring, and X1 is CR21121;
RA is H, C1-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
W1 is 0, S, N-RA, or C(R8a)(Rgb);
W2 is 0, S, N-RA, or C(R8')(R8(f);
W3 is 0, S, N-RA, or C(R8e)(R8f); provided that the ring comprising W1, W2 and W3 does not comprise two adjacent oxygen atoms or sulfur atoms;
R2a R2b, R2e, R2d ¨2e, x and R2f are independently selected from H, substituted or unsubstituted C1-C6alky1, substituted or unsubstituted C1-C6beteroalkyl, substituted or unsubstituted C3-Cocycloalkyl, substituted or unsubstituted C7-C4leterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨CI -C6alkyl-(substituted or unsubstituted heteroaryl) and ¨
RB is substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨
NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted CI-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted aryl), or -Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
m is 0, 1 or 2;
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NT(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or CI-C3fluoroalkyl;
R4 is -NHR5, -N(R5)2, -N(R5)3 or -0R5;
each R5 is independently selected from H, C1-C3a1kyl, C1-C3haloalkyl, C1-C3heteroalkyl and -C1-elalkyl-(C3-05cycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is -NHC(=0)R7, -C(=0)NHR7, -NHS(=0)2R7, -S(=0)2NHR7; -NHC(=0)NHR7, -NHS (=0)2NHR7, -(C1 -C3 alkyl)-NHC(=0)R7, -(C 1-C3 alkyl)-C(=0)NHR5, -(C1 -C
3 alkyl)-NHS(=0)2R7, -(Ci-C3alkyl)-S(=0)2NHR7; -(Ci-C3alkyl)-NHC(=0)NHR7, -(C1-C3alkyl)-NHS(=0)2NHR7, substituted or unsubstituted C2-Cioheterocycloalkyl, or substituted or unsubstituted heteroaryl;
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, C1-C6heteroalkyl, a substituted or unsubstituted C3-C1ocycloalkyl, a substituted or unsubstituted C oheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C1ocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)5-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0,1 or 2;
Rga, Rgb, R8c, X-8d, Rgeand Rgf are independently selected from H, Ci-C6alkyl, C1-C6fluoroalkyl, C--C6 alkoxy, Ci-C6heteroalkyl, and substituted or unsubstituted aryl;
or:
Rga, Rgd, Rgeand Rgf are as defined above, and Rgb and fee together form a bond;
or:
Rga, Rgb, led, and R8f are as defined above, and lee and Rge together form a bond;
or:
Rga, K¨ 8d, Rgeand R8f are as defined above, and Rgb and Rge together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
Rga, Rgb, led, and Rgf are as defined above, and Rs' and Rge together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
8d, R8ealld R8f are as defined above, and R82 and Rgb together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
Rs', Rgb, Rgeand Rgf are as defined above, and Rge and Rgd together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
Rga, Rgb, R8c, and led are as defined above, and lee and R8f together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S. 0 and N;
where each substituted alkyl, heteroalkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, C1-C4alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(C1-C4alkyl), -NH(Ci-C4alky1)2, -C(=0)0H, -C(=0)NH2, -C(=0)Ci-C3alkyl, -S(=0)2CH2, -NH(Ci-C4alkyl)-OH, -NH(C1-C4alkyl)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(C1-C4alkyl)-NH-(C1-C4alkyl), and -0(C1-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
[00311] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-II:
RI
X2¨ I
X \/W
X3 w2 Formula E-II
[00312] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-II-1, Formula E-II-2, or Formula E-II-3:
R81 R8e RI W
X2¨ XI Red \-21\1\/3 Rsc X3 w2 ___________________________ Rab R3 (Nj\¨R813 R3 _________________________ Y\R8a R8a ___________ U 0 U 0 Formula E-II-1 Formula E-II-2 D8f e A
X3 _________________________________________ R8c ____________________________ U 0 Formula E-11-3 [00313] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-III:
Rae X2¨ X'11 R8d X3 ___________ R8c Ns.\\ _______________________________________ R8b R3 R8a ____________________________ U 0 Formula E-III
[00314] Among the compounds of Formula Elf described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-IV:
X2¨ X1 R1 Red X3 ____________________________________________ R8c R3 (N
Formula E-TV
[00315] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, or -S(=0)2NH-.
[00316] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof, is one group of compounds wherein, -U- is -NHC(=0)-, or -C(=0)NH-.
[00317] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stereoisomer thereof, is one group of compounds wherein, R3 is Ci-Clalkyl.
[00318] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R4 is¨NHR% -N(R5)2, or -1\14(125)3; and each R5 is independently selected from H, C1-C3alkyl, arid -C1-C7a1kyl-(C3-05cycloalkyl).
[00319] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R3 N )2( R4 U)22. is R3 [00320] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R4/I\ N
is H
z [00321] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring.
[00322] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, (R9)0-2 N
is H ;and q is 1, 2 or 3.
[00323] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein le is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring.
[00324] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, ,\-/-14q is (R9)0-2 ;and (1 is 1, 2 or 3.
[00325] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, X1 is selected from N-RA, S, S(0) and S(0)2; and X2 is CH2.
[00326] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-V-1 or Formula E-V-2 or Formula E-V-3:
R2 R2c R 2d R2d R8f 8e R1 R1 R 8d R2b R2b R 2a _______________________ sW3 _____________________________________________________________ R8 c /NW
1 z N ..,,,,=\ R85 ...,.,...
) ___________________________ U 0 R6 ) __ U 0 Formula E-V-1 Formula E-V-2 R2c R2d R21 R8d R2a sR1 \ION.
______________________________________________ R8 N ____________________________________________ R85 R3 I µR8a ) __ U 0 Formula E-V-3 [00327] Among the compounds of Formula E-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-VI-1 or Formula E-VT-2 or Formula E-VI-3:
R 2d R2c 0 0 R2d "2C
0 0 R8f R8e R2 b ISIII\2N R1 R2b µSµ11 R1 R8d '.w2 R2a ______________ R8c I
/NW 1 zN,.õ..,.,\ Rap \\ R6 R8a ) ________________________ U 0 R6 ) __ U 0 Formula E-VI-1 Formula E-VI-2 R2d 00 R2c R2b 11/ R1 R8d \.,.Ø,i R2a _____________ Rsc ____________________________________________ R8b /N
R3 R8a ) __ U 0 Formula E-VI-3 [00328] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable saltõN-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-VII-1 or Formula E-VII-2 or Formula E-VII-3:
02c R2 c R ge R 2d RI R8f R2 b 0 R1 R2b 0 FXREsd R2a \.-'w3 w2 R 2a _____________ R8c I
/N
,. d __________________________ R8b -.-vv R3 R3 ____ ''N --y R6 -NR8a ) ____________ u 0 R6 ) __ U 0 Formula E-VII-1 Formula E-VII-2 R2c R2d R2b Rld R22 R8c z N R 8b R3 R6 R8a ) __ U 0 Formula E-VII-3 [003291Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-VIII-1 or Formula E-VIII-2 or Formula E-VIII-3:
R2c A R2c RA pp8f R2d R R2d / ' s R 8e R2b N/ Ri\A& w2 R2b N K/R8d R2a R2a _________________ R8 c I
, .,1 _________________________ R8b /N vv,...
R3 R3 ,NYNR8a ) ___________ U 0 R6 ) __ U 0 Formula E-VIII-3 Formula E-VIII-3 R2 c RA
R2d R2b N/ Rld \\......õ,=0 R2a R8 /N _________________________________________ R8b R3 R6 Rsa ) __ U 0 Formula E-VIII-3 [003301Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein X1 is CIF; and X2 is selected from 0, N-RA, S, S(0), and S(0)2.
[00331] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, raccmatc or stercoisomer thereof; is one group of compounds having the structure of Formula E-IX-1 or Formula E-IX-2:
R2d R2f R20 3 R2a R1 b R2bW2 w2 /N wi wi _________________ u 0 u 0 Formula E-IX-1 Formula E-IX-2 [00332] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-X-1 or Formula E-X-2:
A R2e R2f R2a R1A R1 R2b W3 w w2 2 Formula E-X-1 Formula E-X-2 wherein ring A is a fused substituted or unsubstituted saturated or partially saturated 3-10 membered cycloalkyl ring, substituted or unsubstituted saturated or partially saturated 3-10 membered heterocycloalkyl ring, substituted or unsubstituted 5-10 membered aryl ring, or substituted or unsubstituted 5-10 membered heteroaryl ring.
[00333] Within such a group of compounds are compounds wherein ring A is selected from indolyl and phenyl.
[00334] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-XI or Formula E-XI-2:
X2¨X1 R8d X2¨X1 X3 __________ Rsc X3 _______________________________ R8b /N R8b R3 \(N
Rsa R3 \ R8 a Formula E-XI-1 Formula E-XI-2 [00335] Among the compounds of Formula &I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-XIT:
x2¨x1 R1 _______________________________ U 0 Formula E-XII
[00336] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-XIII:
x3 N
Formula E-XIII
[00337] Within the group of compounds of Formula E-XI, Formula E-XII and Formula E-XIII are compounds wherein X1 is 0, S or S(0)2, and X2 is CH2.
[00338] Within the group of compounds of Formula E-XI, Formula E-XII and Formula E-XIII are compounds wherein X1 is N-RA, and X2 CH,.
[00339] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein Rs') and Rgc together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N.
[00340] Within such a group of compounds are compounds having the structure of Formula E-XIV:
y2¨x1 /¨
X3 (R9)0-3 /N
__________________________ U 0 Formula E- XIV
where ring B is an aryl or heteroaryl ring.
[00341] In some embodiments, ring B is an aryl. In some embodiments, ring B is phenyl. In some embodiments, ring B is a heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring or a bicyclic heteroaryl ring. In some embodiments, ring B is a monocyclic heteroaryl ring. In some embodiments, ring B is a bicyclic heteroaryl ring. In some embodiments, ring B
is selected from phenyl, pyridinyl and thiophenyl. In some embodiments, ring B is selected from pyridinyl and thiophenyl.
[00342] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R8d and R8b together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N; or R8e and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N.
[00343] Within this group are compounds having the structure of Formula E-XV-1, Formula E-XV-2, Formula E-XV-3, or Formula E-XV-4:
y2¨x1 R1 x2 ¨xl Ri )1-4 )2 /N /N
)1-4 Formula E-XV-1 Formula E-XV-2 X3 X3 ) y2_x1 R1 x2¨xl R1 /'s 1-3 2 )2 /N
________________ U 0 U 0 Formula E-XV-3 Formula E-XV-4;
or Formula E-XVI-1 or Formula E-XVI-2:
,RA
x2¨x1 R1 D1 IN
x2_xl )1-3 )2 N
R ____________________________________________ U
Formula E-XVI-1 Formula E-XVI-2 wherein RA is H, Ci-C3alkyl or ¨C(=0)Ci-C3alkyl.
[00344] Among the compounds of Formula E-1 described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein e and le together form a bond.
[00345] Among the compounds of Formula E-I described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein e and e together form a bond.
[00346] Within this group are compounds having the structure of Formula E-XVII-1 or Formula E-XVII-2:
R1 R8f X2¨X1 X2¨X1 7R8c \/R8d R3 R3 R8a _____________ U 0 U 0 Formula E-XV11-1 Formula E-XV11-2.
[00347] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-XV1H:
X2¨X1 R1 3 X3 w2 w1 R3 __________________________________ Ny u 0 R6 Formula E-XVIII
[00348] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-XIX:
x2-x1 R1 ______________________________ U 0 R6 Formula E-XIX
[00349] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure of Formula E-XX:
x2-x1 R1 ______________________________ U 0 R6 Formula E-XX
[00350] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds having the structure Formula E-XXI, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof:
R2b 1R1 X
R2a _____________________________________ NR
sb 0 <
HN
Formula E-XX1 wherein, w3 is 0, S, or C(R8e)(R8f);
R1 is H, or C1-C6alkyl;
X' is 0, N-RA, S, S(0), or S(0)2;
RA is H, C1-C6alkyl, ¨C(=0)C1-C6alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2a and R2b are independently selected from H, substituted or unsubstituted Ci-C6alkyl, and -C(0)RD;
RD is substituted or unsubstituted Ci-C6alkyl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or -NRDRE;
RD and RE are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), -C1-C6alkyl-(substituted or unsubstituted aryl), or -C1-C6alkyl-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or C1-C3fluoroalkyl;
each R5 is independently selected from H, Ci-C3alkyl, C1-C3haloalkyl, Ci-C3heteroalkyl and -CI-C3alkyl-(C3-05cycloalkyl);
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, Ci-C6heteroalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C10heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -CI-C6alkyl-(substituted or unsubstituted C3-Ciocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-C10heterocycloalkyl, -C1-C6alkyl-(substituted or unsubstituted aryl), -C1-C6alkyksubstituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2, -(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
Rga and Rgb are independently selected from H, C1-C6alkyl, and CI-C6fluoroalkyl;
R8e and Rare independently selected from H, Ci-C6alkyl, and Ci-C6fluoroalkyl;
where each substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-Caalkyl, Ci-C4 fluoroalkyl, C1-C4 alkoxy, CI-Ca fluoroalkoxy, -NH2, -NH(CI-Caalkyl), -NH(Ci-C4alky1)2, -C(=0)0H, -C(=0)NH2, -C(=0)C1-C3alkyl, -S(=0)2CH3, -NH(C1-C4alkyl)-OH, -NH(C1-C4alkyl)-0-(Ci-C4alkyl), -0(C1-C4alkyl)-NH2; -0(C -C4alkyl)-NH-(C -C4alkyl), and -0(C -C4alkyl)-N-(C1-C4alkyl)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
[00351] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R22, R2b R2c, R2d, R2e, and R2' are independently selected from H, Ci-C;alkyl and -C(=O)RE; and RE is substituted or unsubstituted C1-C6alky1, -C1-C6alkyl-(substituted or unsubstituted C5-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨Ci-C6alkyksubstituted or unsubstituted heteroaryl).
[00352] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R2', R2b R2e, R2d, R2e, and R2f are independently H or Ci-C3 alkyl.
[00353] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein 12' is H or methyl.
[00354] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein 121 is H.
[00355] Among the compounds of Formula E described above or below, or pharmaceutically acceptable saltõN-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is ¨NHC(=0)127, -C(=0)NH127, ¨NHS(=0)2127, -S(=0)2NHR7; ¨NHC(=0)NH127, -NH S (=0)2NHR7, ¨(C1-C3alkyl)-NHC(=0)127, ¨(C -C3alkyl)-C(=0)NHR5, ¨(C1-C
3alkyl)-NH S (=0)2127, ¨(C -C3alkyl)-S (=0)2NHR7; ¨(C i-C3alkyl)-NHC(=0)NH127, or ¨(Ci-C3alkyl)-NHS(=0)2NH127.
[00356] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is substituted or unsubstituted C2-C10heterocyc1oa1ky1, or substituted or unsubstituted heteroaryl.
[00357] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted C2-C1oheterocycloalkyl.
[00358] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is a substituted or unsubstituted heteroaryl.
[00359] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NHI27, -S(=0)2NH127,¨(CI-C3alkyl)-C(=0)NH125, or ¨(Ci-C3alkyl)-S(=0)2NH127.
[00360] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R6 is -C(=0)NH127, or -S(=0)3NHR7.
[003611Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein R6 is ¨C(=0)NHR7.
[00362] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, each R7 is independently selected from a substituted or unsubstituted Cl-Ciocycloalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -C1-C6alkyksubstituted or unsubstituted C3-C iocycloalkyl), -C i-C6alkyl-(substituted or unsubstituted C,-C
wheterocycloalkyl, -CI -C6alkyl-(substituted or unsubstituted aryl), -C1 -C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2),-CH(substituted or unsubstituted ary1)2-(CH2),-CH(substituted or unsubstituted heteroary1)2, -(CH2),-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl).
[00363] Among the compounds of Formula E described above or below, or pharmaceutically acceptable saltõ AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R7 is independently selected from a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C2-Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, and ¨(CH2)p-CH(substituted or unsubstituted aryl)).
[00364] Among the compounds of Formula E described above or below, or pharmaceutically acceptable salt, AT-oxide, racemate or stereoisomer thereof, is one group of compounds wherein, R7 is selected from N
:32z µ31t.
Me Csss 110 N , N Me NV, 'csss Me srisc , Me , and H .
[00365] Also provided herein are pharmaceutical compositions comprising a compound of Formula E, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, and a pharmaceutically acceptable carrier.
[00366] Also contemplated within the scope of embodiments described herein are dimeric compounds. In one aspect, provided herein are compounds of Formula F:
Formula F
wherein Z1 and Z2 are compounds selected from any one of Formula A, Formula B, Formula C, Formula D or Formula E described above or below; and L is a bridge between the compounds such that a compound of Formula F is a dimeric compound. In some embodiments, L is a bond (e.g., a bond between two aryl groups of Z1 and Z2. In some embodiments, L is a disulfide linkage.
In some embodiments, L is an ether, amide or ester linkage. In some embodiments, L is a cycle (e.g., a cyclopropyl ring, a pyrrolidine ring, a phenyl ring). In some embodiments, a compound of Formula F is selected from:
11111µ
Me H
Ss-S H 0 Me- Me Me Me 0 [00367] Also contemplated within the scope of embodiments described herein are trimeric compounds. In one aspect, provided herein are compounds of Formula G:
= Z3 Z-7 ss , Formula G
wherein Z1 and Z2 and Z3 are compounds selected from any one of Formula A, Formula B, Formula C, Formula D or Formula E described above or below; and 1.õ1 and L2 are a bridges between the compounds such that a compound of Formula G is a trimeric compound. In some embodiments, L1 and L2 are independently selected from a bond (e.g., a bond between two aryl groups of Z1 and Z2 or Z3), a disulfide linkage, an ether, amide or ester linkage and the like.
[00368] Any combination of the groups described above or below for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.
Methods [00369] Provided herein are methods of treating a hyperproliferative disorder in an individual in need thereof comprising administration of a therapeutically effective amount of a compound of any one Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G, to the individual in need thereof.
[00370] In some of such embodiments, the hyperproliferative disorder is cancer or an autoimmune disease.
[00371] In some of such embodiments, the autoimmune disease is hemolytic anemia, autoimmune hepatitis, Berger's disease or IgA nephropathy, celiac sprue, chronic fatigue syndrome, Crohn's disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, or vitiligo.
[00372] Also provided herein are methods of treating cancer in an individual in need thereof comprising administration of a therapeutically effective amount of a compound of any one of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G,to the individual in need thereof.
[00373] In some embodiments, the cancer is an epithelial cancer, a carcinoma, a neoplasm, a sarcoma, a chondrosarcoma, a blastoma, a cancer of the central nervous system, or a haematological cancer. In some embodiments, the cancer is an epithelial cancer or a carcinoma. In sonic embodiments, the cancer is a neoplasm or a sarcoma or a chondrosarcoma or a blastoma or a cancer of the central nervous system. In some embodiments, the cancer is a haematological cancer.
[00374] Also provided herein are methods of treating a disease associated with angiogenesis in an individual in need thereof comprising administration of a therapeutically effective amount of a compound of any one of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F
or Formula G, to the individual in need thereof.
[00375] In some embodiments the disease associated with angiogenesis is macular degeneration, rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, sclerodeinia or hypertrophic scarring.
[00376] Also provided herein are methods of inhibiting the activity of inhibitor of apoptosis (IAP) proteins in an individual in need thereof comprising administration of a therapeutically effective amount of a compound of any one of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G, to the individual in need thereof [003771In some embodiments, the TAP protein is XIAP, cIAP-1, clAP-2, ML-IAP, survivin, NAIP, apollon, or ILP2.
1003781 Also provided herein are methods of inducing apoptosis in a cell comprising contacting the cell with a therapeutically effective amount of a compound of any one of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G. In some of such embodiments the compound of any one of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G, binds a XIAP BIR3 domain, thus antagonizing the action of IAPs.
Synthesis of Compounds [00379] In some embodiments, the synthesis of compounds described herein are accomplished using means described in the chemical literature, using the methods described herein, or by a combination thereof. In addition, solvents, temperatures and other reaction conditions presented herein may vary.
[00380] In other embodiments, the starting materials and reagents used for the synthesis of the compounds described herein are synthesized or are obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, FischerScientific (Fischer Chemicals), and AcrosOrganics.
1003811 In further embodiments, the compounds described herein, and other related compounds having different substituents are synthesized using techniques and materials described herein as well as those that are recognized in the field, such as described, for example, in Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4th Ed., (Wiley 1992); Carey and Sundberg, Advanced Organic Chemistry 4th Ed., Vols. A
and B (Plenum 2000, 2001), and Green and Wuts, Protective Groups in Organic Synthesis jrd Ed., (Wiley 1999). General methods for the preparation of compounds as disclosed herein may be derived from reactions and the reactions may be modified by the use of appropriate reagents and conditions, for the introduction of the various moieties found in the formulae as provided herein. As a guide the following synthetic methods may be utilized.
Formation of Covalent Linkages by Reaction of an Electrophile with a Nucleophile [00382] The compounds described herein can be modified using various electrophiles and/or nucleophiles to form new functional groups or substituents. Table IA entitled "Examples of Covalent Linkages and Precursors Thereof' lists selected non-limiting examples of covalent linkages and precursor functional groups which yield the covalent linkages. Table IA may be used as guidance toward the variety of electrophiles and nucleophiles combinations available that provide covalent linkages. Precursor functional groups are shown as electrophilic groups and nucleophilic groups.
Table 1: Examples of Covalent Linkages and Precursors Thereof Covalent Linkage Product Electrophile Nucleophile Carboxamides Activated esters amines/anilines Carboxamides acyl azides amines/anilines Carboxamides acyl halides amines/anilines Esters acyl halides alcohols/phenols Esters acyl nitrites alcohols/phenols Carboxamides acyl nitrites amines/anilines Imines Aldehydes amines/anilines Alkyl amines alkyl halides amines/anilines Esters alkyl halides carboxylic acids Thioethers alkyl halides Thiols Ethers alkyl halides alcohols/phenols Thioethers alkyl sulfonates Thiols Esters Anhydrides alcohols/phenols Carboxamides Anhydrides amines/anilines Thiophenols aryl halides Thiols Aryl amines aryl halides Amines Thioethers Azindines Thiols Carboxamides carboxylic acids amines/anilines Esters carboxylic acids Alcohols hydrazines Hydrazides carboxylic acids N-acylureas or Anhydrides carbodiimides carboxylic acids Esters diazoalkancs carboxylic acids Thioethers Epoxides Thiols Thioethers haloacetamides Thiols Ureas Isocyanates amines/anilines Urethanes 1socyanates alcohols/phenols Thioureas isothiocyanates amines/anilines Thioethers Maleimides Thiols Alkyl amines sulfonate esters amines/anilines hioethers sulfonate esters Thiols Sulfonamides sulfonyl halides amines/anilines Sul fonate esters sulfonyl halides phenols/alcohols Use of Protecting Groups [00383] In the reactions described, it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, in order to avoid their unwanted participation in reactions. Protecting groups are used to block some or all of the reactive moieties and prevent such groups from participating in chemical reactions until the protective group is removed. It is preferred that each protective group be removable by a different means. Protective groups that are cleaved under totally disparate reaction conditions fulfill the requirement of differential removal.
[00384] Protective groups can be removed by acid, base, reducing conditions (such as, for example, hydrogenolysis), and/or oxidative conditions. Groups such as trityl, dimethoxytrityl, acetal and t-butyldimethylsily1 are acid labile and may be used to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected with Cbz groups, which are removable by hydrogenolysis, and Fmoc groups, which are base labile. Carboxylic acid and hydroxy reactive moieties may be blocked with base labile groups such as, but not limited to, methyl, ethyl, and acetyl in the presence of amines blocked with acid labile groups such as t-butyl carbamate or with carbamates that are both acid and base stable but hydrolytically removable.
1003851 Carboxylic acid and hydroxy reactive moieties may also be blocked with hydrolytically removable protective groups such as the benzyl group, while amine groups capable of hydrogen bonding with acids may be blocked with base labile groups such as Fmoc. Carboxylic acid reactive moieties may be protected by conversion to simple ester compounds as exemplified herein, which include conversion to alkyl esters, or they may be blocked with oxidatively-removable protective groups such as 2,4-dimethoxybenzyl, while co-existing amino groups may be blocked with fluoride labile silyl carbamates.
1003861 Allyl blocking groups are useful in then presence of acid- and base-protecting groups since the former are stable and can be subsequently removed by metal or pi-acid catalysts. For example, an allyl-blocked carboxylic acid can be deprotected with a Pd -catalyzed reaction in the presence of acid labile t-butyl carbamate or base-labile acetate amine protecting groups. Yet another form of protecting group is a resin to which a compound or intermediate may be attached. As long as the residue is attached to the resin, that functional group is blocked and cannot react. Once released from the resin, the functional group is available to react.
1003871 Typically blocking/protecting groups may be selected from:
1-13,=-\ H3C5 / SSIC
(C6H5)3C--/
Me Et allyl 1-11C0 Bn PMB trityl t-butyl B) c/ 0 \
(CH3)3C--'hr\ HiC0 jLss5S 0)LsSSS H,C CH, 0 (H3C)3C..,S1,, Cbz Hoc acetyl alloc TBDMS
Fmoc 1003881 Other protecting groups, plus a detailed description of techniques applicable to the creation of protecting groups and their removal are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994.
Synthesis of compounds of Formula A
1003891 In some embodiments, a compound of Formula A-I is synthesized as shown below in Scheme 1 and in the Chemistry Examples section:
Scheme 1 Me0 ) \ HO Me MO e yoc o 1,11,\EI:i----yoc OH o flr Me0 o_/ ___________________________________ ,..
,Nljt, N
,N.,)L. OH ¨ ¨ [tW, 80 C - N
R5 - N n R5 -=4 H /R7 1-2 20 mi 1-1 30% 1 TFA
R7 (2 steps) 25 C
/
+
_ ///N
H
C 0 :
1-4 0 I'D
H
rAV'YN R7 = H /
Formula A-I
[00390] Starting with a compound of Formula 1-1, a four component Ugi reaction provides a compound of Formula 1-2, which is then cyclized and deprotected to provide a compound of Formula A-I.
[00391] In a further embodiment, compounds of Formula A-I are synthesized starting with compound 1-6 as shown in Scheme 2 below:
Scheme 2 yoc OR284,1/4_,OH Me0 412a Me0 Me H
Rza 0 :
meo)D CF3CH2OH yoc 0 TEA
_,.. H 0 25 C me' NYLNifyi Me . N Tr õIN.,-A, I-13_ 0¨
E/le H 0 11W, 80 C Me _- N
R7 ,R7 1-2 20 min fVle H 0 H 0 1-6 \ , N
- + 0 - ,.., H
CI\I¨R7 NH3 1-7 Formula A-I
[00392] Table 1-1 shows data for certain compounds of Formula A-I.
Table 1-1 Yield XIAP BIR1/2 XIAP BIR3 Product R28 R2 (2 steps) K1(0) K1 (LM) 7a H 11 . 30% C B
7b H -1 IF CI 69% C B
H
7c ,,,, 67% C A
Me 79%. C A
7d õ 0 Me 63% C B
7e All IC% .
Me 46% C B
7f KEY: A = <25 micromolar; B > 25 and < 50 micromolar; C >50 micromolar [00393] Other compounds that are useful for the Ugi reaction shown above or below include and are not limited to:
OH 2- c-e.,,,OH Hi Boc OM ) 0 CI N+ N+
1 , me.NJI,N,OH
e-NIT,,OH 6s-ri .-.- H II BocHN
me 0 SCPh3 + IP ) Me0 . Me0 BocHN
r,OH Me0 MeCb<Me -+N
0¨ 0¨ Me -C- OMe LJ
0 OMe OH
HO OH
BocHN( OH OH
OHBocHN
BocHN 0 0 BocHN OH
0 0 .
Synthesis of compounds of Formula B
[00394] In some embodiments, a compound of Formula B-I is synthesized as shown below in Scheme 3:
Scheme 3 X
) e0 X
(,kile0 Me y I:I
M
BocHNOH ) __________________ _) CF3CH2OH
H TFA
Me0 JAW, 80 C BocHNIIir N ,, NR7 25 C H2N N /R7 20 min ¨ H
NH3 CEN ¨R7 2-2 0 H
1-3 1-4 Boc-N-Me-Ala-OH
HOBT, EDC, NMM
THF, 23 C
Y 1:1 Y LI H
%.....7 . TEA Nc, .--?
Boc, R7 Boo, N--)LN IR7 -,...
Me' i\-õe 0 H Me i Me 0 H w Me 0 ---H
Formula B-I
[00395] Starting with a compound of Formula 2-1, a four component Ugi reaction provides a compound of Formula 2-2. X is a protected thiol, or protected hydroxyl, or N-RA as described herein. The compound of Formula 2-2 is cyclized and a reaction with a protected alaninc provides a compound of Formula B-I as a mixture of diastereomers. The mixture of diastereomers is separated by silica gel chromatography to provide a compound of Formula B-I having the structure 2-4.
Where Y is S, the sulfur atom is optionally oxidized.
[00396] Table 2-1 and below and Figure 1 show certain data for compounds of Formula B:
Table 2-1 Yield XIAP BIR1/2 XIAP BIR3 ML-IAP
Product Y R1 (4 steps) K1 ( M) Ki ( M) Ki (uM) 16a 0 õle 44% C A A
s¶:?Z 110 16b 0 36% A A -X
47% C A A
16c S
=":;. IP
ND C A A
16d 0 41% C B -16e 0 N 0 \
KEY: A = < 25 micromolar; B > 25 and <50 micromolar; C >50 micromolar [0039711n an alternative embodiment, compounds of Formula B-XV are synthesized according to Scheme 4 shown below.
Scheme 4 X
) Me() ---, , H ---,, Y
BocHNoe.r0H ) Me0 B) Steps of Scheme 2 B ') N
NH3 CI\I¨R7 Me/
Me 0 H
Formula B-XV
[00398] Starting with a compound of Formula 2-1, a four component Ugi reaction comprising a compound of Formula 3-1 followed by cylization and a reaction with a protected alaninc as shown in Scheme 3 provides a compound of Formula B-XV. Table 2-2 below shows certain data for compounds of Formula B-XV:
Table 2-2 Yield XIAP BIR1/2 XIAP BIR3 ML-IAP
Product Structure (4 steps) Ki (.iM) Ki (pM) Ki (pM) H
0 c , 17a 43% C A A
N
Me e M
17b 49% A A A
1\1 -- H 0 N
Me/
Me H
c.._.S 1.....__1,414 60% A A A
0 N..
17c MeeH 0 M
KEY: A = <25 micromolar; B > 25 and < 50 micromolar; C >50 micromolar [003991 It will be understood that the reactions shown in Schemes 1-4 above are illustrative and arc also applicable to synthesis of compounds of Formula C, Formula D and Formula E, and such disclosure is contemplated within the scope of embodiments described herein. Synthesis of compounds of Formula C, Formula D and Formula E is shown in further detail in the Chemistry Examples section.
Administration and Pharmaceutical Composition [00400] In general, the compounds of this invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities.
Therapeutically effective amounts of compounds of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G may range from about 0.01 to about 500 mg per kg patient body weight per day, which can be administered in single or multiple doses.
Preferably, the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably about 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to about 250 mg/kg per day, about 0.05 to about 100 mg/kg per day, or about 0.1 to about 50 mg/kg per day. Within this range the dosage can be about 0.05 to about 0.5, about 0.5 to about 5 or about 5 to about 50 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing about 1.0 to about 1000 milligrams of the active ingredient, particularly about 1.0, 5.0, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient. The actual amount of the compound of this invention, i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the potency of the compound being utilized, the route and form of administration, and other factors.
[00401] In general, compounds of this invention will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., intranasal, suppository, intrapulmonaary), or parenteral (e.g., intramuscular, intravenous, intrathecal, or intraperitoneal) administration. The preferred manner of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.
[00402] The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules are preferred) and the bioavailability of the drug substance. Recently, pharmaceutical formulations have been developed especially for drugs that show poor bioavailability based upon the principle that bioavailability can be increased by increasing the surface area i.e., decreasing particle size. For example, U.S. Pat. No.
4,107,288 describes a pharmaceutical formulation having particles in the size range from 10 to 1,000 um in which the active material is supported on a crosslinked matrix of macromolecules. U.S. Pat. No.
5,145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 nm) in the presence of a surface modifier and then dispersed in a liquid medium to give a pharmaceutical formulation that exhibits remarkably high bioavailability.
[00403] The compositions are comprised of in general, a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G. Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
[00404] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.
Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.
[00405] Compressed gases may be used to disperse a compound of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, etc.
[00406] Other suitable pharmaceutical excipients and their formulations are described in Remington's Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 20th ed., 2000).
[00407] The level of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F
or Formula G based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 1-80 wt %.
[00408] The compounds of the present invention may be used in combination with one or more other drugs in the treatment of diseases or conditions for which compounds of the present invention or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone. Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound of the present invention is preferred. However, the combination therapy may also include therapies in which the compound of the present invention and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of the present invention and the other active ingredients may be used in lower doses than when each is used singly.
[00409] Accordingly, the pharmaceutical compositions of the present invention also include those that contain one or more other active ingredients, in addition to a compound of the present invention.
[00410] The above combinations include combinations of a compound of the present invention not only with one other active compound, but also with two or more other active compounds. Likewise, compounds of the present invention may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which compounds of the present invention are useful. Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the present invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred. Accordingly, the pharmaceutical compositions of the present invention also include those that also contain one or more other active ingredients, in addition to a compound of the present invention. The weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
[00411] In the case wherein the patient's status does improve, upon the doctor's discretion the administration of a compound described herein is optionally given continuously; alternatively, the dose of drug being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a "drug holiday"). The length of the drug holiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. The dose reduction during a drug holiday includes from 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
[00412] Once improvement of the patient's conditions has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, is reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In some embodiments, patients require intermittent treatment on a long-term basis upon any recurrence of symptoms.
Combination therapy [00413] In some cases, a compound described herein is administered in combination with a second anti-cancer agent. Examples of anti-cancer agents for use in combination with a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G include inhibitors of mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; mTOR
inhibitors; and antibodies (e.g., rituxan).
[00414] Other anti-cancer agents that can be employed in combination with a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Fornmla G include Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin;
acodazole hydrochloride;
acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide;
amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine;
azetepa; azotomycin; batimastat;
benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate;
bizelesin; bleomycin sulfate;
brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone;
caracemide; carbetimer; carboplatin;
carmustinc; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil;
cirolcmycin; cladribinc;
crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine;
dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin;
doxorubicin hydrochloride;
droloxifene; droloxifene citrate; dromostanolonc propionate; duazomycin;
edatrexate; cflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole;
esorubicin hydrochloride; estramustine; estramustine phosphate sodium;
etanidazole; etoposide; etoposide phosphate; ctoprinc; fadrozolc hydrochloride; fazarabinc; fenrctinidc;
floxtuidinc; fludarabinc phosphate;
fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine;
gemcitabine hydrochloride;
hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleulin II
(including recombinant interleukin 11, or r1L2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl; interferon alfa-n3;
interferon beta-1a; interferon gamma-1 b; iproplatin; irinotecan hydrochloride; lanreotide acetate;
letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium;
lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride;
megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metopiine;
meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin;
mitomycin; mitosper;
mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole;
nogalamycin; ormaplatin;
oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate;
perfosfamide; pipobroman;
piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin;
prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride;
pyrazofurin; riboprine;
rogletimide; safingol; safingol hydrochloride; semustine; simtrazene;
sparfosate sodium; sparsomycin;
spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin;
streptozocin; sulofenur;
talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride;
temoporfin; teniposide; teroxirone;
testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine;
toremifene citrate; trestolone acetate; triciribinc phosphate; trimetrexatc; trimetrexate glucuronate;
triptorclin; tubulozolc hydrochloride;
uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate;
vincristine sulfate; vindesine;
vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate;
vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin;
zorubicin hydrochloride.
[00415] Other anti-cancer agents that can be employed in combination with a compound of Formula A, Fonnula B, Formula C, Formula D, Formula E, Formula F or Formula G include: 20-epi-1, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene;
adecypenol; adozelesin;
aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine;
aminolevulinic acid;
amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D;
antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1;
antiandrogen, pro static carcinoma;
antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine;
atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3;
azasetron; azatoxin; azatyrosine;
baccatin III derivatives; balanol; batimastat; BCRIABL antagonists;
benzochlorins; benzoylstaurosporine;
beta lactam derivatives; beta-alethinc; betaclamycin B; bctulinic acid; bFGF
inhibitor; bicalutamidc;
bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin;
breflate; bropirimine; budotitane;
buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives;
canarypox IL-2;
capecitabinc; carboxamide-amino-triazolc; carboxyamidotriazolc; CaRest M3;
CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS);
castanospermine; cecropin B; cetrorelix;
chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine;
clomifene analogues;
clotrimazole; collismycin A; collismycin B; combrctastatin A4; combretastatin analogue; conagenin;
crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives;
curacin A;
cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate;
cytolytic factor; cytostatin;
dacliximab; decitabinc; dchydrodidemnin B; deslorclin; dexamethasone;
dexifosfamidc; dcxrazoxanc;
dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin;
diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene;
dronabinol; duocarmycin SA;
ebselen; ecomustine; edelfosine; edrecolomab; eflomithine; elemene; emitefur;
epirubicin; epristeride;
estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole;
etoposide phosphate;
exemestane; fadrozole; fazarabine; fenretinide; filgrastim; fmasteride;
flavopiridol; flezelastine;
fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex;
formestane; fostriecin;
fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix;
gelatinase inhibitors;
gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin;
ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat;
imidazoacridones; imiquimod;
immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor;
interferon agonists; interferons;
interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact;
irsogladine; isobengazole;
isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N
triacetate; lanreotide;
leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorclin; levamisole;
liarozole; linear polyaminc analogue; lipophilic disaccharide peptide; lipophilic platinum compounds;
lissoclinamide 7; lobaplatin;
lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine;
lurtotecan; lutetium texaphyrin;
lysofylline; lytic peptides; maitansine; mannostatin A; marimastat;
masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone;
meterelin; methioninase;
metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim;
mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol;
multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B;
mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin;
nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim;
nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators;
nitroxide antioxidant;
nitrullyn; 06-benzylguanine; octreotide; okicenone; oligonucleotides;
onapristone; ondansetron;
ondansctron; oracin; oral cytokinc inducer; ormaplatin; osaterone;
oxaliplatin; oxaunomycin; palauaminc;
palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin;
pazelliptine; pegaspargase;
peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron;
perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatasc inhibitors; picibanil;
pilocarpine hydrochloride;
pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex;
platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin;
prednisone; propyl bis-acridonc; prostaglandin J2; protcasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine;
pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists; raltitrexcd; ramosctron; ras farnesyl protein transferasc inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated;
rhenium Re 186 etidronate;
rhizoxin; ribozymes; R11 retinamide; rogletimide; rohitukine; romurtide;
roquinimex; rubiginone Bl;
ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine;
senescence derived 1; sense oligonucleotides; signal transduction inhibitors;
signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane;
sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D;
spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor;
stem-cell division inhibitors;
stipiamide; stromelysin inhibitors; sulfinosine; sup eractive vasoactive intestinal peptide antagonist;
suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine;
tamoxifen methiodide;
tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium;
telomerase inhibitors; temoporfin;
temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine;
thiocoraline; thrombopoietin;
thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist;
thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride;
topsentin; toremifene; totipotent stem cell factor; translation inhibitors; trctinoin; triacctyluridinc;
triciribine; trimarexate; triptorclin;
tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC
inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists;
vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin;
vinorelbine; vinxaltine;
vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.
[00416] Yet other anticancer agents that can be employed in combination with a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G include alkylating agents, antimetabolites, natural products, or hormones, e.g., nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, etc.), or triazenes (decarbazine, etc.). Examples of antimetabolites include but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
[00417] Examples of natural products useful in combination with a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G include but are not limited to vinca alkaloids (e.g., vinblastin, vincristinc), cpipodophyllotoxins (e.g., ctoposidc), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon alpha).
[00418] Examples of alkylating agents that can be employed in combination a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G include, but are not limited to, nitrogen mustards (e.g., mcchloroethamine, cyclophosphamidc, chlorambucil, mclphalan, etc.), ethylenimine and methylmelamines (e.g., hexamethlymelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomusitne, semustine, streptozocin, etc.), or triazenes (dccarbazinc, etc.). Examples of antimctabolitcs include, but are not limited to folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxuridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin.
[00419] Examples of hormones and antagonists useful in combination a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G include, but are not limited to, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), gonadotropin releasing hormone analog (e.g., leuprolide). Other agents that can be used in the methods and compositions described herein for the treatment or prevention of cancer include platinum coordination complexes (e.g., cisplatin, carboblatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide).
[00420] Examples of anti-cancer agents which act by arresting cells in the G2-M phases due to stabilized microtubules and which can be used in combination with an irreversible EGFR
tyrosine kinasc inhibitor compound include without limitation the following marketed drugs and drugs in development: Erbulozole (also known as R-55104), Dolastatin 10 (also known as DLS-10 and NSC-376128), Mivobulin isethionate (also known as C1-980), Vincristine, N SC-639829, Discodermolide (also known as NVP-XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtins (such as Altorhyrtin A
and Altorhyrtin C), Spongistatins (such as Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (also known as LU-103793 and NSC-D-669356), Epothilones (such as Epothilone A, Epothilone B, Epothilone C (also known as desoxyepothilone A or dEpoA), Epothilone D (also referred to as KOS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B (also known as BMS-310705), 21-hydroxyepothilone D (also known as Desoxyepothilone F and dEpoF), 26-fluoroepothilone), Auristatin PE (also known as NSC-654663), Soblidotin (also known as TZT-1027), LS-4559-P (Pharmacia, also known as LS-4577), LS-4578 (Pharmacia, also known as LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), (Aventis), Vincristinc sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, also known as WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, also known as ILX-651 and LU-223651), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko), 1DN -5005 (lndena), Cryptophycin 52 (also known as LY-355703), AC-7739 (Ajinomoto, also known as AVE-8063A and CS-39.HC1), AC-7700 (Ajinomoto, also known as AVE-8062, AVE-8062A, CS-39-L-Ser.HC1, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (also known as NSC-106969), T-138067 (Tularik, also known as T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, also known as DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin Al (also known as BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijian tide B.
Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, also known as SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, also known as MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU
(CytoskeletonlMt. Sinai School of Medicine, also known as MF-191), TMPN
(Arizona State University), Vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, Inanocine (also known as NSC-698666), 3-1AABE (Cytoskeleton/Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, also known as T-900607), RPR-115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, Isoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (also known as NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, also known as D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (also known as SPA-110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi).
[00421] In some cases, a compound described herein (e.g., a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G) is administered in combination with INF-alpha and/or INF-related apoptosis-inducing ligand (TRAIL). TRAIL shows homology to other members of the TNF-alpha family of proteins. In some cases, a compound described herein (e.g., a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G) is administered in combination with a INF-alpha modulator and/or a INF-alpha analogue (e.g., lenalidomide, revlimid, CC-5013; CC-4047, ACTIMID. Tthalidomide and the like). In some cases, a compound described herein (e.g., a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F or Formula G) is administered in combination with an adjuvant, hormone therapy, immunotherapy or any combination thereof.
Methods of Use [00422] Disclosed herein, in certain embodiments, are methods of inhibiting the activity of an inhibitor of apoptosis (IAP) protein in an individual in need thereof comprising administering a therapeutically effective amount of a compound disclosed herein to the individual. In some embodiments, the TAP protein is XIAP, cIAP-1, cIAP-2, ML-IAP, survivin, NAIP, apollon, ILP2, or any combinations thereof.
[00423] In some embodiments, inhibiting the activity of an TAP protein induces apoptosis in a plurality of cells. In some embodiments, the cells are cancerous cells. In some embodiments, the cancer is a sarcoma, carcinoma, blastoma, myeloma, leukemia, lymphoma, or combinations thereof In some embodiments, the cancer is a skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, uterine cancer, pancreatic cancer, liver cancer, or any combinations thereof In some embodiments, the cancer is acute myelogenous leukemia (AML). In some embodiments, the cancer is renal cell carcinoma.
In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer.
In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is gastric carcinoma. In some embodiments, the cancer is esophageal squamous cell carcinoma. In some embodiments, the cancer is a lung cancer. In some embodiments, the lung cancer is non-small cell lung carcinoma or small cell lung cancer. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is breast cancer.
[00424] In some embodiments, inhibiting the activity of an IAP protein treats a hyperproliferative disorder. In some embodiments, the hyperproliferative disorder is a cancer or an autoimmune disease. In some embodiments, the autoimmune disease is hemolytic anemia, autoimmune hepatitis, Berger's disease or IgA nephropathy, celiac sprue, chronic fatigue syndrome, Crohn's disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, or vitiligo. In some embodiments, the cancer is a sarcoma, carcinoma, blastoma, myeloma, leukemia, lymphoma, or combinations thereof In some embodiments, the cancer is a skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, uterine cancer, pancreatic cancer, liver cancer, or any combinations thereof. In some embodiments, the cancer is acute myelogenous leukemia (AML). In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is gastric carcinoma. In some embodiments, the cancer is esophageal squamous cell carcinoma. In some embodiments, the cancer is a lung cancer. In some embodiments, the lung cancer is non-small cell lung carcinoma or small cell lung cancer. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is breast cancer.
[00425] Disclosed herein, in certain embodiments, are methods of treating a cancer in an individual in need thereof comprising administering a therapeutically effective amount of a compound disclosed herein to the individual. In some embodiments, the cancer is a sarcoma, carcinoma, blastoma, myeloma, leukemia, lymphoma, or combinations thereof In some embodiments, the cancer is a skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, uterine cancer, pancreatic cancer, liver cancer, or any combinations thereof. In some embodiments, the cancer is acute myelogenous leukemia (AML). In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer.
In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is gastric carcinoma. In some embodiments, the cancer is esophageal squamous cell carcinoma.
In some embodiments, the cancer is a lung cancer. In some embodiments, the lung cancer is non-small cell lung carcinoma or small cell lung cancer. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is breast cancer.
[00426] Disclosed herein, in certain embodiments, are methods of treating a disease associated with unwanted angiogenesis in an individual in need thereof comprising administering a therapeutically effective amount of a compound disclosed herein to the individual. In some embodiments, the disease associated with unwanted angiogenesis is macular degeneration, rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, scleroderma or hypertrophic scarring. In some embodiments, the disease associated with unwanted angiogenesis is a cancer. In some embodiments, the cancer is a sarcoma, carcinoma, blastoma, myeloma, leukemia, lymphoma, or combinations thereof. In some embodiments, the cancer is a skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, uterine cancer, pancreatic cancer, liver cancer, or any combinations thereof In some embodiments, the cancer is acute myelogenous leukemia (AML). In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is prostate cancer.
In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is glioblastoma. In some embodiments, the cancer is gastric carcinoma. In some embodiments, the cancer is esophageal squamous cell carcinoma.
In some embodiments, the cancer is a lung cancer. In some embodiments, the lung cancer is non-small cell lung carcinoma or small cell lung cancer. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is breast cancer.
CHEMISTRY EXAMPLES
[00427] The following examples are intended to illustrate but not limit the disclosed embodiments. All solvents were used as purchased from commercial sources or dried over 4A
molecular sieves prior to use in the case of moisture sensitive reactions. Reactions conducted under microwave irradiation were performed in a CEM Discover microwave reactor using either CEM 10 inL reaction vessels or a ChemGlass heavy wall pressure vessel (100 mL, 38 mm x 190 mm). Reaction progress was monitored by reverse-phase HPLC and/or thin-layer chromatography (TLC). High resolution mass spectrometry was performed using ESI-TOFMS, ELMS (reference: perfluorokerosene) and APCI-MS.
TLC was performed using silica gel 60 F254 pre-coated plates (0.25 mm). Flash chromatography was performed using silica gel (32-63 lam particle size) or aluminum oxide (activated, basic, ¨150 mesh size). All products were purified to homogeneity by TLC analysis (single spot, unless stated otherwise), using a UV lamp and/or iodine and/or CAM or basic KMnat for detection purposes. NMR spectra were recorded on 400 MHz and 500 MHz spectrometers at ambient temperature. 1H and 13C NMR chemical shifts are reported as 6 using residual solvent as an internal standard; CDCI3: 7.26, 77.16 ppm; CD3OD: 3.31, 49.00 ppm; DMSO-d6: 2.50, 39.52 ppm, CD3CN: 1.94 (1H), 1.32 (13C) ppm. Abbreviations used: alanine (Ala), 1-hydroxybenzotriazole (HOBT), N-methylmorpholine (NMM), N-(3-dimethylaminopropy1)-N'-ethylcarbodiimide (EDC), palladium on carbon (Pd-C), dichloromethane (DCM), diethyl ether (Et20), ethyl acetate (Et0Ac), 2,2,2-trifluoroethanol (TFE), methanol (Me0H), homoserine (HSer), tetrahydrofuran (THF), trifluoroacetic acid (TFA), diisobutylaluminum hydride (DIBAL).
1004281 Example 1: Preparation of (S)-benzyl 3-(benzyloxy)-2-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)propanoate.
OBn Boc,Me-Ala, NMM OBn HOBT, EDC .. Boc 0 _7c =
H2N Xy0Bn __________________________________ Nj-L OBn THE, 23 C Me' N
= H
o Me 0 95%
1004291 To a solution of the serine derivative (1.74 g, 3.80 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (773 mg, 3.80 mmol, 1.0 equiv), HOBT=xH20 (641 mg, 4.18 mmol, 1.1 equiv) and NMM (1.25 mL, 11.4 mmol, 3 equiv) in THF (45 mL) at 0 C was added EDC=HC1 (766 mg, 3.99 mmol, 1.05 equiv). After 30 min the cold bath was removed. The solution stirred for 14 h and then was quenched with saturated aqueous NaHCO3 (50 mL), extracted with ethyl acetate (2 x 40 mL), dried over sodium sulfate and then concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (5:1->4:1-43:1 hexanes/Et0Ac) to yield the product (1.70 g, 95%). itf= 0.20 (5:1 hexanes/Et0Ac). NMR (400 MHz, CDCI3) 6: 7.34-7.27 (m, 8H), 7.19 (dd, 2H, J= 2.0, 8.0 Hz), 5.18 (q, 2H, J= 12.0 Hz), 4.79-4.74 (m, 1H), 4.45 (q, 2H, J= 12.0 Hz), 3.89 (dd, 1H, J= 3.2, 9.6 Hz), 3.66 (dd, 1H, J= 3.2, 9.6 Hz), 2.75 (s, 3H), 1.45 (s, 9H), 1.34 (t, 3H, J= 7.2 Hz);
13C NMR (100 MHz, CDC13) 6: 171.6, 170.0, 137.5, 135.4, 128.7, 128.5, 128.5, 128.3, 127.9, 127.7, 73.4, 69.8, 67.4, 52.9, 30.0, 28.4, 13.9; HRMS calcd for C26H34N206Na: 493.23091, found 493.23211.
[00430] Example 2: Preparation of (S)-2-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)-3-hydroxypropanoic acid.
OBn OH
Boc o Pd-C, H2 Boc 0 )1'sN Me0H, 23 C N OH
o H
Me H 0 57%
1004311 To a solution of benzyl ester (1.70 g, 3.61 mmol, 1.0 equiv) in methanol (25 mL) was added 10 wt%
Pd-C (100 mg). A balloon of H2 was applied for 16 h, then the mixture was filtered through Celite" with DCM and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (1:1 hexanes/Et0Ac¨>100% DCM-->5% Me0H/DCM) to yield the product (591 mg, 57%). NMR
(400 MHz, CD30D) 6: 4.41 (t, 1H, J = 3.6 Hz), 3.91 (dd, 1H, J = 4.4, 10.8 Hz), 3.83 (dd, 1H, J = 4.0, 11.2 Hz), 3.35-3.34 (m, 1H), 2.86 (s, 3H), 1.47 (s, 9H), 1.38 (d, 3H, J= 6.8 Hz);
"C NMR (100 MHz, CD3CN) 6: 207.9, 173.1, 172.4, 81.0, 62.6, 55.4, 30.9, 28.5. HRMS calcd for Ci2H22N206Na: 313.1370, found 313.1371.
[00432] Example 3: Preparation of (2S,3R)-benzyl 3-(benzyloxy)-24(S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)butanoate.
Me. _..0Bn Boc,Me-Ala, NMM Me, ,OBn ¨
HOBT, EDC Boc 0 se.y.0Bn ____ THF, 23 C u 1411 0 Me¨ 0 57%
[00433] Same procedure as Example 1 using threonine derivative (4.65 g, 11.9 mmol, 1.0 equiv), Boc-AT-Me-Ala-OH (2.43 g, 11.9 mmol, 1.0 equiv), HOBT=xH20 (2.19 g, 14.3 mmol, 1.1 equiv), NMM (3.94 mL, 35.8 mmol, 3 equiv) and EDC=HC1 (2.75 g, 14.3 mmol, 1.05 equiv) in THF
(100 mL). The resultant oil was purified by flash chromatography on silica gel (5:1¨>4:12:1 hexanes/Et0Ac) to yield the product (3.32 g, 57%). Rf= 0.26 (5:1 hexanes/ethyl acetate). Ili NMR (400 MHz, CDC13) 6: 7.31-7.25 (m, 8H), 7.17-7.15 (m, 2H), 5.14 (d, 1H, J= 6.0 Hz), 5.06 (d, 1H, J= 6.0 Hz), 4.67 (dd, 1H, 2.4, 9.2 Hz), 4.48 (d, 1H, J= 12.0 Hz), 4.27 (d, 1H, J= 12.0 Hz),4.15 (qd, 1H, J= 2.0, 6.0 Hz), 2.79 (s, 3H), 1.60 (s, 1H), 1.42 (s, 9H), 1.35 (d, 3H, J= 7.2 Hz), 1.16 (d, 3H, 6.4 Hz); "C NMR
(100 MHz, CDC13) 6:
172.2, 170.4, 135.5, 128.7, 128.7, 128.5, 128.5, 128.5, 128.4, 127.8, 127.8, 74.3, 70.9, 67.3, 56.8, 28.4, 16.4. HRMS calcd for C27H36N206Na: 507.2466, found 507.2468.
[00434] Example 4: Preparation of (25,3R)-24(S)-24(tert-butoxycarbonyl)(methyl)amino)propanamido)-3-hydroxybutanoic acid.
Me, ,OBn Me OH
Boc 0 ¨ Pd-C, H2 Boc 0 N
0Bn OH
Me0H, 23 C Me N
H
Me 0 Me 0 97%
[00435] Same procedure as Example 2 using benzyl ester (3.306 g, 6.82 mmol, 1.0 equiv) and 10 wt% Pd-C (150 mg) in methanol (50 mL). The resultant oil was sufficiently pure as a crude product (2.01 g, 97%).
NMR (400 MHz, CD30D) 6: 7.44 (bs, 1H), 4.70 (bs, 1H), 4.40-4.36 (m, 1H), 4.33 (dd, 1H, J= 2.8, 6.4 Hz), 2.87 (s, 3H), 1.48 (s, 9H), 1.39 (d, 3H, J= 7.2 Hz), 1.18 (d, 3H, J= 6.4 Hz); "C NMR (100 MHz, CD30D) 6: 174.7, 173.7, 157.5, 81.9, 68.2, 59.0, 55.7, 30.9, 28.6, 20.7, 14.9.
HRMS calcd for C 13H24N206Na: 327.15266, found 327.15236.
[00436] Example 5: 4,4-Dimcthoxybutanal.
Me0 Me0 DIBAL
DCM, -78 C Me0 93%
[00437] To a solution of nitrile (1.2 g, 9.29 mmol, 1.0 equiv) in DCM (75 mL) at -78 C under N2 was added 1.1 M DIBAL in cyclohexane (23.23 mL, 10.2 mmol, 1.1 equiv). After 3 hat -78 C, the mixture was slowly warmed to r.t. and quenched with sat. aq. NH4C1 (25 mL) and Rochelle salt (25 mL).
Reaction progress was monitored by TLC (vanillin stain). After stirring for 1 h, the mixture was extracted with DCM (3 x 20 mL). The organics were then washed with brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo to yield a colorless, relatively volatile liquid product (1.14 g, 93%) which was sufficiently pure to use without further purification. The analytical data match those previously reported:
Gricsbaum, K.; Jung, I. C.; Mertens, H. J. Org. Chem. 1990, 55, 6024.
[00438] Example 6: 4,4-Dimethoxy-2,2-dimethylbutanenitrile.
Me0 Me0 LDA, Mel ) /
Me0 Me0 <Me DCM, -78 C Me 87%
[00439] To a solution of diisopropylamine (4.77 mL, 34.1 mmol, 2.2 equiv) in THF (50 mL) at -10 C
under N2 was added 1.5 M n-BuLi in hexanes (22.7 mL, 34.1 mmol, 2.2 equiv).
After 30 min the mixture was cooled to -78 C and a solution of nitrile (2.0 g, 15.5 mmol, 1.0 equiv) in THF (10 mL) was added.
After 1 h iodomethane (2.12 mL, 34.1 mmol, 2.2 equiv) was added. The mixture was slowly warmed to 0 C and kept there for 14 h, at which time it was quenched with sat. aq. NH4C1 (40 mL) and extracted with Et0Ac (3 x 20 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (5:1->3:1 hexanesiEt0Ac) to yield the product (2.105 g, 87%) as a yellow oil. Rf= 0.49 (3:1 hexanes/Et0Ac). 1H NMR
(400 MHz, CDC11) 6:
4.60 (t, 1H, J= 5.6 Hz), 3.37 (s, 6H), 1.83 (d, 2H, J= 4.4 Hz), 1.39 (s, 6H);
13C NMR (100 MHz, CDC13) 6: 124.7, 102.4, 53.3, 43.0, 30.0, 27.5 [00440] Example 7: Preparation of 4,4-dimethoxy-2,2-dimethylbutanal.
Me0 Me0 ) Me0 <Me Me0 __ e DIBAL
= M
Me DCM, -78 C Me O-N
46%
[00441] Same procedure as Example 5 using the nitrile derivative (500 mg, 3.18 mmol, 1.0 equiv) in DCM (25 mL) and 1.1 M DIBAL in cyclohexane (3.18 mL, 10.2 mmol, 1.1 equiv).
The resultant oil was purified by flash chromatography on silica gel (9:1 hexanes/Et0Ac) to yield the product (232 mg, 46%) as a colorless, relatively volatile oil. Rf= 0.39 (7:1 hexanes/Et0Ac).
[00442] Example 8: Preparation of 2-(diethoxymethyl)benzaldehyde.
Et0 n-BuLi Et0 Et0 THE, -78 C. Et0 Br then DMF 0-quant.
[00443] To a solution of aryl bromide (1.94 g, 7.49 mmol, 1.0 equiv) in THF
(20 mL) at -78 C under N2 was added 1.5 M n-BuLi in hexanes (7.49 mL, 11.2 mmol, 1.5 equiv). After 30 min DMF (869 L, 11.2 mmol, 1.5 equiv) was added. The mixture was slowly warmed to r.t. over 4 h, at which time it was quenched with sat. aq. NH4C1 (40 mL) and extracted with Et0Ac (3 x 20 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (95:4:1 hexanes/Et0Ac/Et3N) to yield the product (2.105 g, 87%) as a yellow oil. Rf= 0.46 (3:1 hexanes/Et0Ac). The analytical data match those previously reported:
Ueda, M.; Kawai, S.;
Hayashi, M.; Naito, T.; Miyata., 0. J. Org. Chem. 2010, 75, 914.
[004441Example 9: N-(Naphthalen-l-yl)formamide.
NH2 EtOCHO H. NH
LHMDS
THF, 85 C ftjj 64%
[00445] To a mixture of 1-naphthylamine (6.0 g, 41.9 mmol, 1.0 cquiv) and ethyl formate (6.74 mL, 83.8 mmol, 2 equiv) in THF (200 mL) was added 1 M LHMDS in THF (75.4 mL, 75.4 mmol, 1.8 equiv). The mixture was heated to 85 C for 14 11 and then concentrated. The resulting solid was filtered and rinsed with hexanes to yield the product. The filtrate was concentrated and the filtration procedure was repeated for a second batch of product to yield overall the product (3.05 g, 64%) as a brown solid and a 2:1 mixture of rotational isomers. R1= 0.10 (5:1 hexanes/ethyl acetate). 1H NMR (400 MHz, CDC13) 6: 8.65-8.61 (m, 2H), 8.45 (bs, 1H), 8.04-7.99 (m, 2H), 7.92-7.85 (m, 2H), 7.80 (d, 1H, ./= 8.4 Hz), 7.73 (d, 1H, ./= 8.0 Hz), 7.63-7.51 (m, 3H), 7.50-7.44 (m, 2H), 7.32 (d, 1H, J= 7.6 Hz); 13C NMR
(100 MHz, CDC13) 6:
164.1, 159.7, 134.4, 134.2, 132.2, 131.1, 129.0, 128.7, 127.9, 127.2, 127.2, 127.2, 127.0, 126.7, 126.4, 126.3, 125.9, 125.7, 121.4, 121.0, 120.5, 119.3. HRMS calcd for C11H9N0:
171.0679, found 171.0681.
[00446] Example 10: Preparation of 1-isocyanonaphthalene.
HA NH N-POCI3, E13N
DCM, 0 C
79%
[00447] To a solution of formamide derivative (1.048 g, 6.12 mmol, 1.0 equiv) in DCM (20 mL) at 0 C
was added Et3N (4.33 mL, 31.2 mmol, 5.1 equiv) followed by phosphorus oxychloride (841 uL, 9.18 mmol, 1.5 equiv). The mixture was warmed to 23 'V and stirred for 2 h, at which time it was poured into a mixture of saturated NaHCO3 (40 mL) and 1 M NaOH (20 mL) and extracted with DCM (3 x 20 mL).
The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (1:1 hexanes/DCM) to yield the product (740 mg, 79%) as a brown oil which was stored at 0 C. Rf= 0.72 (3:1 hexanes/Et0Ac). [FT NMR (400 MHz, CDC13) 6: 8.19 (d, 1H, J= 8.4 Hz), 7.90 (d, 2H, J= 8.0 Hz), 7.68 (t, 1H, J= 7.6 Hz), 7.61 (t, 2H, J=
7.2 Hz), 7.45 (td, 1H, J=
2.4, 8.4 Hz); [3C NMR (100 MHz, CDC13) 6: 167.3, 133.7, 129.9, 128.5, 128.2, 128.1, 127.6, 125.1, 124.7, 123.1. HRMS calcd for CiiHgN: 154.06513, found 154.06671.
[00448] Example 11: Preparation of N-benzhydrylformamide.
iLj EtOCHO 0 H
70%
[00449]A mixture of benzhydrylamine (4.0 g, 21.8 mmol, 1.0 equiv) and ethyl formate (2.0 mL, 24.9 mmol, 1.14 equiv) was heated to 75 C for 14 b. Ethyl acetate was added and the mixture was triturated by sonication, then filtered and rinsed with Et20 to yield the product (3.24g, 70%) as a white solid. The compound exists as a mixture of rotational isomers. Rf= 0.29 (3:1 hexanes/Et0Ac). 'H NMR (400 MHz, CDC13) 6: 8.15 (s, 1H), 7.34-7.19 (m, 10H), 6.69 (d, 1H, J = 6.0 Hz), 6.27 (d, 1H, J = 8.4 Hz); 13C NMR
(100 MHz, CDC13) 6: 160.4, 141.0, 128.8, 127.7, 127.5, 55.7. HRMS calcd for C14Ht4N0: 212.10699, found 212.100748.
[00450] Example 12: Preparation of (isocyanomethylene)dibenzene.
0 POCI3, Et3 N
H N
DCM, 0 C +N
93%
[00451] To a solution of formamide derivative (1.727 g, 8.17 mmol, 1.0 equiv) in DCM (35 mL) at 0 C
was added Et3N (5.79 mL, 41.7 mmol, 5.1 equiv) followed by phosphorus oxychloride (1.12 mL, 12.3 mmol, 1.5 equiv). The mixture was warmed to 23 C and stirred for 18 h, at which time it was poured into a mixture of saturated NaHCO3 (50 mL) and 1 M NaOH (20 mL) and extracted with DCM (3 x 30 mL).
The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (DCM->5:1 DCM/Et0Ac) to yield the product (1.467 g, 93%) as an orange solid which was stored at 0 C. Rf= 0.73 (7:1 hexanes/Et0Ac). 1H NMR
(400 MHz, CDC13) 6:
7.41-7.33 (m, 10H), 5.92 (s, 1H); 13C NMR (100 MHz, CDC13) 6: 158.5, 137.7, 129.1, 128.6, 126.7, 77.2, 62.1. HRMS calcd for C14H11NNa: 216.07837, found 216.07971.
[00452] Example 13: Preparation of (R)-N-(1,2,3,4-tetrahydronaphthalen-l-yl)formamide.
EtOCHOiii 11111J T
63%
[00453[A mixture of (R)-(-)-1,2,3,4-tetrahydro-l-naphthylamine (10.0 g, 67.9 mmol, 1 equiv) and ethyl formate (6.23 mL, 77.4 mmol, 1.14 equiv) was heated to 80 C for 14 h. Hexanes was added and the mixture was triturated by sonication, then filtered and rinsed with hexanes to yield the product (7.44 g, 63%) as a tan solid. Rf= 0.22 (3:1 hexanes/Et0Ac). NMR (400 MHz, CDC13) 6:
8.23 (s, 1H), 7.29-7.25 (m, 1H), 7.23-7.16 (m, 2H), 7.13-7.08 (m, 1H), 5.82 (bs, 1H), 5.28 (dd, 1H, J= 5.2, 14.0 Hz), 2.85-2.73 (m, 2H), 2.15-2.03 (m, 1H), 1.88-1.81 (m, 3H); 13C NMR (100 MHz, CDC13) 6: 160.5, 137.7, 136.1, 129.4, 128.8, 127.6, 126.5, 46.4, 30.3, 29.3, 20Ø HRMS calcd for C111-113NONa: 198.0889, found 198.0890.
[00454] Example 14: Preparation of (R)-1-isocyano-1,2,3,4-tetrahydronaphthalene.
III
HANH N+
r-Lõ, nai 3, ciGni DCM, 0 C
69%
[00455] To a solution of formamide derivative (2.85 g, 16.3 mmol, 1.0 equiv) in DCM (40 mL) at 0 C
was added Et3N (11.51 mL, 82.9 mmol, 5.1 equiv) followed by phosphorus oxychloride (2.23 mL, 24.4 mmol, 1.5 equiv). The mixture was warmed to 23 C and stirred for 2 h, at which time it was poured into saturated NaHCO3 (200 mL) and extracted with DCM (2 x 100 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (3:1->1 :1 hexanes/DCM) to yield the product (1.76 g, 69%) as a brown oil which was stored at 0 C. It1= 0.59 (5:1 hexanes/Et0Ac). Ifi NMR (400 MHz, CDC13) 6: 7.45-7.43 (m, 1H), 7.26-7.23 (m, 2H), 7.14-7.11 (m, 1H), 4.83 (app. s, 1H), 2.92-2.84 (m, 1H), 2.80-2.72 (m, 1H), 2.18-2.12 (m, 2H), 2.11-2.01 (m, 1H), 1.87-1.78 (m, 1H); '3C NMR (100 MHz, CDC13) 6: 155.2, 136.5, 132.1, 129.5,128.6, 128.6, 126.7, 52.6, 30.7, 28.6, 19.4. HRMS calcd for CiiHi2N: 158.0964, found 158.0966.
[00456] Example 15: Preparation of 1-(2,2-dimethoxyethyl)-2-isocyanobenzene.
, Me OMe OMe [00457] The isocyanide was prepared according to the established literature procedure; see Gilley, C. B.;
Buller, M. J.; Kobayashi, Y. Org. Lett. 2007, 9, 3631.
[00458] Example 16: General synthetic scheme for the preparation of 6,5-heterobicyclic compounds described below:
Boc 0 R2a,¨ ,OH MeO\
R2a 0 e 0 Me - NIIIM=r HM 0_) a-b A
- H
Me Me N1(13 Me 0 N
NH3 CA\J--R7 0 H
a) CF3CH2OH, JAW, 80 C; b) TFA, DCM, 23 C
[00459] Example 17: Preparation of (3S,8aS)-N-benzy1-3-((S)-2-(methylamino)propanamido)-4-oxohexahydro-2H-pyrrolo[2,1-b][1,3]oxazine-6-carboxamide.
Me0 OH meo)D OMe HO Me TFA
Boc 0 fy CF3CH2OH DCM 0 7 0- _______________________ Boc 0 jyH õ 0 MeNOH
Ark 23.c N
pW, 80 C- MeN
Ae H 0 NH3 20 min = H
Me 0 N
0 H IFP 30% Re H 0 NO
(2 steps) [00460] A mixture of carboxylic acid (93 mg, 0.320 mmol, 1.0 equiv), aldehyde (44 mg, 0.336 mmol, 1.05 equiv), benzyl isocyanide (38 mg, 0.320 mmol, 1.0 equiv) and 7 M ammonia in Me0H (92 pt, 0.641 mmol, 2.0 equiv) in TFE (3 mL) was stirred under microwave iffadiation at a set temperature of 80 C for 20 min. The mixture was then transferred to a round bottom flask and concentrated in vacuo, then 1 M
NaOH (15 mL) was added and the mixture was extracted with DCM (3 x 7 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was combined with TFA (147 1.92 mmol, 6 equiv) in DCM (5 mL) and stiffed at 23 C for 14 h. The mixture was concentrated in vacuo and purified by flash chromatography on basic alumina (3:1 hexanesiEt0Ac¨>DCM-97%
Me0H/DCM) to yield the product as a 1:1 diastereomixture of the the free base (36 mg, 30%
over 2 steps). Some of the material was further purified by preparative scale HPLC for use in biological assays. 11-I NMR (400 MHz, CD30D) 6: 8.51 (bs, 1H), 7.33-7.28 (m, 8H), 7.26-7.21 (m, 2H), 5.23 (t, 1H, =
5.2 Hz), 5.16 (dd, I H, = 5.2, 8.4 Hz), 4.68 (dd, 1H, J = 3.2, 6.4 Hz), 4.61-4.56 (m, 2H), 4.48 (d, 1H, 1= 15.2 Hz), 4.42-4.33 (m, 4H), 4.28 (dd, 1H, J= 6.4, 11.6 Hz), 4.24 (dd, 1H, J= 6.0, 11.6 Hz), 4.01 (dd, 1H, J= 3.2, 11.6 Hz), 3.92 (dd, 1H, J= 3.2, 11.6 Hz), 3.69 (q, 2H, J= 6.8 Hz), 2.61 (s, 3H), 2.60 (s, 3H), 2.41-2.29 (m, 2H), 2.26-2.16 (m, 2H), 1.94-1.82 (m, 2H), 1.49 (d, 3H, J= 7.2 Hz), 1.47 (d, 3H, 1= 7.2 Hz); 13C NMR (100 MHz, CD30D) 6: 173.6, 173.4, 167.9, 167.1, 139.7, 139.7, 129.5, 129.5, 128.4, 128.4, 128.2, 128.2, 91.1, 90.9, 71.7, 70.8, 60.7, 59.8, 58.8, 44.2, 44.0, 32.3, 32.2, 32.2, 31.2, 27.2, 26.7, 16.8, 16.7. HRMS calcd for C19H27N404: 375.2027, found 375.2028.
[00461] Example 18: Preparation of (3S,8a5)-N-(4-chloropheny1)-3-((S)-2-(methylamino)propanamido)-4-oxohexahydro-2H-pyrrolo[2,1-b][1,3]oxazine-6-carboxamide.
Me0 OH Me TFA
me ElBoc 0 m.o)D CF3CH2OH _ c e0 CI DCM
=
¨ H
W, so Me c N 23 C dit CI
Ae 0 NH3... CI 120 min H 0 N
(2 steps) A H
me 0 N
-csN
[00462] Same procedure as Example 17 with carboxylic acid (105 mg, 0.362 mmol, 1.0 equiv), aldehyde (50 mg, 0.380 mmol, 1.05 equiv), isocyanide (50 mg, 0.362 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(103 litL, 0.723 mmol, 2.0 equiv) in TFE (3 mL). The resultant oil was combined with TFA (166 !at, 2.17 mmol, 6 equiv) in DCM (5 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and purified by flash chromatography on basic alumina (3:1 hexanes/Et0Ac-9DCM-97%
Me0H/DCM) to yield the product as a 1:1 diastereomixture of the free base (98 mg, 69% over 2 steps). 1H NMR (400 MHz, CDC13) 6: 8.53 (bs, I H), 7.58 (d, 2H, J= 3.2 Hz), 7.57 (d, 2H, = 3.6 Hz), 7.32 (d, 2H, J= 2.0 Hz), 7.30 (d, 2H, J = 3.6 Hz), 5.29 (dd, 1H, J = 5.2, 7.2 Hz), 5.21 (dd, 1H, J =
4.8, 6.8 Hz), 4.71-4.68 (m, 2H), 4.66-4.63 (m, 1H), 4.49 (d, 1H, J = 8.8 Hz), 4.31 (dd, 1H, J= 6.8, 11.6 Hz), 4.26 (dd, 1H, J= 6.4, 11.6 Hz), 4.01 (dd, 1H, J= 2.8, 11.6 Hz), 3.94 (dd, 1H, J= 2.8, 11.6 Hz), 3.62 (q, 1H, J= 6.8 Hz), 3.60 (q, 1H, J= 6.8 Hz), 2.56 (s, 6H), 2.47-2.35 (m, 2H), 2.30-2.25 (m, 2H), 2.13-2.07 (m, 2H), 2.02-1.87 (m, 2H), 1.45 (d, 3H, J= 7.2 Hz), 1.43 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CDC13) 6:
171.8, 171.6, 167.8, 167.3, 138.5, 138.2, 130.5, 130.3, 129.8, 129.8, 122.8, 122.5, 91.0, 90.9, 71.4, 70.9, 61.1, 60.3, 59.0, 32.6, 32.6, 32.3, 31.3, 27.1, 26.7, 17.2, 17Ø HRMS calcd for ClgH24C1N404:
395.1481, found 395.1479.
[00463] Example 19: Preparation of (3S,8a5)-3-((S)-2-(methylamino)propanamido)-4-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)hexahydro-2H-pyrrolo[2,1-b][1,3]oxazine-6-carboxamide.
Me0 OH ) Z
Me oe 0=) CF3CH2OH 0 Me0q3..
Bo OH Me DTLAm 0 w Me' OH
Ae H 0 NH3 p (268m0i 23 C e e H 0 110 Me 0 N
0 H Mr 67% u H
(2 steps) [00464] Same procedure as Example 17 with carboxylic acid (97 mg, 0.334 mmol, 1.0 equiv), aldehyde (46 mg, 0.351 mmol, 1.05 equiv), isocyanide (53 mg, 0.334 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(97 L, 0.668 mmol, 2.0 equiv) in TFE (3 mL). The resultant oil was combined with TFA (177 uL, 1.55 mmol, 6 equiv) in DCM (5 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and purified by flash chromatography on basic alumina (3:1 hexanesiEt0Ac-9DCM-97%
McOH/DCM) to yield the product as the free base (72 mg, 67% over 2 steps). Some of the material was further purified by preparative scale HPLC for use in biological assays. 'H NMR (400 MHz, CDC13) 6: 8.51 (s, 1H), 7.40-7.36 (m, 1H), 7.17-7.06 (m, 7H), 5.24 (dd, 1H, J= 4.8, 6.4 Hz), 5.17 (dd, 1H, J= 4.8, 8.0 Hz), 5.10-5.04 (m, 2H), 4.66-4.62 (m, 2H), 4.57 (t, J= 8.0 Hz), 4.35 (d, 1H, J= 7.6 Hz), 4.27 (dd, 1H, J= 6.4, 11.6 Hz), 4.24 (dd, 1H, J= 6.0, 12.0 Hz), 3.76-3.65 (m, 2H), 2.87-2.72 (m, 4H), 2.63 (s, 3H), 2.61 (s, 3H), 2.43-2.31 (m, 2H), 2.28-2.17 (1n, 2H), 2.05-1.88 (m, 7H), 1.86-1.74 (m, 5H), 1.52 (d, 3H, J= 7.2 Hz), 1.49 (d, 3H, J= 7.2 Hz); l'C NMR (100 MHz, CDC13) 6: 206.6, 172.9, 172.8, 171.7, 167.7, 167.0, 138.7, 138.5, 137.6, 137.6, 130.1, 129.9, 129.7, 129.3, 128.2, 128.1, 127.2, 127.2, 127.1, 91.1, 91.0, 71.6, 70.9, 60.8, 59.8, 58.9, 58.8, 58.8, 32.3, 32.3, 32.2, 31.3, 31.3, 31.2, 30.2, 30.2, 27.2, 26.8, 21.8, 21.5, 16.8, 16.7.
HRMS calcd for C22H3oN404Na: 437.21593, found 437.20535.
[00465] Example 20: Preparation of (2R,3S,8aS)-2-methy1-34(S)-2-(methylamino)propanamido)-4-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-y1)hexahydro-2H-pyrrolo[2,1-b][1,3]oxazine-6-carboxamide.
Me0 Me OH
Boc 0 Me0)-) Me0 Me TFA
111., OH ¨ Boc (r DCM 0Me 0 w Me' IFAry e Ae 0 NH3 RW, me N 1111, 23 C N =
7 20 min H 0 Ke Me 0 I 0 H ND
[00466] Same procedure as Example 17 with carboxylic acid (85 mg, 0.279 mmol, 1.0 equiv), aldehyde (39 mg, 0.293 mmol, 1.05 equiv), isocyanide (44 mg, 0.279 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(80 L, 0.559 mmol, 2.0 cquiv) in TFE (3 mL). The resultant oil was combined with TFA (128 _L, 1.67 mmol, 6 equiv) in DCM (5 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and purified by flash chromatography on basic alumina (3:1 hexanes/Et0Ac¨>DCM-97%
Me0H/DCM) to yield the product as a slightly impure free base (94 mg, yield not calculated). Some of the material was further purified by preparative scale HPLC for use in biological assays. 1H
NMR (400 MHz, DMSO-d6) 6:8.28 (d, 1H, J= 8.8 Hz), 8.26 (d, 1H, J= 8.8 Hz), 8.24 (s, 2H), 8.18 (d, 1H, J= 8.8 Hz), 8.00 (d, 1H, J
= 8.8 Hz), 7.28 (d, 1H, J= 7.2 Hz), 7.16-7.06 (in, 6H), 5.25 (t, 1H, J= 5.6 Hz), 5.20 (dd, 1H, .1= 5.2, 7.6 Hz), 4.99-4.92 (m, 2H), 4.60 (dd, 1H, J= 5.6, 8.4 Hz), 4.50 (dd, 1H, J= 5.2, 8.4 Hz), 4.46 (t, 1H, J= 7.2 Hz), 4.34-4.27 (m, 2H), 4.24 (t, 2H, J= 8.4 Hz), 3.13 (q, 1H, J= 6.8 Hz), 3.09 (q, 1H, J= 6.8 Hz), 2.76-2.70 (m, 3H), 2.24 (s, 3H), 2.22 (s, 3H), 1.93-1.80 (m, 6H), 1.80-1.60 (m, 6H), 1.17 (d, 3H, J= 6.8 Hz), 1.15 (d, 3H, J= 6.8 Hz), 1.07 (d, 3H, J= 6.4 Hz), 1.00 (d, 3H, J= 6.4 Hz); 13C
NMR (100 MHz, DMSO-d6) 6: 174.1, 170.3, 169.9, 165.7, 165.2, 137.6, 137.4, 137.0, 136.9, 128.7, 128.5, 128.3, 127.7, 126.7, 126.6, 125.8, 125.7, 99.5, 87.7, 87.6, 73.4, 72.6, 59.2, 58.8, 58.7, 57.9, 50.5, 50.3, 46.6, 46.5, 34.0, 33.7, 30.7, 30.0, 29.9, 28.8, 28.8, 26.0, 25.7, 20.5, 18.9, 18.7, 16.5. HRMS calcd for C231-132N404Na:
451.23158, found 451.23286.
[00467] Example 21: Preparation of (2R,3S,8aS)-2-methy1-3-((S)-2-(methylamino)propanamido)-N-(naphthalen-1-y1)-4-oxohexahydro-2H-pyrrolo[2,1-b][1,3]oxazine-6-carboxamide.
Me0 Me OH
Boc 0 Me )D
0¨ CF3CH2OH Boc MeO OMe TFA
DCM
ONle 13, me, N NoThrOH
C W, 80 C* Me N 63 H
23 % C nie-NNe-yN 111 Me H 0 NH3 + 20 min Me H 0 Me H 0 N
0 El 0 H
(2 steps) [00468] Same procedure as Example 17 with carboxylic acid (100 mg, 0.328 mmol, 1.0 equiv), aldehyde (46 mg, 0.344 mmol, 1.05 equiv), isocyanide (50 mg, 0.328 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(94 uL, 0.657 mmol, 2.0 equiv) in TFE (3 mL). The resultant oil was combined with TFA (151 uL, 1.97 mmol, 6 equiv) in DCM (5 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and purified by flash chromatography on basic alumina (1:1 hexanes/Et0Ac¨>DCM-97%
Me0H/DCM) to yield the product as the free base (88 mg, 63% over 2 steps). Some of the material was further purified by preparative scale HPLC for use in biological assays. 1H NMR (400 MHz, CD30D) 6: 8.53 (bs, 1H), 8.13-8.09 (m, 1H), 8.05 (d, 1H, J= 6.8 Hz), 7.92-7.87 (m, 2H), 7.81 (t, 2H, J= 6.4 Hz), 7.56-7.46 (m, 8H), 5.29 (dd, 1H, J= 5.2, 8.0 Hz), 5.21 (dd, 1H, J= 4.8, 8.4 Hz), 4.83 (t, 1H, J=
8.4 Hz), 4.71-4.67 (m, 2H), 4.62 (d, 1H, J = 4.0 Hz), 4.36-4.24 (m, 2H), 3.70 (q, 1H, I = 6.8 Hz), 3.65 (q, 1H, J = 6.8 Hz), 2.59 (s, 3H), 2.52 (s, 3H), 2.42-2.32 (m, 2H), 2.31-2.18 (m, 2H), 2.16-2.02 (m, 2H), 1.96-1.85 (m, 1H), 1.50 (d, 3H, J= 6.8 Hz), 1.38 (d, 3H, J= 7.2 Hz), 1.24 (t, 6H, J= 6.8 Hz); '3C NMR (100 MHz, CD30D) 6: 173.3, 173.2, 172.7, 172.4, 168.3, 167.5, 135.7, 135.7, 134.0, 133.7, 130.6, 130.6, 129.3, 129.2, 128.2, 128.1, 127.5, 127.4, 127.3, 127.2, 126.4, 126.4, 124.6, 124.3, 124.1, 123.8, 91.0, 90.9, 76.3, 75.7, 60.6, 59.5, 59.1, 58.9, 52.8, 52.5, 32.6, 32.4, 32.2, 31.2, 26.7, 26.2, 17.3, 17.2, 16.7.
HRMS calcd for C23H29N404:
425.2183, found 425.2181.
[00469] Example 22: Preparation of (2R,3S,8a5)-N-benzhydry1-2-methy1-3-((S)-2-(methylamino)propanamido)-4-oxohexahydro-2H-pyrrolo[2,1-b][1,3]oxazine-6-carboxamide.
Me0 )-) 0 Me0 Me 20:.)IMe OH Me0 ,NX,y0H 0_ CF3CH2OH TFA Me 0 nW, 80 C Me' N DCM
Me H 0 NH3 H Me . N
20 min Me 0 N 23 C H
0 Me 0 H N
u H
46%
(2 steps) [00470] Same procedure as Example 17 with carboxylic acid (105 mg, 0.345 mmol, 1.0 equiv), aldehyde (47 mg, 0.362 mmol, 1.05 cquiv), isocyanidc (67 mg, 0.345 mmol, 1.0 cquiv) and 7 M ammonia in McOH
(99 uL, 0.690 mmol, 2.0 equiv) in TFE (3 mL). The resultant oil was combined with TFA (159 pt, 2.07 mmol, 6 equiv) in DCM (5 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and purified by flash chromatography on basic alumina (1:1 hexanesiEt0Ac-9DCM-97%
Me0H/DCM) to yield the product as the free base (73 mg, 46% over 2 steps). IFINMR (400 MHz, CD30D) 6: 7.38-7.18 (m, 20H), 6.17 (s, 1H), 6.15 (s, 1H), 5.21 (dd, 1H, J = 5.2, 8.0 Hz), 5.13 (dd, 1H, J = 4.8, 8.8 Hz), 4.66 (t, 1H, J= 7.6 Hz), 4.62 (d, 1H, J= 4.4 Hz), 4.56 (d, 1H, J= 4.4 Hz), 4.47 (d, 1H, J= 8.4 Hz), 4.28 (dd, 1H, = 4.4, 6.4 Hz), 4.22 (dd, 1H, J= 4.4, 6.4 Hz), 3.25 (q, 1H, J= 6.8 Hz), 3.21 (q, 1Hõ/ = 6.8 Hz), 2.36 (s, 3H), 2.30 (s, 3H), 2.39-2.25 (m, 2H), 2.19-2.12 (m, 2H), 2.06-1.86 (m, 4H), 1.85-1.79 (m, 2H), 1.31 (d, 3H, J= 6.8 Hz), 1.26 (d, 3H, J= 7.2 Hz), 1.20 (d, 3H, J= 6.4 Hz), 1.18 (d, 3H, J= 6.4 Hz); '3C NMR
(100 MHz, CD30D) 6: 176.8, 176.6, 173.0, 172.7, 168.0, 167.6, 143.0, 142.8, 142.6, 142.6, 129.7, 129.6, 129.5, 129.4, 128.9, 128.8, 128.7, 128.6, 128.5, 128.5, 128.3, 128.1, 90.7, 90.6, 76.3, 75.5, 60.4, 60.3, 60.0, 59.2, 58.5, 58.4, 52.5, 52.2, 34.2, 34.1, 32.1, 31.1, 29.5, 26.7, 26.1, 19.2, 19.1, 16.8, 16.7. HRMS
calcd for C26H32N404Na: 487.23158, found 487.23308.
[00471J Example 23: General synthetic scheme for the preparation of 7,5-heterobicyclic Smac peptidomimetics.
X
)1-2 me0 X
¨).-BocHN Me0 B `) 1-2 0 0¨ R1 Ri Bo c (S)- WR 7 -+ 0 N /N---!)LH 0 NH3 CNI H Me--R7 'N'Ae H
12 B> d B
R1,R7 Bock (R) R1 R7 /1\1 H 0 N /F\I H 0 0 N
Me Klie 0 H Me icne a) CF3CH2OH, W, 80 C; b) TFA, DCM, 23 C;
c) Boc-N-Me-Ala-OH, EDC, NMM, HOBT, THF, 23 C; d) TFA, DCM
[004721 Example 24: Preparation of (4S,9aS)-4-amino-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)octahydropyrrolo[2,1-b][1,31oxazepine-7-carboxamide.
OH Me0 BocHN Xr Me0)D
OH 0¨ CF3CH2OH
C- ____________________ ' OH
me0\13.0Me H
N __________________________________________________ ' ti 0 Hi BocHN DCM H,N---\(:(-0 1 al f 20 min 0 Ns 35 TFA C - 0 , N *
[00473] A mixture of Boc-N-HSer-OH (318 mg, 1.45 mmol, 1.0 equiv), aldehyde (201 mg, 1.52 mmol, 1.05 equiv), isocyanide (228 mg, 1.45 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(414 uL, 2.90 mmol, 2.0 equiv) in TFE (5 mL) was stirred under microwave irradiation at a set temperature of 80 C for 20 min. The mixture was then transferred to a round bottom flask and concentrated in vacuo, then 1 M
NaOH (15 inL) was added and the mixture was extracted with DCM (3 x 7 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was combined with TFA (834 L, 10.9 mmol, 8 equiv) in DCM (5 mL) and stirred at 35 C for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[004741 Example 25: Preparation of tert-butyl methyl((2S)-1-oxo-1-(((4S,9aS)-5-oxo-7-(((R)-1,2,3,4-tetrahydronaphthalen- 1-yl)carbamoyl)octahydropyrrolo [2,1 -b] [1,3] oxazep in-4 -y1) amino)propan-2-yl)carbamate.
(01:1 01;1 H
Boc,Me-Ala, HOBT, EDC 0 0 _________________________ 1.- Boc Boo, \\__N
=
H2N¨e% Ali* NMM, THF, 23 C m ;N-1?-1 0 NI N----7 *
IP Me' l'. µ... H
4..., H Me Me 44% combined (3 steps) [00475] To a solution of amine (622 mg, 1.36 mmol, 1.0 equiv), Boc-N-Me-Ala-OH
(276 mg, 1.36 mmol, 1.0 equiv), HOBT=xH20 (229 mg, 1.50 mmol, 1.1 equiv) and NMM (598 uL, 5.44 mmol, 4 equiv) in THF
(15 mL) at 0 C was added EDC-1-1C1 (274 mg, 1.43 mmol, 1.05 equiv). After 30 mm the cold bath was removed. The solution stirred for 14 h and then was quenched with saturated aqueous NaHCO3 (25 mL), extracted with ethyl acetate (2 x 20 mL), dried over sodium sulfate and then concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (2:1¨>1:1¨>1:3 hexanes/Et0Ac) to yield, after 3 steps, partially separated diastereomers S-isomer (30 mg, 4%, -3:1 d.r.) and R-isomer (40 mg, 5%, -3:1 d.r.), along with unseparated R+S isomers (267 mg, 35%). Data for S-isomer: Rf= 0.40 (1:3 hexanes/Et0Ac). 1H NMR (400 MHz, CDC13) 6: 7.23-7.05 (m, 4H), 6.84 (d, 1H, J=
8.0 Hz), 5.22 (t, 1H, J= 6.4 Hz), 5.18-5.08 (m, 1H), 4.69 (dd, 1H, ./= 5.6, 10.8 Hz), 4.62 (d, 1H, ./= 7.6 Hz), 4.13-4.03 (m, 1H), 3.95 (q, 1H, J= 12.8 Hz), 2.75 (s, 3H), 2.80-2.74 (m, 1H), 2.47-2.37 (m, 1H), 2.17-1.89 (m, 4H), 1.88-1.69 (m, 5H), 1.43 (s, 9H), 1.32 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 171.4, 169.9, 169.8, 137.6, 137.3, 136.9, 136.7, 129.3, 129.2, 128.6, 128.3, 27.4, 127.3, 126.4, 126.2, 90.3, 90.0, 70.7, 70.6, 61.1, 60.6, 53.1, 52.6, 47.7, 47.7, 33.3, 32.7, 32.5, 30.2, 30.1, 29.8, 29.3, 29.3, 28.4, 28.4, 25.9, 20.5, 20.1. Data for R-isomer: Rf= 0.55 (1:3 hexanes/Et0Ac). 11-INMR (400 MHz, CDC13) 6: 7.24-7.11 (m, 4H), 7.11-7.05 (m, 1H), 6.69 (bs, 1H), 5.21 (d, 1H, J= 5.6 Hz), 5.10 (q, 1H, J= 6.8 Hz), 4.75 (dd, 1H, J-7.6, 11.6 Hz), 4.55 (d, 1H, J= 8.0 Hz), 4.47 (t, 1H, 1= 8.8 Hz), 4.01 (d, 1H, J= 12.8 Hz), 3.97 (t, 1H, J=
12.4 Hz), 2.82-2.75 (m, 2H), 2.77 (s, 3H), 2.45-2.33 (m, 1H), 2.32-2.24 (m, 1H), 2.24-2.13 (m, 2H), 2.06-E93 (m, 3H), 1.84-1.76 (m, 2H), 1.74-1.64 (m, 5H), 1.45 (s, 9H), 1.34 (d, 3H, J= 6.8 Hz); 13C NMR (100 MHz, CDC13) 6: 172.1, 171.0, 169.8, 137.6, 136.7, 129.3, 128.6, 127.4, 126.4, 90.0, 70.6, 66.0, 61.2, 53.2, 47.8, 33.3, 32.7, 30.2, 29.3, 28.5, 25.8, 20.2, 14Ø HRMS calcd for C281-140N406: 551.2840, found 551.2838.
[00476] Example 26: Preparation of (4S,7S,9aS)-4-((S)-2-(methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-l-yl)octahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide.
TFA -DCM
N N H 0 Ny Me' tvi e 0 H Me' Le 0 H
quant.
[00477] To a solution of carbamate (30 mg, 0.057 mmol, 1 equiv, ¨7:3 d.r.) in DCM (2 mL) was added TFA (35 .1., 0.454 mmol, 8 equiv). After stirring for 20 h at 23 C, the solution was concentrated. The product was eluted through a short plug (-400 mg) of Silicyle TMA-chloride ion exchange resin with Me0H to yield product=HC1 (26 mg, quantitative) as the major diastereomer (-7:3). 1H NMR (400 MHz, CD30D) 6:7.38-7.35 (m, 1H), 7.15-7.06 (m, 3H), 5.41-5.38 (m, 1H), 5.09-5.03 (m, 1H), 4.42 (t, 1H, J=
6.4 Hz), 4.15 (dt, 1H, J= 2.8, 12.8 Hz), 4.04-3.96 (m, 1H), 3.95-3.89 (m, 1H), 2.86-2.71 (m, 2H), 2.67 (s, 3H), 2.32-2.25 (m, 1H), 2.12 (q, 2H, J= 7.2 Hz), 2.06-1.96 (m, 2H), 1.94-1.85 (m, 1H), 1.85-1.74 (m, 2H), 1.58 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CD30D) 6: 173.4, 172.7, 172.7, 172.2, 169.6, 169.3, 138.6, 138.5, 137.8, 137.7, 130.0, 130.0, 129.6, 129.2, 128.2, 128.1, 127.1, 91.0, 71.3, 71.2, 62.4, 62.4, 58.4, 58.3, 54.4, 54.2, 34.0, 33.6, 33.3, 33.2, 31.8, 31.3, 31.2, 30.2, 30.2, 28.2, 28.0, 21.7, 21.6, 16.4, 16.4.
HRMS calcd for C231-133N404: 429.2496, found 429.2495.
[00478] Example 27: Preparation of (4S,9aS)-4-amino-N-(naphthalen-l-y1)-5-oxooctahydropyffolo [2,1-b][1,3]oxazepine-7-carboxamide.
OH Me BocHN0 Hc9 OH
me0\01f4.
H TFA
____________________________________________________ y IN + N
0 W, 80 DCM C BocHN 7NCI
ti H 0 H
[00479] Same procedure as Example 24 with Boc-N-HSer-OH (150 mg, 0.684 mmol, 1.0 equiv), aldehyde (95 mg, 0.718 mmol, 1.05 equiv), isocyanide (105 mg, 0.684 mmol, 1.0 equiv) and 7 M ammonia in Me0H (195 tiL, 1.37 mmol, 2.0 equiv) in TFE (4 mL). The resultant oil was combined with TFA (314 [IL, 4.10 mmol, 6 equiv) in DCM (5 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00480] Example 28: Preparation of tert-butyl methyl((2S)-1-(((4S,9aS)-7-(naphthalen-l-ylcarbamoy1)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepin-4-yl)amino)-1-oxopropan-2-yl)carbamate.
01:1 0 t1 Boc,Me-Ala, HOBT, EDC 0 0 __________________________ Boc H2NCR NMM, THF, 23 C 0 N
H Me Me 36% combined (3 steps) [00481] Same procedure as Example 25 above using amine derivative (209 mg, 0.615 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (125 mg, 0.615 mmol, 1.0 equiv), HOBT-xH20 (104 mg, 0.677 mmol, 1.1 equiv), NMM (338 !IL, 3.08 mmol, 5 equiv [to soak up xs TFA]) and EDC=HC1 (124 mg, 0.646 mmol, 1.05 equiv) in THF (10 mL). The resultant oil was purified by flash chromatography on silica gel (2:11:1¨>1:3 hexanes/Et0Ac) to yield, after 3 steps, S-isomer (43 mg, 12%, ¨6:1 d.r.) and R-isomer (37 mg, 10%, ¨6:1 d.r.), along with unseparated mixture (49 mg, 14%). Data for S-isomer: Rf= 0.33 (1:3 hexanes/Et0Ac). 1H NMR (400 MHz, CDC13) J: 9.11 (s, 111), 8.10 (d, 1H, J= 7.6 Hz), 7.98 (d, 1H, J=
8.8 Hz), 7.86 (d, 1H, J= 8.0 Hz), 7.67 (d, 1H, J= 8.4 Hz), 7.56-7.44 (m, 3H), 7.32 (s, 1H), 5.33 (t, 1H, J
= 6.4 Hz), 4.90 (d, 1H, J= 6.4 Hz), 4.81 (dd, 1H, 5.2, 10.4 Hz), 4.19 (dt, 1H, J= 2.8, 12.8 Hz), 4.07-3.98 (m, 1H), 2.78 (s, 3H), 2.59-2.46 (m, 2H), 2.32-2.21 (m, 1H), 2.01-1.91 (m, 3H), 1.85-1.74 (m, 1H), 1.44 (s, 9H), 1.36 (d, 3H, J= 6.8 Hz); 13C NMR (100 MHz, CDC13) : 172.1, 171.4, 169.1, 168.5, 134.1, 132.7, 128.9, 126.6, 126.5, 126.0, 125.9, 125.5, 120.7, 119.8, 90.7, 70.8, 61.2, 52.8, 32.8, 32.6, 30.2, 28.5, 28.4, 25.6. Data for R-isomer: Ri= 0.42 (1:3 hexanes/Et0Ac). 1H NMR (400 MHz, CDC13) 6: 9.47 (s, 1H), 8.03 (d, 1H, J= 7.2 Hz), 7.94 (d, 1H, J= 7.6 Hz), 7.82 (d, 1H, J= 7.6 Hz), 7.63 (d, 1H, J= 8.0 Hz), 7.55 (s, 1H), 7.50-7.40 (m, 2H), 7.31 (s, 1H), 5.21 (s, 1H), 4.96 (d, 1H, J=
7.6 Hz), 4.85-4.78 (m, 1H), 4.43 (t, 1H, J= 8.8 Hz), 4.14 (d, 1H, J= 12.8 Hz), 3.99 (t, 1H, J= 12.0 Hz), 2.79 (s, 3H), 2.61-2.53 (m, 1H), 2.26-2.14 (m, 1H), 2.11-1.97 (m, 2H), 1.90-1.78 (m, 1H), 1.46 (s, 9H), 1.34 (d, 3H, J= 7.2 Hz); 13C
NMR (100 MHz, CDC13) 6: 175.0, 173.3, 172.4, 168.5, 134.1, 132.8, 128.7, 126.5, 126.1, 125.8, 125.4, 121.0, 119.5, 90.3, 70.6, 65.9, 61.6, 53.2, 49.2, 33.6, 32.5, 30.3, 30.3, 28.5, 28.5, 28.4, 24.6. HRMS calcd for C2g1-136N406Na: 547.25271, found 547.25362.
[00482] Example 29: Preparation of (4S,7S,9aS)-4-((S)-2-(methylamino)propanamido)-N-(naphthalen-1-y1)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide.
H H
O TFA
o( _s(r1- ¨
DCM o Boc, .....)\_.
N - H 0 N ,N H 0 N
MetµAe 0 H Me t'= 0 H
quant. Me [00483] To a solution of carbamate (12 mg, 0.023 mmol, 1 equiv, -6:1 d.r.) in DCM (1 mL) was added TFA (14 pL, 0.183 mmol, 8 equiv). After stirring for 20 h at 23 C, the solution was concentrated to yield product=TFA (12 mg, quantitative) as the major diastereomer. 1H NMR (400 MHz, CD30D) 6: 8.12-8.08 (m, 1H), 7.92-7.88 (m, 1H), 7.79 (d, 1H, J= 8.4 Hz), 7.67 (dd, 1H, J = 1.2, 7.2 Hz), 7.56-7.45 (m, 3H), 5.48 (q, 1H, J= 2.8 Hz), 4.99 (d, 1H, J= 12.0 Hz), 4.75 (t, 2H, J= 6.8 Hz), 4.21 (dt, 1H, J= 2.8, 12.4 Hz), 4.10-4.00 (m, 1H), 3.96-3.87 (m, 1H), 2.68 (s, 3H), 2.44-2.29 (m, 2H), 2.22-2.07 (m, 2H), 1.83 (dd, 1H, J= 2.0, 14.4 Hz), 1.60 (d, 3H, J= 6.8 Hz); 13C NMR (100 MHz, CD30D) 6:
172.9, 172.5õ 169.7, 135.7, 134.0, 129.9, 127.3, 127.2, 126.5, 123.5, 91.1, 71.4, 62.8, 58.4, 54.3, 49.0, 33.8, 33.4, 31.8, 28.1, 16.4. HRMS calcd for C23H28N404Na: 447.20028, found 447.20189.
[00484] Example 30: Preparation of (4S,9aS)-4-amino-7-(1H-indole-1-carbonyl)hexahydropyrrolo[2,1-b][1,3]oxazepin-5(2H)-one.
OH Me0 BocHN Xr Me0) OH 0=) CF3CH2OH OH
Me0 OMe N =20 min 113..
(0.
0 + s ...,,,,.. C BocHN TFA
DCM
NH3 cS 0 N 23 C H2N
OH)0 ¨OMe OMe OMe OMe [00485] Same procedure as Example 24 with Boc-N-HSer-OH (313 mg, 1.43 mmol, 1.0 equiv), aldehyde (198 mg, 1.50 mmol, 1.05 equiv), isocyanide (273 mg, 1.43 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(408 uL, 2.85 mmol, 2.0 equiv) in TFE (5 mL). The resultant oil was combined with TFA (1.09 mL, 14.3 mmol, 10 equiv) in DCM (5 nit) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00486]Example 31: Preparation of tert-Butyl ((2S)-14(4S,9aS)-7-(1H-indole-1-carbony1)-5-oxooctahydropyrrolo[2,1-b] [1,31 oxazepin-4 -yl)amino)-1-oxopropan-2-y1)(methyl)carbamate.
H H
0 s .1.õ-\
0 s Boc,Me-Ala, :
HOBT, EDC 0 cN---1 N ow... Boc 1110 NMM, THF, 23 C B 14--/ 1101 H2Nr13-0 N MI k. H 0 N
0 ¨ MI Is H 0 ----N
0 ¨
0 ¨ Me Me 41% combined (3 steps) [00487] Same procedure as Example 25 above using crude amine (611 mg, 1.43 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (291 mg, 1.43 mmol, 1.0 equiv), HOBT=xH20 (241 mg, 1.57 mmol, 1.1 equiv), NMM (786 [IL, 7.15 mmol, 5 equiv [to soak up xs TFA]) and EDC=HCI (288 mg, 1.50 mmol, 1.05 equiv) in THF (15 mL). The resultant oil was purified by flash chromatography on silica gel (2:1 1:11:4 hexanes/Et0Ac) to yield, after 3 steps, S-isomer (150 mg, 21%) and R-isomer (144 mg, 20%). Data for S-isomer: Rf= 0.27 (1:3 hexanes/Et0Ac). H NMR (400 MHz, CDC13) 6: 8.51 (d, 1H, J= 8.4 Hz), 7.57 (d, 1H, J= 8.0 Hz), 7.50 (d, 1H, J= 4.0 Hz), 7.35 (t, 1H, J= 8.4 Hz), 7.28 (t, 1H, J= 7.6 Hz), 7.16 (s, 1H), 6.69 (d, 1H, J= 3.6 Hz), 5.35 (dd, 1H, J= 3.6, 6.4 Hz), 5.28 (dd, 1H, .1=4.8, 8.0 Hz), 4.80 (dd, 1H, J= 6.0, 10.8 Hz), 4.75-4.65 (m, 1H), 4.31 (dt, 1H, J= 3.2, 12.8 Hz), 4.12 (q, 1H, J= 7.2 Hz), 4.05 (t, 1H, J= 13.2 Hz), 2.76 (s, 3H), 2.44-2.31 (m, 2H), 2.30-2.19 (m, 2H), 2.05-1.98 (m, 2H), 1.42 (s, 9H), 1.34 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 171.1, 170.8, 168.8, 135.9, 130.2, 125.3, 124.0, 124.0, 120.8, 117.0, 110.0, 89.7, 80.6, 80.6, 77.2, 70.8, 64.3, 60.4, 59.7, 53.0, 32.6, 30.3, 28.3, 28.3, 28.3, 27.2, 21Ø Data for R-isomer: Rf= 0.50 (1:3 hexanes/Et0Ac). 1H NMR (400 MHz, CDC13) 6: 8.38 (s, 1H), 7.57 (d, 1H, J= 7.6 Hz), 7.49 (d, 1H, J= 4.0 Hz), 7.35 (t, 1H, J= 7.2 Hz), 7.28 (d, 1H, J= 7.6 Hz), 7.18 (s, 1H), 6.71 (d, 1H, J= 3.6 Hz), 5.44-5.39 (iii, 2H), 4.88 (dd, 1H, J= 5.6, 11.2 Hz), 4.75-4.69 (m, 1H), 4.47(t, 2H, J= 8.8 Hz), 4.31-4.24 (m, 1H), 4.17 (dt, 1H, J= 3.2, 12.8 Hz), 4.13-4.04(m, 1H), 3.72-3.66 (m, 1H), 3.56-3.48 (m, 1H), 2.79 (s, 3H), 2.66-2.54 (m, 1H), 2.37 (sept, 1H, J= 6.8 Hz), 2.21-2.06 (m, 4H), 1.81 (qd, 1H, J= 3.6, 14.0 Hz), 1.67-1.58 (m, 1H), 1.43 (s, 9H), 1.33 (d, 3H, J= 7.2 Hz); 13C NMR
(100 MHz, CDC13) 6: 172.3, 171.1, 168.7, 135.8, 130.2, 125.4, 124.1, 123.8, 121.0, 116.7, 110.3, 89.6, 70.7, 65.8, 60.0, 53.0, 49.1, 33.1, 32.2, 30.4, 28.4, 28.4, 28.4, 26.9. HRMS
calcd for C26H34N406Na:
521.2371, found 521.2372.
[00488] Example 32: Preparation of (S)-N-445,7S,9a5)-7-(1H-indole-1-earbonyl)-oxooetahydropyrrolo[2,1-b][1,3]oxazepin-4-y1)-2-(methylamino)propanamide.
0 17=1 0 1:1 TFA
IN' DCM
Boc N
0 n 0 Me Me' Me' quant. Me [00489] Same procedure as Example 29 above using carbamate (52 mg, 0.104 mmol, 1 equiv) and TFA
(64 uL, 0.834 mmol, 8 equiv) in DCM (2 mL). After stirring for 20 h at 23 C, the solution was concentrated to yield product-TFA (53 mg, quantitative) as a single diastereomer. 'H NMR (400 MHz, CD30D) 6: 8.39 (d, 1H, J= 8.0 Hz), 7.84 (d, 1H, J= 4.0 Hz), 7.58 (d, 1H, J=
7.2 Hz), 7.33-7.24 (m, 2H), 6.73 (d, 1H, J= 4.0 Hz), 5.50-5.46 (m, 1H), 5.34 (t, 1H, J= 6.8 Hz), 4.26 (dt, 1H, J= 3.2, 12.4 Hz), 4.10-4.02 (m, 1H), 3.92-3.84 (m, 2H), 2.65 (s, 3H), 2.28 (qd, 1H, J= 3.6, 12.4 Hz), 2.19-2.05 (m, 2H), 1.86 (d, 1H, J= 14.0 Hz), 1.55 (dd, 2H, J= 4.0, 7.2 Hz), 1.50 (d, 3H, J= 7.2 Hz); 13C
NMR (100 MHz, CD30D) 6: 172.2, 171.0, 169.6, 137.2, 131.9, 126.0, 126.0, 125.0, 122.0, 117.4, 110.7, 90.9, 71.4, 61.5, 58.3, 54.4, 49.0, 33.7, 33.2, 31.7, 28.3, 16.3. HRMS calcd for C2IF126N404Na: 421.18463, found 421.18593.
[00490] Example 33: Preparation of (S)-N-((4S,7R,9aS)-7-(1H-Indole-1-carbony1)-oxooctahydropyrrolo[2,1-b][1,3]oxazepin-4-y1)-2-(methylamino)propanamide.
H H
DCM
0 ¨... 0 c...\(L?' 010 23 C FN1-}11 0 so---N ¨
Me' '-'= ...., -- Me l' Me quant. Me [00491] Same procedure as Example 29 above using carbamate (51 mg, 0.102 mmol, 1 equiv) and TFA
(117 L, 1.02 mmol, 10 equiv) in DCM (2 mL). After stirring for 20 hat 23 C, the solution was concentrated to yield product-TFA (52 mg, quantitative) as a single diastereomer. Ili NMR (400 MHz, CDC13) 6: 8.34 (d, 1H, J= 8.0 Hz), 7.85 (d, 1H, J= 4.0 Hz), 7.59 (d, 1H, J=
6.8 Hz), 7.34-7.24 (m, 2H), 6.75 (d, 1H, J= 4.0 Hz), 5.57-5.53 (m, 2H), 5.09 (dd, 1H, 1=2.0, 11.2 Hz), 4.67 (dd, 1H, J= 9.2, 10.8 Hz), 4.46 (td, 1H, J= 1.6, 8.8 Hz), 4.35-4.27 (m, 1H), 4.19 (dt, 1H, J= 2.8, 12.4 Hz), 4.12-4.04 (m, 1H), 3.90 (t, 2H, J= 6.8 Hz), 3.74-3.66 (m, 1H), 2.68 (s, 3H), 2.62-2.53 (m, 2H), 2.39-2.27 (m, 2H), 2.07 (dd, 2H, J= 7.2, 13.2 Hz), 1.93-1.87 (m, 1H), 1.55 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CD30D) 6:
176.8, 172.5, 171.1, 170.4, 169.4, 137.1, 131.9, 126.1, 125.9, 125.1, 122.0, 117.4, 111.0, 90.9, 71.3, 67.2, 61.5, 58.4, 58.2, 54.3, 50.2, 34.1, 33.2, 31.8, 31.8, 29.2, 27.9, 16.3, 16.2.
HRMS calcd for C2iH27N404:
399.2027, found 399.2028.
[00492] Example 34: Preparation of (45,75,9a5)-4-amino-5-oxo-N#R)-1,2,3,4-tetrahydronaphthalen-1-yl)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide.
STrt Me0 BocHN 1)).(2 Me0) OH 0=) CF3CH2OH STrt meo C\1).1 H TFA
_,.. S I:I
N
0 AW, 80 C BocHN 60 C
H2NCorNi N +
T 20 min 0 NI
[00493] Same procedure as Example 24 with Boc-N-HCys(Trt)-OH (665 mg, 1.39 mmol, 1.0 equiv), aldehyde (193 mg, 1.46 mmol, 1.05 equiv), isocyanide (219 mg, 1.39 mmol, 1.0 equiv) and 7 M ammonia in Me0H (398 !IL, 2.78 mmol, 2.0 equiv) in TFE (5 mL). The resultant oil was combined with TFA (1.07 mL, 13.9 mmol, 10 equiv) in DCM (5 mL) and stirred at 60 C for 6 h. The mixture was concentrated in vacuo, then partially purified (trityl byproduct removed and more polar product(s) collected) by flash chromatography on basic alumina (3:1 hexanes/Et0Ac¨*DCM¨>7% Me0H/DCM) to yield semi-pure product.
[00494] Example 35: Preparation of tert-Butyl methyl((2S)-1-oxo-1-(44S,9aS)-5-oxo-7-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)octahydropyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)propan-2-yl)carbamate.
rs s 1:1 S
Boc,Me-Ala, 1111 HOBT, EDC
___________________________ Boc 0 Boc 0 0 N * NMM, THF, 23 C /iµi¨/-111 0 n Ns.10 Me Hi 0 r., F110=117 H Me t H Me H
Me 47% combined (3 steps) [00495] Same procedure as Example 25 above using crude amine (658 mg, 1.39 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (282 mg, 1.39 mmol, 1.0 equiv), HOBT=xH20 (234 mg, 1.39 mmol, 1.1 equiv), NMM (917 !AL, 8.34 mmol, 6 equiv [to soak up xs TEA]) and EDC=HC1 (280 mg, 1.46 mmol, 1.05 equiv) in THF (18 mL). The resultant oil was purified by flash chromatography on silica gel (1:1¨>1:21:3 hexanes/Et0Ac) to yield, after 3 steps, S-isomer (121 mg, 16%, ¨3:1 d.r.) and R-isomer (100 mg, 13%, ¨3:1 d.r.) along with unseparated mixture (136 mg, 18%). Data for S-isomer:
R1= 0.27 (1:3 hexancs/Et0Ac). 1H NMR (400 MHz, CDCI3) 6: 7.32 (d, 1H, J= 7.6 Hz), 7.25-7.21 (m, 1H), 7.16-7.04 (m, 4H), 5.17 (q, 1H, J= 7.2 Hz), 5.08 (t, 1H, J= 7.2 Hz), 4.74 (d, 1H, J= 8.0 Hz), 4.53 (dd, 1H, J= 6.0, 10.8 Hz), 3.35-3.22 (m, 1H), 2.76 (s, 3H), 2.63-2.46 (m, 1H), 2.20 (d, 1H, J=
12.8 Hz), 2.12-1.98 (m, 2H), 1.92-1.71 (m, 5H), 1.59 (q, 1H, J= 12.4 Hz), 1.43 (s, 9H), 1.31 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 171.3, 169.6, 169.3, 137.3, 129.2, 129.1, 128.8, 127.2, 126.1, 62.3, 61.8, 52.8, 47.6, 33.0, 32.1, 30.4, 30.2, 29.3, 28.4, 28.4, 26.5, 20.5. Data for R-isomer: Rf= 0.44 (1:3 hexanes/Et0Ac). 1H NMR
(400 MHz, CDC13) 6: 7.22-7.12 (m, 4H), 7.09-7.04 (m, 1H), 6.62 (bs, 1H), 5.28 (d, 1H, J= 7.6 Hz), 5.09 (d, 1H, J= 6.4 Hz), 4.66-4.56 (m, 2H), 3.32 (t, 1 H, J= 12.0 Hz), 2.87-2.68 (m, 3H), 2.75 (s, 3H), 2.35-2.19 (m, 3H), 2.08-1.96 (m, 2H), 1.85-1.69 (m, 5H), 1.45 (s, 9H), 1.29 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 170.9, 169.6, 137.6, 136.6, 129.3, 128.6, 127.4, 126.3, 63.8, 61.3, 53.5, 47.7, 33.7, 31.7, 30.1, 29.3, 28.5, 28.4, 20.1. HRMS calcd for C28H401\1403SNa: 567.26116, found 567.26151.
[00496] Example 36: Preparation of (45,7S,9a5)-4-((S)-2-(methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide.
S S
TFA
DCM
Bog, C\I\ ¨11o. 0 Qi H M
H 0 Ni 0 N't Me' Le H e 0 H
quant.
[00497] Same procedure as Example 24 using carbamate (90 mg, 0.165 mmol, 1 equiv, ¨3:1 d.r.) and TFA
(126 [IL, 1.65 mmol, 10 equiv) in DCM (4 InL). After stirring for 20 hat 32 C, the solution was concentrated. The product was eluted through a short plug (-500 mg) of Silicyle TMA-chloride ion exchange resin with Me0H to yield product=HC1 (79 mg, quantitative) as the major diastereomer.
NMR (400 MHz, CD30D) 6: 7.39-7.34 (m, 1H), 7.17-7.05 (m, 4H), 5.46-5.39 (m, 1H), 5.07 (t, 1H, J=
6.8 Hz), 4.77 (dd, 1H, J = 2.0, 11.2 Hz), 4.57 (dd, 1H, J = 5.2, 7.6 Hz), 3.94-3.87(m, 1H), 3.29-3.21 (m, 1H), 3.02 (ddd, 1H, J = 2.8, 6.0, 14.4 Hz), 2.82-2.75 (m, 2H), 2.66 (s, 3H), 2.60-2.49 (m, 1H), 2.25-2.17 (m, 2H), 2.15-2.09 (m, 1H), 2.05-1.95 (m, 2H), 1.95-1.74 (m, 4H), 1.53 (d, 3H, J= 7.2 Hz); 13C NMR
(100 MHz, CD30D) 6: 172.3, 171.9, 169.5, 138.7, 138.5, 137.6, 137.3, 130.2, 130.0, 129.9, 129.5, 128.4, 128.3, 127.2, 127.1, 63.9, 63.4, 63.1, 58.4, 58.3, 55.1, 54.2, 54.1, 34.1, 33.3, 31.8, 31.8, 31.3, 31.0, 30.1, 30.1, 28.8, 28.5, 21.5, 21.1, 16.4, 16.3. HRMS calcd for C23H33N403S:
445.2268, found 445.2267.
[00498] Example 37: Preparation of (4S,7R,9aS)-4-((S)-2-(methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-l-yl)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide.
H H
S E
TFA
DCM
N H 0 0 Ne Mel H
quant. Me [00499] Same procedure as Example 24 using carbamate (24 mg, 0.0441 mmol, 1 equiv, ¨3:1 dr.) and TFA (34 [IL, 0.441 mmol, 10 equiv) in DCM (2 mL). After stirring for 20 h at 32 C, the solution was concentrated. The product was eluted through a short plug (-500 mg) of Silicyle TMA-chloride ion exchange resin with Me0H to yield product=HC1 (21 mg, quantitative) as the major diastereomer. 1H
NMR (400 MHz, CD30D) 6: 7.16-7.08 (m, 4H), 5.51 (d, 1H, J= 7.2 Hz), 5.08-5.03 (m, 1H), 4.83 (s, 1H), 4.57 (d, 1H, J= 8.8 Hz), 3.93 (q, 1H, J= 7.2 Hz), 3.37-3.34 (m, 1H), 2.90 (ddd, 1H, J= 2.8, 5.6, 12.0 Hz), 2.82-2.75 (m, 2H), 2.66 (s, 3H), 2.60-2.50 (m, 1H), 2.49-2.39 (m, 2H), 2.26-2.19 (m, 1H), 2.10-1.89 (m, 6H), 1.86-1.74 (m, 4H), 1.46 (d, 3H, J= 6.8 Hz); 13C NMR (100 MHz, CD30D) 6: 173.3, 172.3, 169.0, 138.7, 137.8, 130.0, 129.8, 129.2, 128.7, 128.1, 127.1, 64.6, 62.4, 58.3, 54.6, 53.8, 34.2, 33.7, 32.1, 31.8, 31.2, 30.3, 29.6, 21.7, 16.4. HRMS calcd for C23H33N403S: 445.2268, found 445.2267.
[00500] Example 38: Preparation of (4S,11bS)-4-amino-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-y1)-2,3,4,5,7,11b-hexahydro 41,3 ] oxazepino [2,3-a] is oindo le-7-carb oxamide.
OH Me0 .
BocHN XrMe0 OH
Me0 Me H
N TFA
,.. H
cN
0 RI+ ON, 80 C BocHN DCM
20 min 0 Nr. 23 C 0 Ni NH3 se, 0 H 0 H
[00501] Same procedure as Example 24 with Boc-N-HSer-OH (175 mg, 0.800 mmol, 1.0 cquiv), aldehyde (144 mg, 0.800 mmol, 1.0 equiv), isocyanide (126 mg, 0.800 mmol, 1.0 equiv) and 7 M ammonia in Me0H (229 L, 1.60 mmol, 2.0 equiv) in TFE (4 mL). The resultant oil was combined with TFA (490 !IL, 6.40 mmol, 8 equiv) in DCM (3 mL) and stirred at 23 C for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00502] Example 39: Preparation of tert-Butyl methyl((2S)-1-oxo-1-(((4S,11bS)-5-oxo-7-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoy1)-2,3,4,5,7,11b-hexahydro- [1,3] oxazepino [2,3-a]is oindo1-4-yflamino)propan-2-Acarbamate.
E
0 s Boc,Me-Ala, 0 HOBT, EDC 0 c......1c1V
H2NC H Boo NMM, THF, 23 C Me N 0ri H
H Me 43%
(3 steps) [00503] Same procedure as Example 25 using crude amine (323 mg, 0.640 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (130 mg, 0.640 mmol, 1.0 equiv), HOBT=xH20 (108 mg, 0.704 mmol, 1.1 equiv), NMM (281 nt, 2.56 mmol, 4 equiv) and EDC=HC1 (129 mg, 0.672 mmol, 1.05 equiv) in THF
(12 mL). The resultant oil was purified by flash chromatography on silica gel (3:1¨>1:11:2 hexanes/Et0Ac) to yield, after 3 steps, the unseparated diastercomixture (200 mg, 43%). By NMR, one of the diastereomers seems to exist as a pair of rotational isomers. R1= 0.18 (1:1 hexanes/Et0Ac). 1H NMR (400 MHz, CDC13) 6: 7.56 (d, 1H, J= 7.6 Hz), 7.47 (q, 1H, J= 4.4 Hz), 7.44-7.39 (m, 5H), 7.38-7.34 (m, 1H), 7.32-7.27 (m, 1H), 7.18-7.14 (m, 3H), 7.10-7.06 (m, 1H), 7.03 (d, 1H, J= 7.2 Hz), 6.90 (d, 1H, J= 7.2 Hz), 6.74 (d, 1H, J= 7.6 Hz), 6.44-6.36 (m, 3H), 6.21 (s, 1H), 5.50 (bs, 2H), 5.17-5.10 (m, 1H), 5.03 (dd, 1H, J = 8.0, 14.4 Hz), 4.88-4.80 (m, 2H), 4.72-4.66 (m, 1H), 4.44 (td, 2H, J= 8.8 Hz), 4.31-4.15 (m, 5H), 2.80 (s, 3H), 2.79 (s, 3H), 2.77 (s, 3H), 2.71 (t, 4H, J= 6.4 Hz), 2.22-2.08 (m, 3H), 2.06-1.98 (m, 2H), 1.86-1.73 (m, 5H), 1.71-1.61 (m, 2H), 1.48 (s, 9H), 1.46 (s, 9H), 1.35 (d, 3H, J= 7.2 Hz), 1.34 (d, 3H, J= 7.2 Hz), 1.33 (d, 3H, J=
7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 175.0, 172.4, 170.5, 168.3, 168.1, 137.7, 137.2, 136.8, 136.5, 136.5, 135.9, 135.7, 135.7, 135.2, 130.7, 130.5, 129.4, 129.3, 129.0, 128.7, 127.8, 127.4, 127.2, 126.4, 126.2, 125.0, 125.0, 122.9, 122.3, 122.3, 92.0, 91.5, 71.4, 71.4, 66.7, 66.5, 65.9, 53.3, 52.8, 49.2, 47.9, 47.7, 30.3, 29.3, 29.2, 28.5, 28.4, 28.4, 20.4, 20.2. HRMS calcd for C32H41N406Na: 599.28401, found 599.28561.
[00504] Example 40: Preparation of (4S,11bS)-4-((S)-2-(Methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1 -y1)-2,3,4,5,7,11b-hexahydro-[1,3] oxazepino [2,3-a] iso indole-7-carboxamide.
Bo 0 1:1 DCM
c 28 C
iq¨)Lri M e' e 0 H quant. Me' Le 0 0 H
[00505] Same procedure as Example 29 using carbamate (38 mg, 0.066 mmol, 1 equiv) and TFA (40 !AL, 0.527 mmol, 8 equiv) in DCM (2 mL). After stirring for 20 h at 28 C, the solution was concentrated to yield product=TFA (38 mg, quantitative) as a 1:1 diastereomixture. Data for the 1:1 diastereomixture: 11-1 NMR (400 MHz, CD:30D) 6: 7.53-7.45 (m, 7H), 7.39-7.35 (m, 1H), 7.26(d, 1H, ./
= 7.2 Hz), 7.16-7.07(d, 2H, J= 2.0 Hz), 6.53 (d, 1H, J= 1.6 Hz), 6.47 (s, 1H), 5.57 (d, 1H, J= 1.6 Hz), 5.47 (s, 1H), 5.11-5.03 (m, 3H), 4.66 (dd, 1H, J= 9.2, 11.2Hz), 4.46 (td, 1H, J= 2.0, 9.2 Hz), 4.35-4.27 (m, 4H), 3.97 (q, 1H, J=
6.8 Hz), 3.88 (q, 1H, J= 7.2 Hz), 2.89-2.74 (m, 3H), 2.70 (s, 3H), 2.69 (s, 3H), 2.62-2.54 (m, 1H), 2.33 (II, 1H, J= 1.6, 10.8 Hz), 2.02-1.92 (m, 6H), 1.85-1.76 (m, 3H), 1.62 (d, 3H, J= 7.2 Hz), 1.55 (d, 3H, J=
7.2 Hz), 1.54 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CD30D) 6:176.8, 172.2, 172.0, 171.0, 170.5, 170.4, 169.7, 169.2, 162.8, 162.4, 138.7, 138.6, 138.5, 138.4, 137.7, 137.5, 136.9, 136.6, 131.3, 131.3, 130.3, 130.2, 130.1, 130.0, 129.7, 129.5, 128.2, 128.2, 127.1, 126.3, 123.2, 123.2, 101.3, 93.2, 92.4, 72.1, 72.0, 67.3, 67.2, 66.9, 58.4, 58.4, 58.2, 54.6, 54.4, 50.2, 34.2, 33.5, 31.8, 31.8, 31.4, 31.0, 30.2, 30.2, 29.2, 21.6, 21.4, 16.4, 16.4, 16.2. HRMS calcd for C27H33N404: 477.2496, found 477.2493.
[00506]Example 41: Preparation of (45,9a5)-4-Amino-8,8-dimethy1-5-oxo-N#R)-1,2,3,4-tetrahydronaphthalen-1-y1)octahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide.
OH Me0 BocH N Lir. WO) _)< Me OH
OH 0- -e CF3CH2OH
C - -0.
Me0\1 Me Role H
N I 0 c W, 80 C BocHN TFA
Mem[t DCM
20 min 0 Ni 30 C 0 N
[00507] Same procedure as Example 24 with Boc-N-HSer-OH (157 mg, 0.718 mmol, 1.0 equiv), aldehyde (144 mg, 0.718 mmol, 1.0 equiv), isocyanide (113 mg, 0.718 mmol, 1.0 equiv) and 7 M ammonia in Me0H (205 L, 1.44 mmol, 2.0 equiv) in TFE (4 mL). The resultant oil was combined with TFA (473 ilL, 7.18 mmol, 10 equiv) in DCM (4 mL) and stirred at 30 C for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00508]Example 42: tert-Butyl ((5)-1-4(45,75,9aS)-8,8-dimethy1-5-oxo-7-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)octahydropyrrolo[2,1-b][1,3]oxazepin-4-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate.
H 0 tl 0 lil me c Boc,Me-Ala, (07.24_ (N)-1?-mdik HOBT, EDC
Boc 0 cP I*
H2N 4,1111/0 NMM, THF, 23 C ro ,N"----CH 0 0 NI 11110 0 n N e H e H
.../ H Me Me 49% combined (3 steps) [00509] Same procedure as Example 25 using crude amine (270 mg, 0.555 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (113 mg, 0.555 mmol, 1.0 equiv), HOBT-xH20 (93 mg, 0.610 mmol, 1.1 equiv), NMM (366 ilL, 3.33 mmol, 6 equiv [to soak up xs TFA]) and EDC=HC1 (112 mg, 0.582 mmol, 1.05 equiv) in THF (10 mL). The resultant oil was purified by flash chromatography on silica gel (3:1 1:11:3 hexanes/Et0Ac) to yield, after 3 steps, S-isomer (29 mg, 7%, >10:1 d.r.) along with unseparated mixture (168 mg, 42%). Data for S-isomer: Rf= 0.30 (1:1 hexanes/Et0Ac). 1HNMR (400 MHz, CDC13) 6: 7.29-7.25 (m, 2H), 7.17-7.12(m, 2H), 7.09-7.05 (m, 1H), 6.72 (d, 1H, J = 8.0 Hz), 5.24(t, 1H, J = 5.6 Hz), 5.16 (dd, 1H, J= 5.6, 6.8 Hz), 4.70 (dd, 1H, J= 5.6, 11.2 Hz), 4.16 (s, 1H), 4.05-3.98 (m, 1H), 3.93 (q, 1H, J= 12.4 Hz), 2.79 (s, 3H), 2.78-2.73 (in, 2H), 2.19 (dd, 1H, J= 6.8, 14.0 Hz), 2.06-1.96 (m, 2H), 1.88 (dd, 1H, J = 6.0, 14.0 Hz), 1.87-1.69 (m, 5H), 1.66-1.60(m, 1H), 1.47(s, 9H), 1.34(d, 3H, J = 7.2 Hz), 1.18 (s, 3H), 1.07 (s, 3H); 13C NMR (100 MHz, CDC13) 6: 170.7, 168.8, 137.3, 136.7, 136.6, 129.2, 128.9, 127.4, 126.4, 89.3, 89.2, 70.9, 70.7, 52.6, 47.5, 46.1, 39.6, 30.2, 29.7, 29.2, 28.5, 28.4, 23.8, 21.2, 19.9, 14.3, 14Ø Data for R-isomer: Rf= 0.39 (1:3 hexanes/Et0Ac). HRMS calcd for C301-144N406Na:
579.3153, found 579.3155.
[00510] Example 43: Preparation of (4S,7S,9aS)-8,8-Dimethy1-44(S)-2-(methylamino)propanamido)-5-oxo-N4R)-1,2,3,4-tetrahydronaphthalen-l-yl)octahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide.
H H
DCM
quant. NI¨)LHN 0 Ns.
Mel V H Mel t`= 0 H
Me Me [00511] Same procedure as Example 29 using carbamate (25 mg, 0.045 mmol, 1 equiv, 8:3 d.r.) and TEA
(35 L, 0.449 mmol, 10 equiv) in DCM (1 mL). After stirring for 20 h at 33 C, the solution was concentrated to yield product-TFA (25 mg, quantitative) as the major diastereomer. 1H NMR (400 MHz, CD30D) 6: 8.15 (d, 1H, J= 8.4 Hz), 7.32 (d, 1H, J= 6.4 Hz), 7.17-7.07 (m, 3H), 5.44 (t, 1H, J= 6.4 Hz), 5.10 (q, 1H, J= 6.8 Hz), 4.14 (dt, 1H, J= 3.2, 12.0 Hz), 4.08 (s, 1H), 3.99-3.91 (m, 2H), 2.80 (p, 2H, J =
6.0 Hz), 2.68 (s, 3H), 2.20 (dd, 1H, J= 6.4, 13.2 Hz), 2.08-1.96 (m, 3H), 1.89-1.77 (m, 4H), 1.58 (d, 3H, J
= 7.2 Hz); 13C NMR (100 MHz, CD30D) 6: 172.2, 171.5, 169.6, 138.5, 137.6, 130.1, 129.7, 128.3, 127.1, 117.5, 114.6, 90.5, 71.7, 71.3, 58.4, 54.2, 47.0, 40.1, 33.2, 31.8, 31.4, 30.1, 29.3, 24.2, 21.4, 16.3. HRMS
calcd for C25H3N404: 457.2809, found 457.2811.
[00512] Example 44: Preparation of (4S,7S,9aS)-4-Amino-8,8-dimethy1-5-oxo-N4R)-1,2,3,4-tetrahydronaphthalen-1-y1)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide.
STrt Me0 Me0) N i"
0C- =-)<MeMe STrt _...
OH
Me0 Me rt e H S 1:1 m BocHX
TFA cl---re N
BocHN N DCM
38 C H2N . 20 min i %., ..., H
[005131 Same procedure as Example 24 with Boc-N-HCys(Trt)-OH (500 mg, 1.05 mmol, 1.0 equiv), aldehyde (176 mg, 1.10 mmol, 1.05 equiv), isocyanide (165 mg, 1.05 mmol, 1.0 equiv) and 7 M ammonia in Me0H (299 tit, 2.09 mmol, 2.0 equiv) in TFE (5 mL). The resultant oil was combined with TFA (804 uL, 10.5 mmol, 10 equiv) in DCM (5 mL) and stirred at 38 C for 141-1. The mixture was concentrated in vacuo, then partially purified (trityl byproduct removed and more polar product(s) collected) by flash chromatography on basic alumina (3:1 hexanes/Et0Ac¨>DCM¨>7% Me0H/DCM) to yield semi-pure product.
[005141 Example 45: Preparation of tert-butyl a2S)-1-4(45,9a5)-8,8-dimethyl-5-oxo-7-4(R)-1,2,3,4-tetrahydronaphthalen-1-y1)carbamoyl)octahydropyrrolo[2,1-b][1,3]thiazepin-4-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate.
s mp S E S
Boc,Me-Ala, Me HOBT, EDC 0 N \r-DI-N
H2NP? = _____ BOR Boo, 0 * NMM, THF, 23 *C "H 0 No' H 0 -141 Me Me 60% combined (3 steps) [005151 Same procedure as Example 25 using amine (387 mg, 0.998 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (202 mg, 0.998 mmol, 1.0 equiv), HOBT=xH20 (168 mg, 1.10 mmol, 1.1 equiv), NMM (329 !AL, 2.99 mmol, 3 equiv) and EDC=HC1 (201 mg, 1.05 mmol, 1.05 equiv) in THF (10 mL). The resultant oil was purified by flash chromatography on silica gel (3:1¨>1:1¨>1:3 hexanes/Et0Ac) to yield, after 3 steps, 5-isomer (12 mg, 2%) and R-isomer (47 mg, 8%), along with unseparated mixture (300 mg, 50%) and unreacted Boc-protected starting material (59 mg, 12%) left over from the previous reaction. Data for diastereomixture: 1H NMR (400 MHz, CD30D) 6: 7.32-7.28 (m, 1H), 7.18-7.11 (m, 6H), 7.10-7.06 (m, 2H), 5.49 (d, 1H, = 9.2 Hz), 5.41 (q, 1H, = 8.0 Hz), 5.09 (t, 1H, = 6.0 Hz), 5.03 (t, 1H, .1= 6.0 Hz), 5.03 (t, 1H, J= 12.0 Hz), 4.69-4.57 (m, 4H), 4.24 (d, 1H, J= 12.4 Hz), 4.19-4.16 (m, 1H), 3.31 (d, 2H, J
= 2.0 Hz), 3.29-3.21 (m, 2H), 2.86 (s, 6H), 2.81 (s, 3H), 2.80-2.75 (m, 2H), 2.68-2.56 (m, 1H), 2.31-2.20 (m, 3H), 2.02-1.75 (m, 13H), 1.48 (s, 18H), 1.37 (d, 3H, .I= 7.6 Hz), 1.32 (d, 3H, .1= 7.2 Hz), 1.15 (s, 3H), 1.13 (s, 3H); 13C NMR (100 MHz, CD30D) 6: 172.7, 171.8, 171.4, 138.8, 138.5, 137.4, 137.4, 130.2, 130.1, 130.0, 130.0, 129.8, 129.8, 128.5, 128.3, 128.2, 127.2, 73.3, 73.3, 63.9, 61.9, 61.7, 54.8, 54.2, 54.1, 47.6, 47.2, 40.9, 40.9, 40.8, 33.8, 33.2, 32.2, 31.3, 31.2, 31.1, 30.8, 30.2, 30.1, 28.7, 28.7, 28.7, 25.3, 23.9, 21.3, 21Ø Data for S-isomer: Rf= 0.24 (1:1 hexanes/Et0Ac). Data for R-isomer: Rf = 0.38 (1:1 hexanes/Et0Ac). 1H NMR (400 MHz, CDC13) 6: 7.34-7.29 (m, 1H), 7.20-7.12 (m, 3H), 7.08 (d, 1H, J=
7.2 Hz), 6.00 (d, 1H, J= 8.8 Hz), 5.33 (d, 1H, J= 8.8 Hz), 5.14-5.07 (m, 1H), 4.57-4.47 (m, 1H), 4.06-4.02 (in, 1H), 3.28 (t, 1H, J= 12.8 Hz), 2.85-2.79 (m, 2H), 2.76 (s, 3H), 2.34-2.26 (m, 1H), 2.01-1.90 (in, 2H), 1.87-1.73 (m, 6H), 1.47 (s, 9H), 1.35 (s, 3H), 1.30 (d, 3H, J= 7.2 Hz), 1.25-1.20 (m, 1H), 1.15 (s, 3H); 13C NMR (100 MHz, CDC13) 6: 171.5, 170.6, 170.6, 169.3, 137.9, 136.3, 129.4, 129.1, 129.0, 127.5, 126.3, 73.0, 62.8, 53.9, 47.8, 46.5, 39.9, 39.8, 33.3, 32.7, 30.6, 30.1, 29.3, 28.5, 28.5, 24.6, 19.8. HRMS
calcd for C30f144N4055: 595.2925, found 595.2922.
[00516] Example 46: Preparation of (4S,9aS)-8,8-dimethy1-4-((S)-2-(methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-l-y1)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide.
TFA S 1:1 DCM Mzi Boc, N
1.1 0 Me' H
Me quant. Me [00517] Same procedure as Example 24 using carbamate (62 mg, 0.108 mmol, 1 equiv) and TFA (66 L, 0.866 mmol, 8 equiv) in DCM (3 mL). After stirring for 20 h at 38 C, the solution was concentrated.
The product was eluted through a short plug (-500 mg) of Silicyle TMA-chloride ion exchange resin with Me0H to yield product=HC1 (54 mg, quantitative) as a 1:1 diastereomixture. 1H NMR (400 MHz, CD30D) 6: 7.34-7.27 (m, 2H), 7.18-7.06 (m, 7H), 5.54-5.45 (m, 1H), 5.41 (t, 1H, J= 8.0 Hz), 5.11-5.06 (m, 1H), 5.06-5.01 (m, 1H), 4.77-4.71 (m, 2H), 4.23 (s, 1H), 4.16 (s, 1H), 3.97-3.89 (m, 2H) 3.29-3.19 (m, 2H), 2.93-2.84 (m, 2H), 2.78 (dd, 4H, J= 6.4, 12.8 Hz), 2.68 (s, 6H), 2.32-2.21 (m, 3H), 2.01-1.75 (m, 12H), 1.55 (d, 3H, J= 7.2 Hz), 1.54-1.50 (m, 2H), 1.47 (d, 3H, J= 6.8 Hz), 1.40-1.37 (m, 2H), 1.16 (s, 6H), 1.14 (s, 3H), 1.13 (s, 3H); i3C NMR (100 MHz, CD30D) 6: 172.4, 172.3, 171.8, 171.4, 169.3, 168.9, 138.8, 138.5, 137.4, 137.4, 130.1, 130.1, 129.8, 128.3, 127.1, 127.0, 73.4, 63.8, 61.8, 58.3, 55.1, 54.4, 40.9, 40.9, 40.7, 33.6, 32.1, 31.8, 31.7, 31.3, 31.1, 30.9, 30.2, 30.1, 28.7, 23.9, 21.3, 21.0, 16.3, 16.2.
HRMS calcd for C25H371\14035: 473.2581, found 473.2579.
[00518] Example 47: Preparation of (4S,7S,9aS)-4-((S)-2-((tert-Butoxycarbonyl)(methyl)amino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxylic acid.
c NaOH, H20 0 = c__1(1ri Boc Me0H, 23 C Boc 'NJ [1 0 'Nil 0 OH
Mel 0 ¨ 0 Me 75% Me/ Me [00519] To a solution of amide (142 mg,-0.285 mmol, 1.0 equiv) in Me0H (6 mL) was added 1M NaOH
(1 mL). After stirring for 3 h, the methanol was removed in vacuo. Then Et0Ac (10 mL) and 1 M NaOH
(8 mL) were added and an extraction was performed, with the organic layer being discarded. The aqueous layer was acidified with 3M HCl to pH < 2 and then extracted with DCM (3 x 5 mL). The organics were dried over sodium sulfate, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (1:3 hexanes/Et0Ac-9DCM-95% Me0H/DCM) to yield the product as a colorless oil (85 mg, 75%). Rf= 0.17 (7% Me0H/DCM). 11-1 NMR (400 MHz, CDC13) 6: 7.30 (bs, 1H), 5.22 (m, 1H), 4.77 (t, 1H, J= 8.0 Hz), 4.52-4.46 (m, 1H), 4.14 (d, 1H, J= 12.8 Hz), 3.95 (t, 1H, J= 12.0 Hz), 2.78 (s, 3H), 2.32-2.18 (m, 2H), 2.13-2.02 (m, 2H), 2.00-1.85 (m, 2H), 1.44 (s, 9H), 1.33 (d, 3H, J=
7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 171.5, 171.5, 156.2, 156.1, 89.8, 80.8, 80.7, 70.7, 59.7, 52.9, 32.7, 30.4, 30.4, 28.4, 28.4, 26.5, 26.5, 14.2. HRMS calcd for C181-129N307Na:
422.18977, found 422.19015.
[00520] Example 48: Preparation of tert-butyl ((S)-14(4S,7S,9aS)-74(R)-chroman-4-ylcarbamoy1)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepin-4-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate.
c _____________________________________ =
Bos N--)11 0 HOBT, EDC
0H NMM, THF, 23 C 0Bos H 0 *
Me Le Me H
880/ Me [00521] To a solution of carboxylic acid (50 mg, 0.125 mmol, 1.0 equiv), (R)-chroman-4-ylamine-HC1 (23 mg, 0.125 mmol, 1.0 equiv), HOBT=xH20 (21 mg, 0.138 mmol, 1.1 equiv) and NMM
(41 L, 0.376 mmol, 3 equiv) in THF (5 mL) at 0 C was added EDC=HC1 (25 mg, 0.131 mmol, 1.05 equiv). After 30 min the cold bath was removed. The solution stirred for 14 h and then was quenched with saturated aqueous NaHCO3 (15 mL), extracted with ethyl acetate (2 x 10 mL), dried over sodium sulfate and then concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (1:3 hexanes/Et0Ac) to yield the product (58 mg, 88%). Rf= 0.11 (1:2 hexanes/Et0Ac). 'H NMR (400 MHz, CDC13) 6: 7.16-7.10 (m, 3H), 6.91 (d, 1H, J= 7.2 Hz), 6.86-6.77 (m, 2H), 5.22 (t, 1H, J= 6.0 Hz), 5.12 (q, 1H, J= 6.8 Hz), 4.68 (dd, 1H, J= 6.0, 11.2 Hz), 4.59 (d, 1H, J= 7.2 Hz), 4.22 (td, 1H, J= 2.8, 7.2 Hz), 4.15-4.08 (m, 1H), 4.06-4.01 (m, 1H), 3.92 (t, 1H, J= 12.4 Hz), 2.74 (s, 3H), 2.41-2.37 (m, 2H), 2.25-2.17 (m, 1H), 2.16-2.07 (m, 1H), 2.02 (dd, 1H, J= 2.8, 7.2 Hz), 1.95-1.84 (m, 2H), 1.61-1.45 (m, 1H), 1.42 (s, 9H), 1.31 (d, 3H, J = 7.2 Hz); 13C NMR (100 MHz, CDC13) 6:
171.5, 170.1, 155.0, 129.3, 128.9, 122.3, 120.7, 117.2, 90.2, 77.2, 70.6, 63.6, 60.5, 52.6, 43.8, 32.7, 32.5, 30.2, 29.0, 28.4, 25.9.
HRMS calcd for C271-138N407Na: 553.26327, found 553.26399.
[00522J Example 49: Preparation of (4S,7S,9aS)-N-((R)-chroman-4-y1)-4-((S)-2-(methylamino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide.
0 1:1 01:1 TFA
0 c 0 DCM
Me Bos 0 -11 0 Ni 110, 32 C
Me N4' p 0 H
Me quant. oe [00523] To a solution of carbamate (58 mg, 0.109 mmol, 1 equiv) in DCM (2 mL) was added TFA (83 nL, 1.09 mmol, 10 equiv). After stirring for 20 h at 32 C, the solution was concentrated. The product was eluted through a short plug (-500 mg) of Silicyle TMA-chloride ion exchange resin with Me0H to yield product=HC1 (51 mg, quantitative). 11-I NMR (400 MHz, CD30D) 6: 7.33 (d, 1H, J= 7.6 Hz), 7.13 (t, 1H, J= 8.4 Hz), 6.86 (t, 1H, J= 7.2 Hz), 6.76 (d, 1H, J= 8.0 Hz), 5.39 (dd, 1H, J= 3.6, 6.8 Hz), 5.08 (t, 1H, J= 6.0 Hz), 4.40 (d, 1H, J= 6.8 Hz), 4.26-4.12 (m, 3H), 4.03-3.89 (m, 2H), 2.67 (s, 3H), 2.33-2.24 (m, 1H), 2.14-1.97 (m, 6H), 1.81 (dd, 1H, J= 2.0, 14.0 Hz), 1.58 (d, 3H, J=
6.8 Hz); 13C NMR (100 MHz, CD30D) 6: 172.9, 172.2, 169.6, 156.4, 130.5, 130.0, 123.5, 121.6, 117.8, 91.0, 71.3, 64.6, 62.3, 58.4, 54.2, 49.0, 44.9, 33.6, 33.3, 31.8, 30.2, 28.0, 16.4. HRMS calcd for C22H3IN405: 431.2289, found 431.2286.
[00524] Example 50: Preparation of (4S,7R,9aS)-4-((S)-2-((tert-butoxycarbonyl)(methyl)amino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxylic acid.
0Nr_e_NE
NaOH, H20 0 110 _________________ 0 c IL/
BojN c Me0H, 23 C Boc 0 ¨ 'Nil] 0 so,¨OH
MI 1/4/le 26% Me' Me [00525] To a solution of amide (105 mg, 0.211 mmol, 1.0 equiv) in Me0H (4 mL) was added 1M NaOH
(1 mL). After stirring for 3 h, the methanol was removed in vacuo. HPLC
analysis of the crude reaction mixture revealed that the R-isomer didn't react as cleanly as the S-isomer (Example 47). Then DCM (10 mL) and 1 M NaOH (8 mL) were added and an extraction was performed, with the organic layer being discarded. The aqueous layer was acidified with 3M HC1 to pH < 2 and then extracted with DCM (3 x 5 mL). The organics were dried over sodium sulfate, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (1:3 hexanes/Et0Ac¨>DCM¨>5%
Me0H/DCM) to yield the product as a colorless oil (22 mg, 26%). Rf= 0.14 (7% Me0H/DCM). 1H
NMR (400 MHz, CDC13) 6: 5.25 (d, 1H, J= 6.8 Hz), 4.83 (dd, 1H, J= 5.6, 9.6 Hz), 4.65 (d, 1H, J= 8.8 Hz), 4.14-4.09 (m, 1H), 4.0 (t, 1H, *7= 12.0 Hz), 2.79 (s, 3H), 2.41-2.31 (m, 1H), 2.27-2.11 (m, 2H), 2.06-1.96 (m, 1H), 1.78 (qd, 1H, J= 3.6, 12.0 Hz), 1.46 (s, 9H), 1.33 (d, 3H, J= 7.6 Hz); 13C NMR (100 MHz, CDC13) 6: 173.9, 172.0, 171.3, 89.6, 80.9, 70.7, 60.6, 59.8, 53.1, 33.0, 32.5, 30.5, 28.5, 26.1, 21.2, 14.3, 14.1. HRMS calcd for C18H29N307Na: 422.18977, found 422.19015.
[00526] Example 51: Preparation of tert-butyl ((5)-14(4S,7R,9a5)-7-((R)-chroman-4-ylcarbamoy1)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepin-4-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate.
H214" 110 0 c 0 Boc HOBT, EDC Boc, NMM, THF, 23 C
N H 0 *
Me "Lie Me Lie H
33%
[00527] To a solution of carboxylic acid (21 mg, 0.0053 mmol, 1.0 equiv), (R)-chroman-4-ylamine=HC1 (10 mg, 0.0053 mmol, 1.0 equiv), HOBT=xH20 (9 mg, 0.0058 mmol, 1.1 equiv) and NMM (17 L, 0.0158 mmol, 3 equiv) in THF (3 mL) at 0 C was added EDC=HC1 (11 mg, 0.0055 mmol, 1.05 equiv).
After 30 min the cold bath was removed. The solution stirred for 14 h and then was quenched with saturated aqueous NaHCO3 (10 mL), extracted with ethyl acetate (2 x 10 mL), dried over sodium sulfate and then concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (1:1¨>1:3 hexanes/Et0Ac) to yield the product (9 mg, 33%). 1H NMR (400 MHz, CDC13) 6: 7.20-7.12 (m, 3H), 6.89 (t, 1H, J= 7.6 Hz), 6.82 (d, 1H, J= 8.4 Hz), 5.23-5.19 (m, 1H), 5.12-5.05 (m, 1H), 4.79-4.71 (m, 1H), 4.55 (d, 1H, J= 8.0 Hz), 4.26-4.19 (m, 1H), 4.15-4.06 (m, 2H), 3.97 (t, 1H, J= 12.0 Hz), 2.77 (s, 3H), 2.39-2.26 (m, 1H), 2.24-2.13 (m, 2H), 2.07-2.00 (m, 1H), 1.99-1.91 (m, 2H), 1.80-1.70 (m, 2H), 1.44 (s, 9H), 1.34 (d, 3H, J= 7.2 Hz); 13C NMR (100 MHz, CDC13) 6: 172.3, 171.1, 169.9, 155.2, 129.4, 129.3, 122.0, 120.9, 117.3, 90.1, 70.6, 63.4, 61.1, 53.1, 43.8, 33.4, 32.7, 32.1, 29.8, 29.1, 28.5, 25.6, 22.8, 14.3. HRMS calcd for C27H38N407Na: 553.26327, found 553.26399.
[005281 Example 52: Preparation of (4S,7R,9aS)-N-((R)-chroman-4-y1)-4-((S)-2-(methylamino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide.
0 cPN 0 DCM
0 c 0 Boc H N
,N H 0 /7--N1 Mei Lie 0 H Me 0 H
quant. Me [00529] To a solution of carbamate (58 mg, 0.109 mmol, 1 equiv) in DCM (2 mL) was added TEA (83 [a., 1.09 mmol, 10 equiv). After stirring for 20 h at 32 C, the solution was concentrated to yield product=TFA (51 mg, quantitative). 1H NMR (400 MHz, CD30D) 6: 8.43 (d, 1H, J=
8.0 Hz), 7.15-7.09 (m, 2H), 6.85 (t, 1H, J= 8.0 Hz), 6.78-6.73 (m, 1H), 5.40 (d, 2Hõ./= 5.6 Hz), 5.10-5.04 (in, 1H), 4.99 (dd, 1H, J= 2.4, 11.2 Hz), 4.53 (d, 1H, J= 9.2 Hz), 4.21 (t, 2H, J= 5.2 Hz), 4.14 (dt, 1H, J= 3.2, 13.2 Hz), 4.05-3.96 (m, 1H), 3.91 (q, 1H, J= 7.2 Hz), 2.67 (s, 3H), 2.44-2.31 (m, 1H), 2.30-2.18 (m, 1H), 2.16-2.07 (m, 1H), 2.04-1.95 (m, 3H), 1.93-1.81 (m, 2H), 1.52 (d, 3H, J= 6.8 Hz); 13C
NMR (100 MHz, CD30D) 6:
173.5, 172.7, 169.3, 156.5, 130.2, 129.9, 123.5, 121.6, 117.9, 91.1, 71.2, 64.6, 62.3, 58.3, 54.4, 44.9, 34.0, 33.3, 31.8, 30.1, 28.2, 16.4. HRMS calcd for C22H30N405Na: 453.21084, found 453.21280.
[005301 Example 53: Preparation of (S)-ethyl 2-((S)-2-(((benzyloxy)carbonyl)(methyl)amino)propanamido)-3-(1H-indo1-3-yepropanoate.
44Ik Cbz,Me-Ala, NMM
NH HOBT, EDC NH
?bz 0 THF, r.t.
OEt H2N Me OEt 'N
0 rieH
[00531] To a solution of tryptophan derivative (600 mg, 2.23 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (530 mg, 2.23 mmol, 1.0 equiv), HOBT=xH20 (376 mg, 2.46 mmol, 1.1 equiv) and NMM
(736 iL, 6.70 mmol, 3 equiv) in THF (15 mL) at 0 C was added EDC=HC1 (449 mg, 2.34 mmol, 1.05 equiv). After 30 min the cold bath was removed. The solution was stirred for 14 h and then quenched with saturated aqueous NaHCO3 (20 mL), extracted with ethyl acetate (2 x 20 mL), dried over sodium sulfate and then concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (3:11:1 hexanes/Et0Ac) to yield the product (790 mg, 79%). LCMS calcd for M+H: 452.22, found 452.22.
[00532] Example 54: Preparation of (S)-24(S)-2-(((benzyloxy)carbonyl)(methyl)amino)propanamido)-3-(1H-indol-3-yl)propanoic acid (88).
=I.
NH Li0H, H20 NH
Cbz 0 Cbz 0 L THF, r.t. I
OEt OH
Me" '-j.(N
AeH 0 rieH
[00533] To a solution of ester (790 mg, 1.75 mmol, 1.0 equiv) in THE (12 mL) and H20 (3 inL) was added LiOH (84 mg, 3.50 mmol, 2 equiv). After stirring for 3 h, Et20 (10 mL) and 1 M NaOH (8 mL) were added and an extraction was performed, with the organic layer being discarded. The aqueous layer was acidified with 3M HC1 to pH < 2 and then extracted with DCM (3 x 8 mL).
The combined organics were dried over sodium sulfate, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (DCM-95% Me0H/DCM) to yield the product as a colorless oil (574 mg, 78%). LCMS calcd for M+H: 424.19, found 424.18.
[00534] Example 55: Preparation of benzyl ((2S)-1-(42S)-14(5,5-dimethoxy-1-oxo-1-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)amino)pentan-2-yllamino)-3-(1H-indol-3-y1)-1-oxopropan-2-y1)amino)-1-oxopropan-2-y1)(methyl)carbamate.
440 Me0 NH HN 41t LI
Cbz 0 Me0) Me Me OH 0¨ CF3CH2OH
Cbz 0 C-Me H 0 N+ ON, 80 C!).LN
20 min = H
H
[00535] A mixture of carboxylic acid (104 mg, 0.246 mmol, 1.0 equiv), aldehyde (34 mg, 0.258 mmol, 1.0 equiv), isocyanide (39 mg, 0.246 mmol, 1.0 equiv) and 7 M ammonia in Me0H (70 litL, 0.491 mmol, 2.0 equiv) in TFE (3 mL) was stirred under microwave irradiation at a set temperature of 80 C for 20 min.
The mixture was then transferred to a round bottom flask and concentrated in vacuo, then 1 M NaOH (15 mL) was added and the mixture was extracted with DCM (3 x 7 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was used without further purification in the next step. LCMS calcd for M+H: 712.37, found 712.34.
[005361 Example 56: Preparation of benzyl methyk(S)-1-oxo-1-4(35,65,12bR)-5-oxo-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoy1)-1,2,3,5,6,7,12,12b-octahydropyrrolo[1',2':1,2]azepino[3,4-b]indol-6-yl)amino)propan-2-yecarbamate.
HN
NH NH
Me0 Me H
Cbz 0 TFA 7 -me H
j4N1 DCM1 0 N 0 N
rtiA e H 0 n 40 121 Ns. 10 H u H H
Me' Le mw Le [00537] To a solution of dimethyl acetal (166 mg, 0.233 mmol, 1 equiv) in DCM
(4 mL) was added TFA
(143 litL, 1.87 mmol, 8 equiv). After stirring for 20 h at 23 C, the solution was concentrated and then purified by flash chromatography on silica gel (1:1¨>1:2 hexanes/Et0Ac) to yield S-isomer (18 mg, 11%), R-isomer (38 mg, 24%) and a mixture of the two isomers (10 mg, 6%). LCMS calcd for M+H: 648.32, found 648.30.
[005381 Example 57: Preparation of (3S,6S,12bR)-64(S)-2-(methylamino)propanamido)-5-oxo-NAR)-1,2,3,4-tetrahydronaphthalen-l-y1)-1,2,3,5,6,7,12,12b-octahydropyrrolo[1',2':1,2]azepino[3,4-b]indole-3-carboxamide.
NH NH
7 Pd-C, H2 Me0H 0 Cbz Me 0 Nµ
0 H e' lkie -Me [00539] To a solution of carbamate (16 mg, 0.0247 mmol, 1.0 equiv) in methanol (4 mL) was added 10 wt% Pd-C (5 mg). A balloon of H2 was applied for 16 h, then the mixture was filtered through Celite with DCM and concentrated in vacuo. The resultant oil was purified by preparative scale HPLC to yield the product (6 mg, 43%). LCMS calcd for M+H: 514.28, found 514.28.
[005401 Example 58: Preparation of tert-butyl ((S)-1-(((4S,7S,9aS)-1,1-dioxido-5-oxo-7-(((R)-1,2,3,4-tetrahydronaphthalen- 1-yl)carbamoyl)octahydropyffolo [2,1 -b] [1,3 ]
thiazepin-4-yl)amino)-1-oxoprop an-2-yl)(methyl)carbamate.
r mCPBA
0 k-}' =
15 c,N j---ri>----t5Ap, -5 CC Bocisii,\10 0 Nal* Bo -N
Me' Le 0 H
67% overall Me/ Le Mel Me [00541] To a solution of sulfide (48 fig, 0.0881 mmol, 1.0 equiv) in DCM (4 mL) at -5 C was added mCPBA (75% purity, 45 mg, 0.194, 2.2 equiv). After 10 minutes the cold bath was removed and the reaction stirred at 23 C for 3 h, then concentrated. The crude product was purified by flash chromatography on silica gel (3:11:11:2 hexanes/Et0Ac) to yield S-isomer (15 mg, 21%) and R-isomer (32 mg, 46%). LCMS calcd for M+H: 577.27, found 577.29.
[00542] Example 59: Preparation of (4S,7S,9aS)-44(S)-2-(methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-l-y1)octahydropyrrolo[2,1-b][1,3]thiazepine-7-carboxamide 1,1-dioxide.
0,p ,4 1;1 TFA 0 0 DCM
HcoN3N4 Boc 23 C
v H quant. N H 0 0 [1 Me, Le me' Le [00543] To a solution of carbamate (15 mg, 0.026 mmol, 1 equiv) in DCM (2 mL) was added TEA (16 IAL, 0.208 mmol, 8 equiv). After stirring for 20 h at 32 C, the solution was concentrated to yield product=TFA (15 mg, quantitative). LCMS calcd for M+H: 477.22, found 477.23.
[00544] Example 60: Preparation of N,N'-(disulfanediylbis(2,1-phenylene))diformamide.
DMSO; OHC-N
H S-S H
H2N 14111 Ac20, HCO2H
SH THF, -20 C N-CHO
[00545] The disulfide was prepared according to the established literature procedure; see Hyvl, J., Srogl, J.
Eur. Org. Chem. 2010, 2849-2851.
[00546] Example 61: Preparation of 1,2-bis(2-isocyanophenyl)disulfane.
OHC-N POCI3, Et3N
N
H S-s H
-"s- õC_ N
DCM, 0 C C -CHO N.
46%
[00547] To a solution of formamide (2.41 g, 7.92 mmol, 1.0 equiv) in DCM (40 mL) at 0 C was added Et3N (5.60 mL, 40.4 mmol, 5.1 equiv) followed by phosphorus oxychloride (1.09 mL, 11.9 mmol, 1.5 equiv). The mixture was warmed to 23 C and stirred for 2 h, at which time it was poured into saturated NaHCO3 (200 mL) and extracted with DCM (2 x 100 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was purified by flash chromatography on silica gel (5:1 hexanes/Et0Ac) to yield the product (980 mg, 46%) which was stored at 0 C.
It1= 0.38 (5:1 hexanes/Et0Ac). LCMS calcd for M+H: 269.02, found 269.01.
[00548] Example 62: Preparation of (4S,41S,9aS,9a'S)-N,N'-(disulfanediylbis(2,1-phenylene))bis(4-amino-8,8-dimethy1-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide).
Me0 OH OHme0\7eme 0 ti Me Meth<Me N TFA fit 0_ BocHNLIjy BocHNOH CF3CH2OH 0 N H2 N
DCM õ N
NH3 o 41, eW, 80 C 0 H S-s H 0 40 C H S-S H 0 110 e OH
j:3IH2 * N
Me R4e m 110 meo M A o [00549] Same procedure as Example 24 with Boc-N-HSer-OH (159 mg, 0.725 mmol, 2.0 equiv), aldehyde (122 mg, 0.762 mmol, 2.1 equiv), isocyanide (97 mg, 0.363 mmol, 1.0 cquiv) and 7 M ammonia in McOH
(207 uL, 1.45 mmol, 4.0 equiv) in TFE (5 mL). The resultant oil was combined with TFA (302 pt, 3.95 mmol, 16 equiv) in DCM (5 mL) and stirred at 40 C for 14 h. The mixture was concentrated in vacuo, then partially purified by flash chromatography on basic alumina (3:1 hexanes/Et0AcDCM¨>7%
Me0H/DCM), to yield semi-pure product. LCMS calcd for M+H: 697.28, found 697.28.
[00550] Example 63: Preparation of (S,45,4'S,9a5,9a'S)-N,N'-(disulfanediylbis(2,1-phenylene))bis(8,8-dimethy1-44(S)-2-(methylamino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide).
0 MrcA
Boc,Me-Ala, HOBT, EDC
0 c N..)..1 0 N
M!. Me 0 õ H S- H NMM, THE, 23 *C Me/ -Me 0 H S-s H 0 ..
N.
s 0 =
M/t Ni.i2 boc N
Me Mec-L, [00551] Same procedure as Example 25 using bis-amine (69 mg, 0.099 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (40 mg, 0.198 mmol, 2.0 equiv), HOBT=xH20 (33 mg, 0.218 mmol, 2.2 equiv), NMM (65 uL, 0.594 mmol, 6 equiv) and EDC=HC1 (40 mg, 0.208 mmol, 2.1 equiv) in THF (5 mL). The resultant oil was purified by flash chromatography on silica gel (3:1¨>1:1¨>1:3 hexanes/Et0Ac) to yield the product (32 mg, overall yield not determined). LCMS calcd for M+H: 1067.49, found 1067.60.
[00552J Example 64: Preparation of methyl (S,4S,4'S,9aS,9a'S)-N,N'-(disulfanediylbis(2,1-phenylene))bis(8,8-dimethy1-4-((S)-2-(methylamino)propanamido)-5-oxooctahydropyrrolo[2,1-b][1,3]oxazepine-7-carboxamide) o o Boc TFA
NilMe md .1vie H S- 111PS H 0 Hr: .õMe DCM md rvie 0 H S-s H 0 H NIMe N,-ILC!_r(-10c 23 CC
14/VrC¨H
Me Me 0 Me m I:1 A 0 [00553] To a solution of carbamate (10 mg, 9.37 iamol, 1 equiv) in DCM (2 mL) was added TFA (7 pi-, 93.7 pinol, 10 equiv). The mixture was stirred for 16 h, then concentrated in vacuo to give the product=TFA (9.5 mg, 95%). LCMS calcd for [M+ CF3CO2H]/2 + Na: 570.18, found 570.25.
[005541 Example 65: Preparation of (4S,10aS)-4-amino-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)octahydro-2H-pyrido[2,1-b][1,3]thiazepine-7-carboxamide.
OMe STrt OMe Me0) oime BocHNXrOH
CO
0 e BocHN DCM H2N1 )11114 NH3 itiW, 100 C
0 0 NI. ip [00555] A mixture of Boc-N-HCys(Trt)-OH (250 mg, 0.523 mmol, 1.0 equiv), aldehyde (80 mg, 0.550 mmol, 1.05 equiv), isocyanide (82 mg, 0.523 mmol, 1.0 equiv) and 7 M ammonia in Me0H (150 pL, 1.05 mmol, 2.0 equiv) in TFE (4 mL) was stirred under microwave irradiation at a set temperature of 100 C
for 20 min. The mixture was then transferred to a round bottom flask and concentrated in vacuo, then 1 M
NaOH (15 mL) was added and the mixture was extracted with DCM (3 x 7 mL). The combined organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was combined with TFA
(401 5.23 mmol, 10 equiv) in DCM (5 mL) and stirred at 55 C for 14 h. The mixture was concentrated in vacuo, then partially purified by flash chromatography on basic alumina (3:1 hexanes/Et0Ac¨*DCM¨>7% Me0H/DCM), to yield semi-pure product. LCMS calcd for M+H: 374.19, found 374.21.
[005561 Example 66: Preparation of tert-butyl methy142S)-1-oxo-1-(((4S,10aS)-5-oxo-7-(((R)-1,2,3,4-tetrahydronaphthalen-1-y1)carbamoyl)octahydro-2H-pyrido[2,1-b][1,3]thiazepin-4-yl)amino)propan-2-y1)carbamate.
S 7 Boc,Me-Ala, NMM S
HOBT, EDC
Cs\ NW-2 Boc 0 , THF, r.t.
Me/ ive [00557] Same procedure as Example 25 using amine (156 mg, 0.418 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (85 mg, 0.418 mmol, 1.0 equiv), HOBTAH20 (70 mg, 0.459 mmol, 1.1 equiv), NMM (138 pL, 1.25 mmol, 3 equiv) and EDC=HC1 (84 mg, 0.439 mmol, 1.05 equiv) in THF (6 mL). The resultant oil was purified by flash chromatography on silica gel (3:1¨>2:1¨>1:1¨>1:3 hexanes/Et0Ac) to yield, after 3 steps, the product (102 mg, 43% overall). LCMS calcd for M+H: 559.30, found 559.32.
[00558] Example 67: Preparation of (4S,10aS)-4-((S)-2-(methylamino)propanamido)-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-y0octahydro-2H-pyrido[2,1-b][1,3]thiazepine-7-carboxamide.
S S
TFA
Boc DCM
Me Me H
[00559] To a solution of carbamate (41 mg, 0.0734 mmol, 1 cquiv) in DCM (2 mL) was added TFA (56 uL, 0.734 mmol, 10 equiv). The mixture was stirred for 16 h, then concentrated in vacuo to give the product=TFA (42 mg, quantitative). LCMS calcd for M+H: 459.24, found 459.28.
[00560] Example 68: Preparation of tert-butyl ((6S,9aS)-5-oxo-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)hexahydro-2H-oxazolo[2,3-b][1,3]oxazepin-6-yl)carbamate.
C-} gi+ OH 0 1:1 HO
7 (Me0)3CH
BocHN 40H
NH3 H CF3CH2OH Ts0H+120 BocHN< PhH, 80 C BocHN
W, 80 C 0 u H
[00561] A mixture of Boc-N-HSer-OH (150 mg, 0.684 mmol, 1.0 equiv), glycolaldehyde dimer (41 mg, 0.342 mmol, 0.5 equiv), isocyanide (108 mg, 0.684 mmol, 1.0 equiv) and 7 M
ammonia in Me0H (293 uL, 2.05 mmol, 3.0 equiv) in TFE (4 mL) was stirred under microwave irradiation at a set temperature of 80 C for 20 min. The mixture was then transferred to a round bottom flask and concentrated in vacuo, then 1 M NaOH (15 mL) was added and the mixture was extracted with DCM (3 x 7 mL). The organics were dried over Na2SO4, filtered and concentrated in vacuo. The resultant oil was combined with trimethyl orthoformate (89 uL, 0.808 mmol, 2 equiv) and Ts01-1.1-120 (23 mg, 0.121 mmol, 0.3 equiv) in PhH (5 mL) and stirred at 90 C for 10 h. The mixture was concentrated in vacuo and the crude product will be processed as described in preceding examples. LCMS calcd for M+H:
446.23, found 446.23.
[005621 Example 69: Preparation of (6S,11bR)-6-amino-10-hydroxy-2,2-dimethy1-5-oxo-NAR)-1,2,3,4-tetrahydronaphthalen-l-y1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo[1,2-a]azepine-3-carboxamide.
Me0 OH
HO
Me Me0)D< HO Me BocHN Me0 Me 0¨ CF3CH2OH
EyM TFA
OH H2N N : Mem _ BocH N C-pW, 80 C DCM
0 IN+ ,== 0 N
0 es Ns111 lip H
[00563] Same procedure as Example 24 with Boc-Tyr-OH (346 mg, 1.23 mmol, 1.0 equiv), aldehyde (197 mg, 1.23 mmol, 1.0 equiv), isocyanide (193 mg, 1.23 mmol, 1.0 equiv) and 7 M
ammonia in Me0H (351 IAL, 2.46 mmol, 2.0 cquiv) in TFE (4 mL). The resultant oil was combined with TFA (575 ILL, 7.51 mmol, 8 equiv) in DCM (5 mL) and stirred at 35 'V for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[005641Example 70: Preparation of tert-butyl ((2S)-1 -(((6S,11bR)-10-hydroxy-2,2-dimethy1-5-oxo-3 -(((R)-1,2,3,4-tetrahydronaphthalen-1 -yl)carb amoy1)-2,3 ,5,6,7,11b-hexahy dro-1H-b enzo [c] pyrro lo [1,2-a] azepin-6-yl)amino)-1 -oxoprop an-2-y1)(methyl)carb amatc.
OH
OH
Boc,Me-Ala, Me HOBT, EDC
Me MAI;
111, NMM, THF, 23 C Boc (:)\\N
11.
0H Mel Me [00565] Same procedure as Example 25 using crude amine (406 mg, 0.939 mmol, 1.0 equiv), Boc-IV-Me-Ala-OH (191 mg, 0.939 mmol, 1.0 equiv), HOBT-xH20 (158 mg, 1.03 mmol, 1.1 equiv), NMM (310 !IL, 2.82 mmol, 3 equiv and EDC=HC1 (189 mg, 0.986 mmol, 1.05 equiv) in THE (10 mL). The resultant oil was purified by flash chromatography on silica gel (3:1¨>1:1¨>1:3 hexanes/Et0Ac with <5% DCM in all eluant to dissolve) to yield, after 3 steps the unseparated diastereomixture (250 mg, slightly impure).
LCMS calcd for M+H: 619.35, found 619.16.
[005661 Example 71: Preparation of (6S,11bR)-10-hydroxy-2,2-dimethy1-64(S)-2-(methylamino)propanamido)-5-oxo-N#R)-1,2,3,4-tetrahydronaphthalen-1 -y1)-2,3,5,6,7,11 b-hexahydro-1H-benzo [c] pyrrolo [1,2 -a] azepine-3 -carboxamide.
OH OH
H H
7 Me TFA 7 Me MAiik Mak:-Boc\N 0 Ns", 0 H N , H 0 0 HN'lli0 Me Me Mei Me [00567] To a solution of carbamate (47 mg, 0.0760 mmol, 1 equiv) in DCM (2 mL) was added TFA (47 [AL, 0.608 mmol, 8 equiv). The mixture was stirred for 16 h at 40 C, then concentrated in vacuo to give the product=TFA (42 mg, quantitative). The product was purified by reverse phase HPLC. LCMS calcd for M+H: 519.30, found 519.07.
[00568] Example 72: Preparation of (4S,9aR)-4-amino-8,8-dimethy1-2,5-dioxo-N#R)-1,2,3,4-tetrahydronaphthalen-1-ylioctahydro-lH-pyrrolo[1,2-a][1,3]diazepine-7-carboxamide.
Me0 NH2 ) M 0 Me0 NH, eo 0 _)<õ,,e . e CF3CH2OH ),.y.
OH 0¨ m _,.. fs-A OMe FT TFA
¨.- 0 H H
,...12,\..clie m -N
BocHN c BocHN N 4111 s' DCM H2N 0 ,..., Ns 110 OOP
[00569] Same procedure as Example 24 with Boc-Asn-OH (290 mg, 1.25 mmol, 1.0 equiv), aldehyde (200 mg, 1.25 mmol, 1.0 equiv), isocyanide (196 mg, 1.25 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(357 L, 2.50mmol, 2.0 equiv) in TFE (4 mL). The resultant oil was combined with TFA (635 L, 8.30 mmol, 8 equiv) in DCM (5 mL) and stirred at 35 'V for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00570] Example 73: Preparation of tert-butyl ((2S)-1-(44S,9aR)-8,8-dimethy1-2,5-dioxo-7-(((R)-1,2,3,4-tetrahydronaphthalen-l-y1)carbamoylioctahydro-1H-pyrrolo[1,2-a][1,3]diazepin-4-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate.
0 H H Boc,Me-Ala, ..,,,,le .....,\,,õõ1õ,....õ. m,õõ,:
m HOBT, EDC
111.
N Boc MIP NM M, THE, 23 C 1 ....)\---N
Ns' 4104 H2N 0 N.' ....., H
0 H Me Me [00571] Same procedure as Example 25 using crude amine (398 mg, 1.03 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (210 mg, 1.03 mmol, 1.0 equiv), HOBT=xH20 (174 mg, 1.14 mmol, 1.1 equiv), NMM (341 !AL, 3.11 mmol, 3 cquiv and EDC-FIC1 (208 mg, 1.09 mmol, 1.05 cquiv) in THF (10 mL). The resultant oil was purified by flash chromatography on silica gel (1:1-+1:3 hexanes/Et0Ac-->DCM-*3:1 DCMJEt0Ac--> Et0Ac) to yield, after 3 steps the unseparated diastereomixture (300 mg, slightly impure).
LCMS calcd for M+H: 570.33, found 570.14.
[00572]Example 74: Preparation of (4S,9aR)-8,8-dimethy1-44(S)-2-(methylamino)propanamido)-2,5-dioxo-NAR)-1,2,3,4-tetrahydronaphthalen-1-yl)octahydro-1H-pyrrolo[1,2-a][1,3]diazepine-7-carboxamide.
MAIL:
µ
0 TFA 0 N 11, Boc H 0 0 3Docomc ,1 0 0 md -riAe Me Ivie [00573] To a solution of carbamate (58 mg, 0.102 mmol, 1 equiv) in DCM (2 mL) was added TFA (62 fiL, 0.814 mmol, 8 equiv). The mixture was stirred for 16 h at 23 C, then concentrated in vacuo to give the product=TFA, which was purified by reverse phase HPLC to give 17 mg of a polar isomer and 7 mg of a less polar isomer. LCMS calcd for M+H: 470.28, found 470.36.
[00574]Example 75: Preparation of (6S,11bR)-6-amino-9-hydroxy-2,2-dimethy1-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-l-y1)-2,3,5,6,7,11b-hexahydro-1H-benzo [c] pyrro lo[1,2-a] azepine-3 -c arboxamide and (6 S,11bR)-6-amino-11-hydroxy-2,2-dimethy1-5 -ox o-N-((R)-1,2,3,4-tetrahydronaphthalen-l-y1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo[1,2-a]azepine-3-carboxamide.
OH
Me0 OH
Me0) \(Me meo OMe 0=7 'Me CF3CH2OH
NH3 BocHN
FyM DCM TFA :
uW
BocHN , 80 C N
JICJIJ two isomers: R1 or R2 = OH
other substituent = H
[00575] Same procedure as Example 24 with Boc-m-Tyr-OH (306 mg, 1.09 mmol, 1.0 equiv), aldehyde (192 mg, 1.20 mmol, 1.0 equiv), isocyanide (171 mg, 1.09 mmol, 1.0 equiv) and 7 M ammonia in Me0H
(311 p.L, 2.18 mmol, 2.0 equiv) in TFE (4 mL). The resultant oil was combined with TFA (625 viL, 8.16 mmol, 8 cquiv) in DCM (5 mL) and stirred at 23 'V for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00576]Example 76: Preparation of tert-butyl ((2S)-1-(46S,11bR)-9-hydroxy-2,2-dimethy1-5-oxo-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-y1)carbamoy1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo [1,2-azepin -6-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate and tert-butyl ((2S)-1-(((6S,11bR)- l 1-hydroxy-2,2-dimethy1-5-oxo-3-4(R)-1,2,3,4-tetrahydronaphthalen-1-yllcarbamoy1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo[1,2-a]azepin-6-yllamino)-1-oxopropan-2-y1)(methyl)carbamate.
Boc,Me-Ala, HOBT, EDC
7 Me : Me MA, ___________ 11. MA
111. 404 Boc W NMM, THF, 23 C
0 AS' H2N Nt' 'Nil 0 0 Els. w Me/
ivie two isomers: al or R2 = OH
two isomers: R1 or R2 = OH
other substituent = H other substituent = H
[00577] Same procedure as Example 25 using crude amine (442 mg, 1.02 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (207 mg, 1.02 mmol, 1.0 equiv), HOBT=xH20 (172 mg, 1.12 mmol, 1.1 equiv), NMM (337 [IL, 3.06 mmol, 3 equiv and EDC-FIC1 (205 mg, 1.07 mmol, 1.05 cquiv) in THF (10 mL). The resultant oil was purified by flash chromatography on silica gel (3:1-+1:1-+1:3 hexanes/Et0Ac¨>7% Me0H/DCM, all eluant with <5% DCM to dissolve) to yield, after 3 steps three product-containing fractions (most polar:
253 mg, medium polarity: 112 mg, least polar: 92 mg). LCMS calcd for M+H:
619.35, found 619.45.
[00578] Example 77: Preparation of (6S,11bR)-9-hydroxy-2,2-dimethy1-64(S)-2-(methylamino)propanamido)-5-oxo-N#R)-1,2,3,4-tetrahydronaphthalen-l-y1)-2,3,5,6,7,11b-hexabydro-1H-benzo[c]pyrrolo[1,2-a]azepine-3-carboxamide and (6S,11bR)-11-hydroxy-2,2-dimethy1-64(S)-2-(methylamino)propanamido)-5-oxo-N#R)-1,2,3,4-tetrahydronaphthalen-1-y1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo[1,2-a]azepine-3-carboxamide.
: Me TEA : Me MA MAIL:
BoR .11110 30 C
0 n N H 0 0 Nµ
H
Me 'Me Me/ Me two isomers: R1 or R2 = OH two isomers: R1 or R2 = OH
other substituent = H other substituent = H
[00579] Each fraction of Example 77 was run separately. To a solution of carbamate (253 mg most polar isomer, 112 mg medium polarity isomer, 92 mg least polar isomer) in DCM (2 nit) was added TFA (250, 111, 91 L, respectively, 8 equiv). The mixture was stiffed for 16 h at 40 C, then concentrated in vacuo to give the product=TFA, which was purified by reverse phase HPLC to give 151 mg of the most polar isomer, 55 mg of the medium polarity isomer and 19 mg of the least polar isomer. LCMS calcd for M+H:
519.30, found 519.41.
[00580] Example 78: Preparation of two regioisomers: (6S,11bR)-6-amino-9,10-dihydroxy-2,2-dimethy1-5-oxo-N#R)-1,2,3,4-tetrahydronaphthalen-1-y1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo[1,2-a]azepine-3-carboxamide and (6S,11bR)-6-amino-10,11-dihydroxy-2,2-dimethy1-5-oxo-N-((R)-1,2,3,4-tetrahydronaphthalen-1-y1)-2,3,5,6,7,11b-hexahydro-1H-benzo [c] pyrro lo [1,2-a] azepine-3 -c arboxamide.
OH Me0 HO Me OH R1 OH
BocHN
Me0) aiki D<Me HO R2 Me W, 80 C Ns 0 Meme TFA : Me B ocHN
N
W
DCM
NH3 Op 0 ' 'PH H2N 0 0 FIN'r alk two isomers: R1 or R2 = OH
other substituent = H
[00581] Same procedure as Example 24 with Boc-3,4-dihydroxy-L-phenylalanine (288 mg, 0.967 mmol, 1.0 equiv), aldehyde (155 mg, 0.967 mmol, 1.0 equiv), isocyanide (152 mg, 0.967 mmol, 1.0 equiv) and 7 M ammonia in Me0H (276 uL, 1.93 mmol, 2.0 equiv) in TFE (4 mL). The resultant oil was combined with TFA (369 uL, 4.82 mmol, 8 equiv) in DCM (5 mL) and stirred at 35 C for 14 h. The mixture was concentrated in vacuo and the crude product used without further purification in the next step.
[00582] Example 79: Preparation of two regioisomers: tert-butyl ((2S)-1-(((6S,11bR)-9,10-dihydroxy-2,2-dimethy1-5-oxo-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-yOcarbamoy1)-2,3,5,6,7,11b-hexahydro-1H-benzo[c]pyrrolo[1,2-a]azepin-6-yl)amino)-1-oxopropan-2-y1)(methyl)carbamate and tert-butyl ((2S)-1-(((6S,11bR)-10,11-dihydroxy-2,2-dimethy1-5-oxo-3-(((R)-1,2,3,4-tetrahydronaphthalen-1-y1)carbamoy1)-2,3,5,6,7,11b-hexahydro-1H-benzo [c]pyrrolo [1,2-a] azepin-6-yl)ami no)-1 -oxopropan-2-yl)(methyl)carbamate.
OH RI OH
Boo, Me-Ala, 7 Me HOBT, EDC 7 Me Mak ThI 111.
NMM, THF, 23 C Boc0 N
Me two isomers: R1 or R2 = OH two isomers: R1 or R2 = OH
other substituent = H other substituent = H
[00583] Same procedure as Example 25 using crude amine (339 mg, 0.602 mmol, 1.0 equiv), Boc-N-Me-Ala-OH (122 mg, 0.602 mmol, 1.0 equiv), HOBT=xH20 (101 mg, 0.662 mmol, 1.1 equiv), NMM (198 uL, 1.80 mmol, 3 equiv and EDC=HC1 (121 mg, 0.632 mmol, 1.05 equiv) in THF (10 mL). The resultant oil was not purified (to avoid degradation) and used crude in the next step.
LCMS calcd for M+H: 635.34, found 635.16.
[00584] Example 80: Preparation of two regioisomers: (6S,11bR)-9,10-dihydroxy-2,2-dimethy1-64(S)-2-(methylamino)propanamido)-5-oxo-N#R)-1,2,3,4-tetrahy dronaphthalen-1 -y1)-2,3,5,6,7,11b-hexahydro-1H-benzo [c] pyrrolo [1,2 -a] azepine-3 -carboxamide and (6 S,11bR)-10,11 -dihydroxy-2,2-dimethy1-64(S)-2-(methylamino)prop anamido)-5-oxo-N-( (R)-1,2,3,4-tetrahydronaphthalen-1 -y1)-2,3,5,6,7,11b-hexahydro-1H-benzo [c]pyrrolo [1,2 -a] azepine-3 -carboxamide.
w OH
OH OH
7 Me M;- TFA OH
7 Me : Me 0 Maltz-Boc N0 N API* DCM
111. 0 Mel Me N. H 00 N l f Fr two isomers: W or R2 = OH Me ' me Me :me other substituent = H
[00585] To a solution of carbamate (54 mg, 0.00851 mmol, 1 equiv) in DCM (2 mL) was added TFA (52 !AL, 0.681 mmol, 8 equiv). The mixture was stirred for 16 h at 25 C, then concentrated in vacuo to give the product=TFA, which was purified by reverse phase HPLC to give 3.7 mg of a more polar isomer and 7 mg of a less polar isomer. LCMS calcd for M+H: 535.29, found 535.17.
BIOLOGY EXAMPLES
[00586] Example B-1: 5000 PPC-1 cells were plated and grown overnight.
Compounds were plated and 4 hrs later, TRAIL was added to half of the plate while RPMI was added to the other half of the plate as a control. Plates were return to the incubator for 24 hrs. Plates were removed from the incubator and placed on the bench for 30 mm and then 25 uL of Cell Titer Glo were added per well. Plates were placed on a rocker and then read on a luminometer. 5000 MDA-MB-231 cells were plated per well. Compound was added and 4 hrs later, TRAIL was added at 5 ng/mL.; RPMI was added for a minus TRAIL control.
Plates were incubated an additional 24 hrs, removed to the bench for 30 min.
and then 25 uL of cell titer glo was added per well. Plates were placed on a rocker and read on a luminometer. Data were fit using PRISM.
[00587] Table B-1 below shows assay data for certain compounds described herein.
Table B-1 Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFa) 16 (WO (I1M) Ki LD50 LD50 LD50 (11M) (11M) (11M) (11-1M) o Me N N'N
Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFc,t) Ki (I-1M) (j1M) Ki LD50 LD50 LD50 (j1,M) (W) (I-1M) (1-1M) AcHNO,,N H
N-N .
r,o .
H 0 OMe MeAl N)'Irli Me H 0 N
H ' 4 C B ' o .
ti 0 OMe Me-IN--)LeCiri s Me H 0 N
H ' 5 ' C B ' o , mErki jc I -1N----..
Me H- X
N *
o r o meNort:IN----.
Me H 0 0 HN *
0 OMe H
me,Isl,N1,1(1% 111 Me H 0 N
0 H . . . .
o 3... CI
me,N,....No=N 140 m H
e 8 , N
=-= H
H
me,Islj-LNI,r el Me H 0 N'' IP
ome o , H II
me,N,...,,N 1111 X).ri me H 0 N,s, .,r,0 , ti 0me Me' N --/- Nr-i Me H 0 N
H3-_N-c( =
N _ H Me 0 Nis 1p -me 0 H
Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFc,t) 160-im) (j-1.m) Ki LD50 LD50 (j1,M) (" (" (1-1M) 0 F=1 o 13 A A
Q.--rsil-1 NI
Me' me 0 -n H
0 ti 0 14 C A A
NQI---Hi\---Me' - %-= H
Me H Me 0 15 C B
:
me, : r.i.rN
Me 0 N
H sjj NHH
roe,N,,,,Ncp Me 0 H
HI*"
Mel 17 A A
t--""Nci - H
Me 0 0p HN
Me 18 C B
0yMe0 --õH
meN=cp ' H N
Me 0 of HN
Me 19 C B
Oymeo ,c-NN:-L,Ei 0 Nj=L
Me' = N N ' Me H 0 HN
Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFc,t) Ki 0-1M) (j1M) Ki LD50 LD50 LD50 (PM (" (1-1,M) (1-1M) 0 NjEr H
, Me _ Nj N H ()N Ala ., me 0 41k.
MII;LA_e N p - H
Me 0 HN,"
0H 22 C B z ,õ.....,\_ 0 ck....) 0 H
NI---2\--HN 0 -})--N
0 ¨
Me fvie rot! 23 C B
o L-Ncµrfj--i_ 0 , _ H 0 N
0 _ Me fvie s li 0 24 C A A A A A
c11"-- 0 Hi---N
Me ,NI - H 0 Ns. .
-me - H
6:1 dr. 25 A A 0 11;1 0 )%;----H N
Mel .- N
Me 00 >10:1 dr. c 0 H Me 26 A A A A A A
0 i-=s1-1-M
L)LN
. OH [I' Me, Me 0 H
N--.)---N me' 0 NAlp :- 0 H
Me Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFc,t) Ki 0-1M) (j1M) Ki LD50 LD50 LD50 (PM) (" (1-1,M) (1-1M) H)------e._ flp N¨' H 0 N\
Me' Ivie 0 H
(--N,I.Th:
N0-3 -N-----el. 1110 . H 00 rf Me' me NH
H
-- _ O N
H. j\---N
N . H 0 n Nµ ir ... H
Me/ -Me NH
H
O N
IIIL-H j-N
N . H 0 Ns ir M6,me O o , o N
H\--NCI-.._ s=
N¨' H 0 0 iti 111#
MI itAe 3:1 d.r. 33 C A A A A
HiLO Nccr-= ilk Me irvie 0 0 H
>8:1 d.r. 34 C A A A A
Hi\---N N
Me, Me 0 H
H 35 slem A A A A A
c;r Hi\--N , N . H 0 0 if Me' iidie 3:1 d.r.
Me "i-Ae 0 0 --N H
Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFc,t) Ki (1-LM) (j1M) Ki LD50 LD50 LD50 (PM) (" (" (Jim) o,9 37 C A
'S .17I
j N H 0 0 ill IP
Me/ .Me Os? 38 C B
'SNr__Ej 0 cN....)- =
H j-N
Me/ 11e cPN , 0 H
N . H 0 ,' 110 Me,--t Me o H
rosLmT4 40 A A
11- )C04;;R:.
kid iA. --sH 00 H Me' ,A.
fIcs'i -..-,..
0 cN illi Me/ _ N H uci rw'illp 'me H
cN
H j\--N
md Me H r0 7 i\---NNNI;:j, N H 0 nin Me .iiie Structure Compd No. BIR1/2 BIR3 Ki IAP MB-231 (TRAIL) (TNFc,t) Ki 0-1M) (j1M) Ki LD50 LD50 LD50 (PM) (" (P,M) (1-1M) : Me MAI
111, N H 0 Ns Me/ 'ftle OH
OH
Me MAI;
!IP
N . H 0 Ns H
Me -me / Me Mak !IF
N H 0 Ns H
Mei me N Me mAik:
11.
N H 0 Ns H
Me/ -me : 0 Me MAIL, !IP
H j¨N
= H
Me me OH
: Me 111, H
Me/ me KEY: A = <25 micromolar; B > 25 and < 50 micromolar; C >50 micromolar Example B-2: Clinical trial for Leukemia [00588] Study Type: Interventional [00589] Endpoint Classification: Safety/Efficacy Study [00590] Intervention Model: Single Group Assignment [00591] Masking: Open Label [00592] Primary Purpose: Treatment Purpose [00593] The purpose of this study is to determine how well a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, works to treat relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia in blastic phase.
Intervention [00594] Patients are administered 35 mg/kg of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, by IV infusion, once every two weeks for 14 weeks.
Outcome Measures [00595] The primary outcome measure is the patient's response to a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, as first-line treatment in patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia in blastic phase.
[00596] The secondary outcome measure is (a) to evaluate the side-effects of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof; (b) the efficacy of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, on relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia in blastic phase;
and (c) to evaluate quality of life in patients following treatment.
Detailed Description [00597] Patients will be given a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, intravenously once, every two weeks for 14 weeks. Prior to each injection of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, a physical exam, blood work and assessment of any side effects will be performed. Every 5 weeks the patient's cancer will be re-evaluated to determine whether the treatment is working. Participation in this study will last at least 14 weeks, however patients may remain on the study as long as there is no disease progression, and they are able to tolerate the study drug without severe side effects.
Eligibility [00598] Ages Eligible for Study: 18 Years and older [00599] Genders Eligible for Study: Male or female
-184-Disease Characteristics [00600] Diagnosis of 1 of the following: Acute myeloid leukemia, Acute lymphoblastic leukemia, Myelodysplastic syndromes (Refractory anemia with excess blasts [RAEB], RAEB
in transformation, Chronic myelomonocytic leukemia in transformation with > 10% peripheral blood/bone marrow blasts), Chronic myelogenous leukemia in blastic phase [00601] Disease status must meet 1 of the following criteria: primary resistant disease (i.e., failed to achieve a complete response [CR] to a prior standard induction regimen), or relapsed disease after achieving a CR
[00602] Documented failure to most recent cytotoxic regimen [00603] No other potentially curative options [00604] No known CNS disease Patient Characteristics [00605] Over 18 [00606] Performance status: ECOG 0-2 [00607] Life expectancy: Not specified [00608] Hematopoietic: Not specified [00609] Hepatic: SGOT or SGPT <3 times upper limit of normal*; Bilirubin < 2 mg/dL* NOTE: *Unless due to organ leukemic involvement [00610] Renal: Creatininc < 2 mg/dL (unless due to organ leukemic involvement) [00611] Cardiovascular: no symptomatic congestive heart failure; no unstable angina pectoris; no cardiac arrhythmia [00612] Not pregnant or nursing [00613] Negative pregnancy test [00614] Fertile patients must use effective contraception [00615] No ongoing or active infection [00616] No psychiatric illness or social situation that would preclude study compliance [00617] No AIDS-defining disease - HIV positive allowed if CD4 counts normal [00618] No other concurrent uncontrolled illness [00619] No concurrent prophylactic hematopoietic colony-stimulating factors [00620] Chemotherapy: More than 2 weeks since prior cytotoxic chemotherapy (except hydroxyurea) and recovered [00621] Endocrine therapy: Not specified [00622] Radiotherapy: More than 2 weeks since prior radiotherapy and recovered [00623] Surgery: Not specified [00624] No concurrent combination antiretroviral therapy for HIV-positive patients [00625] No other concurrent investigational agents
in transformation, Chronic myelomonocytic leukemia in transformation with > 10% peripheral blood/bone marrow blasts), Chronic myelogenous leukemia in blastic phase [00601] Disease status must meet 1 of the following criteria: primary resistant disease (i.e., failed to achieve a complete response [CR] to a prior standard induction regimen), or relapsed disease after achieving a CR
[00602] Documented failure to most recent cytotoxic regimen [00603] No other potentially curative options [00604] No known CNS disease Patient Characteristics [00605] Over 18 [00606] Performance status: ECOG 0-2 [00607] Life expectancy: Not specified [00608] Hematopoietic: Not specified [00609] Hepatic: SGOT or SGPT <3 times upper limit of normal*; Bilirubin < 2 mg/dL* NOTE: *Unless due to organ leukemic involvement [00610] Renal: Creatininc < 2 mg/dL (unless due to organ leukemic involvement) [00611] Cardiovascular: no symptomatic congestive heart failure; no unstable angina pectoris; no cardiac arrhythmia [00612] Not pregnant or nursing [00613] Negative pregnancy test [00614] Fertile patients must use effective contraception [00615] No ongoing or active infection [00616] No psychiatric illness or social situation that would preclude study compliance [00617] No AIDS-defining disease - HIV positive allowed if CD4 counts normal [00618] No other concurrent uncontrolled illness [00619] No concurrent prophylactic hematopoietic colony-stimulating factors [00620] Chemotherapy: More than 2 weeks since prior cytotoxic chemotherapy (except hydroxyurea) and recovered [00621] Endocrine therapy: Not specified [00622] Radiotherapy: More than 2 weeks since prior radiotherapy and recovered [00623] Surgery: Not specified [00624] No concurrent combination antiretroviral therapy for HIV-positive patients [00625] No other concurrent investigational agents
-185-[006261No other concurrent anticancer agents or therapies Example B-3: Clinical trial for renal cancer [00627] Study Type: Interventional [00628] Study Design: Endpoint Classification: Safety/Efficacy Study [00629] Intervention Model: Single Group Assignment [00630] Masking: Open Label [00631] Primary Purpose: Treatment Purpose [00632] The purpose of this study is to determine overall survival of patients with renal cancer after treatment with a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof.
Intervention [00633] Patients are orally administered a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, at 15 mg/kg, every 4 days for 12 weeks.
[00634] Every week a physical exam, blood work and assessment of any side effects will be performed.
Every 4 weeks the patient's cancer will be re-evaluated to determine whether the treatment is working.
[00635] Participation in this study will last until patient death or as long as there is no disease progression, and they are able to tolerate the study drug without severe side effects.
Outcome Measures [00636] Primary Outcome Measures: The primary outcome measure is the patient's response to a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof [00637] Secondary Outcome Measures: The second outcome measures are (a) an evaluation of the side-effects of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof; (b) an evaluation of the proportion of patients that have complete or partial response or stable disease at 6 months; and (c) an evaluation of the time to progression and overall survival of patients treated with a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof Eligibility [00638] Ages Eligible for Study: 18 Years and older [00639] Genders Eligible for Study: Male or female
Intervention [00633] Patients are orally administered a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, at 15 mg/kg, every 4 days for 12 weeks.
[00634] Every week a physical exam, blood work and assessment of any side effects will be performed.
Every 4 weeks the patient's cancer will be re-evaluated to determine whether the treatment is working.
[00635] Participation in this study will last until patient death or as long as there is no disease progression, and they are able to tolerate the study drug without severe side effects.
Outcome Measures [00636] Primary Outcome Measures: The primary outcome measure is the patient's response to a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof [00637] Secondary Outcome Measures: The second outcome measures are (a) an evaluation of the side-effects of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof; (b) an evaluation of the proportion of patients that have complete or partial response or stable disease at 6 months; and (c) an evaluation of the time to progression and overall survival of patients treated with a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof Eligibility [00638] Ages Eligible for Study: 18 Years and older [00639] Genders Eligible for Study: Male or female
-186-Inclusion Criteria [00640] Patients must have histologically confirmed metastatic or unresectable renal cell carcinoma.
Predominant clear cell component is required. Pure papillary and chromophobc renal cell carcinoma, collecting duct tumors and transitional cell carcinoma are not eligible.
[00641] Patients must have at least one measurable site of disease according to RECIST criteria that has not been previously irradiated. If the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since radiation.
[00642] Patients must have metastatic disease which has progressed on or within 6 months of stopping treatment with VEGFR receptor tyrosine kinase inhibitors. Previous therapy with bevacizumab, interleukin 2, or interferon alpha is also permitted.
[00643] Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.
[00644] Patients must meet the following laboratory criteria: serum albumin >3 g/dL; AST/SGOT and ALT/SGPT <2.5 x upper limit of normal (ULN); serum bilirubin <1.5 x ULN; serum creatinine <1.5 x ULN or 24 hour creatinine clearance? 50 ml/min; serum potassium >LLN; serum phosphorus >LLN;
serum total calcium (corrected for serum albumin) or serum ionized calcium >LLN; serum magnesium >LLN; TSH and free T4 within normal limits (WNL) (patients may be on thyroid hormone replacement);
adequate bone marrow function as shown by: ANC >1.5 x 10 to the 9th power/L, Platelets >100 x 10 to the 9th power, Hb >9 g/dL; INR <1.3; fasting serum cholesterol <300 mg/dL OR
<7.75 mmol/L AND
fasting triglycerides <2.5 x ULN.
[00645] Baseline MUGA or ECHO must demonstrate LVEF > the lower limit of the institutional normal.
[00646] EC OG Performance Status of <2 Exclusion Criteria [00647] Patients currently receiving anticancer therapy within 4 weeks of the study drug (including chemotherapy, radiation therapy, antibody therapy, etc.) [00648] Patients who have had major surgery or significant traumatic injury within 4 weeks of start of study drug patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study [00649] Prior treatment with any investigational drug within the preceding 4 weeks [00650] Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed [00651] Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period [00652] Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticosteroids for brain or leptomeningeal metastases [00653] Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin
Predominant clear cell component is required. Pure papillary and chromophobc renal cell carcinoma, collecting duct tumors and transitional cell carcinoma are not eligible.
[00641] Patients must have at least one measurable site of disease according to RECIST criteria that has not been previously irradiated. If the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since radiation.
[00642] Patients must have metastatic disease which has progressed on or within 6 months of stopping treatment with VEGFR receptor tyrosine kinase inhibitors. Previous therapy with bevacizumab, interleukin 2, or interferon alpha is also permitted.
[00643] Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.
[00644] Patients must meet the following laboratory criteria: serum albumin >3 g/dL; AST/SGOT and ALT/SGPT <2.5 x upper limit of normal (ULN); serum bilirubin <1.5 x ULN; serum creatinine <1.5 x ULN or 24 hour creatinine clearance? 50 ml/min; serum potassium >LLN; serum phosphorus >LLN;
serum total calcium (corrected for serum albumin) or serum ionized calcium >LLN; serum magnesium >LLN; TSH and free T4 within normal limits (WNL) (patients may be on thyroid hormone replacement);
adequate bone marrow function as shown by: ANC >1.5 x 10 to the 9th power/L, Platelets >100 x 10 to the 9th power, Hb >9 g/dL; INR <1.3; fasting serum cholesterol <300 mg/dL OR
<7.75 mmol/L AND
fasting triglycerides <2.5 x ULN.
[00645] Baseline MUGA or ECHO must demonstrate LVEF > the lower limit of the institutional normal.
[00646] EC OG Performance Status of <2 Exclusion Criteria [00647] Patients currently receiving anticancer therapy within 4 weeks of the study drug (including chemotherapy, radiation therapy, antibody therapy, etc.) [00648] Patients who have had major surgery or significant traumatic injury within 4 weeks of start of study drug patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study [00649] Prior treatment with any investigational drug within the preceding 4 weeks [00650] Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed [00651] Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period [00652] Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticosteroids for brain or leptomeningeal metastases [00653] Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin
-187-1006541 Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: symptomatic congestive heart failure of New York Heart Association Class III or IV; unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant heart disease; concomitant use of drugs with a risk of causing torsades de pointes; severly impaired lung function (02 saturation 90% or less at rest on room air); uncontrolled diabetes as defined be fasting serum glucose >1.5 ULN; active (acute or chronic) or uncontrolled severe infections; liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis 100655] A known history of HIV seropositivity [00656] Impairment of gastrointestinal (GI) function or GI disease 1006571 Patients with an active, bleeding diathesis 1006581 Female patients who are pregnant or breast feeding or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are used, these must be continued throughout the trial by both sexes. Hormonal contraceptives are not acceptable as a sole method of contraception.
[00659] History of non-compliance to medical regimens 1006601 Patients unwilling to or unable to comply with the protocol Example B-4: Parenteral Composition 1006611 To prepare a parenteral pharmaceutical composition suitable for administration by injection, 100 mg of a water-soluble salt of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is dissolved in 2% HPMC, 1% Tween 80TM in DI water, pH 2.2 with MSA, q.s. to at least 20 mg/mL. The mixture is incorporated into a dosage unit form suitable for administration by injection.
Example B-5: Oral Composition 1006621 To prepare a pharmaceutical composition for oral delivery, 400 mg of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, and the following ingredients are mixed intimately and pressed into single scored tablets.
Tablet Formulation Ingredient Quantity per tablet mg compound 400 cornstarch 50 croscarmellose sodium 25 lactose 120 magnesium stearate 5
[00659] History of non-compliance to medical regimens 1006601 Patients unwilling to or unable to comply with the protocol Example B-4: Parenteral Composition 1006611 To prepare a parenteral pharmaceutical composition suitable for administration by injection, 100 mg of a water-soluble salt of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, is dissolved in 2% HPMC, 1% Tween 80TM in DI water, pH 2.2 with MSA, q.s. to at least 20 mg/mL. The mixture is incorporated into a dosage unit form suitable for administration by injection.
Example B-5: Oral Composition 1006621 To prepare a pharmaceutical composition for oral delivery, 400 mg of a compound of Formula A, Formula B, Formula C, Formula D, Formula E, Formula F, or Formula G, or pharmaceutically acceptable salt, N-oxide, racemate or stereoisomer thereof, and the following ingredients are mixed intimately and pressed into single scored tablets.
Tablet Formulation Ingredient Quantity per tablet mg compound 400 cornstarch 50 croscarmellose sodium 25 lactose 120 magnesium stearate 5
-188-[00663] The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.
Capsule Formulation Ingredient Quantity per capsule mg compound 200 lactose spray dried 148 magnesium stearate 2 [00664] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only.
Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Capsule Formulation Ingredient Quantity per capsule mg compound 200 lactose spray dried 148 magnesium stearate 2 [00664] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only.
Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
-189-
Claims (95)
1. A compound having the structure of Formula B-III-1, or pharmaceutically acceptable salt thereof:
wherein, R' is H, Ci-C6alkyl, C3-C6cycloalkyl, ¨Cl-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, ¨Cl-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
X' is selected from S, S(0) and S(0)2, X2 is CR2.0, and X' is CR2aR213;
R2a, R2b, R2C, an ¨ ic2d a are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Csheterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl) and ¨C(=0)1e;
le is substituted or unsubstituted Ci-C6alky1, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6a1kyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alky1-(substituted or unsubstituted heteroaryl), or ¨NIORE;
R" and RE are independently selected from H, substituted or unsubstituted Cl-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted Date recue/Date received 2023-04-20 C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Csheterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or Ci-C3fluoroalkyl;
R4 is ¨NHR5, -N(R5)2, or ¨0R5;
each R5 is independently selected from H, Cl-C3haloalkyl, and -C1-C3alkyl-(C3-Cscycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is ¨NHC(=0)R7, -C(=0)NHR7, ¨NHC(=0)NHR7, ¨(Ci-C3alkyl)-NHC(=0)R7, ¨(Ci-C3alkyl)-C(=0)NHR5, or ¨(C1-C3alky1)-NHC(=0)NHR7;
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C2-Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-Ciocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted aryl)2, -(CH2)p-CH(substituted or unsubstituted heteroaryl)2, -(CH2)p-CH(substituted or unsubstituted aryl)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), or -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
Date recue/Date received 2023-04-20 p is 0, 1 or 2;
Rsa, Rsb, R8C, and x ¨8d are independently selected from H, Ci-C6alkyl, Ci-C6fiuoroalkyl, Ci-C6 alkoxy, and substituted or unsubstituted aryl;
or:
R8a and R" are independently selected from H, Ci-C6alkyl, Cl-C6fluoroalkyl, C1-C6 alkoxy, and substituted or unsubstituted aryl, and WI' and R8C together form a bond;
or:
R8a and R8d are independently selected from H, Ci-C6alkyl, C1-C6fluoroalkyl, Cl-C6 alkoxy, and substituted or unsubstituted aryl, and R81' and R8C together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8C and R" are independently selected from H, C1-C6alkyl, C1-C6fluoroalkyl, Ci-C6 alkoxy, and substituted or unsubstituted aryl, and lea and R8" together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8a and R81' are independently selected from H, Cl-C6alkyl, Cl-C6fluoroalkyl, C1-C6 alkoxy, and substituted or unsubstituted aryl, and lec and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, Ci-C4alky1, Cl-C4 fluoroalkyl, C l-C4 alkoxy, fluoroalkoxy, -NH2, -NH(Ci-C4a1ky1), Date recue/Date received 2023-04-20 -NH(C -C4alky1)2, -C(=0)0H, -C(=0)NH2, -C(= 0)C -C3 alkyl, -S (=0)2 CH3, -NH(C -C4alkyl)-0H, -NH(C 1-C4alkyl)-0-(C1-C4alkyl), -0(C -C4alkyl)-NH2 ;
-0(Ci-C4alkyl)-NH-(Ci-C4alkyl), and -0(Ci-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
wherein, R' is H, Ci-C6alkyl, C3-C6cycloalkyl, ¨Cl-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, ¨Cl-C6alkyl-(substituted or unsubstituted aryl), or ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl);
X' is selected from S, S(0) and S(0)2, X2 is CR2.0, and X' is CR2aR213;
R2a, R2b, R2C, an ¨ ic2d a are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Csheterocycloalkyl), ¨C1-C6alkyl-(substituted or unsubstituted aryl), ¨C1-C6alkyl-(substituted or unsubstituted heteroaryl) and ¨C(=0)1e;
le is substituted or unsubstituted Ci-C6alky1, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6a1kyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alky1-(substituted or unsubstituted heteroaryl), or ¨NIORE;
R" and RE are independently selected from H, substituted or unsubstituted Cl-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted Date recue/Date received 2023-04-20 C2-05heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Csheterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl);
-U- is -NHC(=0)-, -C(=0)NH-, -NHS(=0)2-, -S(=0)2NH-, -NHC(=0)NH-, -NH(C=0)0-, -0(C=0)NH-, or -NHS(=0)2NH-;
R3 is Ci-C3alkyl, or Ci-C3fluoroalkyl;
R4 is ¨NHR5, -N(R5)2, or ¨0R5;
each R5 is independently selected from H, Cl-C3haloalkyl, and -C1-C3alkyl-(C3-Cscycloalkyl);
or:
R3 and R5 together with the atoms to which they are attached form a substituted or unsubstituted 5-7 membered ring;
or:
R3 is bonded to a nitrogen atom of U to form a substituted or unsubstituted 5-7 membered ring;
R6 is ¨NHC(=0)R7, -C(=0)NHR7, ¨NHC(=0)NHR7, ¨(Ci-C3alkyl)-NHC(=0)R7, ¨(Ci-C3alkyl)-C(=0)NHR5, or ¨(C1-C3alky1)-NHC(=0)NHR7;
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C2-Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-Ciocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted aryl)2, -(CH2)p-CH(substituted or unsubstituted heteroaryl)2, -(CH2)p-CH(substituted or unsubstituted aryl)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted aryl), -(substituted or unsubstituted aryl)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted aryl), or -(substituted or unsubstituted heteroaryl)-(substituted or unsubstituted heteroaryl);
Date recue/Date received 2023-04-20 p is 0, 1 or 2;
Rsa, Rsb, R8C, and x ¨8d are independently selected from H, Ci-C6alkyl, Ci-C6fiuoroalkyl, Ci-C6 alkoxy, and substituted or unsubstituted aryl;
or:
R8a and R" are independently selected from H, Ci-C6alkyl, Cl-C6fluoroalkyl, C1-C6 alkoxy, and substituted or unsubstituted aryl, and WI' and R8C together form a bond;
or:
R8a and R8d are independently selected from H, Ci-C6alkyl, C1-C6fluoroalkyl, Cl-C6 alkoxy, and substituted or unsubstituted aryl, and R81' and R8C together with the atoms to which they are attached form a substituted or unsubstituted fused 5-7 membered saturated, or partially saturated carbocyclic ring or heterocyclic ring comprising 1-3 heteroatoms selected from S, 0 and N, a substituted or unsubstituted fused 5-10 membered aryl ring, or a substituted or unsubstituted fused 5-10 membered heteroaryl ring comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8C and R" are independently selected from H, C1-C6alkyl, C1-C6fluoroalkyl, Ci-C6 alkoxy, and substituted or unsubstituted aryl, and lea and R8" together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
or:
R8a and R81' are independently selected from H, Cl-C6alkyl, Cl-C6fluoroalkyl, C1-C6 alkoxy, and substituted or unsubstituted aryl, and lec and R8d together with the atoms to which they are attached form a substituted or unsubstituted saturated, or partially saturated 3-7 membered spirocycle or heterospirocycle comprising 1-3 heteroatoms selected from S, 0 and N;
where each substituted alkyl, fused ring, spirocycle, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each R9 is independently selected from halogen, -0H,-SH, (C=0), CN, Ci-C4alky1, Cl-C4 fluoroalkyl, C l-C4 alkoxy, fluoroalkoxy, -NH2, -NH(Ci-C4a1ky1), Date recue/Date received 2023-04-20 -NH(C -C4alky1)2, -C(=0)0H, -C(=0)NH2, -C(= 0)C -C3 alkyl, -S (=0)2 CH3, -NH(C -C4alkyl)-0H, -NH(C 1-C4alkyl)-0-(C1-C4alkyl), -0(C -C4alkyl)-NH2 ;
-0(Ci-C4alkyl)-NH-(Ci-C4alkyl), and -0(Ci-C4alkyl)-N-(Ci-C4alky1)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or Ci-C3alkyl.
2. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:
is H or C1-C6alkyl; and R2a, R2b, x ¨2c, and R2d are independently selected from H, Ci-C3alky1, and -C(=0)RB.
is H or C1-C6alkyl; and R2a, R2b, x ¨2c, and R2d are independently selected from H, Ci-C3alky1, and -C(=0)RB.
3. The compound of claim 1 or 2, or pharmaceutically acceptable salt thereof, wherein:
-U- is -NHC(=0)- or -C(=0)NH-;
It3 is Ci-C3alkyl;
R4 is¨NHR5, or -N(R5)2; and each R5 is independently selected from H, Ci-C3alkyl, and -Ci-C3alkyl-(C3-Cscycloalkyl).
-U- is -NHC(=0)- or -C(=0)NH-;
It3 is Ci-C3alkyl;
R4 is¨NHR5, or -N(R5)2; and each R5 is independently selected from H, Ci-C3alkyl, and -Ci-C3alkyl-(C3-Cscycloalkyl).
4. The compound of any one of claims 1-3, or pharmaceutically acceptable salt thereof, wherein:
5. The compound of any one of claims 1-4, or pharmaceutically acceptable salt thereof, wherein,
6. The compound of any one of claims 1-5, or pharmaceutically acceptable salt thereof, wherein R2a,R2b R2c, and R2d are independently H or Ci-C3 alkyl.
7. The compound of any one of claims 1-6, or pharmaceutically acceptable salt thereof, having the structure of Formula B-V-2, or Formula B-VI-2:
Date recue/Date received 2023-04-20
Date recue/Date received 2023-04-20
8. The compound of any one of claims 1-6, or pharmaceutically acceptable salt thereof, having the structure of Foimula B-XII:
wherein R8 and R81) are independently selected from H and C1-C3alkyl.
wherein R8 and R81) are independently selected from H and C1-C3alkyl.
9. The compound of claim 8, or pharmaceutically acceptable salt thereof, wherein:
Xi is S or S(0)2, and X2 is CH2.
Xi is S or S(0)2, and X2 is CH2.
10. The compound of any one of claims 1-6, or pharmaceutically acceptable salt thereof, having the structure of Formula B-XV:
wherein ring B is an aryl or heteroaryl ring.
wherein ring B is an aryl or heteroaryl ring.
11. The compound of claim 10, or pharmaceutically acceptable salt thereof, wherein ring B is selected from phenyl, pyridinyl and thiophenyl.
12. The compound of any one of claims 1-6, or pharmaceutically acceptable salt thereof, having the structure of Foimula B-XVI-1, Formula B-XVI-2, or Formula B-XVI-3:
Date recue/Date received 2023-04-20
Date recue/Date received 2023-04-20
13. The compound of any one of claims 1-12, or pharmaceutically acceptable salt thereof, wherein RI is H or methyl.
14. The compound of any one of claims 1-13, or pharmaceutically acceptable salt thereof, wherein RI is H.
15. The compound of any one of claims 1-14, or pharmaceutically acceptable salt thereof, wherein R6 is ¨C(=-0)NHR7.
16. The compound of claim 1, or phalmaceutically acceptable salt thereof, wherein the compoi nd of Formula B-III-1 has the structure of Formula B-XXII, or pharmaceutically acceptable salt thereof:
wherein, W2 is C(R8C)(led);
R' is H, or Ci-C6alkyl;
X' is S, S(0), or S(0)2;
Date recue/Date received 2023-04-20 R2' and R21) are independently selected from H, substituted or unsubstituted and ¨C(=-0)RB;
le is substituted or unsubstituted Ci-C6alkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨Nlele;
R" and le are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-Csheterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-Csheterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨Ci-C6alky1-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or Ci-C3fluoroalkyl;
each R5 is independently selected from H, Ci-C3alkyl, Ci-C3haloalkyl, and -Ci-C3alky1-(C3-Cscycloalkyl);
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C2-Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-Ciocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted ary1)-(substituted or unsubstituted aryl), -(substituted or unsubstituted ary1)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroary1)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroary1)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
le' and Rn are independently selected from H, Ci-C6alky1, and Ci-C6fluoroalkyl;
R8C and R" are independently selected from H, Ci-C6alky1, and Ci-C6fluoroalky1;
where each substituted alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each le is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-Caalkyl, CI-Ca fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(C1-C4alkyl), -NH(C -C4alky1)2, -C(=0)0H, -C(=0)NH2, -C(=0)C i-C3alkyl, -S(=0)2CH3, -NH(Ci-Caalkyl)-0H, -NH(Ci-Caalky1)-0-(Ci-Caalkyl), -0(Ci-Caalkyl)-NH2;
-0(Ci-Caalkyl)-NH-(Cl-Caalkyl), and -0(Ci-Caalky1)-N-(Ci-C4alkyl)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
wherein, W2 is C(R8C)(led);
R' is H, or Ci-C6alkyl;
X' is S, S(0), or S(0)2;
Date recue/Date received 2023-04-20 R2' and R21) are independently selected from H, substituted or unsubstituted and ¨C(=-0)RB;
le is substituted or unsubstituted Ci-C6alkyl, -C1-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-05heterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), ¨Ci-C6alkyl-(substituted or unsubstituted heteroaryl), or ¨Nlele;
R" and le are independently selected from H, substituted or unsubstituted Ci-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-Csheterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-C6cycloalkyl), -C1-C6alkyl-(substituted or unsubstituted C2-Csheterocycloalkyl), ¨Ci-C6alkyl-(substituted or unsubstituted aryl), or ¨Ci-C6alky1-(substituted or unsubstituted heteroaryl);
R3 is Ci-C3alkyl, or Ci-C3fluoroalkyl;
each R5 is independently selected from H, Ci-C3alkyl, Ci-C3haloalkyl, and -Ci-C3alky1-(C3-Cscycloalkyl);
each R7 is independently selected from Ci-C6alkyl, Ci-C6haloalkyl, a substituted or unsubstituted C3-Ciocycloalkyl, a substituted or unsubstituted C2-Cioheterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, -Ci-C6alkyl-(substituted or unsubstituted C3-Ciocycloalkyl), -Ci-C6alkyl-(substituted or unsubstituted C2-Cioheterocycloalkyl, -Ci-C6alkyl-(substituted or unsubstituted aryl), -Ci-C6alkyl-(substituted or unsubstituted heteroaryl), -(CH2)p-CH(substituted or unsubstituted ary1)2, -(CH2)p-CH(substituted or unsubstituted heteroary1)2, -(CH2)p-CH(substituted or unsubstituted ary1)(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted ary1)-(substituted or unsubstituted aryl), -(substituted or unsubstituted ary1)-(substituted or unsubstituted heteroaryl), -(substituted or unsubstituted heteroary1)-(substituted or unsubstituted aryl), -(substituted or unsubstituted heteroary1)-(substituted or unsubstituted heteroaryl);
p is 0, 1 or 2;
le' and Rn are independently selected from H, Ci-C6alky1, and Ci-C6fluoroalkyl;
R8C and R" are independently selected from H, Ci-C6alky1, and Ci-C6fluoroalky1;
where each substituted alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted with 1-3 R9; and each le is independently selected from halogen, -OH, -SH, (C=0), CN, Ci-Caalkyl, CI-Ca fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, -NH2, -NH(C1-C4alkyl), -NH(C -C4alky1)2, -C(=0)0H, -C(=0)NH2, -C(=0)C i-C3alkyl, -S(=0)2CH3, -NH(Ci-Caalkyl)-0H, -NH(Ci-Caalky1)-0-(Ci-Caalkyl), -0(Ci-Caalkyl)-NH2;
-0(Ci-Caalkyl)-NH-(Cl-Caalkyl), and -0(Ci-Caalky1)-N-(Ci-C4alkyl)2, or two R9 together with the atoms to which they are attached form a methylene dioxy or ethylene dioxy ring substituted or unsubstituted with halogen, -OH, or C1-C3alkyl.
17. The compound of claim 16, or pharmaceutically acceptable salt thereof, wherein:
RI is H;
lea, R2b are independently selected from H, and Ci-C3alkyl;
R8a, R8b, R8C, R8d are independently selected from H and Ci-C3alkyl.
RI is H;
lea, R2b are independently selected from H, and Ci-C3alkyl;
R8a, R8b, R8C, R8d are independently selected from H and Ci-C3alkyl.
18. The compound of any one of claims 1-17, or pharmaceutically acceptable salt thereof, wherein, R7 is selected from
19. The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein the compound has one of the following structures:
or pharmaceutically acceptable salt thereof.
or pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition comprising the compound of any one of claims 1-19, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
21. Use of the compound of any one of claims 1-19, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a hyperproliferative disorder.
22. Use of the compound of any one of claims 1-19, or pharmaceutically acceptable salt thereof, for treatment of a hyperproliferative disorder.
23. The compound of any one of claims 1-19, or pharmaceutically acceptable salt thereof, for use in the treatment of a hyperproliferative disorder.
Date recue/Date received 2023-04-20
Date recue/Date received 2023-04-20
24. The use of claim 21 or 22, wherein the hyperproliferative disorder is cancer or an autoimmune disease.
25. The compound of claim 23, or pharmaceutically acceptable salt thereof, wherein the hyperproliferative disorder is cancer or autoimmune disease.
26. The use of claim 24, wherein the autoimmune disease is hemolytic anemia, autoimmune hepatitis, Berger's disease or IgA nephropathy, celiac sprue, chronic fatigue syndrome, Crohn's disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, or vitiligo.
27. The compound of claim 25, or pharmaceutically acceptable salt thereof, wherein the autoimmune disease is hemolytic anemia, autoimmune hepatitis, Berger's disease or IgA
nephropathy, celiac sprue, chronic fatigue syndrome, Crohn's disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, or vitiligo.
nephropathy, celiac sprue, chronic fatigue syndrome, Crohn's disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, or vitiligo.
28. Use of the compound of any one of claims 1-19, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer.
29. Use of the compound of any one of claims 1-19, or pharmaceutically acceptable salt thereof, for the treatment of cancer.
30. The compound of any one of claims 1-19, or pharmaceutically acceptable salt thereof, for use in the treatment of cancer.
31. The use of claim 28 or 29, wherein the cancer is a sarcoma, carcinoma, blastoma, myeloma, leukemia, lymphoma, or combinations thereof.
32. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is a sarcoma, carcinoma, blastoma, myeloma, leukemia, lymphoma, or combinations thereof.
Date recue/Date received 2023-04-20
Date recue/Date received 2023-04-20
33. The use of claim 28 or 29, wherein the cancer is a skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, uterine cancer, pancreatic cancer, liver cancer, or any combinations thereof.
34. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is a skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, uterine cancer, pancreatic cancer, liver cancer, or any combinations thereof.
35. The use of claim 28 or 29, wherein the cancer is acute myelogenous leukemia (AML).
36. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is acute myelogenous leukemia (AML).
37. The use of claim 28 or 29, wherein the cancer is renal cell carcinoma.
38. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is renal cell carcinoma.
39. The use of claim 28 or 29, wherein the cancer is ovarian cancer.
40. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is ovarian cancer.
41. The use of claim 28 or 29, wherein the cancer is prostate cancer.
42. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is prostate cancer.
43. The use of claim 28 or 29, wherein the cancer is glioblastoma.
44. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is gli oblastoma.
45. The use of claim 28 or 29, wherein the cancer is gastric carcinoma.
46. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is gastric carcinoma.
47. The use of claim 28 or 29, wherein the cancer is esophageal squamous cell carcinoma.
48. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is esophageal squamous cell carcinoma.
49. The use of claim 28 or 29, wherein the cancer is a lung cancer.
50. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is a lung cancer.
Date recue/Date received 2023-04-20
Date recue/Date received 2023-04-20
51. The use of claim 49, wherein the cancer is non-small cell lung carcinoma or small cell lung cancer.
52. The compound of claim 50, or pharmaceutically acceptable salt thereof, wherein the cancer is non-small cell lung carcinoma or small cell lung cancer.
53. The use of claim 28 or 29, wherein the cancer is multiple myeloma.
54. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is multiple myeloma.
55. The use of claim 28 or 29, wherein the cancer is pancreatic cancer.
56. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is pancreatic cancer.
57. The use of claim 28 or 29, wherein the cancer is breast cancer.
58. The compound of claim 30, or pharmaceutically acceptable salt thereof, wherein the cancer is breast cancer.
59. Use of the compound of any one of claims 1-19, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease associated with unwanted angiogenesis, wherein the disease associated with unwanted angiogenesis is cancer, macular degeneration, rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, sclerodenna or hypertrophic scarring.
60. Use of the compound of any one of claims 1-19, or pharmaceutically acceptable salt thereof, for treatment of a disease associated with unwanted angiogenesis, wherein the disease associated with unwanted angiogenesis is cancer, macular degeneration, rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, scleroderma or hypertrophic scarring.
61. The compound of any one of claims 1-19, or pharmaceutically acceptable salt thereof, for use in the treatment of a disease associated with unwanted angiogenesis, wherein the Date recue/Date received 2023-04-20 disease associated with unwanted angiogenesis is cancer, macular degeneration, rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, scleroderma or hypertrophic scarring.
62. The use of claim 59 or 60, wherein the disease associated with unwanted angiogenesis is macular degeneration, rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, scleroderma or hypertrophic scarring.
63. The compound of claim 61, or pharmaceutically acceptable salt thereof, wherein the disease associated with unwanted angiogenesis is macular degeneration, rheumatoid arthritis, psoriasis, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, intestinal adhesions, atherosclerosis, scleroderma or hypertrophic scarring.
64. The use of claim 59 or 60, wherein the disease associated with unwanted angiogenesis is a cancer.
65. The compound of claim 61, or pharmaceutically acceptable salt thereof, wherein the disease associated with unwanted angiogenesis is a cancer.
66. The use of claim 64, wherein the cancer is a sarcoma, carcinoma, blastoma, myeloma, leukemia, lymphoma, or combinations thereof.
67. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is a sarcoma, carcinoma, blastoma, myeloma, leukemia, lymphoma, or combinations thereof.
68. The use of claim 64, wherein the cancer is a skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, uterine cancer, pancreatic cancer, liver cancer, or any combinations thereof.
Date recue/Date received 2023-04-20
Date recue/Date received 2023-04-20
69. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is a skin cancer, lung cancer, breast cancer, prostate cancer, colorectal cancer, cervical cancer, uterine cancer, pancreatic cancer, liver cancer, or any combinations thereof.
70. The use of claim 64, wherein the cancer is acute myelogenous leukemia (AML).
71. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is acute myelogenous leukemia (AML).
72. The use of claim 64, wherein the cancer is renal cell carcinoma.
73. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is renal cell carcinoma.
74. The use of claim 64, wherein the cancer is ovarian cancer.
75. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is ovarian cancer.
76. The use of claim 64, wherein the cancer is prostate cancer.
77. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is prostate cancer.
78. The use of claim 64, wherein the cancer is renal cell carcinoma.
79. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is renal cell carcinoma.
80. The use of claim 64, wherein the cancer is glioblastoma.
81. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is glioblastoma.
82. The use of claim 64, wherein the cancer is gastric carcinoma.
83. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is gastric carcinoma.
84. The use of claim 64, wherein the cancer is esophageal squamous cell carcinoma.
85. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is esophageal squamous cell carcinoma.
86. The use of claim 64, wherein the cancer is a lung cancer.
87. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is a lung cancer.
Date recue/Date received 2023-04-20
Date recue/Date received 2023-04-20
88. The use of claim 86, wherein the lung cancer is non-small cell lung carcinoma or small cell lung cancer.
89. The compound of claim 87, or pharmaceutically acceptable salt thereof, wherein the lung cancer is non-small cell lung carcinoma or small cell lung cancer.
90. The use of claim 64, wherein the cancer is multiple myeloma.
91. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is multiple myeloma.
92. The use of claim 64, wherein the cancer is pancreatic cancer.
93. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is pancreatic cancer.
94. The use of claim 64, wherein the cancer is breast cancer.
95. The compound of claim 65, or pharmaceutically acceptable salt thereof, wherein the cancer is breast cancer.
Date recue/Date received 2023-04-20
Date recue/Date received 2023-04-20
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261731794P | 2012-11-30 | 2012-11-30 | |
US61/731,794 | 2012-11-30 | ||
PCT/US2013/072064 WO2014085489A1 (en) | 2012-11-30 | 2013-11-26 | Inhibitor of apoptosis protein (iap) antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2896577A1 CA2896577A1 (en) | 2014-06-05 |
CA2896577C true CA2896577C (en) | 2024-01-23 |
Family
ID=50828427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2896577A Active CA2896577C (en) | 2012-11-30 | 2013-11-26 | Inhibitor of apoptosis protein (iap) antagonists |
Country Status (5)
Country | Link |
---|---|
US (5) | US9546174B2 (en) |
EP (1) | EP2925764B1 (en) |
JP (2) | JP6382831B2 (en) |
CA (1) | CA2896577C (en) |
WO (1) | WO2014085489A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2925764B1 (en) | 2012-11-30 | 2023-03-01 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
JP6768522B2 (en) | 2014-06-04 | 2020-10-14 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Use of apoptotic protein inhibitor (IAP) antagonists in the treatment of HIV |
WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
CN109152843A (en) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | PROTAC antibody conjugates and its application method |
US10870663B2 (en) | 2018-11-30 | 2020-12-22 | Glaxosmithkline Intellectual Property Development Limited | Compounds useful in HIV therapy |
EP3886987B1 (en) * | 2018-11-30 | 2023-11-15 | GlaxoSmithKline Intellectual Property Development Limited | Compounds useful in hiv therapy |
EP3911316A1 (en) | 2019-01-17 | 2021-11-24 | Debiopharm International SA | Combination product for the treatment of cancer |
CN110028508B (en) * | 2019-05-16 | 2021-05-28 | 南京华威医药科技集团有限公司 | Antitumor diazo bicyclic apoptosis protein inhibitor |
CN114727984A (en) | 2019-09-25 | 2022-07-08 | 德彪药业国际股份公司 | Dosing regimen for treating patients with locally advanced squamous cell carcinoma |
CA3179329A1 (en) * | 2020-04-30 | 2021-11-04 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis protein (iap) antagonists |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
EP4426707A1 (en) * | 2021-11-04 | 2024-09-11 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (iap) protein antagonists |
WO2024121395A1 (en) * | 2022-12-09 | 2024-06-13 | Debiopharm International Sa | Iap inhibitors, methods of making the same and uses thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5457196A (en) | 1991-09-27 | 1995-10-10 | Merrell Dow Pharmaceuticals Inc. | 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
US5455242A (en) | 1991-09-27 | 1995-10-03 | Merrell Dow Pharmaceuticals Inc. | Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace |
CA2146238C (en) | 1992-10-30 | 2001-03-13 | Gary A. Flynn | Novel mercaptoacetylamide bicyclic lactam derivatives useful as inhibitors of enkephalinase and ace |
US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
FR2803594B1 (en) * | 2000-01-11 | 2002-07-19 | Centre Nat Rech Scient | OLIGOMERS OF NON-PEPTIDE CONSTRAINED MIMES OF DIPEPTIDES OR TRIPEPTIDES, AND USES THEREOF |
CN1960728A (en) * | 2004-01-16 | 2007-05-09 | 密歇根大学董事会 | Conformationally constrained SMAC mimetics and the uses thereof |
WO2006014361A1 (en) | 2004-07-02 | 2006-02-09 | Genentech, Inc. | Inhibitors of iap |
US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
US20100190688A1 (en) * | 2004-07-12 | 2010-07-29 | Bin Chao | Tetrapeptide analogs |
RU2007147959A (en) * | 2005-06-08 | 2009-07-20 | Новартис АГ (CH) | ORGANIC COMPOUNDS |
WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
US20090010941A1 (en) | 2007-04-09 | 2009-01-08 | University Of Massachusetts | Methods for treating HIV |
WO2008128171A2 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
CN102066361B (en) | 2008-04-11 | 2014-08-06 | 密歇根大学董事会 | Heteroaryl-substituted bicyclic SMAC mimetics and the uses thereof |
JP2010174138A (en) | 2009-01-29 | 2010-08-12 | Nok Kluber Kk | Method for producing grease composition and grease composition produced by the same |
EP2413955A4 (en) * | 2009-04-01 | 2012-12-26 | Amylin Pharmaceuticals Inc | N-terminus conformationally constrained glp-1 receptor agonist compounds |
WO2012125622A1 (en) | 2011-03-14 | 2012-09-20 | Bristol-Myers Squibb Company | Substituted adipic acid amides and uses thereof |
WO2013182662A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Vaccine |
EP2925764B1 (en) | 2012-11-30 | 2023-03-01 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
JP6768522B2 (en) | 2014-06-04 | 2020-10-14 | サンフォード−バーンハム メディカル リサーチ インスティテュート | Use of apoptotic protein inhibitor (IAP) antagonists in the treatment of HIV |
-
2013
- 2013-11-26 EP EP13859485.8A patent/EP2925764B1/en active Active
- 2013-11-26 JP JP2015545193A patent/JP6382831B2/en active Active
- 2013-11-26 WO PCT/US2013/072064 patent/WO2014085489A1/en active Application Filing
- 2013-11-26 CA CA2896577A patent/CA2896577C/en active Active
- 2013-11-26 US US14/648,435 patent/US9546174B2/en active Active
-
2016
- 2016-11-29 US US15/363,935 patent/US10047119B2/en active Active
-
2018
- 2018-05-25 JP JP2018101004A patent/JP2018162256A/en active Pending
- 2018-07-10 US US16/031,837 patent/US10544188B2/en active Active
-
2020
- 2020-01-10 US US16/740,240 patent/US11111270B2/en active Active
-
2021
- 2021-07-29 US US17/389,171 patent/US11912786B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20220119444A1 (en) | 2022-04-21 |
US11111270B2 (en) | 2021-09-07 |
US20150307499A1 (en) | 2015-10-29 |
US20170081362A1 (en) | 2017-03-23 |
US10047119B2 (en) | 2018-08-14 |
EP2925764A4 (en) | 2016-08-03 |
EP2925764A1 (en) | 2015-10-07 |
CA2896577A1 (en) | 2014-06-05 |
JP2018162256A (en) | 2018-10-18 |
EP2925764B1 (en) | 2023-03-01 |
US10544188B2 (en) | 2020-01-28 |
US11912786B2 (en) | 2024-02-27 |
JP6382831B2 (en) | 2018-08-29 |
JP2016501223A (en) | 2016-01-18 |
US9546174B2 (en) | 2017-01-17 |
US20190135861A1 (en) | 2019-05-09 |
US20200317731A1 (en) | 2020-10-08 |
WO2014085489A1 (en) | 2014-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11111270B2 (en) | Inhibitor of apoptosis protein (IAP) antagonists | |
ES2910108T3 (en) | Histone methyltransferase inhibitors | |
EP3902787A1 (en) | Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | |
US9676778B2 (en) | Substituted pyrrolo[2,3-b]pyrazines as JAK3 inhibitors | |
ES2883450T3 (en) | Histone methyltransferase inhibitors | |
CA3160666A1 (en) | Inhibitor of apoptosis (iap) protein antagonists | |
US20230295181A1 (en) | Inhibitor of apoptosis (iap) protein antagonists | |
BR112019025770A2 (en) | AZAINDOL COMPOUNDS AS HYSTONE METHYLTRANSPHERASE INHIBITORS | |
AU2021212770A1 (en) | Strad-binding agents and uses thereof | |
WO2020028525A1 (en) | Sumo inhibitor compounds and uses thereof | |
WO2022197734A1 (en) | Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | |
WO2022212488A1 (en) | Bicyclic heteroaryl phosphonate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | |
EP4426707A1 (en) | Inhibitor of apoptosis (iap) protein antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20181116 |
|
EEER | Examination request |
Effective date: 20181116 |
|
EEER | Examination request |
Effective date: 20181116 |
|
EEER | Examination request |
Effective date: 20181116 |
|
EEER | Examination request |
Effective date: 20181116 |
|
EEER | Examination request |
Effective date: 20181116 |
|
EEER | Examination request |
Effective date: 20181116 |
|
EEER | Examination request |
Effective date: 20181116 |
|
EEER | Examination request |
Effective date: 20181116 |
|
EEER | Examination request |
Effective date: 20181116 |
|
EEER | Examination request |
Effective date: 20181116 |